CA2915325C - Amino-triazine derivatives and pharmaceutical composition containing said derivative - Google Patents
Amino-triazine derivatives and pharmaceutical composition containing said derivative Download PDFInfo
- Publication number
- CA2915325C CA2915325C CA2915325A CA2915325A CA2915325C CA 2915325 C CA2915325 C CA 2915325C CA 2915325 A CA2915325 A CA 2915325A CA 2915325 A CA2915325 A CA 2915325A CA 2915325 C CA2915325 C CA 2915325C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- substituted
- unsubstituted
- date received
- date recue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention provides a novel compound having P2X3 and/or P2X2/3 receptor antagonism. A compound indicated by formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), Ra and Rb together, and Rd and Re together form an oxo or the like; R4a and R4b are hydrogen or the like; n is 1 or the like; R2 is an aryl or the like; s and s' are 0 or the like; R9 and R9 ' are a halogen or the like; R20a and R20b are hydrogen, an alkyl, or the like; u is 1-4; and R13 is hydrogen or the like.
Description
[Document Name] Specification [Title of Invention] Amino-Triazine Derivatives And Pharmaceutical Composition Containing Said Derivative [Technical field]
[0001]
The invention relates to a compound useful for the treatment of diseases or conditions associated with P2X receptor, specifically to P2X3 and/or P2X2/3 receptor, and a pharmaceutical composition comprising such compound.
[Background Art]
[0001]
The invention relates to a compound useful for the treatment of diseases or conditions associated with P2X receptor, specifically to P2X3 and/or P2X2/3 receptor, and a pharmaceutical composition comprising such compound.
[Background Art]
[0002]
Adenosine triphosph ate (ATP) is known to serve as a source of energy in cells and a substrate of phosphorylation, as well as an extracellular messenger. It is known that ATP is released from a cell by various stimulation such as cellular injury, inflammation, nociceptive stimulus, reduced blood oxygen level, and also known to be released together with another messenger from a primary sensory nerve terminal. ATP
thus released mediates various extracellular signal transductions through an ATP
receptor (Non-Patent Document 4, Non-Patent Document 5).
Adenosine triphosph ate (ATP) is known to serve as a source of energy in cells and a substrate of phosphorylation, as well as an extracellular messenger. It is known that ATP is released from a cell by various stimulation such as cellular injury, inflammation, nociceptive stimulus, reduced blood oxygen level, and also known to be released together with another messenger from a primary sensory nerve terminal. ATP
thus released mediates various extracellular signal transductions through an ATP
receptor (Non-Patent Document 4, Non-Patent Document 5).
[0003]
ATP receptor is categorized into ionotropic P2X family and G protein-coupled P2Y family. For P2X family, seven subtypes have been reported, and a member of this family forms a homo-trimeric structure or a hetero-trimeric structure together with another member of this subtype and functions as a non-specific cation channel (Non-Patent Document 6).
ATP receptor is categorized into ionotropic P2X family and G protein-coupled P2Y family. For P2X family, seven subtypes have been reported, and a member of this family forms a homo-trimeric structure or a hetero-trimeric structure together with another member of this subtype and functions as a non-specific cation channel (Non-Patent Document 6).
[0004]
ATP is known to cause pain, and studies with P2X3 knockout and knockdown methodologies have shown that P2X3 receptor mediates transmission of chronic pain.
P2X3 receptors are expressed in a specific manner on peripheral sensory nerve to form a homo-complex or hetero-complex with P2X2 (P2X2/3) (Non-Patent Document 1).
ATP is known to cause pain, and studies with P2X3 knockout and knockdown methodologies have shown that P2X3 receptor mediates transmission of chronic pain.
P2X3 receptors are expressed in a specific manner on peripheral sensory nerve to form a homo-complex or hetero-complex with P2X2 (P2X2/3) (Non-Patent Document 1).
[0005]
Later, the compound A-317491 was reported as a specific antagonist to P2X3 and P2X2/3 receptors. A-317491 is tri-substituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide derivative represented by the formula:
OH
HO
(Patent Document 1). It was reported to exhibit an antagonist activity to P2X3 and P2X2/3 receptors and analgesic action in neuropathic pain model and inflammatory pain model in rats (Non-Patent Document 7). This indicates that pain sensation is transmitted via P2X3 or P2X2/3 receptor and that a compound having a P2X3 or receptor antagonistic activity is useful as an analgesic. Also, compounds that exhibit Date Recue/Date Received 2020-11-26 P2X3 or P2X2/3 receptor antagonistic activity are described in Patent Documents 2-7.
Later, the compound A-317491 was reported as a specific antagonist to P2X3 and P2X2/3 receptors. A-317491 is tri-substituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide derivative represented by the formula:
OH
HO
(Patent Document 1). It was reported to exhibit an antagonist activity to P2X3 and P2X2/3 receptors and analgesic action in neuropathic pain model and inflammatory pain model in rats (Non-Patent Document 7). This indicates that pain sensation is transmitted via P2X3 or P2X2/3 receptor and that a compound having a P2X3 or receptor antagonistic activity is useful as an analgesic. Also, compounds that exhibit Date Recue/Date Received 2020-11-26 P2X3 or P2X2/3 receptor antagonistic activity are described in Patent Documents 2-7.
[0006]
Additionally, it was recently reported that vesical reflex was strongly reduced in P2X3 knockout mouse (Non-Patent Document 2), suggesting that a compound having P2X3 antagonistic activity is useful in the treatment of diseases caused by overactive bladder. Also, compounds that exhibit P2X3 or P2X2/3 receptor antagonistic activity are described in Patent Documents 2-7.
Additionally, it was recently reported that vesical reflex was strongly reduced in P2X3 knockout mouse (Non-Patent Document 2), suggesting that a compound having P2X3 antagonistic activity is useful in the treatment of diseases caused by overactive bladder. Also, compounds that exhibit P2X3 or P2X2/3 receptor antagonistic activity are described in Patent Documents 2-7.
[0007]
In addition, P2X3 receptor is expressed in neuroepithelial bodies (NEB) of the lung (Non-Patent Document 9), ATP induces cough (Non-Patent Document 10), and the like, therefore it ie suggested that P2X3 receptor participates in signal transduction in the respiratory system (Non-Patent Document 11). These reports suggest the possibility that compounds that exhibit P2X3 receptor antagonistic activity are useful in the treatment of respiratory diseases.
In addition, P2X3 receptor is expressed in neuroepithelial bodies (NEB) of the lung (Non-Patent Document 9), ATP induces cough (Non-Patent Document 10), and the like, therefore it ie suggested that P2X3 receptor participates in signal transduction in the respiratory system (Non-Patent Document 11). These reports suggest the possibility that compounds that exhibit P2X3 receptor antagonistic activity are useful in the treatment of respiratory diseases.
[0008]
Later, the compound A-317491 known as a specific antagonist to P2X3 and P2X2/3 receptors was reported inhibiting an activity of afferent vagal A fiber in pulmonary diseases (Patent Document 16). Additionally, biphenyl and phenyl-pyridine derivatives were reported as a specific antagonist to P2X3 and P2X2/3 receptors, and it is suggested that the biphenyl and phenyl-pyridine derivatives exhibit improving effect on respiratory diseases in asthma and lung model (Patent Document 17). Also, compounds that exhibit P2X3 or P2X2/3 receptor antagonistic activity are described in Patent Documents 2-7.
Later, the compound A-317491 known as a specific antagonist to P2X3 and P2X2/3 receptors was reported inhibiting an activity of afferent vagal A fiber in pulmonary diseases (Patent Document 16). Additionally, biphenyl and phenyl-pyridine derivatives were reported as a specific antagonist to P2X3 and P2X2/3 receptors, and it is suggested that the biphenyl and phenyl-pyridine derivatives exhibit improving effect on respiratory diseases in asthma and lung model (Patent Document 17). Also, compounds that exhibit P2X3 or P2X2/3 receptor antagonistic activity are described in Patent Documents 2-7.
[0009]
Patent Documents 8, 9, 10, 11, and 15 and Non-Patent Document 14 disclose compounds having similar structure to the compounds of the present invention but they do not disclose analgesic effect and P2X3 or P2X2/3 receptor antagonistic activity. Non-Patent Document 8 discloses compounds having similar structure to the compounds of the present invention and having analgesic effect, but it does not discloses P2X3 nor P2X2/3 receptor antagonistic activity. Patent Document 12 and Non-Patent Documents 12 and 13 disclose compounds having P2X3 receptor antagonistic activity but the structures are different with those of the compounds of the present invention. Patent Documents 13, 14, and 18 disclose compounds having P2X3 or P2X2/3 receptor antagonistic activity with a triazine structure.
[Prior Art]
[Patent Document]
Patent Documents 8, 9, 10, 11, and 15 and Non-Patent Document 14 disclose compounds having similar structure to the compounds of the present invention but they do not disclose analgesic effect and P2X3 or P2X2/3 receptor antagonistic activity. Non-Patent Document 8 discloses compounds having similar structure to the compounds of the present invention and having analgesic effect, but it does not discloses P2X3 nor P2X2/3 receptor antagonistic activity. Patent Document 12 and Non-Patent Documents 12 and 13 disclose compounds having P2X3 receptor antagonistic activity but the structures are different with those of the compounds of the present invention. Patent Documents 13, 14, and 18 disclose compounds having P2X3 or P2X2/3 receptor antagonistic activity with a triazine structure.
[Prior Art]
[Patent Document]
[0010]
[Patent Document 1] W002/094767 [Patent Document 2] W02005/095359 [Patent Document 3] US2007/0037974 [Patent Document 4] US2007/0049758 [Patent Document 5] US2007/0049610 [Patent Document 6] US2007/0049609 [Patent Document 7] US2007/0049534 [Patent Document 8] JP12-072757A
[Patent Document 9] W02006/104713 [Patent Document 10] W02006/104715 [Patent Document 11] W02006/102112 [Patent Document 12] W02010/051188 [Patent Document 13] W02010/092966 Date Recue/Date Received 2020-11-26 [Patent Document 14] W02012/020749 [Patent Document 15] W02011/017347 [Patent Document 16] W02006/012639 [Patent Document 17] W02010/149578 [Patent Document 18] W02013/089212 [Non-patent Document]
[Patent Document 1] W002/094767 [Patent Document 2] W02005/095359 [Patent Document 3] US2007/0037974 [Patent Document 4] US2007/0049758 [Patent Document 5] US2007/0049610 [Patent Document 6] US2007/0049609 [Patent Document 7] US2007/0049534 [Patent Document 8] JP12-072757A
[Patent Document 9] W02006/104713 [Patent Document 10] W02006/104715 [Patent Document 11] W02006/102112 [Patent Document 12] W02010/051188 [Patent Document 13] W02010/092966 Date Recue/Date Received 2020-11-26 [Patent Document 14] W02012/020749 [Patent Document 15] W02011/017347 [Patent Document 16] W02006/012639 [Patent Document 17] W02010/149578 [Patent Document 18] W02013/089212 [Non-patent Document]
[00011]
[Non-Patent Document 1] Neuroscientist (2005), 11, pp.345-356 [Non-Patent Document 2] J. Physiol. 567.2 (2005), pp.621-639 [Non-Patent Document 3] Expert Opin. Ther. Patens (2006), 16(8), pp.113-1127 [Non-Patent Document 4] J. Physiology (2003), 554(2), pp.301-308 [Non-Patent Document 5] J. Physiology (2003), 553(3), pp.683-694 [Non-Patent Document 6] Pflungers Arch Eur J physiol (2006), p.452, 513-537 [Non-Patent Document 7] PNAS (2002), 99(26), pp.17179-17184 [Non-Patent Document 8] Journal of Medicinal Chemistry (2008), 51(23), pp.7635-[Non-Patent Document 9] Brouns et al. Am J Respir Cell MoI Biol (2000), 23, pp.52-61 [Non-Patent Document 10] Basoglu et al. Chest. (2005), 128(4), pp.1905-9 [Non-Patent Document 11] Adriaensen et al. THE ANATOMICAL RECORD PART A
(2003), 270A, pp.25-40 [Non-Patent Document 12] Cantin, L.-D. et al. Bioorg. Med. Chem. Lett. (2012), 22(7), pp.2565-2571 [Non-Patent Document 13] Jahangir, A. et al. Bioorg. Med. Chem. Lett. (2009), 19, pp.1632-1635 [Non-Patent Document 14] Chemistry--A European Journal (2012), 18(5), pp.1476-[Summary of the invention]
[Problems to be solved by the Invention]
[Non-Patent Document 1] Neuroscientist (2005), 11, pp.345-356 [Non-Patent Document 2] J. Physiol. 567.2 (2005), pp.621-639 [Non-Patent Document 3] Expert Opin. Ther. Patens (2006), 16(8), pp.113-1127 [Non-Patent Document 4] J. Physiology (2003), 554(2), pp.301-308 [Non-Patent Document 5] J. Physiology (2003), 553(3), pp.683-694 [Non-Patent Document 6] Pflungers Arch Eur J physiol (2006), p.452, 513-537 [Non-Patent Document 7] PNAS (2002), 99(26), pp.17179-17184 [Non-Patent Document 8] Journal of Medicinal Chemistry (2008), 51(23), pp.7635-[Non-Patent Document 9] Brouns et al. Am J Respir Cell MoI Biol (2000), 23, pp.52-61 [Non-Patent Document 10] Basoglu et al. Chest. (2005), 128(4), pp.1905-9 [Non-Patent Document 11] Adriaensen et al. THE ANATOMICAL RECORD PART A
(2003), 270A, pp.25-40 [Non-Patent Document 12] Cantin, L.-D. et al. Bioorg. Med. Chem. Lett. (2012), 22(7), pp.2565-2571 [Non-Patent Document 13] Jahangir, A. et al. Bioorg. Med. Chem. Lett. (2009), 19, pp.1632-1635 [Non-Patent Document 14] Chemistry--A European Journal (2012), 18(5), pp.1476-[Summary of the invention]
[Problems to be solved by the Invention]
[0012]
The present invention provides a novel compound having a P2X3 and/or P2X2/3 receptor antagonistic activity. It also provides a pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic activity.
[Means for Solving the Problem]
The present invention provides a novel compound having a P2X3 and/or P2X2/3 receptor antagonistic activity. It also provides a pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic activity.
[Means for Solving the Problem]
[0013]
Through their extensive research to solve the aforementioned problems, the inventors have found novel compounds that bind specifically to P2X3 and/or receptor and exhibit an antagonistic activity, and novel compounds that bind specifically to P2X3 and/or P2X2/3 receptor. Additionally, they have discovered pharmaceutical compositions that have P2X3 and/or P2X2/3 antagonistic activity.
The compounds and pharmaceutical compositions encompassed by the present invention produced excellent results of P2X3 receptor inhibitory effect, P2X3 receptor inhibitory effect in the presence of rat serum albumin (hereinafter referred to as RSA) and the like. The compounds encompassed by the present invention or the pharmaceutical compositions encompassed by the present invention also produced excellent results in CYP enzyme inhibition assay, FAT assay, solubility assay, metabolic stability assay, hERG inhibitory activity assay, pharmacokinetic assay (bioavailability assay, total body clearance assay, etc.) and/or protein binding assay and the like.
Date Recue/Date Received 2020-11-26
Through their extensive research to solve the aforementioned problems, the inventors have found novel compounds that bind specifically to P2X3 and/or receptor and exhibit an antagonistic activity, and novel compounds that bind specifically to P2X3 and/or P2X2/3 receptor. Additionally, they have discovered pharmaceutical compositions that have P2X3 and/or P2X2/3 antagonistic activity.
The compounds and pharmaceutical compositions encompassed by the present invention produced excellent results of P2X3 receptor inhibitory effect, P2X3 receptor inhibitory effect in the presence of rat serum albumin (hereinafter referred to as RSA) and the like. The compounds encompassed by the present invention or the pharmaceutical compositions encompassed by the present invention also produced excellent results in CYP enzyme inhibition assay, FAT assay, solubility assay, metabolic stability assay, hERG inhibitory activity assay, pharmacokinetic assay (bioavailability assay, total body clearance assay, etc.) and/or protein binding assay and the like.
Date Recue/Date Received 2020-11-26
[0014]
This invention relates to the following (1) to (44):
(1) A compound of Formula (I):
(R9)s' ii R20a R20b (R9)S
Ra Rb N N IA Re u CO2R13 (I) HI
(c(R4a)(R4b))n wherein, Ra and Rb are both hydrogen atoms, or Ra and Rb are taken together to form oxo, thioxo or =N-Rx;
Rd and Re are both hydrogen atoms, or Rd and Re are taken together to form oxo, thioxo or =N-RY;
Rx and RY are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R4a is each independently a hydrogen atom or substituted or unsubstituted alkyl; R4b is each independently a hydrogen atom or substituted or unsubstituted alkyl;
or R4a and 114b attached to the same carbon atom are taken together to form oxo or thioxo;
n is an integer of 1 to 4;
R2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy;
Date Recue/Date Received 2020-11-26 R9' is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy;
s and s' are each independently an integer of 0 to 3;
R20a is each independently a hydrogen atom, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkyloxy;
R2ob is each independently a hydrogen atom, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkyloxy;
or R20a and R2ob attached to the same carbon atom or the different carbon atoms are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring; provided that all R20a and R2ob are not hydrogen atoms at the same time;
u is an integer of 1 to 4; and R1-3 is a hydrogen atom or substituted or unsubstituted alkyl, provided that the following compounds:
HNAN H)1 11'LOH 0 Sand 401 are excluded, or its pharmaceutically-acceptable salt.
(2) The compound according to the above (1), wherein the group represented by the formula:
Date Recue/Date Received 2020-11-26 R20a R20b q 11,(ks fs is a group represented by the formula:
, 0 ' tt.nZn;t1 , or , L.t.
or its pharmaceutically-acceptable salt.
(3) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b is a group represented by the formula:
, 0 , -,,L-z, -/=,-z-, OH , 0 , or , or its pharmaceutically-acceptable salt.
(4) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b Date Recue/Date Received 2020-11-26 is a group represented by the formula:
1-4-) ¨Ø¨
or or its pharmaceutically-acceptable salt.
(5) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b is a group represented by the formula:
`1-=-,`Zn 9.-.7-r, 11-L:PL'Lln or or its pharmaceutically-acceptable salt.
(6) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b (112_,(ksfs is a group represented by the formula:
)y?-=;2-, or its pharmaceutically-acceptable salt.
(7) The compound according to any one of the above (1) to (6), wherein n is 1, R4a and R4b are both hydrogen atoms, and R2 is substituted or unsubstituted phenyl or substituted or unsubstituted cycloalkyl, or its pharmaceutically-acceptable salt.
Date Recue/Date Received 2020-11-26 (8) The compound according to any one of the above (1) to (7), wherein n is 1, R4a and R4b are both hydrogen atoms, and R2 is substituted or unsubstituted phenyl, or its pharmaceutically-acceptable salt.
(9) The compound according to any one of the above (1) to (8), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is phenyl substituted with chloro or methyl, or its pharmaceutically-acceptable salt.
(10) The compound according to any one of the above (1) to (9), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is phenyl substituted with methyl, or its pharmaceutically-acceptable salt.
(11) The compound according to any one of the above (1) to (8), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is phenyl substituted with halogen, or its pharmaceutically-acceptable salt.
(12) The compound according to any one of the above (1) to (8), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is 4-methylphenyl, 4-chlorophenyl, 2, 4-dichlorophenyl, or 4-methy1cyc1ohexy1, or its pharmaceutically-acceptable salt.
(13) The compound according to any one of the above (1) to (10) and (12), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is 4-methylphenyl, or its pharmaceutically-acceptable salt.
(14) The compound according to any one of the above (1) to (9), (11) and (12), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is 4-chlorolphenyl, or its pharmaceutically-acceptable salt.
This invention relates to the following (1) to (44):
(1) A compound of Formula (I):
(R9)s' ii R20a R20b (R9)S
Ra Rb N N IA Re u CO2R13 (I) HI
(c(R4a)(R4b))n wherein, Ra and Rb are both hydrogen atoms, or Ra and Rb are taken together to form oxo, thioxo or =N-Rx;
Rd and Re are both hydrogen atoms, or Rd and Re are taken together to form oxo, thioxo or =N-RY;
Rx and RY are each independently a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
R4a is each independently a hydrogen atom or substituted or unsubstituted alkyl; R4b is each independently a hydrogen atom or substituted or unsubstituted alkyl;
or R4a and 114b attached to the same carbon atom are taken together to form oxo or thioxo;
n is an integer of 1 to 4;
R2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R9 is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy;
Date Recue/Date Received 2020-11-26 R9' is each independently halogen, hydroxy, carboxy, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkenylthio, substituted or unsubstituted alkynylthio, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted amino, substituted or unsubstituted sulfamoyl, substituted sulfonyl, substituted sulfinyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyloxy, substituted or unsubstituted cycloalkenyloxy, substituted or unsubstituted non-aromatic heterocyclyloxy, substituted or unsubstituted aryloxy or substituted or unsubstituted heteroaryloxy;
s and s' are each independently an integer of 0 to 3;
R20a is each independently a hydrogen atom, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkyloxy;
R2ob is each independently a hydrogen atom, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted alkyloxy;
or R20a and R2ob attached to the same carbon atom or the different carbon atoms are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring; provided that all R20a and R2ob are not hydrogen atoms at the same time;
u is an integer of 1 to 4; and R1-3 is a hydrogen atom or substituted or unsubstituted alkyl, provided that the following compounds:
HNAN H)1 11'LOH 0 Sand 401 are excluded, or its pharmaceutically-acceptable salt.
(2) The compound according to the above (1), wherein the group represented by the formula:
Date Recue/Date Received 2020-11-26 R20a R20b q 11,(ks fs is a group represented by the formula:
, 0 ' tt.nZn;t1 , or , L.t.
or its pharmaceutically-acceptable salt.
(3) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b is a group represented by the formula:
, 0 , -,,L-z, -/=,-z-, OH , 0 , or , or its pharmaceutically-acceptable salt.
(4) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b Date Recue/Date Received 2020-11-26 is a group represented by the formula:
1-4-) ¨Ø¨
or or its pharmaceutically-acceptable salt.
(5) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b is a group represented by the formula:
`1-=-,`Zn 9.-.7-r, 11-L:PL'Lln or or its pharmaceutically-acceptable salt.
(6) The compound according to the above (1), wherein the group represented by the formula:
R20a R20b (112_,(ksfs is a group represented by the formula:
)y?-=;2-, or its pharmaceutically-acceptable salt.
(7) The compound according to any one of the above (1) to (6), wherein n is 1, R4a and R4b are both hydrogen atoms, and R2 is substituted or unsubstituted phenyl or substituted or unsubstituted cycloalkyl, or its pharmaceutically-acceptable salt.
Date Recue/Date Received 2020-11-26 (8) The compound according to any one of the above (1) to (7), wherein n is 1, R4a and R4b are both hydrogen atoms, and R2 is substituted or unsubstituted phenyl, or its pharmaceutically-acceptable salt.
(9) The compound according to any one of the above (1) to (8), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is phenyl substituted with chloro or methyl, or its pharmaceutically-acceptable salt.
(10) The compound according to any one of the above (1) to (9), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is phenyl substituted with methyl, or its pharmaceutically-acceptable salt.
(11) The compound according to any one of the above (1) to (8), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is phenyl substituted with halogen, or its pharmaceutically-acceptable salt.
(12) The compound according to any one of the above (1) to (8), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is 4-methylphenyl, 4-chlorophenyl, 2, 4-dichlorophenyl, or 4-methy1cyc1ohexy1, or its pharmaceutically-acceptable salt.
(13) The compound according to any one of the above (1) to (10) and (12), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is 4-methylphenyl, or its pharmaceutically-acceptable salt.
(14) The compound according to any one of the above (1) to (9), (11) and (12), wherein n is 1, R4. and R4b are both hydrogen atoms, and R2 is 4-chlorolphenyl, or its pharmaceutically-acceptable salt.
(15) The compound according to any one of the above (1) to (14), wherein Ra and Rb are taken together to form oxo, or its pharmaceutically-acceptable salt.
(16) The compound according to any one of the above (1) to (15), wherein Rd and R. are taken together to form oxo, or its pharmaceutically-acceptable salt.
(17) The compound according to any one of the above (1) to (16), wherein s is 0, or its pharmaceutically-acceptable salt.
(18) The compound according to any one of the above (1) to (16), wherein s is 1 or 2, and R9 is each independently halogen, unsubstituted alkyl, haloalkyl, unsubstituted alkenyl, or unsubstituted alkynyl, or its pharmaceutically-acceptable salt.
(19) The compound according to the above (18), wherein s is 1, R9 is fluoro, chloro or methyl, or its pharmaceutically-acceptable salt.
(20) The compound according to any one of the above (1) to (19), wherein s' is 0, or its pharmaceutically-acceptable salt.
(21) The compound according to any one of the above (1) to (19), wherein s' is an integer of 1 to 3, or its pharmaceutically-acceptable salt.
Date Recue/Date Received 2020-11-26
Date Recue/Date Received 2020-11-26
(22) The compound according to the above (21), wherein s' is 1 or 2, and R9' is each independently halogen, carboxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkyloxycarbonyl, or substituted or unsubstituted aryl, or its pharmaceutically-acceptable salt.
(23) The compound according to the above (21) or (22), wherein s is 1, and R9' is fluor , chloro, bromo, iodo, carboxy, cyano, methyl, ethyl, propyl, isopropyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methyloxycarbonyl, or ethyloxycarbonyl, or its pharmaceutically-acceptable salt.
(24) The compound according to any one of the above (21) to (23), wherein s' is 1, and R9' is fluoro, chloro, carboxy, cyano, methyl, hydroxymethyl, trifluoromethyl, methyloxy, isopropyloxy, difluoromethyl, methyloxycarbonyl, or ethyloxycarbonyl, or its pharmaceutically-acceptable salt.
(25) The compound according to the above (1), wherein Ra and Rb are taken together to form oxo:
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
R2 is phenyl substituted with methyl;
s is 0; and s' is 1, or its pharmaceutically-acceptable salt.
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
R2 is phenyl substituted with methyl;
s is 0; and s' is 1, or its pharmaceutically-acceptable salt.
(26) The compound according to the above (1), wherein Ra and Rb are taken together to form oxo:
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
R2 is phenyl substituted with halogen; and s and s' are both 0, or its pharmaceutically-acceptable salt.
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
R2 is phenyl substituted with halogen; and s and s' are both 0, or its pharmaceutically-acceptable salt.
(27) The compound according to the above (26), wherein R1-3 is a hydrogen atom and the group represented by the formula:
R20a R20b (ksfs is a group represented by the formula:
Date Recue/Date Received 2020-11-26 or its pharmaceutically-acceptable salt.
R20a R20b (ksfs is a group represented by the formula:
Date Recue/Date Received 2020-11-26 or its pharmaceutically-acceptable salt.
(28) A compound of formula:
F
OF
F
I ,N
HN N
A
00)HN)(NOH OH
NJ-N . N.).N.L0 0 0 i ' CI 'CI
CI
0 I\1 0 0 HN N e 0 0 HANI)LOH 0 0 le , 0 i 0 0 1\1) Nr 0 0 0 ,L
O 0 HN )LN 0 0 L,) , HNANOH
NNO
* i 0 i F
I J.
N ) 0 0 1\1 0 0 O 0 HNANA)e 0 40 HI)Lni)LOH
eLN0 0, SI
, CI , 'CI
F
OF 0 o rrCi NNO
N
N N 0 , or 0 , NII., 0 0 HNANe * leLNILO
*
Date Recue/Date Received 2020-11-26 or its pharmaceutically-acceptable salt.
F
OF
F
I ,N
HN N
A
00)HN)(NOH OH
NJ-N . N.).N.L0 0 0 i ' CI 'CI
CI
0 I\1 0 0 HN N e 0 0 HANI)LOH 0 0 le , 0 i 0 0 1\1) Nr 0 0 0 ,L
O 0 HN )LN 0 0 L,) , HNANOH
NNO
* i 0 i F
I J.
N ) 0 0 1\1 0 0 O 0 HNANA)e 0 40 HI)Lni)LOH
eLN0 0, SI
, CI , 'CI
F
OF 0 o rrCi NNO
N
N N 0 , or 0 , NII., 0 0 HNANe * leLNILO
*
Date Recue/Date Received 2020-11-26 or its pharmaceutically-acceptable salt.
(29) A pharmaceutical composition comprising the compound according to any one of the above (1) to (28), or its pharmaceutically-acceptable salt.
(30) The pharmaceutical composition according to the above (29), wherein the composition has a P2X3 and/or P2X2i3 receptor antagonistic activity.
(31) The pharmaceutical composition according to the above (30), wherein the composition has an effect of treatment for and/or prevention of chronic pain, urination disorder, or respiratory disease.
(32) A compound according to any one of the above (1) to (28), or its pharmaceutically-acceptable salt, for use in a method for treating and/or preventing a disease related to P2X3 and/or P2X2i3 receptor.
(33) The compound according to the above (32), or its pharmaceutically-acceptable salt, for use in a method for treating and/or preventing chronic pain, urination disorder, or respiratory disease.
(34) A method for treating and/or preventing a disease related to P2X3 and/or P2X2i3 receptor comprising administering the compound according to any one of the above (1) to (28), or its pharmaceutically-acceptable salt.
(35) The method according to the above (34), for treating and/or preventing chronic pain, urination disorder, or respiratory disease.
(36) Use of the compound of any one of the above (1) to (28), or its pharmaceutically-acceptable salt, in the manufacturing of an agent for treating and/or preventing a disease related to P2X3 and/or P2X2i3 receptor.
(37) The use according to the above (36), in the manufacturing of an agent for treating and/or preventing chronic pain, urination disorder, or respiratory disease.
(38) A pharmaceutical composition comprising the compound of any one of the above (1) to (28), or a pharmaceutically-acceptable salt thereof, for oral administration.
(39) The pharmaceutical composition of the above (38), which is a tablet, powder, granule, capsule, pill, film, suspension, emulsion, elixir, syrup, lemonade, spirit, aromatic water, extract, decoction or tincture.
(40) The pharmaceutical composition of the above (39), which is a sugar-coated tablet, film-coated tablet, enteric-coated tablet, sustained-release tablet, troche tablet, sublingual tablet, buccal tablet, chewable tablet, orally dispersing tablet, dry syrup, soft capsule, micro capsule or sustained-release capsule.
(41) A pharmaceutical composition comprising the compound of any one of the above (1) to (28), or a pharmaceutically-acceptable salt thereof, for parenteral administration.
Date Recue/Date Received 2020-11-26
Date Recue/Date Received 2020-11-26
(42) The pharmaceutical composition of the above (41), for dermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, transnasal, ophthalmic, inner ear or vaginal administration.
(43) The pharmaceutical composition of the above (41) or (42), which is injection, infusion, eye drop, nose drop, ear drop, aerosol, inhalation, lotion, impregnation, liniment, mouthwash, enema, ointment, plaster, jelly, cream, patch, cataplasm, external powder or suppository.
(44) A pharmaceutical composition comprising the compound of any one of the above (1) to (28), or a pharmaceutically-acceptable salt thereof, for a pediatric or geriatric patient.
[Effect of the Invention]
[0015]
The compound of the invention has a P2X3 and/or P2X2/3 receptor antagonistic activity and is useful in the treatment of diseases or conditions associated with a P2X3 and/or P2X2/3 receptor.
[Mode for Carrying Out the Invention]
[0016]
As used throughout the specification, the following terms have the following meaning unless specifically indicated.
[0017]
The term "halogen" means fluor , chloro, bromo and iodo.
[0018]
The halogen moiety in said "haloalkyl", "haloalkylcarbamoyl" and "haloalkyloxy"
is as defined above for "halogen".
[0019]
The term "alkyl" includes a straight or branched chain monovalent hydrocarbon group of a carbon number of 1 to 15, as one embodiment a carbon number of 1 to 10, and as another embodiment a carbon number of 1 to 6. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, n-decyl, n-undecanyl, dodecanyl, tridecanyl, and the like.
In the present specification, the carbon number in the term "alkyl" may be limited. For example, C3-C6 alkyl means "alkyl" of a carbon number of 3 to 6.
Examples of "alkyl" for R1-3 are methyl, ethyl, and the like.
[0020]
The alkyl moiety in said "haloalkyl", "hydroxyalkyl", "aminoalkyl", "alkylaminoalkyl", "alkylamino", "alkylimino", "alkylsulfonyl", "alkylsulfamoyl", "alkylcarbamoyl", "arylalkyl", "alkylsilylalkynyl", "alkylsulfonyl", "alkylsulfinyl", "alkylcarbamoyl", "alkylcarbamoylalkyl", "alkylcarbamoylalkyloxy", "alkylsulfamoyl", "alkylsulfamoylalkyl", "haloalkylcarbamoyl", "hydroxyalkylcarbamoyl", "alkyloxycarbonylalkyl", "alkylcarbamoylamino", "alkyloxycarbonylamino", "alkylsulfonylcarbamoyl", and "arylalkylamino" is as defined above for "alkyl".
[0021]
The term "alkyloxy" includes an alkyloxy group of which alkyl moiety is as defined above for "alkyl". For example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, etc are exemplified as alkyloxy.
[0022]
Date Recue/Date Received 2020-11-26 The alkyloxy moiety in said "haloalkyloxy", "arylalkyloxy", "alkyloxycarbonyl", "alkyloxycarbonylalkyl", "alkyloxyalkyloxy", "alkylcarbamoylalkyloxy", "carbamoylalkyloxy", "carboxyalkyloxy", and "alkyloxyimino" is as defined above for "alkyloxy".
[0023]
For example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, and the like are exemplified as "alkylthio".
[0024]
For example, methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl, n-pentyloxycarbonyl, and the like are exemplified as "alkyloxycarbonyl".
[0025]
For example, mono- or di- alkylcarbamoyl, such as methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, n-butylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, and the like are exemplified as "alkylcarbamoyl".
[0026]
The term "alkenyl" includes linear or branched alkenyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, and as another embodiment a carbon number of 2 to 6 having one or more double bonds at any available position.
Examples include vinyl, prop enyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl and the like.
In the present specification, the carbon number in the term "alkenyl" may be limited. For example, C3-C6 alkenyl means "alkenyl" of a carbon number of 3 to 6.
[0027]
The alkenyl moiety in said "alkenyloxy", "alkenylthio", "alkenylcarbamoyl", "alkenylsulfamoyl" and "alkenyloxycarbonyl" is as defined above for "alkenyl".
[0028]
The term "alkynyl" includes a linear or branched alkynyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, as another embodiment a carbon number 2 to 6. Examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl. These have one or more triple bonds at any available position and may further a double bond.
In the present specification, the carbon number in the term "alkynyl" may be limited. For example, C3-C6 alkynyl means "alkynyl" of a carbon number of 3 to 6.
[0029]
The alkynyl moiety in said "alkynyloxy", "alkynylthio" and "alkynyloxycarbonyl"
is as defined above for "alkynyl".
[0030]
The term "acyl" includes a group of the formula R-C(=0)-, wherein R is, for example, "hydrogen", "alkyl", "alkenyl" or "alkynyl" as defined above and "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl" or "heteroaryl" as defined below.
[0031]
The acyl moiety in "acylamino" and "acylimino" is as defined above for "acyl ".
[0032]
The term "cycloalkane" includes a monocyclic or polycyclic saturated cyclic carbocyclic ring containing from 3 to 10 carbons. Monocyclic cycloalkane includes, for Date Recue/Date Received 2020-11-26 example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, etc. Polycyclic cycloalkane includes norbornanane, tetrahydronaphthalene, etc.
[0033]
The term "cycloalkyl" includes a monovalent group derived from "cycloalkane"
as defined above. Monocyclic cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, etc.
As one embodiment, C3 to C8 cycloalkane is exemplified. As another embodiment, C3 to cycloalkane is exemplified. Polycyclic cycloalkyl includes norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, etc.
Examples of "cycloalkyl" for R2 are cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
[0034]
The cycloalkyl moiety in said "cycloaokylcarbonyl", "cycloalkyloxycarbonyl"
and "cycloalkyloxy" is as defined above for "cycloalkyl".
[0035]
The term "cycloalkene" includes a non-aromatic monocyclic or polycyclic ring of 3 to 10 carbons containing at least one carbon-carbon double bond. As one embodiment C3 to C8 cycloalkene is exemplified. As another embodiment C3 to C7 cycloalkene is exemplified. Monocyclic cycloalkene includes, for example, cyclopentene, cyclohexene, etc. Polycyclic cycloalkene includes norbornene, indene, etc.
[0036]
The term "cycloalkenyl" includes a monovalent group derived from "cycloalkene"
as defined above. Monocyclic cycloalkenyl includes cyclopentenyl, cyclohexenyl, etc. As one embodiment, C3 to C8 cycloalkyl is exemplified. As another embodiment, C3 to C7 cycloalkyl is exemplified. Polycyclic cycloalkenyl includes norbornenyl, indene-1-yl, indene-2-yl, indene-3-yl, etc.
[0037]
The cycloalkenyl moiety in said "cycloalkenyloxycarbonyl" and "cyclolalkenyloxy" is as defined above for "cycloalkenyl".
[0038]
The term "aromatic carbocyclic ring" includes an aromatic hydrocarbocyclic ring which is monocyclic or fused-cyclic, such as benzene, naphthalene, anthracene, phenanthrene, etc.
[0039]
The term "aryl" includes a monovalent group derived from "aromatic carbocyclic ring" as defined above. For example, phenyl, 1-naphthyl, 2-naphthyl, anthryl, phenanthryl, etc. are exemplified.
Preferable "aryl" for R2 is phenyl.
[0040]
The aryl moiety in said "aryloxy", "arylthio" and "aryloxycarbonyl" is as defined above for "aryl".
[0041]
The term "heterocyclic ring" includes an aromatic or a non-aromatic monocyclic or fused-cyclic ring, which includes a five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused ring consisting of two or more said five- to seven-membered rings; or a fused ring consisting of said five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring", "cycloalkane" or "cycloalkene" as defined above.
Date Recue/Date Received 2020-11-26 For example, a monocyclic non-aromatic heterocyclic ring such as pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydropyrane, dihydropyridine, dihydropyridazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazole, tetrahydroisothiazole, etc.;
a monocyclic aromatic heterocyclic ring such as pyrrole, pyrazine, pyrazole, tetrazole, furan, thiophene, pyridine, imidazole, triazole, tetrazole, triazine, pyridazine, pyrimidine, isoxazole, thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a fused heterocyclic ring such as indole, isoindole, indazole, indolizine, indoline, isoindoline, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, purine, pteridine, benzopyrane, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, benzimidazole, benzodioxane, tetrahydroquinoline, tetrahydrobenzothiophene, etc. are exemplified.
[0042]
The term "heterocyclic group" includes a monovalent group derived from "heterocyclic ring" as defined above.
For example, monocyclic non-aromatic heterocyclic groups such as pyrrolinyl, pyrrolidino, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydroisothiazolinyl, etc.;
monocyclic aromatic heterocyclic groups such as pyrrolyl, pyrazinyl, pyrazolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, etc; and fused heterocyclic groups such as indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, benzimidazolinyl, benzodioxanyl, tetrahydroquinoline, tetrahydrobenzothienyl, etc. are exemplified.
[0043]
The term "non-aromatic carbocyclic ring" includes "cycloalkane" as defined above, "cycloalkene" as defined above, a fused ring consisting of "aromatic carbocyclic ring" as defined above fused to "cycloalkane" or "cycloalkene" as defined above. As a fused ring, indene and the like are exemplified.
[0044]
The term "non-aromatic carbocyclic group" includes a monovalent group derived from "non-aromatic carbocyclic ring" as defined above. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, norbornenyl, inden-l-yl, inden-2-yl, inden-3-y1 and the like are exemplified.
[Effect of the Invention]
[0015]
The compound of the invention has a P2X3 and/or P2X2/3 receptor antagonistic activity and is useful in the treatment of diseases or conditions associated with a P2X3 and/or P2X2/3 receptor.
[Mode for Carrying Out the Invention]
[0016]
As used throughout the specification, the following terms have the following meaning unless specifically indicated.
[0017]
The term "halogen" means fluor , chloro, bromo and iodo.
[0018]
The halogen moiety in said "haloalkyl", "haloalkylcarbamoyl" and "haloalkyloxy"
is as defined above for "halogen".
[0019]
The term "alkyl" includes a straight or branched chain monovalent hydrocarbon group of a carbon number of 1 to 15, as one embodiment a carbon number of 1 to 10, and as another embodiment a carbon number of 1 to 6. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, n-decyl, n-undecanyl, dodecanyl, tridecanyl, and the like.
In the present specification, the carbon number in the term "alkyl" may be limited. For example, C3-C6 alkyl means "alkyl" of a carbon number of 3 to 6.
Examples of "alkyl" for R1-3 are methyl, ethyl, and the like.
[0020]
The alkyl moiety in said "haloalkyl", "hydroxyalkyl", "aminoalkyl", "alkylaminoalkyl", "alkylamino", "alkylimino", "alkylsulfonyl", "alkylsulfamoyl", "alkylcarbamoyl", "arylalkyl", "alkylsilylalkynyl", "alkylsulfonyl", "alkylsulfinyl", "alkylcarbamoyl", "alkylcarbamoylalkyl", "alkylcarbamoylalkyloxy", "alkylsulfamoyl", "alkylsulfamoylalkyl", "haloalkylcarbamoyl", "hydroxyalkylcarbamoyl", "alkyloxycarbonylalkyl", "alkylcarbamoylamino", "alkyloxycarbonylamino", "alkylsulfonylcarbamoyl", and "arylalkylamino" is as defined above for "alkyl".
[0021]
The term "alkyloxy" includes an alkyloxy group of which alkyl moiety is as defined above for "alkyl". For example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, etc are exemplified as alkyloxy.
[0022]
Date Recue/Date Received 2020-11-26 The alkyloxy moiety in said "haloalkyloxy", "arylalkyloxy", "alkyloxycarbonyl", "alkyloxycarbonylalkyl", "alkyloxyalkyloxy", "alkylcarbamoylalkyloxy", "carbamoylalkyloxy", "carboxyalkyloxy", and "alkyloxyimino" is as defined above for "alkyloxy".
[0023]
For example, methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, and the like are exemplified as "alkylthio".
[0024]
For example, methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, tert-butyloxycarbonyl, n-pentyloxycarbonyl, and the like are exemplified as "alkyloxycarbonyl".
[0025]
For example, mono- or di- alkylcarbamoyl, such as methylcarbamoyl, ethylcarbamoyl, n-propylcarbamoyl, isopropylcarbamoyl, cyclopropylcarbamoyl, n-butylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, dipropylcarbamoyl, and the like are exemplified as "alkylcarbamoyl".
[0026]
The term "alkenyl" includes linear or branched alkenyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, and as another embodiment a carbon number of 2 to 6 having one or more double bonds at any available position.
Examples include vinyl, prop enyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl and the like.
In the present specification, the carbon number in the term "alkenyl" may be limited. For example, C3-C6 alkenyl means "alkenyl" of a carbon number of 3 to 6.
[0027]
The alkenyl moiety in said "alkenyloxy", "alkenylthio", "alkenylcarbamoyl", "alkenylsulfamoyl" and "alkenyloxycarbonyl" is as defined above for "alkenyl".
[0028]
The term "alkynyl" includes a linear or branched alkynyl of a carbon number of 2 to 15, as one embodiment a carbon number of 2 to 10, as another embodiment a carbon number 2 to 6. Examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl and decynyl. These have one or more triple bonds at any available position and may further a double bond.
In the present specification, the carbon number in the term "alkynyl" may be limited. For example, C3-C6 alkynyl means "alkynyl" of a carbon number of 3 to 6.
[0029]
The alkynyl moiety in said "alkynyloxy", "alkynylthio" and "alkynyloxycarbonyl"
is as defined above for "alkynyl".
[0030]
The term "acyl" includes a group of the formula R-C(=0)-, wherein R is, for example, "hydrogen", "alkyl", "alkenyl" or "alkynyl" as defined above and "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl" or "heteroaryl" as defined below.
[0031]
The acyl moiety in "acylamino" and "acylimino" is as defined above for "acyl ".
[0032]
The term "cycloalkane" includes a monocyclic or polycyclic saturated cyclic carbocyclic ring containing from 3 to 10 carbons. Monocyclic cycloalkane includes, for Date Recue/Date Received 2020-11-26 example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, etc. Polycyclic cycloalkane includes norbornanane, tetrahydronaphthalene, etc.
[0033]
The term "cycloalkyl" includes a monovalent group derived from "cycloalkane"
as defined above. Monocyclic cycloalkyl includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, etc.
As one embodiment, C3 to C8 cycloalkane is exemplified. As another embodiment, C3 to cycloalkane is exemplified. Polycyclic cycloalkyl includes norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, etc.
Examples of "cycloalkyl" for R2 are cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
[0034]
The cycloalkyl moiety in said "cycloaokylcarbonyl", "cycloalkyloxycarbonyl"
and "cycloalkyloxy" is as defined above for "cycloalkyl".
[0035]
The term "cycloalkene" includes a non-aromatic monocyclic or polycyclic ring of 3 to 10 carbons containing at least one carbon-carbon double bond. As one embodiment C3 to C8 cycloalkene is exemplified. As another embodiment C3 to C7 cycloalkene is exemplified. Monocyclic cycloalkene includes, for example, cyclopentene, cyclohexene, etc. Polycyclic cycloalkene includes norbornene, indene, etc.
[0036]
The term "cycloalkenyl" includes a monovalent group derived from "cycloalkene"
as defined above. Monocyclic cycloalkenyl includes cyclopentenyl, cyclohexenyl, etc. As one embodiment, C3 to C8 cycloalkyl is exemplified. As another embodiment, C3 to C7 cycloalkyl is exemplified. Polycyclic cycloalkenyl includes norbornenyl, indene-1-yl, indene-2-yl, indene-3-yl, etc.
[0037]
The cycloalkenyl moiety in said "cycloalkenyloxycarbonyl" and "cyclolalkenyloxy" is as defined above for "cycloalkenyl".
[0038]
The term "aromatic carbocyclic ring" includes an aromatic hydrocarbocyclic ring which is monocyclic or fused-cyclic, such as benzene, naphthalene, anthracene, phenanthrene, etc.
[0039]
The term "aryl" includes a monovalent group derived from "aromatic carbocyclic ring" as defined above. For example, phenyl, 1-naphthyl, 2-naphthyl, anthryl, phenanthryl, etc. are exemplified.
Preferable "aryl" for R2 is phenyl.
[0040]
The aryl moiety in said "aryloxy", "arylthio" and "aryloxycarbonyl" is as defined above for "aryl".
[0041]
The term "heterocyclic ring" includes an aromatic or a non-aromatic monocyclic or fused-cyclic ring, which includes a five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused ring consisting of two or more said five- to seven-membered rings; or a fused ring consisting of said five- to seven-membered ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring", "cycloalkane" or "cycloalkene" as defined above.
Date Recue/Date Received 2020-11-26 For example, a monocyclic non-aromatic heterocyclic ring such as pyrroline, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, tetrahydropyrane, dihydropyridine, dihydropyridazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazole, tetrahydroisothiazole, etc.;
a monocyclic aromatic heterocyclic ring such as pyrrole, pyrazine, pyrazole, tetrazole, furan, thiophene, pyridine, imidazole, triazole, tetrazole, triazine, pyridazine, pyrimidine, isoxazole, thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a fused heterocyclic ring such as indole, isoindole, indazole, indolizine, indoline, isoindoline, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, purine, pteridine, benzopyrane, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, benzimidazole, benzodioxane, tetrahydroquinoline, tetrahydrobenzothiophene, etc. are exemplified.
[0042]
The term "heterocyclic group" includes a monovalent group derived from "heterocyclic ring" as defined above.
For example, monocyclic non-aromatic heterocyclic groups such as pyrrolinyl, pyrrolidino, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydroisothiazolinyl, etc.;
monocyclic aromatic heterocyclic groups such as pyrrolyl, pyrazinyl, pyrazolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, etc; and fused heterocyclic groups such as indolyl, isoindolyl, indazolyl, indolizinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, benzimidazolinyl, benzodioxanyl, tetrahydroquinoline, tetrahydrobenzothienyl, etc. are exemplified.
[0043]
The term "non-aromatic carbocyclic ring" includes "cycloalkane" as defined above, "cycloalkene" as defined above, a fused ring consisting of "aromatic carbocyclic ring" as defined above fused to "cycloalkane" or "cycloalkene" as defined above. As a fused ring, indene and the like are exemplified.
[0044]
The term "non-aromatic carbocyclic group" includes a monovalent group derived from "non-aromatic carbocyclic ring" as defined above. For example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopentenyl, cyclohexenyl, norbornyl, tetrahydronaphthalene-5-yl, tetrahydronaphthalene-6-yl, norbornenyl, inden-l-yl, inden-2-yl, inden-3-y1 and the like are exemplified.
[0045]
The non-aromatic carbocyclyl moiety in said "non-aromatic carbocyclyloxy" and "non-aromatic carbocyclylalkyloxy" is as defined above for "non-aromatic carbocyclic Date Recue/Date Received 2020-11-26 ring".
The non-aromatic carbocyclyl moiety in said "non-aromatic carbocyclyloxy" and "non-aromatic carbocyclylalkyloxy" is as defined above for "non-aromatic carbocyclic Date Recue/Date Received 2020-11-26 ring".
[0046]
The term "aromatic heterocyclic ring" includes aromatic rings of "heterocyclic ring" as defined above.
"Aromatic heterocyclic ring" includes a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused aromatic ring consisting of two or more said rings; and a fused ring consisting of a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" as defined above.
For example, a monocyclic aromatic heterocyclic ring such as pyrazine, pyrazole, tetrazole, furan, thiophene, pyridine, imidazole, triazole, triazine, pyridazine, pyrimidine, pyrazine, isoxazole, thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a fused aromatic heterocyclic ring such as indole, isoindole, indazole, indolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, purine, pteridine, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, benzimidazoline, etc. are exemplified.
The term "aromatic heterocyclic ring" includes aromatic rings of "heterocyclic ring" as defined above.
"Aromatic heterocyclic ring" includes a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused aromatic ring consisting of two or more said rings; and a fused ring consisting of a five- to seven-membered aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" as defined above.
For example, a monocyclic aromatic heterocyclic ring such as pyrazine, pyrazole, tetrazole, furan, thiophene, pyridine, imidazole, triazole, triazine, pyridazine, pyrimidine, pyrazine, isoxazole, thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, etc; and a fused aromatic heterocyclic ring such as indole, isoindole, indazole, indolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, naphthyridine, quinoxaline, purine, pteridine, benzimidazole, benzisoxazole, benzoxazole, benzoxadiazole, benzisothiazole, benzothiazole, benzothiadiazole, benzofuran, isobenzofuran, benzothiophene, benzotriazole, imidazopyridine, triazolopyridine, imidazothiazole, pyrazinopyridazine, benzimidazoline, etc. are exemplified.
[0047]
The term "heteroaryl" includes a monovalent group derived from "aromatic heterocyclic ring" as defined above. "Heteroaryl" includes a five- to seven-membered aromatic group having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused aromatic group consisting of two or more said rings; and a fused ring consisting of a five- to seven-membered aromatic group having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" as defined above.
For example, monocyclic heteroaryl such as pyrrolyl, pyrazinyl, pyrazolyl, indolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, etc; and fused heteroaryl such as isoindolyl, indazolyl, indolizinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, benzimidazolinyl, etc. are exemplified.
The term "heteroaryl" includes a monovalent group derived from "aromatic heterocyclic ring" as defined above. "Heteroaryl" includes a five- to seven-membered aromatic group having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused aromatic group consisting of two or more said rings; and a fused ring consisting of a five- to seven-membered aromatic group having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" as defined above.
For example, monocyclic heteroaryl such as pyrrolyl, pyrazinyl, pyrazolyl, indolyl, tetrazolyl, furyl, thienyl, pyridyl, imidazolyl, triazolyl, tetrazolyl, triazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, etc; and fused heteroaryl such as isoindolyl, indazolyl, indolizinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, benzimidazolinyl, etc. are exemplified.
[0048]
One of examples of "heteroaryl" for R2 is pyridyl.
One of examples of "heteroaryl" for R2 is pyridyl.
[0049]
The heteroaryl moiety in said "heteroaryloxy" and "heteroaryloxycarbonyl" is as defined above for "heteroaryl".
The heteroaryl moiety in said "heteroaryloxy" and "heteroaryloxycarbonyl" is as defined above for "heteroaryl".
[0050]
The term "non-aromatic heterocyclic ring" includes non-aromatic rings of "heterocyclic ring" as defined above.
"Non-aromatic heterocyclic ring" includes, a four- to seven-membered non-aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused non-aromatic ring consisting of two or more said rings;
a fused ring consisting of a five- to seven-membered aromatic ring having at least one Date Recue/Date Received 2020-11-26 nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "cycloalkane" or "cycloalkene" as defined above; and a fused ring consisting of a five- to seven-membered non-aromatic heterocyclic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" or "non-aromatic carbocyclic ring" as defined above.
For example, monocyclic non-aromatic heterocyclic ring such as oxetane, thietane, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine, tetrahydropyran, for example, 2-tetrahydropyran, 3-tetrahydropyran, 4-tetrahydropyran, dihydropyridine, dihydropyridazine, dihydropyrazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazoline, tetrahydroisothiazoline etc.;
a fused non-aromatic heterocyclic ring such as indoline, isoindoline, benzopyrane, benzodioxane, tetrahydroquinoline, benzo[d]oxazole-2(3H)-one, tetrahydrobenzothiophene etc. are exemplified.
The term "non-aromatic heterocyclic ring" includes non-aromatic rings of "heterocyclic ring" as defined above.
"Non-aromatic heterocyclic ring" includes, a four- to seven-membered non-aromatic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a fused non-aromatic ring consisting of two or more said rings;
a fused ring consisting of a five- to seven-membered aromatic ring having at least one Date Recue/Date Received 2020-11-26 nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "cycloalkane" or "cycloalkene" as defined above; and a fused ring consisting of a five- to seven-membered non-aromatic heterocyclic ring having at least one nitrogen atom, oxygen atom, and/or sulfur atom in the ring fused to one or more "aromatic carbocyclic ring" or "non-aromatic carbocyclic ring" as defined above.
For example, monocyclic non-aromatic heterocyclic ring such as oxetane, thietane, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, piperidine, piperazine, morpholine, thiomorpholine, thiomorpholine, tetrahydropyran, for example, 2-tetrahydropyran, 3-tetrahydropyran, 4-tetrahydropyran, dihydropyridine, dihydropyridazine, dihydropyrazine, dioxane, oxathiolane, thiane, tetrahydrofuran, tetrahydropyran, tetrahydrothiazoline, tetrahydroisothiazoline etc.;
a fused non-aromatic heterocyclic ring such as indoline, isoindoline, benzopyrane, benzodioxane, tetrahydroquinoline, benzo[d]oxazole-2(3H)-one, tetrahydrobenzothiophene etc. are exemplified.
[0051]
"Non-aromatic heterocyclic group" includes a monovalent group derived from "non-aromatic heterocyclic ring" as defined above.
Examples are monocyclic non-aromatic heterocyclic group such as pyrrolinyl, pyrrolidino, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydroisothiazolinyl etc. and a fused heterocyclic group such as benzodioxane, tetrahydroquinoline, benzo[d]oxazole-2(3H)-one, tetrahydfobenzothiophene etc.
"Non-aromatic heterocyclic group" includes a monovalent group derived from "non-aromatic heterocyclic ring" as defined above.
Examples are monocyclic non-aromatic heterocyclic group such as pyrrolinyl, pyrrolidino, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydropyranyl, dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl, dioxanyl, oxathiolanyl, thianyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolinyl, tetrahydroisothiazolinyl etc. and a fused heterocyclic group such as benzodioxane, tetrahydroquinoline, benzo[d]oxazole-2(3H)-one, tetrahydfobenzothiophene etc.
[0052]
The non-aromatic heterocyclyl moiety in said "non-aromatic heterocyclyloxy"
and "non-aromatic heterocyclyloxycarbonyl" is as defined above for "non-aromatic heterocyclic ring".
The non-aromatic heterocyclyl moiety in said "non-aromatic heterocyclyloxy"
and "non-aromatic heterocyclyloxycarbonyl" is as defined above for "non-aromatic heterocyclic ring".
[0053]
The term "nitrogen-containing non-aromatic heterocyclic group" includes a group derived from a four- to seven-membered non-aromatic ring which contains at least one nitrogen atom in the ring and may contain one or more atoms arbitrarily selected from an oxygen atom and a sulfur atom in the ring, or a fused ring consisting of two or more said rings. Examples are pyrrolinyl, pyrrolidino, pyrrolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholino etc.
The term "nitrogen-containing non-aromatic heterocyclic group" includes a group derived from a four- to seven-membered non-aromatic ring which contains at least one nitrogen atom in the ring and may contain one or more atoms arbitrarily selected from an oxygen atom and a sulfur atom in the ring, or a fused ring consisting of two or more said rings. Examples are pyrrolinyl, pyrrolidino, pyrrolidinyl, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino, thiomorpholino etc.
[0054]
The non-aromatic heterocyclyl moiety in said "non-aromatic heterocyclyloxycarbonyl" is as defined above for "non-aromatic heterocyclic ring".
The non-aromatic heterocyclyl moiety in said "non-aromatic heterocyclyloxycarbonyl" is as defined above for "non-aromatic heterocyclic ring".
[0055]
Substituents for "substituted alkyl", "substituted alkenyl", "substituted alkynyl", "substituted alkyloxy", "substituted alkenyloxy", "substituted alkynyloxy", "substituted alkylthio", "substituted alkenylthio", "substituted alkynylthio", "substituted alkyloxycarbonyl", "substituted alkenyloxycarbonyl", "substituted alkynyloxycarbonyl"
and "substituted alkylcarbamoyl" include but are not limited to one or more same or different substituents selected from the group consisting of:
hydroxy, carboxy, halogen (F, Cl, Br, I), haloalkyloxy (e.g., CF30), cycloalkyl (e.g., Date Recue/Date Received 2020-11-26 cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, alkylsulfonylamino (e.g., methanesulfonylamino), alkylsulfinylamino (e.g., methanesulfinylamino), non-aromatic heterocyclylamino (e.g. 4-tetrahydropyranylamino etc.) imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino, etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino, etc.), acylimino (e.g., acetylimino, benzoylimino, etc.), azido, aryl (e.g., phenyl, etc.), arylalkyl (e.g., benzyl, phenylethyl etc.), arylalkyloxy (e.g., benzyloxy), a non-aromatic heterocyclic group (e.g., pyrrolinyl, piperidyl, piperazinopyrrolidino, pyrrolidinyl, morpholinyl, morpholino , 2,2-dimethyl-1,3-dioxopyranyl etc.), heteroaryl (e.g., furyl, thienyl, pyridyl, isoxazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, tetrazolyl, indolyl, benzofuryl etc.), heteroarylalkyl (e.g., pyridylmethyl, pyridylethyl etc.), cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio, etc.), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, etc.), sulfamoyl, alkylsulfamoyl, acyl (e.g., formyl, acetyl, etc.), formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazino, azido, ureido, amidino, guanidino, phthalimido, tri-alkylsilyl (e.g., trimethylsilyl, etc.), hydroxyalkylcarbamoyl (hydroxyethylcarbamoyl, etc.), tetrahydropyranyloxy, carbamoylamino, alkylcarbamoylamino (e.g., methylcarbamoylamino, etc.), haloalkylcarbamoyl (e.g., trifluoroethylcarbamoyl, etc.), alkyloxyalkyloxy (e.g., methyloxymethyloxy, etc.), carbamoylcarbamoyl, alkylsulfonylcarbamoyl (e.g., methanesulfonylcarbamoyl) and oxo.
Substituents for "substituted alkyl", "substituted alkenyl", "substituted alkynyl", "substituted alkyloxy", "substituted alkenyloxy", "substituted alkynyloxy", "substituted alkylthio", "substituted alkenylthio", "substituted alkynylthio", "substituted alkyloxycarbonyl", "substituted alkenyloxycarbonyl", "substituted alkynyloxycarbonyl"
and "substituted alkylcarbamoyl" include but are not limited to one or more same or different substituents selected from the group consisting of:
hydroxy, carboxy, halogen (F, Cl, Br, I), haloalkyloxy (e.g., CF30), cycloalkyl (e.g., Date Recue/Date Received 2020-11-26 cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, alkylsulfonylamino (e.g., methanesulfonylamino), alkylsulfinylamino (e.g., methanesulfinylamino), non-aromatic heterocyclylamino (e.g. 4-tetrahydropyranylamino etc.) imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino, etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino, etc.), acylimino (e.g., acetylimino, benzoylimino, etc.), azido, aryl (e.g., phenyl, etc.), arylalkyl (e.g., benzyl, phenylethyl etc.), arylalkyloxy (e.g., benzyloxy), a non-aromatic heterocyclic group (e.g., pyrrolinyl, piperidyl, piperazinopyrrolidino, pyrrolidinyl, morpholinyl, morpholino , 2,2-dimethyl-1,3-dioxopyranyl etc.), heteroaryl (e.g., furyl, thienyl, pyridyl, isoxazolyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, tetrazolyl, indolyl, benzofuryl etc.), heteroarylalkyl (e.g., pyridylmethyl, pyridylethyl etc.), cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio, etc.), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, etc.), sulfamoyl, alkylsulfamoyl, acyl (e.g., formyl, acetyl, etc.), formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazino, azido, ureido, amidino, guanidino, phthalimido, tri-alkylsilyl (e.g., trimethylsilyl, etc.), hydroxyalkylcarbamoyl (hydroxyethylcarbamoyl, etc.), tetrahydropyranyloxy, carbamoylamino, alkylcarbamoylamino (e.g., methylcarbamoylamino, etc.), haloalkylcarbamoyl (e.g., trifluoroethylcarbamoyl, etc.), alkyloxyalkyloxy (e.g., methyloxymethyloxy, etc.), carbamoylcarbamoyl, alkylsulfonylcarbamoyl (e.g., methanesulfonylcarbamoyl) and oxo.
[0056]
Substituents for "substituted acyl" are selected from the substituents as defined above for "substituted alkyl", the above "alkyl", the above "alkenyl" and the above "alkynyl". If R in acyl (R-C(=0)-) is "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl", or "heteroaryl", then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.), haloalkyl (e.g., CF3, CH2CF3, CH2CC13, etc.), alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like.
Substituents for "substituted acyl" are selected from the substituents as defined above for "substituted alkyl", the above "alkyl", the above "alkenyl" and the above "alkynyl". If R in acyl (R-C(=0)-) is "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl", or "heteroaryl", then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.), haloalkyl (e.g., CF3, CH2CF3, CH2CC13, etc.), alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like.
[0057]
Substituents for "substituted carbamoyl" or "substituted sulfamoyl" are one or more same or different groups selected from, but are not limited to, the group consisting of:
hydroxy, carboxy, carboxyalkyl (e.g., carboxymethyl, carboxyethyl etc.), halogen (F, Cl, Br, I), alkyl (e.g., methyl, ethyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), alkyloxycarbonylalkyl (e.g., methoxycarbonylmethyl, ethoxycarbonylmethyl etc.), amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, aryl (e.g., phenyl, etc.), a non-aromatic heterocyclic group (e.g., 4-tetrahydropyranyl etc.), heteroaryl (e.g., pyridyl etc.), cyano, isocyano, isocyanato, thiocyanato, isothiocyanato and acyl (e.g., formyl, acetyl, etc.).
Substituents for "substituted carbamoyl" or "substituted sulfamoyl" are one or more same or different groups selected from, but are not limited to, the group consisting of:
hydroxy, carboxy, carboxyalkyl (e.g., carboxymethyl, carboxyethyl etc.), halogen (F, Cl, Br, I), alkyl (e.g., methyl, ethyl), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), alkyloxycarbonylalkyl (e.g., methoxycarbonylmethyl, ethoxycarbonylmethyl etc.), amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, aryl (e.g., phenyl, etc.), a non-aromatic heterocyclic group (e.g., 4-tetrahydropyranyl etc.), heteroaryl (e.g., pyridyl etc.), cyano, isocyano, isocyanato, thiocyanato, isothiocyanato and acyl (e.g., formyl, acetyl, etc.).
[0058]
Substituents for "substituted sulfonyl" or "substituted sulfinyl" are selected from the above "substituted or unsubstituted alkyl", the above "substituted or Date Recue/Date Received 2020-11-26 unsubstituted alkenyl", the above "substituted or unsubstituted alkynyl", the after-mentioned "substituted or unsubstituted cycloalkyl", the after-mentioned "substituted or unsubstituted cycloalkenyl", the after-mentioned "a substituted or unsubstituted non-aromatic heterocyclic group", the after-mentioned "substituted or unsubstituted aryl", and the after-mentioned "substituted or unsubstituted heteroaryl". If R in R-S(=0)2- or RS(0) - is "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl", "heteroaryl" or the like, then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.), haloalkyl (e.g., CF3, CH2CF3, CH2CC13, etc.), alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like.
Substituents for "substituted sulfonyl" or "substituted sulfinyl" are selected from the above "substituted or unsubstituted alkyl", the above "substituted or Date Recue/Date Received 2020-11-26 unsubstituted alkenyl", the above "substituted or unsubstituted alkynyl", the after-mentioned "substituted or unsubstituted cycloalkyl", the after-mentioned "substituted or unsubstituted cycloalkenyl", the after-mentioned "a substituted or unsubstituted non-aromatic heterocyclic group", the after-mentioned "substituted or unsubstituted aryl", and the after-mentioned "substituted or unsubstituted heteroaryl". If R in R-S(=0)2- or RS(0) - is "cycloalkyl", "cycloalkenyl", "non-aromatic heterocyclic group", "aryl", "heteroaryl" or the like, then each ring may be substituted with alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl, etc.), haloalkyl (e.g., CF3, CH2CF3, CH2CC13, etc.), alkenyl, alkynyl (e.g., ethynyl), alkyloxy (e.g., methoxy, ethoxy, isopropyloxy), halogen (e.g., fluoro, chloro etc.) or the like.
[0059]
Substituents for "substituted amino", "substituted imino" and "substituted guanidyl" are one or more same or different groups selected from, but are not limited to, the group consisting of:
alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl (e.g., CF3, CH2CF3, CH2CC13, etc.), hydroxyalkyl (e.g., hydroxyethyl, -C(CH3)2CH2OH, etc.), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), haloalkyloxy (e.g., CF30), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (methoxycarbonyl, tert -butyloxycarbonyl, etc.), alkyloxycarbonylalkyl, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino, etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino, etc.), acylimino (e.g., acetylimino, benzoylimino, etc.), aryl (e.g., phenyl, etc.), arylalkyl (e.g., benzyl, etc.), aryloxy (e.g., phenoxy etc.), a non-aromatic heterocyclic group (e.g., pyrrolinyl, pyrrolidino, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g., pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g., pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.), non-aromatic heterocyclyloxy (pipierazinooxy, piperidinooxy etc.), heteroaryloxy (pyridyloxy etc.), hydroxy, halogen,(F, Cl, Br, I), cyano, acyl (e.g., formyl, acetyl, etc.), non-aromatic heterocyclicylcarbonyl (e.g., 4-tetrahydropyranylcarbonyl etc.), alkylsulfonyl (e.g., methanesulfonyl etc.), non-aromatic heterocyclicylsulfonyl (e.g., 4-tetrahydropyranylsulfonyl etc.), alkylsulfinyl (e.g., methansulfinyl), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl, alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl (e.g., methylsulfamoylmethyl etc.), and sulfamoylalkyl (e.g, sulfamoylmethyl etc.).
Substituents for "substituted amino", "substituted imino" and "substituted guanidyl" are one or more same or different groups selected from, but are not limited to, the group consisting of:
alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl (e.g., CF3, CH2CF3, CH2CC13, etc.), hydroxyalkyl (e.g., hydroxyethyl, -C(CH3)2CH2OH, etc.), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), haloalkyloxy (e.g., CF30), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (methoxycarbonyl, tert -butyloxycarbonyl, etc.), alkyloxycarbonylalkyl, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino, etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino, etc.), acylimino (e.g., acetylimino, benzoylimino, etc.), aryl (e.g., phenyl, etc.), arylalkyl (e.g., benzyl, etc.), aryloxy (e.g., phenoxy etc.), a non-aromatic heterocyclic group (e.g., pyrrolinyl, pyrrolidino, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g., pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g., pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.), non-aromatic heterocyclyloxy (pipierazinooxy, piperidinooxy etc.), heteroaryloxy (pyridyloxy etc.), hydroxy, halogen,(F, Cl, Br, I), cyano, acyl (e.g., formyl, acetyl, etc.), non-aromatic heterocyclicylcarbonyl (e.g., 4-tetrahydropyranylcarbonyl etc.), alkylsulfonyl (e.g., methanesulfonyl etc.), non-aromatic heterocyclicylsulfonyl (e.g., 4-tetrahydropyranylsulfonyl etc.), alkylsulfinyl (e.g., methansulfinyl), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl, alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl (e.g., methylsulfamoylmethyl etc.), and sulfamoylalkyl (e.g, sulfamoylmethyl etc.).
[0060]
Substituents for "substituted cycloalkyl", "substituted cycloalkenyl", "substituted aryl", "substituted phenyl", "a substituted heterocyclic group", "substituted heteroaryl", "a substituted non-aromatic carbocyclic group", "a substituted non-aromatic heterocyclic group", "a substituted nitrogen-containing non-aromatic heterocyclic group", "substituted cycloalkyloxycarbonyl", "substituted cycloalkyenyloxycarbonyl", "substituted non-aromatic heterocyclyloxycarbonyl", "substituted aryloxycarbonyl", "substituted heteroaryloxycarbonyl", "a substituted cyclopropane ring", "a substituted cyclopropene ring", "a substituted oxetane ring", "a substituted thietane ring" and "a substituted azetizine ring" are one or more same or different groups selected from, but are not limited to, the group consisting of:
alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl (e.g., CF3, CH2CF3, Date Recue/Date Received 2020-11-26 CH2CC13, etc.), haloalkyloxy (e.g., CF30, CHCF20 etc.), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, amino substituted with one or two same or different substituent selected from the after-mentioned substituent Group Y, imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino etc.), acylimino (e.g., acetylimino, benzoylimino etc.), azido, aryl (e.g., phenyl etc.), arylalkyl (e.g., benzyl etc.), unsubstituted non-aromatic carbocyclyloxy (e.g., cyclopropyloxy etc.), non-aromatic carbocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted non-aromatic carbocyclylalkyloxy (e.g., cyclopropylmethyloxy etc.), non-aromatic carbocyclylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted aryloxy (e.g., phenoxy etc.), aryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted arylalkyloxy (e.g., benzyloxy etc.), arylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, a non-aromatic heterocyclic group (e.g., pyrrolinyl, pyrrolidino, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g., pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g., pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.), unsubstituted non-aromatic heterocyclyloxy (e.g., piperazinooxy, piperizinooxy etc.), non-aromatic heterocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted heteroaryloxy (e.g., pyridyloxy, pyridazinyloxy, pyrimidinyloxy, pyrazinyloxy, oxazolyloxy, isoxazolyloxy, oxadiazolyloxy, thiazolyloxy, isothiazolyloxy, thiadiazolyloxy, furyloxy, thienyloxy, etc.), heteroaryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio etc.), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), substituted or unsubstituted carbamoyl (e.g., carbamoyl, N-methyl -N-methoxycarbamoyl etc.), substituted or unsubstituted alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, hydroxyethylcarbamoyl, trifluoromethylcarbamoyl, trifluoroethylcarbamoyl etc.), sulfamoyl, alkylsulfamoyl, hydroxy, carboxy, halogen (F, Cl, Br, I), acyl (e.g., formyl, acetyl etc.), formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazino, azido, ureido, amidino, guanidino, phthalimido and oxo.
Substituents for "substituted cycloalkyl", "substituted cycloalkenyl", "substituted aryl", "substituted phenyl", "a substituted heterocyclic group", "substituted heteroaryl", "a substituted non-aromatic carbocyclic group", "a substituted non-aromatic heterocyclic group", "a substituted nitrogen-containing non-aromatic heterocyclic group", "substituted cycloalkyloxycarbonyl", "substituted cycloalkyenyloxycarbonyl", "substituted non-aromatic heterocyclyloxycarbonyl", "substituted aryloxycarbonyl", "substituted heteroaryloxycarbonyl", "a substituted cyclopropane ring", "a substituted cyclopropene ring", "a substituted oxetane ring", "a substituted thietane ring" and "a substituted azetizine ring" are one or more same or different groups selected from, but are not limited to, the group consisting of:
alkyl (e.g., methyl, ethyl, isopropyl, tert-butyl etc.), haloalkyl (e.g., CF3, CH2CF3, Date Recue/Date Received 2020-11-26 CH2CC13, etc.), haloalkyloxy (e.g., CF30, CHCF20 etc.), alkenyl (e.g., vinyl), alkynyl (e.g., ethynyl), cycloalkyl (e.g., cyclopropyl), cycloalkenyl (e.g., cyclopropenyl), alkyloxy (e.g., methoxy, ethoxy, propoxy, butoxy, etc.), alkenyloxy (e.g., vinyloxy, allyloxy, etc.), alkyloxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), nitro, nitroso, amino, alkylamino (e.g., methylamino, ethylamino, dimethylamino, etc.), acylamino (e.g., acetylamino, benzoylamino, etc.), arylalkylamino (e.g., benzylamino, tritylamino), hydroxyamino, amino substituted with one or two same or different substituent selected from the after-mentioned substituent Group Y, imino, hydroxyimino, alkylimino (e.g., methylimino, ethylimino, dimethylimino etc.), alkyloxyimino (e.g., methoxyimino, ethoxyimino etc.), acylimino (e.g., acetylimino, benzoylimino etc.), azido, aryl (e.g., phenyl etc.), arylalkyl (e.g., benzyl etc.), unsubstituted non-aromatic carbocyclyloxy (e.g., cyclopropyloxy etc.), non-aromatic carbocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted non-aromatic carbocyclylalkyloxy (e.g., cyclopropylmethyloxy etc.), non-aromatic carbocyclylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted aryloxy (e.g., phenoxy etc.), aryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted arylalkyloxy (e.g., benzyloxy etc.), arylalkyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, a non-aromatic heterocyclic group (e.g., pyrrolinyl, pyrrolidino, piperidino, piperidyl, piperazino, piperazinyl, morpholinyl, morpholino etc.), heteroaryl (e.g., pyridyl, thienyl, thiazolyl, furyl etc.), heteroarylalkyl (e.g., pyridylmethyl, thienylmethyl, thiazolylmethyl, furylmethyl etc.), unsubstituted non-aromatic heterocyclyloxy (e.g., piperazinooxy, piperizinooxy etc.), non-aromatic heterocyclyloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, unsubstituted heteroaryloxy (e.g., pyridyloxy, pyridazinyloxy, pyrimidinyloxy, pyrazinyloxy, oxazolyloxy, isoxazolyloxy, oxadiazolyloxy, thiazolyloxy, isothiazolyloxy, thiadiazolyloxy, furyloxy, thienyloxy, etc.), heteroaryloxy substituted with one or more same or different substituents selected from the after-mentioned Substituent Group Z, cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio (e.g., methylthio etc.), alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl), substituted or unsubstituted carbamoyl (e.g., carbamoyl, N-methyl -N-methoxycarbamoyl etc.), substituted or unsubstituted alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, hydroxyethylcarbamoyl, trifluoromethylcarbamoyl, trifluoroethylcarbamoyl etc.), sulfamoyl, alkylsulfamoyl, hydroxy, carboxy, halogen (F, Cl, Br, I), acyl (e.g., formyl, acetyl etc.), formyloxy, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, hydrazino, azido, ureido, amidino, guanidino, phthalimido and oxo.
[0061]
A substituent Group Y includes hydroxyalkyl (e.g., hydroxyethyl, -C(CH3)2CH2OH etc.), alkyloxycarbonyl (methoxycarbonyl, tert-butyloxycarbonyl etc.), alkyloxycarbonylalkyl, alkylsulfonyl (e.g., methanesulfonyl etc.), alkylsulfinyl (e.g., methanesulfinyl etc.), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl, alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl (e.g., methylsulfamoylmethyl etc.) and sulfamoylalkyl (e.g., sulfamoylmethyl etc.).
A substituent Group Z includes halogen (e.g., F, Cl etc.), hydroxy, carboxy, carboxyalkyloxy (e.g., carboxymethyloxy etc.), cyano, nitro, alkyl (e.g., methyl etc.), Date Recue/Date Received 2020-11-26 hydroxyalkyl (e.g., hydroxymethyl etc.), aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, acyl, alkyloxycarbonyl (e.g., methyloxycarbonyl, ethyloxycarbonyl etc.), alkenyloxycarbonyl, alkynyloxycarbonyl, carbamoyl, carbamoylalkyloxy (e.g., carbamoylmethyloxy etc.), alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl etc.), haloalkylcarbamoyl, cycloalkylcarbamoyl (e.g., cyclopropylcarbamoyl etc), alkylcarbamoylalkyloxy (e.g., methylcarbamoylmethyloxy etc), hydroxyalkylcarbamoyl (e.g., hydroxyethylcarbamoyl etc), cyanocarbamoyl, amino, acylamino, amino substituted with one or two same or different substituent selected from the above substituent Group Y, sulfamoyl, methylsulfonyl, methylsulfinyl, cycloalkyl, cycloalkenyl, a non-aromatic heterocyclic group, aryl, heteroaryl (e.g., tetrazolyl etc), cycloalkyloxy, cycloalkenyloxy, non-aromatic heterocyclyloxy, aryloxy heteroaryloxy and oxo.
A substituent Group Y includes hydroxyalkyl (e.g., hydroxyethyl, -C(CH3)2CH2OH etc.), alkyloxycarbonyl (methoxycarbonyl, tert-butyloxycarbonyl etc.), alkyloxycarbonylalkyl, alkylsulfonyl (e.g., methanesulfonyl etc.), alkylsulfinyl (e.g., methanesulfinyl etc.), carbamoyl, alkylcarbamoyl (e.g., methylcarbamoyl etc.), alkylcarbamoylalkyl (e.g., methylcarbamoylmethyl etc.), carbamoylalkyl (e.g., carbamoylmethyl etc.), carboxyalkyl (e.g., carboxymethyl etc.), sulfamoyl, alkylsulfamoyl (e.g., methylsulfamoyl etc.), alkylsulfamoylalkyl (e.g., methylsulfamoylmethyl etc.) and sulfamoylalkyl (e.g., sulfamoylmethyl etc.).
A substituent Group Z includes halogen (e.g., F, Cl etc.), hydroxy, carboxy, carboxyalkyloxy (e.g., carboxymethyloxy etc.), cyano, nitro, alkyl (e.g., methyl etc.), Date Recue/Date Received 2020-11-26 hydroxyalkyl (e.g., hydroxymethyl etc.), aminoalkyl, alkylaminoalkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy, alkynyloxy, alkylthio, alkenylthio, alkynylthio, acyl, alkyloxycarbonyl (e.g., methyloxycarbonyl, ethyloxycarbonyl etc.), alkenyloxycarbonyl, alkynyloxycarbonyl, carbamoyl, carbamoylalkyloxy (e.g., carbamoylmethyloxy etc.), alkylcarbamoyl (e.g., methylcarbamoyl, ethylcarbamoyl etc.), haloalkylcarbamoyl, cycloalkylcarbamoyl (e.g., cyclopropylcarbamoyl etc), alkylcarbamoylalkyloxy (e.g., methylcarbamoylmethyloxy etc), hydroxyalkylcarbamoyl (e.g., hydroxyethylcarbamoyl etc), cyanocarbamoyl, amino, acylamino, amino substituted with one or two same or different substituent selected from the above substituent Group Y, sulfamoyl, methylsulfonyl, methylsulfinyl, cycloalkyl, cycloalkenyl, a non-aromatic heterocyclic group, aryl, heteroaryl (e.g., tetrazolyl etc), cycloalkyloxy, cycloalkenyloxy, non-aromatic heterocyclyloxy, aryloxy heteroaryloxy and oxo.
[0062]
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, halogen, alkyl, alkenyl, alkynyl, alkyloxy, haloalkyl, cycloalkyl, alkylsilylalkynyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, alkyl, haloalkyl, and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for 112, halogen and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, halogen, alkyl, alkenyl, alkynyl, alkyloxy, haloalkyl, cycloalkyl, alkylsilylalkynyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, alkyl, haloalkyl, and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for 112, halogen and the like are exemplified.
[0063]
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, isopropyl, propenyl, vinyl, ethynyl, methyloxy, fluoromethyl, difluoromethyl, trifluoromethyl, cyclopropyl, trimethylsilylethynyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, isopropyl, propenyl, vinyl, ethynyl, methyloxy, fluoromethyl, difluoromethyl, trifluoromethyl, cyclopropyl, trimethylsilylethynyl and the like are exemplified.
[0064]
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, fluoro, chloro, methyl, fluoromethyl, difluoromethyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, fluoro, chloro, methyl, difluoromethyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, fluoro, chloro, methyl, fluoromethyl, difluoromethyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, fluoro, chloro, methyl, difluoromethyl and the like are exemplified.
[0065]
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, chloro, methyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, chloro, methyl and the like are exemplified.
[0066]
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, methyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, chloro and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, methyl and the like are exemplified.
As substituents for "substituted aryl" and "substituted heteroaryl" for R2, chloro and the like are exemplified.
[0067]
Examples of R2 are 4-methylphenyl, 4-chlorophenyl, 4-fluoromethyl, 4-difluoromethylphenyl, 2,4-difluorophenyl, 2,4-dichloromethyl, 4-methylcyclohexyl and the like.
Examples of R2 are 4-methylphenyl, 4-chlorophenyl, 2,4-difluorophenyl, 4-methylcyclohexyl and the like.
Examples of R2 are 4-methylphenyl, 4-chlorophenyl, 4-fluoromethyl, 4-difluoromethylphenyl, 2,4-difluorophenyl, 2,4-dichloromethyl, 4-methylcyclohexyl and the like.
Examples of R2 are 4-methylphenyl, 4-chlorophenyl, 2,4-difluorophenyl, 4-methylcyclohexyl and the like.
[0068]
Examples of R2 are 4-methylphenyl and the like.
Examples of R2 are 4-chlorophenyl and the like.
Examples of R2 are 4-methylphenyl and the like.
Examples of R2 are 4-chlorophenyl and the like.
[0069]
Examples of R9 are halogen, alkyl, haloalkyl, alkenyl, alkynyl and the like.
Examples of R9 are halogen, alkyl, haloalkyl, alkenyl, alkynyl and the like.
[0070]
Date Recue/Date Received 2020-11-26 Examples of R9 are fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, isopropyl and the like.
Date Recue/Date Received 2020-11-26 Examples of R9 are fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, isopropyl and the like.
[0071]
Examples of R9 are fluoro, chloro, methyl and the like.
Examples of R9 are fluoro, chloro, methyl and the like.
[0072]
Examples of R9' are halogen, carboxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted sulfonyl, or substituted or unsubstituted aryl, and the like.
Examples of R9' are halogen, carboxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aryl, and the like.
Examples of R9' are halogen, carboxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted acyl, substituted or unsubstituted alkyloxycarbonyl, substituted sulfonyl, or substituted or unsubstituted aryl, and the like.
Examples of R9' are halogen, carboxy, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted aryl, and the like.
[0073]
Examples of R9' are fluoro, chloro, bromo, iodo, carboxy, cyano, methyl, ethyl, propyl, isopropyl, hydroxymethyl, hydroxyethyl, methyloxymethyl, ethyloxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, formyl, acetyl, methyloxycarbonyl, ethyloxycarbonyl, methanesulfonyl, ethanesulfonyl, and the like.
Examples of IV are fluoro, chloro, bromo, iodo, carboxy, cyano, methyl, ethyl, propyl, isopropyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methyloxycarbonyl, ethyloxycarbonyl, and the like.
Examples of R9' are fluoro, chloro, bromo, iodo, carboxy, cyano, methyl, ethyl, propyl, isopropyl, hydroxymethyl, hydroxyethyl, methyloxymethyl, ethyloxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, formyl, acetyl, methyloxycarbonyl, ethyloxycarbonyl, methanesulfonyl, ethanesulfonyl, and the like.
Examples of IV are fluoro, chloro, bromo, iodo, carboxy, cyano, methyl, ethyl, propyl, isopropyl, hydroxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, ethyloxy, propyloxy, isopropyloxy, methyloxycarbonyl, ethyloxycarbonyl, and the like.
[0074]
Examples of R9' are fluoro, chloro, carboxy, cyano, methyl, ethyl, hydroxymethyl, hydroxyethyl, methyloxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, isopropyloxy, acetyl, methyloxycarbonyl, ethyloxycarbonyl, methanesulfonyl, and the like.
Examples of R9' are fluoro, chloro, carboxy, cyano, methyl, hydroxymethyl, trifluoromethyl, methyloxy, isopropyloxy, difluoromethyl, methyloxycarbonyl, ethyloxycarbonyl, and the like.
Examples of R9' are carboxy, hydroxymethyl, isopropyloxy, difluoromethyl, methyloxycarbonyl, ethyloxycarbonyl, and the like.
Examples of R9' are fluoro, chloro, carboxy, cyano, methyl, ethyl, hydroxymethyl, hydroxyethyl, methyloxymethyl, fluoromethyl, difluoromethyl, trifluoromethyl, methyloxy, isopropyloxy, acetyl, methyloxycarbonyl, ethyloxycarbonyl, methanesulfonyl, and the like.
Examples of R9' are fluoro, chloro, carboxy, cyano, methyl, hydroxymethyl, trifluoromethyl, methyloxy, isopropyloxy, difluoromethyl, methyloxycarbonyl, ethyloxycarbonyl, and the like.
Examples of R9' are carboxy, hydroxymethyl, isopropyloxy, difluoromethyl, methyloxycarbonyl, ethyloxycarbonyl, and the like.
[0075]
In Formula (I), "R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo" includes the followings:
Date Recue/Date Received 2020-11-26 (c(R4a)(R4b))n 7--,t1 R2 is 0 R4a R4b 0 R4a R4b 2 (%)1.X.k' R2 to R2 LaL-2.)-R
, R4a R4b 1 R4a R4b , R4a R4b R4b , R4a R4a R4a R48 R4b4b R4a R4b 0 R2 R4a R4b R4b RR 42 R4b R2 dr, L2L--4-1 % R2 til -S-1>i*L R2 R4a R4b 0 , OR R4b , , R4a R4a R4b 0 L,z,_30>cAR2 R4a R4b R4b R4a R4b R4b 4-52._ R4a R4b 0 , S R4a R4b S R4a R4b 2 (.4õ).--x-k.R2 <¨,_<-i, La<-:?_, , R4a R4b , Rila R4b , R4a R4b R4b , R4a R4a R4a R4a R4b R4b R4a R4b S
R4a R4b R4b R4a R4b R2 do S ' L-41 s R4a R4b, R4a R4b , S
R4a R4a R4b S
L2L-2P R4a R4b R4b R4a R4b R4b R4a , or R4a R4b S
wherein n, R4a, R4b and R2 are as defined in the above (1) or the like.
In Formula (I), "R4a and R4b attached to the same carbon atom are taken together to form oxo or thioxo" includes the followings:
Date Recue/Date Received 2020-11-26 (c(R4a)(R4b))n 7--,t1 R2 is 0 R4a R4b 0 R4a R4b 2 (%)1.X.k' R2 to R2 LaL-2.)-R
, R4a R4b 1 R4a R4b , R4a R4b R4b , R4a R4a R4a R48 R4b4b R4a R4b 0 R2 R4a R4b R4b RR 42 R4b R2 dr, L2L--4-1 % R2 til -S-1>i*L R2 R4a R4b 0 , OR R4b , , R4a R4a R4b 0 L,z,_30>cAR2 R4a R4b R4b R4a R4b R4b 4-52._ R4a R4b 0 , S R4a R4b S R4a R4b 2 (.4õ).--x-k.R2 <¨,_<-i, La<-:?_, , R4a R4b , Rila R4b , R4a R4b R4b , R4a R4a R4a R4a R4b R4b R4a R4b S
R4a R4b R4b R4a R4b R2 do S ' L-41 s R4a R4b, R4a R4b , S
R4a R4a R4b S
L2L-2P R4a R4b R4b R4a R4b R4b R4a , or R4a R4b S
wherein n, R4a, R4b and R2 are as defined in the above (1) or the like.
[0076]
Examples of the group represented by the following formula:
AF
I
(c(R4a)(R4b))n I
are groups represented by the following formula:
Date Recue/Date Received 2020-11-26 AF AF oRF AP M
S 0 F Se, F rel F , CI il CI , , , JiF AF Ac 0 F 1 Sz CI HOv or Examples of the group represented by the following formula:
AF
I
(c(R4a)(R4Nn I
are groups represented by the following formula:
AP ,PS AF
1101 OF 0 CI , ,, M M AF
le 0 F F, CI CI, or Ha
Examples of the group represented by the following formula:
AF
I
(c(R4a)(R4b))n I
are groups represented by the following formula:
Date Recue/Date Received 2020-11-26 AF AF oRF AP M
S 0 F Se, F rel F , CI il CI , , , JiF AF Ac 0 F 1 Sz CI HOv or Examples of the group represented by the following formula:
AF
I
(c(R4a)(R4Nn I
are groups represented by the following formula:
AP ,PS AF
1101 OF 0 CI , ,, M M AF
le 0 F F, CI CI, or Ha
[0077]
Examples of the group represented by the following formula:
AF
I
(c(R4a)(R4b))n I
are groups represented by the following formula:
d;:F AF ,PS
0 lei le CI\
, CI , F F , or
Examples of the group represented by the following formula:
AF
I
(c(R4a)(R4b))n I
are groups represented by the following formula:
d;:F AF ,PS
0 lei le CI\
, CI , F F , or
[0078]
Example of the group represented by the following formula:
Date Recue/Date Received 2020-11-26 (c(R4a)(R4Nn is a group represented by the following formula:
Example of the group represented by the following formula:
(c(R4a)(R4Nn is a group represented by the following formula:
Sc'
Example of the group represented by the following formula:
Date Recue/Date Received 2020-11-26 (c(R4a)(R4Nn is a group represented by the following formula:
Example of the group represented by the following formula:
(c(R4a)(R4Nn is a group represented by the following formula:
Sc'
[0079]
In Formula (I), "R20a and R2ob attached to the same carbon atom are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring"
includes the followings:
Date Recue/Date Received 2020-11-26 R20a R20b CO2R We X. *Ve CO2R13 `--/_.,CO2R13 u 13 iS
R20a R20a e R20b Ve R2 b Ve V
( COR13 CO2R13 CO2R13 ti-,-4 2 to dg--) R2 R20a R20b 0a R20b R20b R20a R20b R20a , R20a R20a R20a Ra)b R20a R20 R20b toR204:z20b R20b L, CO2R13 , CO2R13 )/*
Ve , b R20b , Ve Ve R20a R20b R20b R213a Ve R20a Ve R20 CO2R13 R204R20b R2ob tp CO2R13 L(2-3nR20a R20b Rath <21-) R20a R20b R20a R20a Ve , R2ob , , R20a R20a VVe We R2ob We R2ob L.c.,..S.A.,CO2R13 (-1/21 ti--, CO2R13 to R20a R20b R20a R20b R208 R20bR20b R20a , R20a R213a R20a R2C33 R20b R20a R20b R20b R204R.20b <21-) Lt6) CO2R13 t--) R20b W
We We We R20a R
R20b 20b We R20a We R20 R208 CO2R13 R20R20b R20b to CO2R13 4243PR20a R20b Rath CO2R13 R20a R20b R20a 3 5 or R20a We R2ob wherein u, R20a and R2ob are as defined in the above (1);
Ve is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 0);
-We- is -0-, -S- or -N(R17d)- (e.g., -0-);
R17dis a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl or the like.
In Formula (I), "R20a and R2ob attached to the same carbon atom are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring"
includes the followings:
Date Recue/Date Received 2020-11-26 R20a R20b CO2R We X. *Ve CO2R13 `--/_.,CO2R13 u 13 iS
R20a R20a e R20b Ve R2 b Ve V
( COR13 CO2R13 CO2R13 ti-,-4 2 to dg--) R2 R20a R20b 0a R20b R20b R20a R20b R20a , R20a R20a R20a Ra)b R20a R20 R20b toR204:z20b R20b L, CO2R13 , CO2R13 )/*
Ve , b R20b , Ve Ve R20a R20b R20b R213a Ve R20a Ve R20 CO2R13 R204R20b R2ob tp CO2R13 L(2-3nR20a R20b Rath <21-) R20a R20b R20a R20a Ve , R2ob , , R20a R20a VVe We R2ob We R2ob L.c.,..S.A.,CO2R13 (-1/21 ti--, CO2R13 to R20a R20b R20a R20b R208 R20bR20b R20a , R20a R213a R20a R2C33 R20b R20a R20b R20b R204R.20b <21-) Lt6) CO2R13 t--) R20b W
We We We R20a R
R20b 20b We R20a We R20 R208 CO2R13 R20R20b R20b to CO2R13 4243PR20a R20b Rath CO2R13 R20a R20b R20a 3 5 or R20a We R2ob wherein u, R20a and R2ob are as defined in the above (1);
Ve is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 0);
-We- is -0-, -S- or -N(R17d)- (e.g., -0-);
R17dis a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl or the like.
[0080]
Date Recue/Date Received 2020-11-26 In Formula (I), "1120a and Rmb attached to the different carbon atoms are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring"
includes the followings:
R20a R20b Y* CO2R ' 13 is _W
CO2R13 , _<(")>V2 u Wf Vf , -53-s-5-0\/2 45 Vf .
Rna Vf' R20a Wf R20b , R20b , Vf CO2R13 Vf CO2R13 Rzob Vf Rath Wf R20a R20a , , 45 Vf CO2R13 45 Vf CO2R13 R20a Rzob Rzob Wf Vf R20a R20a R20a R20b , or R20b wherein u, Rma and R2ob are as defined in the above (1);
Vf is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 1);
Vf is an integer of 1 to 3 (e.g., 1);
-Wf- is -0-, -S- or -N(111d7)- (e.g., -0-);
111-7d is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl or the like.
Date Recue/Date Received 2020-11-26 In Formula (I), "1120a and Rmb attached to the different carbon atoms are taken together to form substituted or unsubstituted cycloalkane, substituted or unsubstituted cycloalkene, or a substituted or unsubstituted non-aromatic heterocyclic ring"
includes the followings:
R20a R20b Y* CO2R ' 13 is _W
CO2R13 , _<(")>V2 u Wf Vf , -53-s-5-0\/2 45 Vf .
Rna Vf' R20a Wf R20b , R20b , Vf CO2R13 Vf CO2R13 Rzob Vf Rath Wf R20a R20a , , 45 Vf CO2R13 45 Vf CO2R13 R20a Rzob Rzob Wf Vf R20a R20a R20a R20b , or R20b wherein u, Rma and R2ob are as defined in the above (1);
Vf is an integer of 0 to 3 (e.g., 0 or 1, and e.g., 1);
Vf is an integer of 1 to 3 (e.g., 1);
-Wf- is -0-, -S- or -N(111d7)- (e.g., -0-);
111-7d is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acyl or the like.
[0081]
In Formula (I), the group represented by the following formula:
R20a R20b is the same as a group represented by the following formula:
Date Recue/Date Received 2020-11-26 R20a R20b a 430 u sfs.
wherein the bond a is attached to the nitrogen atom of the triazine ring, and the bond b is attached to the "C" atom of the "-0O2R13" group.
Examples of the group represented by the following formula:
R20a R20b s_Ss are groups represented by the following formula:
5"
11; Lt:4' OH , , or As described above, the above formulae are the same as groups represented by the following formula:
t '1 3 b _______ tnZ b OH
, or a wherein the bond a is attached to the nitrogen atom of the triazine ring, and the bond b is attached to the "C" atom of the "-0O2R13" group. The binding mode is the same also in the below formula.
In Formula (I), the group represented by the following formula:
R20a R20b is the same as a group represented by the following formula:
Date Recue/Date Received 2020-11-26 R20a R20b a 430 u sfs.
wherein the bond a is attached to the nitrogen atom of the triazine ring, and the bond b is attached to the "C" atom of the "-0O2R13" group.
Examples of the group represented by the following formula:
R20a R20b s_Ss are groups represented by the following formula:
5"
11; Lt:4' OH , , or As described above, the above formulae are the same as groups represented by the following formula:
t '1 3 b _______ tnZ b OH
, or a wherein the bond a is attached to the nitrogen atom of the triazine ring, and the bond b is attached to the "C" atom of the "-0O2R13" group. The binding mode is the same also in the below formula.
[0082]
Examples of the group represented by the following formula:
Date Recue/Date Received 2020-11-26 R20a R20b q 1' Xs fs are groups represented by the following formula:
0 , -0- , OH , 0 , or
Examples of the group represented by the following formula:
Date Recue/Date Received 2020-11-26 R20a R20b q 1' Xs fs are groups represented by the following formula:
0 , -0- , OH , 0 , or
[0083]
Examples of the group represented by the following formula:
R20a R20b are groups represented by the following formula:
, . , OH , 0..., , or
Examples of the group represented by the following formula:
R20a R20b are groups represented by the following formula:
, . , OH , 0..., , or
[0084]
Examples of the group represented by the following formula:
R20a R20b c 4.1 ,(ksfs are groups represented by the following formula:
Date Recue/Date Received 2020-11-26 OH , 0 , or
Examples of the group represented by the following formula:
R20a R20b c 4.1 ,(ksfs are groups represented by the following formula:
Date Recue/Date Received 2020-11-26 OH , 0 , or
[0085]
Examples of the group represented by the following formula:
R20a R20b ( ksis are groups represented by the following formula:
or
Examples of the group represented by the following formula:
R20a R20b ( ksis are groups represented by the following formula:
or
[0086]
Example of the group represented by the following formula:
R20a R20b is a group represented by the following formula:
Example of the group represented by the following formula:
R20a R20b .2.L3c ,(ksis is a group represented by the following formula:
Date Recue/Date Received 2020-11-26 "
Example of the group represented by the following formula:
R20a R20b is a group represented by the following formula:
Example of the group represented by the following formula:
R20a R20b .2.L3c ,(ksis is a group represented by the following formula:
Date Recue/Date Received 2020-11-26 "
[0087]
The following is a general method for synthesizing the compounds of this invention. The starting materials and reagents used for synthesizing these compounds are commercially available or can be manufactured in accordance with a widely known method in this field using commercially available compounds.
The following is a general method for synthesizing the compounds of this invention. The starting materials and reagents used for synthesizing these compounds are commercially available or can be manufactured in accordance with a widely known method in this field using commercially available compounds.
[0088]
For example, the compounds of the Formula (I) described in this invention can be manufactured by the following synthesis route, or by reference to what is described in W02010/092966 and W02012/020749 if necessary.
For example, the compounds of the Formula (I) described in this invention can be manufactured by the following synthesis route, or by reference to what is described in W02010/092966 and W02012/020749 if necessary.
[0089]
[Method A]
N
.N 0 NH Rc¨NCO N N
y R2¨ (CR4a Rai)) Lg LgAN H2 (ii) or (H)= A
Lg N'Z2 __________________________________________ (iv) Step 1 H Step 2 (i) (iii) A Rc A
N N (vi) N N
Lg N 'Z2 N Z2 Step 3 (0R4aR4b)n (cR48R4b)11 (v) (II') wherein, Lg is a leaving group represented by the formula:
Lg = =¨S , or 1 ¨ N ¨(R27)n' Rio R3 is a group represented by the formula:
(R9.)s' (R9)s Re is a group represented by the formula:
Date Recue/Date Received 2020-11-26 R2oa R2ob u CO2R13 R1-0 is alkyl, R27 is alkyl, Z2 is an oxygen atom or a sulfur atom, X is NH, n is an integer of 0 to 3, Lgl- is a leaving group and other symbols are as defined above.
(Step 1) The compound (i) or its hydrochloride or bromate is reacted with isocyanate (ii) or 1-carbamoyl imidazole (ii)' in a solvent, such as N,N-dimethylformamide, N,N-dimethylacetamide, N,N'-dimethyl imidazolidinone and dimethylsulfoxide, in the presence of a base, such as DBU, triethylamine and pyridine (preferably DBU) at a temperature between -20 and 50 C, preferably at a temperature between -10 C
and below zero. After that, the compound (iii) can be manufactured by reacting the reactive mixture with a carbonylating or thiocarbonylating agent, such as 1,1'-carbonyldiimidazole, 1,1'-thiocarbonyldiimidazole, phosgene, thiophosgene and triphosgene, etc., and a base, such as DBU, triethylamine or pyridine (preferably DBU) at a temperature between -20 and 50 C ,preferably at a temperature between -10 C and below zero.
(Step 2) The compound (v) can be manufactured by reacting the compound (iii) with the compound (iv) in a solvent, such as acetonitrile, acetone, DMF and DMSO, in the presence of a base, such as potassium carbonate and sodium carbonate, at a temperature between 50 C to reflux, preferably at reflux.
The examples of a leaving group include halogen and ¨0S02 (CtF2t+1) wherein t is an integer of 1 to 4. As halogen, chloro, iodo and bromo are preferred. As -(CtF2t+1) group, -0Tf group (trifluoromethanesulfonate) is preferred.
(Step 3) The compound indicated by Formula (II') can be manufactured by reacting the compound (v) with the compound (vii) in a solvent, such as NMP, DMF and DMSO, or under solvent-free conditions under microwave irradiation at a temperature between 150 C and 250 C, preferably at a temperature between 200 C and 230 C, or in a solvent, such as t-butanol, in the presence of an acid, such as acetic acid, at a temperature between 60 C and 150 C, preferably at a temperature between 80 C and 120 C.
Using optically active isocyanate (ii) enables to synthesize optically active compound (II').
[Method A]
N
.N 0 NH Rc¨NCO N N
y R2¨ (CR4a Rai)) Lg LgAN H2 (ii) or (H)= A
Lg N'Z2 __________________________________________ (iv) Step 1 H Step 2 (i) (iii) A Rc A
N N (vi) N N
Lg N 'Z2 N Z2 Step 3 (0R4aR4b)n (cR48R4b)11 (v) (II') wherein, Lg is a leaving group represented by the formula:
Lg = =¨S , or 1 ¨ N ¨(R27)n' Rio R3 is a group represented by the formula:
(R9.)s' (R9)s Re is a group represented by the formula:
Date Recue/Date Received 2020-11-26 R2oa R2ob u CO2R13 R1-0 is alkyl, R27 is alkyl, Z2 is an oxygen atom or a sulfur atom, X is NH, n is an integer of 0 to 3, Lgl- is a leaving group and other symbols are as defined above.
(Step 1) The compound (i) or its hydrochloride or bromate is reacted with isocyanate (ii) or 1-carbamoyl imidazole (ii)' in a solvent, such as N,N-dimethylformamide, N,N-dimethylacetamide, N,N'-dimethyl imidazolidinone and dimethylsulfoxide, in the presence of a base, such as DBU, triethylamine and pyridine (preferably DBU) at a temperature between -20 and 50 C, preferably at a temperature between -10 C
and below zero. After that, the compound (iii) can be manufactured by reacting the reactive mixture with a carbonylating or thiocarbonylating agent, such as 1,1'-carbonyldiimidazole, 1,1'-thiocarbonyldiimidazole, phosgene, thiophosgene and triphosgene, etc., and a base, such as DBU, triethylamine or pyridine (preferably DBU) at a temperature between -20 and 50 C ,preferably at a temperature between -10 C and below zero.
(Step 2) The compound (v) can be manufactured by reacting the compound (iii) with the compound (iv) in a solvent, such as acetonitrile, acetone, DMF and DMSO, in the presence of a base, such as potassium carbonate and sodium carbonate, at a temperature between 50 C to reflux, preferably at reflux.
The examples of a leaving group include halogen and ¨0S02 (CtF2t+1) wherein t is an integer of 1 to 4. As halogen, chloro, iodo and bromo are preferred. As -(CtF2t+1) group, -0Tf group (trifluoromethanesulfonate) is preferred.
(Step 3) The compound indicated by Formula (II') can be manufactured by reacting the compound (v) with the compound (vii) in a solvent, such as NMP, DMF and DMSO, or under solvent-free conditions under microwave irradiation at a temperature between 150 C and 250 C, preferably at a temperature between 200 C and 230 C, or in a solvent, such as t-butanol, in the presence of an acid, such as acetic acid, at a temperature between 60 C and 150 C, preferably at a temperature between 80 C and 120 C.
Using optically active isocyanate (ii) enables to synthesize optically active compound (II').
[0090]
[Method B]
Date Recue/Date Received 2020-11-26 R1 Hal2 NH
...R10 S MO S Rloil (vi) H2N)-LN (CR4aR4b) R2 Step 1 HN.N (CR4a1=2,413.HR2 ¨0-- -n n Step 2 (CIR4aR4))n te H H
(vii) (ix) I P
NJ-LNH Rc¨ Hal3 N A NI ,Rc (x) R3X N 0 (xii) WXN0 ' õ...
I Step ' 4 I , (cR4aR4b)n (CRaR4b)n I I
(xi) (II") wherein Hal2 and Hal3 are halogen and other symbols are as defined above.
(Step 1) The compound (ix) can be manufactured by reacting the compound (vii) with alkylating agent (viii), such as methyl iodide and ethyl iodide, in a solvent, such as methanol and ethanol, at a temperature between ¨ 40 C and 30 C, preferably below zero.
(Step 2) The compound (x) can be manufactured by reacting the compound (ix) with isocyanate, such as N-(chlorocarbonyl) isocyanate, in a solvent, such as dichloromethane, chloroform, 1,2-dichloroethane, in the presence of a base, such as triethylamine and N,N-diisopropylethylamine, at a temperature between ¨ 20 C and 30 C, preferably below zero.
(Step 3) The compound (xi) can be manufactured by reacting the compound (x) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol and acetonitrile, in the presence of an acid, such as acetic acid, formic acid and methanesulfonic acid, at reflux.
(Step 4) The compound represented by Formula (II") can be manufactured by reacting the compound (xi) with the compound (xii) in a solvent, such as DMF or NMP, etc, in the presence of a base, such as potassium t-butoxide, or sodium hydride, at a temperature between 40 C and 100 C, preferably at a temperature between 50 C and 70 C.
Using optically-active compound (xii) enables to synthesize optically-active compound (II").
[Method B]
Date Recue/Date Received 2020-11-26 R1 Hal2 NH
...R10 S MO S Rloil (vi) H2N)-LN (CR4aR4b) R2 Step 1 HN.N (CR4a1=2,413.HR2 ¨0-- -n n Step 2 (CIR4aR4))n te H H
(vii) (ix) I P
NJ-LNH Rc¨ Hal3 N A NI ,Rc (x) R3X N 0 (xii) WXN0 ' õ...
I Step ' 4 I , (cR4aR4b)n (CRaR4b)n I I
(xi) (II") wherein Hal2 and Hal3 are halogen and other symbols are as defined above.
(Step 1) The compound (ix) can be manufactured by reacting the compound (vii) with alkylating agent (viii), such as methyl iodide and ethyl iodide, in a solvent, such as methanol and ethanol, at a temperature between ¨ 40 C and 30 C, preferably below zero.
(Step 2) The compound (x) can be manufactured by reacting the compound (ix) with isocyanate, such as N-(chlorocarbonyl) isocyanate, in a solvent, such as dichloromethane, chloroform, 1,2-dichloroethane, in the presence of a base, such as triethylamine and N,N-diisopropylethylamine, at a temperature between ¨ 20 C and 30 C, preferably below zero.
(Step 3) The compound (xi) can be manufactured by reacting the compound (x) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol and acetonitrile, in the presence of an acid, such as acetic acid, formic acid and methanesulfonic acid, at reflux.
(Step 4) The compound represented by Formula (II") can be manufactured by reacting the compound (xi) with the compound (xii) in a solvent, such as DMF or NMP, etc, in the presence of a base, such as potassium t-butoxide, or sodium hydride, at a temperature between 40 C and 100 C, preferably at a temperature between 50 C and 70 C.
Using optically-active compound (xii) enables to synthesize optically-active compound (II").
[0091]
[Method C]
NANH A "....,,,, pg 1 HO0-Pgi \ /1OH
RI s Rio ,L, s R3 N N-X-H RX
3.J1:N0 s S N 0 (xii) N" '0 (vi) I I Step 1 __ 1.. Step 2 I
(cR4aR4b)n (cFetaR4b)n (cR4aR4b)n I I I
(x) (xiii) (xiv) Date Recue/Date Received 2020-11-26 wherein Pg1 is an appropriate hydroxy protecting group, s is an integer of 1 to 4 and other symbols are as defined above.
(Step 1) The compound (xiii) can be manufactured by reacting a mixture of the compound (x) obtained by the method B, and the alcohol (xii) whose one hydroxyl group is protected, such as 2-(tetrahydro-2H-pyran-2-yloxy) ethanol in a solvent, such as THF or dioxane, etc, with triphenylphosphine, and diethyl azodicarboxylate, etc.
(Step 2) The compound (xiv) can be manufactured by reacting the compound (xiii) with the compound (vi) in the presence of an acid, such as formic acid or acetic acid, etc., at reflux.
[Method C]
NANH A "....,,,, pg 1 HO0-Pgi \ /1OH
RI s Rio ,L, s R3 N N-X-H RX
3.J1:N0 s S N 0 (xii) N" '0 (vi) I I Step 1 __ 1.. Step 2 I
(cR4aR4b)n (cFetaR4b)n (cR4aR4b)n I I I
(x) (xiii) (xiv) Date Recue/Date Received 2020-11-26 wherein Pg1 is an appropriate hydroxy protecting group, s is an integer of 1 to 4 and other symbols are as defined above.
(Step 1) The compound (xiii) can be manufactured by reacting a mixture of the compound (x) obtained by the method B, and the alcohol (xii) whose one hydroxyl group is protected, such as 2-(tetrahydro-2H-pyran-2-yloxy) ethanol in a solvent, such as THF or dioxane, etc, with triphenylphosphine, and diethyl azodicarboxylate, etc.
(Step 2) The compound (xiv) can be manufactured by reacting the compound (xiii) with the compound (vi) in the presence of an acid, such as formic acid or acetic acid, etc., at reflux.
[0092]
[Method D]
õIL ,pg2 N N4---)ZNH2 N N*'NAR11 R
3, t R -COR12 (XVii) 3 X N 0 H ____________________________ X N 0 R 0t H
Step 1 I Step 2 (cRztaDab) (cR4aR4i3) (cRaappab) (xv) (xvi) (xviii) wherein Pg2 is an appropriate amino protecting group, R11 is substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R12 is hydroxy or halogen, t is an integer of 1 to 4 and other symbols are as defined above.) (Step 1) The compound (xvi) can be manufactured by reacting the compound (xv) obtained by the method A or B with acid, such as hydrochloric acid-dioxane solution, hydrochloric acid-methanol, hydrochloric acid-ethyl acetate solution and trifluoroacetic acid, etc.
(Step 2) The compound (xviii) can be manufactured by reacting the compound (xvi) with the acid halide (xvii) (R12 is halogen) in a solvent, such as THF or dioxane, etc., in the presence of a base, such as triethylamine or diisopropylethylamine, etc. If necessary, dimethylaminopyridine, etc., can be added.
Alternatively, the compound (xviii) can be manufactured by reacting the compound (xvi) with the carboxylic acid (xvii, R12 is hydroxy) in a solvent, such as THF or DMF, in the presence of a condensing agent, such as 1-hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, and a base, such as triethylamine or diisipropylethylamine, etc.
[Method D]
õIL ,pg2 N N4---)ZNH2 N N*'NAR11 R
3, t R -COR12 (XVii) 3 X N 0 H ____________________________ X N 0 R 0t H
Step 1 I Step 2 (cRztaDab) (cR4aR4i3) (cRaappab) (xv) (xvi) (xviii) wherein Pg2 is an appropriate amino protecting group, R11 is substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, R12 is hydroxy or halogen, t is an integer of 1 to 4 and other symbols are as defined above.) (Step 1) The compound (xvi) can be manufactured by reacting the compound (xv) obtained by the method A or B with acid, such as hydrochloric acid-dioxane solution, hydrochloric acid-methanol, hydrochloric acid-ethyl acetate solution and trifluoroacetic acid, etc.
(Step 2) The compound (xviii) can be manufactured by reacting the compound (xvi) with the acid halide (xvii) (R12 is halogen) in a solvent, such as THF or dioxane, etc., in the presence of a base, such as triethylamine or diisopropylethylamine, etc. If necessary, dimethylaminopyridine, etc., can be added.
Alternatively, the compound (xviii) can be manufactured by reacting the compound (xvi) with the carboxylic acid (xvii, R12 is hydroxy) in a solvent, such as THF or DMF, in the presence of a condensing agent, such as 1-hydroxybenzotriazole and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, and a base, such as triethylamine or diisipropylethylamine, etc.
[0093]
[Method E]
Date Recue/Date Received 2020-11-26 R20b R20a R20b R20a R20b JL
NJkNH Hal 21µ 13Rio NJLN- 26C0 R13 u R3-X-H N N-4uCO2R13 u Rio (xix) S N 0 (vi) R3.XN0 Step 1 1cR4aR413µ Step 2 (cR4aR4b)n (cR4aR413µ
(xx) (xxi) (X) oR20a R20b R3.X)kN0 Step 3 (cR4aR4b)n (xxii) wherein R13 is substituted or unsubstituted alkyl, R20a and R2ob are hydrogen, halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl or R 2 a and R2ob are taken together to form oxo or thioxo, u is an integer of 1 to 4, and other symbols are as defined above.
(Step 1) The compound (xx) can be manufactured by reacting the compound (x) obtained by the method B with the compound (xix) in a solvent, such as DMF, NMP or THF, etc., in the presence of a base, such as DBU, potassium t-butoxide or sodium hydride, etc., at a temperature between 0 C and 80 C, preferably at a temperature between 30 C and 50 C.
(Step 2) The compound (xxi) can be manufactured by reacting the compound (xx) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol or acetonitrile, etc., in the presence of an acid such as formic acid, acetic acid or methanesulfonic acid, etc., at reflux.
(Step 3) The compound (xxii) can be manufactured by reacting the compound (xxi) with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol or ethanol, etc., or in a mixture of such solvent and a solvent, such as THF or dioxane, etc.
[Method E]
Date Recue/Date Received 2020-11-26 R20b R20a R20b R20a R20b JL
NJkNH Hal 21µ 13Rio NJLN- 26C0 R13 u R3-X-H N N-4uCO2R13 u Rio (xix) S N 0 (vi) R3.XN0 Step 1 1cR4aR413µ Step 2 (cR4aR4b)n (cR4aR413µ
(xx) (xxi) (X) oR20a R20b R3.X)kN0 Step 3 (cR4aR4b)n (xxii) wherein R13 is substituted or unsubstituted alkyl, R20a and R2ob are hydrogen, halogen, cyano, hydroxy, carboxy, sulfo, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkenyloxy, substituted or unsubstituted alkynyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyloxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, substituted or unsubstituted amino, substituted or unsubstituted imino, substituted or unsubstituted guanidyl or R 2 a and R2ob are taken together to form oxo or thioxo, u is an integer of 1 to 4, and other symbols are as defined above.
(Step 1) The compound (xx) can be manufactured by reacting the compound (x) obtained by the method B with the compound (xix) in a solvent, such as DMF, NMP or THF, etc., in the presence of a base, such as DBU, potassium t-butoxide or sodium hydride, etc., at a temperature between 0 C and 80 C, preferably at a temperature between 30 C and 50 C.
(Step 2) The compound (xxi) can be manufactured by reacting the compound (xx) with the compound (vi) in a solvent, such as t-butanol, isopropanol, ethanol or acetonitrile, etc., in the presence of an acid such as formic acid, acetic acid or methanesulfonic acid, etc., at reflux.
(Step 3) The compound (xxii) can be manufactured by reacting the compound (xxi) with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol or ethanol, etc., or in a mixture of such solvent and a solvent, such as THF or dioxane, etc.
[0094]
[Method F]
Date Recue/Date Received 2020-11-26 Rtzto2c 0 0 ,IRc N HO2C I
NNJ R15¨NH R1NOC ,Re (xxv) R15 N N
X NO Step 1 X 1\1-Step 2 X 1\1-(CR4aR4b)n (cR4aDzib, '` in (0R4a Dab, 's in (xxiii) (xxiv) (xxvi) wherein R14 is substituted or unsubstituted alkyl, R15 and R16 are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, u is an integer of 1 to 4 and other symbols are as defined above.
(Step 1) The compound (xxiv) can be manufactured by reacting the compound (xxiii) obtainored by the method A or B with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol or ethanol, etc., or in a mixture of such solvent and a solvent, such as dioxane THF, etc.
(Step 2) The compound (xxvi) can be manufactured by reacting the compound (xxiv) with the compound (xxv) in a solvent, such as THF, DMF or NMP, etc., in the presence of a condensing agent, such as 1-hydroxybenzotriazole, HOAt, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HATU or PyBOP, etc., and a base, such as triethylamine or diisipropylethylamine, etc.
[Method F]
Date Recue/Date Received 2020-11-26 Rtzto2c 0 0 ,IRc N HO2C I
NNJ R15¨NH R1NOC ,Re (xxv) R15 N N
X NO Step 1 X 1\1-Step 2 X 1\1-(CR4aR4b)n (cR4aDzib, '` in (0R4a Dab, 's in (xxiii) (xxiv) (xxvi) wherein R14 is substituted or unsubstituted alkyl, R15 and R16 are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted acyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, u is an integer of 1 to 4 and other symbols are as defined above.
(Step 1) The compound (xxiv) can be manufactured by reacting the compound (xxiii) obtainored by the method A or B with a solution, such as lithium hydroxide aqueous solution, sodium hydroxide aqueous solution and potassium hydroxide aqueous solution, in a solvent, such as methanol or ethanol, etc., or in a mixture of such solvent and a solvent, such as dioxane THF, etc.
(Step 2) The compound (xxvi) can be manufactured by reacting the compound (xxiv) with the compound (xxv) in a solvent, such as THF, DMF or NMP, etc., in the presence of a condensing agent, such as 1-hydroxybenzotriazole, HOAt, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, HATU or PyBOP, etc., and a base, such as triethylamine or diisipropylethylamine, etc.
[0095]
[Method L]
ANH A
N HOR -R e -c N N R3-X-H N
R13 IR11 R3,X)N0 S N 0 (xxxviii) S N 0 (vi) Step 1 Step 2 (CR"R4b)n (CR"R4b)n (cR4aDzib, '` Jri (x) (ixI) (II) wherein the symbols in the formula are as defined above.
(Step 1) The compound (ixl) can be manufactured by reacting a mixture of the compound (x) obtained by the method B and the alcohol (xxxviii) in a solvent, such as THF or dioxane, etc., with triphenylphosphine, etc., and diethyl azodicarboxylate, etc.
(Step 2) The compound (II) can be manufactured by reacting the compound (ix1) with the compound (vi) in the presence of an acid, such as formic acid or acetic acid, etc., at reflux.
Date Recue/Date Received 2020-11-26 Using the optically-active alcohol (xxxviii) enables to synthesize the optically-active compound (II).
The alcohol used as an intermediate (xxxviii) is commercially available or can be manufactured according to a method specified in the following documents:
Tetrahedron (1993), 49(11), 2325-44.
Chemical Communications (2008), (47), 6408-6410.
Tetrahedron (1990), 46(24), 8207-28.
Synlett (1994), (3), 199-200.
Bulletin of the Chemical Society of Japan (1994), 67(8), 2244-7 Canadian Journal of Chemistry (1996), 74, 1731-1737 Chemistry--A European Journal (2010), 16(2), 577-587 Bioorganic & Medicinal Chemistry Letters (2009), 19(21), 6196-6199.
Chemische Berichte (1985), 118(10), 3966-79.
Tetrahedron: Asymmetry (1992), 3(4), 515-16.
Organic Letters (1999), 1(6), 957-959.
Chimia (1986), 40(5), 172-3.
[Method L]
ANH A
N HOR -R e -c N N R3-X-H N
R13 IR11 R3,X)N0 S N 0 (xxxviii) S N 0 (vi) Step 1 Step 2 (CR"R4b)n (CR"R4b)n (cR4aDzib, '` Jri (x) (ixI) (II) wherein the symbols in the formula are as defined above.
(Step 1) The compound (ixl) can be manufactured by reacting a mixture of the compound (x) obtained by the method B and the alcohol (xxxviii) in a solvent, such as THF or dioxane, etc., with triphenylphosphine, etc., and diethyl azodicarboxylate, etc.
(Step 2) The compound (II) can be manufactured by reacting the compound (ix1) with the compound (vi) in the presence of an acid, such as formic acid or acetic acid, etc., at reflux.
Date Recue/Date Received 2020-11-26 Using the optically-active alcohol (xxxviii) enables to synthesize the optically-active compound (II).
The alcohol used as an intermediate (xxxviii) is commercially available or can be manufactured according to a method specified in the following documents:
Tetrahedron (1993), 49(11), 2325-44.
Chemical Communications (2008), (47), 6408-6410.
Tetrahedron (1990), 46(24), 8207-28.
Synlett (1994), (3), 199-200.
Bulletin of the Chemical Society of Japan (1994), 67(8), 2244-7 Canadian Journal of Chemistry (1996), 74, 1731-1737 Chemistry--A European Journal (2010), 16(2), 577-587 Bioorganic & Medicinal Chemistry Letters (2009), 19(21), 6196-6199.
Chemische Berichte (1985), 118(10), 3966-79.
Tetrahedron: Asymmetry (1992), 3(4), 515-16.
Organic Letters (1999), 1(6), 957-959.
Chimia (1986), 40(5), 172-3.
[0096]
[Method M]
R22 0 izt4 ,Rc 0 R21_3,N R23 Q R232¨Xj (xxxviii) R21- Step 2 R23 NAN"
X0 R21_ L
Step 1 X N 0 (CR4aR4b)n (CR4aR4b)n I
(CR'R4b)n (XXXVii) (xxxix) (xi) wherein R21 is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, etc., R22 is bromo or iodo, R23 and R24 are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, and other symbols are as defined above.
(Step 1) The compound (xxxix) can be manufactured by reacting the compound (xxxvii) obtained by the method from A to F or L with the compound (xxxviii) in a solvent, such as THF or dioxane, etc., in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50 C and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120 C and 200 C, preferably at a temperature between 130 C and 150 C.
(Step 2) The compound (xl) can be obtained by dissolving the compound (xxxix) in an alcohols solvent, such as methanol or ethanol, etc., and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10%Pt-C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide, chlorotris (triphenylphosphine) rhodium (I), etc.
[Method M]
R22 0 izt4 ,Rc 0 R21_3,N R23 Q R232¨Xj (xxxviii) R21- Step 2 R23 NAN"
X0 R21_ L
Step 1 X N 0 (CR4aR4b)n (CR4aR4b)n I
(CR'R4b)n (XXXVii) (xxxix) (xi) wherein R21 is hydrogen, substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, etc., R22 is bromo or iodo, R23 and R24 are each independently substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, a substituted or unsubstituted non-aromatic heterocyclic group, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl, and other symbols are as defined above.
(Step 1) The compound (xxxix) can be manufactured by reacting the compound (xxxvii) obtained by the method from A to F or L with the compound (xxxviii) in a solvent, such as THF or dioxane, etc., in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50 C and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120 C and 200 C, preferably at a temperature between 130 C and 150 C.
(Step 2) The compound (xl) can be obtained by dissolving the compound (xxxix) in an alcohols solvent, such as methanol or ethanol, etc., and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10%Pt-C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide, chlorotris (triphenylphosphine) rhodium (I), etc.
[0097]
[Method N]
Date Recue/Date Received 2020-11-26 0 0 0Rc ik ,Rc R24 ik Rc N N
N N
R3.X)kN0 R3,X)N0 R23 \Q R3,X)N0 I (xxxviii) I I
(CR4aR4b) n (CR4aR4b) (RR
n C4a41)\i _),, ._),.._ n Step 2 Step 1 lik_ R 2 2 o ....õ __ _R24 ----- \R24 (xli) (xlii) (xliii) wherein the symbols in the formula are as defined above.
(Step 1) The compound (xlii) can be manufactured by reacting the compound (xli) obtained by the method from A to F or L with the compound (xxxviii) in a solvent, such as THF or dioxane, etc., in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50 C and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120 C and 200 C, preferably at a temperature between 130 C and 150 C.
[Method N]
Date Recue/Date Received 2020-11-26 0 0 0Rc ik ,Rc R24 ik Rc N N
N N
R3.X)kN0 R3,X)N0 R23 \Q R3,X)N0 I (xxxviii) I I
(CR4aR4b) n (CR4aR4b) (RR
n C4a41)\i _),, ._),.._ n Step 2 Step 1 lik_ R 2 2 o ....õ __ _R24 ----- \R24 (xli) (xlii) (xliii) wherein the symbols in the formula are as defined above.
(Step 1) The compound (xlii) can be manufactured by reacting the compound (xli) obtained by the method from A to F or L with the compound (xxxviii) in a solvent, such as THF or dioxane, etc., in the presence of a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50 C and reflux, preferably at reflux, or under microwave irradiation at a temperature between 120 C and 200 C, preferably at a temperature between 130 C and 150 C.
[0098]
(Step 2) The compound (xliii) can be obtained by dissolving the compound (xlii) in an alcohols solvent, such as methanol or ethanol, etc., and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10%Pt-C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide or chlorotris (triphenylphosphine) rhodium (I), etc.
(Step 2) The compound (xliii) can be obtained by dissolving the compound (xlii) in an alcohols solvent, such as methanol or ethanol, etc., and performing catalytic reduction using a hydrogenation reactor (such as H-Cube (10%Pt-C, H2=1 atm)) or a metallic catalyst, such as palladium-carbon, platinum oxide or chlorotris (triphenylphosphine) rhodium (I), etc.
[0099]
[Method 0]
A ,W A ,IRc R3-R26 N N N N N N
,k (XiVii) 103 O H H2N N (:) ¨1.-- . s I
--- A Ab Step 1 I Step 2 H I
(CR-raR¨ )n (CR4aR4b)n (CR4a op\
(xliv) (xlvi) (xlviii) wherein R25 is substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, R26 is bromo or iodo, and other symbols are as defined above.
(Step 1) The compound (xlvi) can be obtained from the compound (xliv) in the presence of Lewis acid or trifluoroacetic acid, etc., under solvent-free conditions or in an appropriate solvent at a temperature between 0 C and reflux.
[Method 0]
A ,W A ,IRc R3-R26 N N N N N N
,k (XiVii) 103 O H H2N N (:) ¨1.-- . s I
--- A Ab Step 1 I Step 2 H I
(CR-raR¨ )n (CR4aR4b)n (CR4a op\
(xliv) (xlvi) (xlviii) wherein R25 is substituted or unsubstituted alkyl or substituted or unsubstituted alkoxy, R26 is bromo or iodo, and other symbols are as defined above.
(Step 1) The compound (xlvi) can be obtained from the compound (xliv) in the presence of Lewis acid or trifluoroacetic acid, etc., under solvent-free conditions or in an appropriate solvent at a temperature between 0 C and reflux.
[0100]
(Step 2) The compound (xlviii) can be manufactured by reacting the compound (xlvi) with the compound (xlvii) in a solvent, such as THF or dioxane, etc., in the presence of Date Recue/Date Received 2020-11-26 a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50 C and reflux, preferably at reflux, or under microwave irradiation at a temperature of 120 C
and 200 C, preferably at a temperature between 130 C and 150 C.
(Step 2) The compound (xlviii) can be manufactured by reacting the compound (xlvi) with the compound (xlvii) in a solvent, such as THF or dioxane, etc., in the presence of Date Recue/Date Received 2020-11-26 a palladium catalyst and a solution, such as potassium carbonate, cesium carbonate or sodium carbonate aqueous solution, etc., at a temperature between 50 C and reflux, preferably at reflux, or under microwave irradiation at a temperature of 120 C
and 200 C, preferably at a temperature between 130 C and 150 C.
[0101]
[Method P]
II ,RC ,RC
N N N N
R R33'XkNO 'X N 0 (cR4aR4la) (cR4aR4la) (xli) wherein the symbols in the formula are as defined above.
The compound (xlii) can be manufactured by reacting the compound (xli) or its hydrochloride or bromate with a reducing agent, such as lithium aluminum hydride, diisobutylaluminum hydride, diborane, lithium borohydride, sodium borohydride etc., in a solvent, such as THF, dioxane, methanol etc., in the presence or absence of Lewis acid or acid, such as titanium tetrachloride, cobalt chloride (II), methane sulfonic acid etc., at a temperature between -20 C and reflux, preferably at room temperature.
[Method P]
II ,RC ,RC
N N N N
R R33'XkNO 'X N 0 (cR4aR4la) (cR4aR4la) (xli) wherein the symbols in the formula are as defined above.
The compound (xlii) can be manufactured by reacting the compound (xli) or its hydrochloride or bromate with a reducing agent, such as lithium aluminum hydride, diisobutylaluminum hydride, diborane, lithium borohydride, sodium borohydride etc., in a solvent, such as THF, dioxane, methanol etc., in the presence or absence of Lewis acid or acid, such as titanium tetrachloride, cobalt chloride (II), methane sulfonic acid etc., at a temperature between -20 C and reflux, preferably at room temperature.
[0102]
The preferred embodiment of the present invention is a compound or its pharmaceutically-acceptable salt as mentioned below.
The preferred embodiment of the present invention is a compound or its pharmaceutically-acceptable salt as mentioned below.
[0103]
A compound of Formula (I):
(R9)s' R20a R20b (R9)S
Ra RbY*, N\)N Rd LI CO R13 N ) N Re (I) HI
(C(R4a)(R4Nn or its pharmaceutically-acceptable salt.
A compound of Formula (I):
(R9)s' R20a R20b (R9)S
Ra RbY*, N\)N Rd LI CO R13 N ) N Re (I) HI
(C(R4a)(R4Nn or its pharmaceutically-acceptable salt.
[0104]
1) The compound of Formula (I), wherein the group represented by the following formula:
Date Recue/Date Received 2020-11-26 R20a R20b q l'Xis fs is a group represented by the following formula:
OH , 0 , or i , and the group represented by the following formula:
diF
I
(c(R4a)(R4b))n I
is a group represented by the following formula:
AF AF
, CI F F, or or its pharmaceutically-acceptable salt.
1) The compound of Formula (I), wherein the group represented by the following formula:
Date Recue/Date Received 2020-11-26 R20a R20b q l'Xis fs is a group represented by the following formula:
OH , 0 , or i , and the group represented by the following formula:
diF
I
(c(R4a)(R4b))n I
is a group represented by the following formula:
AF AF
, CI F F, or or its pharmaceutically-acceptable salt.
[0105]
2) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b q, l'Xis fs is a group represented by the following formula:
Date Recue/Date Received 2020-11-26 /U7nL.Z"' 0 , Ltio/y , or and the group represented by the following formula:
(C(R4a)(R4b))n is a group represented by the following formula:
CI , F F , or or its pharmaceutically-acceptable salt.
2) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b q, l'Xis fs is a group represented by the following formula:
Date Recue/Date Received 2020-11-26 /U7nL.Z"' 0 , Ltio/y , or and the group represented by the following formula:
(C(R4a)(R4b))n is a group represented by the following formula:
CI , F F , or or its pharmaceutically-acceptable salt.
[0106]
3) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b is a group represented by the following formula:
0 , ttg--y,sis OH , 0 ,or and the group represented by the following formula:
(C(R4a)(R4b))u Date Recue/Date Received 2020-11-26 is a group represented by the following formula:
AF AF s_111' JAI' J::F
101 0 11101 Ha , CI , F F ,or or its pharmaceutically-acceptable salt.
3) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b is a group represented by the following formula:
0 , ttg--y,sis OH , 0 ,or and the group represented by the following formula:
(C(R4a)(R4b))u Date Recue/Date Received 2020-11-26 is a group represented by the following formula:
AF AF s_111' JAI' J::F
101 0 11101 Ha , CI , F F ,or or its pharmaceutically-acceptable salt.
[0107]
4) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b is a group represented by the following formula:
, OH , 0 , Or , Lit-1,-).11 and the group represented by the following formula:
AF
I
(c(R4a)(R4Nn I
is a group represented by the following formula:
JF
1.1 or its pharmaceutically-acceptable salt.
4) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b is a group represented by the following formula:
, OH , 0 , Or , Lit-1,-).11 and the group represented by the following formula:
AF
I
(c(R4a)(R4Nn I
is a group represented by the following formula:
JF
1.1 or its pharmaceutically-acceptable salt.
[0108]
5) The compound Formula (I), wherein Date Recue/Date Received 2020-11-26 the group represented by the following formula:
R20a R20b s ,Is is a group represented by the following formula:
Or and the group represented by the following formula:
(c(R4a)(R4Nn is a group represented by the following formula:
or its pharmaceutically-acceptable salt.
5) The compound Formula (I), wherein Date Recue/Date Received 2020-11-26 the group represented by the following formula:
R20a R20b s ,Is is a group represented by the following formula:
Or and the group represented by the following formula:
(c(R4a)(R4Nn is a group represented by the following formula:
or its pharmaceutically-acceptable salt.
[0109]
6) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b ,l(ksfs is a group represetnted by the following formula:
Lt.2n, and the group represented by the following formula:
Date Recue/Date Received 2020-11-26 (C(R4a)(R4Nn is a group represented by the following formula:
or its pharmaceutically-acceptable salt.
7) The compound of Formula (I), wherein Ra and Rb are taken together to form oxo:
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
112 is phenyl substituted with methyl;
s is 0; and s' is 1, or its pharmaceutically-acceptable salt.
8) The compound of Formula (I), wherein Ra and Rb are taken together to form oxo:
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
R2 is phenyl substituted with halogen; and s and s' are both 0, or its pharmaceutically-acceptable salt.
(Subtituent groups not specially defined in the above 1)-8) are as defined in the above (1))
6) The compound of Formula (I), wherein the group represented by the following formula:
R20a R20b ,l(ksfs is a group represetnted by the following formula:
Lt.2n, and the group represented by the following formula:
Date Recue/Date Received 2020-11-26 (C(R4a)(R4Nn is a group represented by the following formula:
or its pharmaceutically-acceptable salt.
7) The compound of Formula (I), wherein Ra and Rb are taken together to form oxo:
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
112 is phenyl substituted with methyl;
s is 0; and s' is 1, or its pharmaceutically-acceptable salt.
8) The compound of Formula (I), wherein Ra and Rb are taken together to form oxo:
Rd and Re are taken together to form oxo;
R4a and R4b are both hydrogen atoms;
n is 1;
R2 is phenyl substituted with halogen; and s and s' are both 0, or its pharmaceutically-acceptable salt.
(Subtituent groups not specially defined in the above 1)-8) are as defined in the above (1))
[0110]
When the group represented by the following formula in the compound of Formula (I):
R20a R20b 31,(kils is the group represented by the following formula:
R20a R20a the absolute configuration of the formula is exemplified by the following configration:
Date Recue/Date Received 2020-11-26 R20a =--) =
R20a
When the group represented by the following formula in the compound of Formula (I):
R20a R20b 31,(kils is the group represented by the following formula:
R20a R20a the absolute configuration of the formula is exemplified by the following configration:
Date Recue/Date Received 2020-11-26 R20a =--) =
R20a
[0111]
When the group represented by the following formula in the compound of Formula (I):
R20a R20b is the group represented by the following formula:
R20a R20a the absolute configuration of the formula is exemplified by the following configration:
R20a c2(YLln Particularly, when the group represented by the following formula:
R20a R20b is the group represented by the following formula:
the absolute configuration of the formula is preferably the following configration:
L2-)( R20a Date Recue/Date Received 2020-11-26 wherein R20a is preferably methyl.
When the group represented by the following formula in the compound of Formula (I):
R20a R20b is the group represented by the following formula:
R20a R20a the absolute configuration of the formula is exemplified by the following configration:
R20a c2(YLln Particularly, when the group represented by the following formula:
R20a R20b is the group represented by the following formula:
the absolute configuration of the formula is preferably the following configration:
L2-)( R20a Date Recue/Date Received 2020-11-26 wherein R20a is preferably methyl.
[0112]
The compounds of Formula (I) are not limited to specific isomers but include all possible isomers (e.g., keto-enol isomers, imine-enamine isomers, diastereoisomers, enantiomers, rotamers or the like), racemates or mixtures thereof. For example, a compound of Formula (I) includes the following tautomer.
Ra Rb Ra Rb ,Rc ,Rc NNRd kRd I Re I Re (c(R4a)(R4b))n (c(R4a)(R4b))n
The compounds of Formula (I) are not limited to specific isomers but include all possible isomers (e.g., keto-enol isomers, imine-enamine isomers, diastereoisomers, enantiomers, rotamers or the like), racemates or mixtures thereof. For example, a compound of Formula (I) includes the following tautomer.
Ra Rb Ra Rb ,Rc ,Rc NNRd kRd I Re I Re (c(R4a)(R4b))n (c(R4a)(R4b))n
[0113]
In addition, one or more hydrogen atoms, carbon atoms or other atoms of the compound of Formula (I) can be replaced by an isotope of the hydrogen atom, carbon atom or other atoms. Compounds of Formula (I) include all radiolabeled forms of compounds of Formula (I). The "radiolabeled," "radiolabeled form" and the like of the compound of Formula (I) are encompassed by the present invention and useful as a research and/or diagnostic tool in metabolism pharmacokinetic studies and in binding assays.
It is also useful for a medicament.
In addition, one or more hydrogen atoms, carbon atoms or other atoms of the compound of Formula (I) can be replaced by an isotope of the hydrogen atom, carbon atom or other atoms. Compounds of Formula (I) include all radiolabeled forms of compounds of Formula (I). The "radiolabeled," "radiolabeled form" and the like of the compound of Formula (I) are encompassed by the present invention and useful as a research and/or diagnostic tool in metabolism pharmacokinetic studies and in binding assays.
It is also useful for a medicament.
[0114]
One or more hydrogen, carbon and/or other atoms in the compounds of Formula (I) may be replaced with isotopes of hydrogen, carbon and/or other atoms respectively.
Examples of isotopes include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 180, 170, 31p, 32p, 35S, 18F, 1231 and 36C1 respectively. The compounds of Formula (I) include the compounds replaced with these isotopes. The compounds replaced with the above isotopes are useful as medicines and include all of radiolabeled compounds of the compound of Formula (I). A "method of radiolabeling" in the manufacture of the "radiolabeled compounds" is encompassed by the present invention, and the "radiolabeled compounds"
are useful for studies on metabolized drug pharmacokinetics, studies on binding assay and/or diagnostic tools.
One or more hydrogen, carbon and/or other atoms in the compounds of Formula (I) may be replaced with isotopes of hydrogen, carbon and/or other atoms respectively.
Examples of isotopes include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 180, 170, 31p, 32p, 35S, 18F, 1231 and 36C1 respectively. The compounds of Formula (I) include the compounds replaced with these isotopes. The compounds replaced with the above isotopes are useful as medicines and include all of radiolabeled compounds of the compound of Formula (I). A "method of radiolabeling" in the manufacture of the "radiolabeled compounds" is encompassed by the present invention, and the "radiolabeled compounds"
are useful for studies on metabolized drug pharmacokinetics, studies on binding assay and/or diagnostic tools.
[0115]
A radiolabeled compound of the compounds of Formula (I) can be prepared using well-known methods in this field of the invention. For example, a tritium-labeled compound of Formula (I) can be prepared by introducing a tritium to a certain compound of Formula (I), through a catalytic dehalogenation reaction using a tritium.
This method comprises reacting with an appropriately-halogenated precursor of the compound of Formula (I) with tritium gas in the presence of an appropriate catalyst, such as Pd/C, and in the presence or absent of a base. The other appropriate method of preparing a tritium-labeled compound can be referred to "Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987)". A 1-4C-labeled compound can be prepared by using a raw material having 14C.
A radiolabeled compound of the compounds of Formula (I) can be prepared using well-known methods in this field of the invention. For example, a tritium-labeled compound of Formula (I) can be prepared by introducing a tritium to a certain compound of Formula (I), through a catalytic dehalogenation reaction using a tritium.
This method comprises reacting with an appropriately-halogenated precursor of the compound of Formula (I) with tritium gas in the presence of an appropriate catalyst, such as Pd/C, and in the presence or absent of a base. The other appropriate method of preparing a tritium-labeled compound can be referred to "Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987)". A 1-4C-labeled compound can be prepared by using a raw material having 14C.
[0116]
The pharmaceutically-acceptable salts of the compounds of Formula (I) include, for example, salts with alkaline metal (e.g., lithium, sodium, potassium or the like), Date Recue/Date Received 2020-11-26 alkaline earth metal (e.g., calcium, barium or the like), magnesium, transition metal (e.g., zinc, iron or the like), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, picoline, quinoline or the like) or amino acids, or salts with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid or the like) or organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or the like). Especially, salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid and the like are included. These salts can be formed by the usual methods.
The compounds of Formula (I) of the present invention or pharmaceutically-acceptable salts thereof may form solvates (e.g., hydrates or the like) and/or crystal polymorphs. The present invention encompasses those various solvates and crystal polymorphs. "Solvates' may be those wherein any numbers of solvent molecules (e.g., water molecules or the like) are coordinated with the compounds of Formula (I). When the compounds of Formula (I) or pharmaceutically-acceptable salts thereof are allowed to stand in the atmosphere, the compounds may absorb water, resulting in attachment of adsorbed water or formation of hydrates. Recrystallization of the compounds of Formula (I) or pharmaceutically-acceptable salts thereof may produce crystal polymorphs.
The compounds of Formula (I) of the present invention or pharmaceutically-acceptable salts thereof may form prodrugs. The present invention also encompasses such various prodrugs. Prodrugs are derivatives of the compounds of the present invention that have chemically or metabolically degradable groups, and compounds that are converted to the pharmaceutically active compounds of the present invention through solvolysis or under physiological conditions in vivo. Prodrugs include compounds that are converted to the compounds of Formula (I) through enzymatic oxidation, reduction, hydrolysis or the like under physiological conditions in vivo, compounds that are converted to the compounds of Formula (I) through hydrolysis by gastric acid etc., and the like. Methods for selecting and preparing suitable prodrug derivatives are described in, for example, "Design of Prodrugs, Elsevier, Amsrdam, 1985". Prodrugs themselves may have some activity.
When the compounds of Formula (I) or pharmaceutically-acceptable salts thereof have hydroxyl group(s), prodrugs include acyloxy derivatives and sulfonyloxy derivatives that are prepared by, for example, reacting compounds having hydroxyl group(s) with suitable acyl halide, suitable acid anhydride, suitable sulfonyl chloride, suitable sulfonyl anhydride and mixed anhydride, or with a condensing agent. For example, they include CH3 C00-, C2H5C00-, tert-BuC00-, C15H31C00-, PhC00-, (m-Na00CPh)C00-, Na0OCCH2 CH2 C00-, CH3 CH(NH2)C00-, CH2 N(CH3 )2 C00-, CH3 S03, CH3 CH2 S03 -, CF3 S03 -, CH2 FS03 CF3 CH2 S03 -, p-CH3 0-PhS03 PhS03 - and p-CH3PhS03.
The pharmaceutically-acceptable salts of the compounds of Formula (I) include, for example, salts with alkaline metal (e.g., lithium, sodium, potassium or the like), Date Recue/Date Received 2020-11-26 alkaline earth metal (e.g., calcium, barium or the like), magnesium, transition metal (e.g., zinc, iron or the like), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, picoline, quinoline or the like) or amino acids, or salts with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid or the like) or organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid or the like). Especially, salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid and the like are included. These salts can be formed by the usual methods.
The compounds of Formula (I) of the present invention or pharmaceutically-acceptable salts thereof may form solvates (e.g., hydrates or the like) and/or crystal polymorphs. The present invention encompasses those various solvates and crystal polymorphs. "Solvates' may be those wherein any numbers of solvent molecules (e.g., water molecules or the like) are coordinated with the compounds of Formula (I). When the compounds of Formula (I) or pharmaceutically-acceptable salts thereof are allowed to stand in the atmosphere, the compounds may absorb water, resulting in attachment of adsorbed water or formation of hydrates. Recrystallization of the compounds of Formula (I) or pharmaceutically-acceptable salts thereof may produce crystal polymorphs.
The compounds of Formula (I) of the present invention or pharmaceutically-acceptable salts thereof may form prodrugs. The present invention also encompasses such various prodrugs. Prodrugs are derivatives of the compounds of the present invention that have chemically or metabolically degradable groups, and compounds that are converted to the pharmaceutically active compounds of the present invention through solvolysis or under physiological conditions in vivo. Prodrugs include compounds that are converted to the compounds of Formula (I) through enzymatic oxidation, reduction, hydrolysis or the like under physiological conditions in vivo, compounds that are converted to the compounds of Formula (I) through hydrolysis by gastric acid etc., and the like. Methods for selecting and preparing suitable prodrug derivatives are described in, for example, "Design of Prodrugs, Elsevier, Amsrdam, 1985". Prodrugs themselves may have some activity.
When the compounds of Formula (I) or pharmaceutically-acceptable salts thereof have hydroxyl group(s), prodrugs include acyloxy derivatives and sulfonyloxy derivatives that are prepared by, for example, reacting compounds having hydroxyl group(s) with suitable acyl halide, suitable acid anhydride, suitable sulfonyl chloride, suitable sulfonyl anhydride and mixed anhydride, or with a condensing agent. For example, they include CH3 C00-, C2H5C00-, tert-BuC00-, C15H31C00-, PhC00-, (m-Na00CPh)C00-, Na0OCCH2 CH2 C00-, CH3 CH(NH2)C00-, CH2 N(CH3 )2 C00-, CH3 S03, CH3 CH2 S03 -, CF3 S03 -, CH2 FS03 CF3 CH2 S03 -, p-CH3 0-PhS03 PhS03 - and p-CH3PhS03.
[0117]
The compound of the Formula (I) has an antagonistic activity on P2X3 and/or P2X2/3 receptor, and therefore, is useful as a therapeutic agent for diseases associated with a P2X3 and/or P2X2/3 receptor. Since P2X3 and/or P2X2/3 receptor is believed to associate with pain, diseases in urinary system and respiratory disease (Nature 407, 26, 1011-1015 (2000), Nature, Vol.407, No.26, 1015-1017 (2000), Non-Patent Document 1, Non-Patent Document 2, Non-Patent Documents 9-11 etc.), the compound of the Date Recue/Date Received 2020-11-26 invention is useful in the treatment, alleviation of symptoms or prevention of diseases, such as for example, pain associated with rheumatoid arthritis, pain associated with osteoarthritis, headache, migraine, orofacial pain, toothache, glossagra, pain associated with temporomandibular arthrosis, trigeminal neuralgia, shoulder pain, pain associated with hernia of intervertebral disk, pain associated with cervical spondylosis deformans, pain associated with spinal canal stenosis, pain associated with thoracic outlet syndrome, pain associated with traumatic brachial plexus injury syndrome, pain associated with shoulder-hand syndrome, pain associated with whiplash injury, chest pain, abdominal pain, colic pain, pain associated with cholelithiasis, pain associated with pancreatitis, pain associated with urinary calculosis, pain associated with irritable bowel syndrome, lumbar backache, sciatica, pain associated with bone fracture, pain associated with osteoporosis, joint pain, pain associated with gout, pain associated with cauda equina syndrome, pain associated with ankylosing spondylitis, sore muscle, pain associated with painful spasm, pain associated with myofascial pain syndrome, pain associated with fibromyalgia syndrome, complex regional pain syndrome, pain associated with arteriosclerosis obliterans, pain associated with Buerger's disease, pain associated with Raynaud's phenomenon, pain associated with zoster, causalgic pain, pain associated with entrapment neuropathy, pain associated with carpal canal syndrome, pain associated with diabetes, pain associated with Guillain-Barre syndrome, pain associated with Hansen's disease, pain associated with drug therapy, pain associated with radiation therapy, pain associated with cord injury, pain associated with syringomyelia, pain associated with stroke, thalamic pain, pain associated with deafferentation, sympathetically-maintained pain, ABC syndrome, multiple sclerosis, pain associated with skin disease, cancer pain, postoperative pain, pain associated with injury, pain associated with gangrene, pain associated with somatoform disorder, pain associated with somatization disorder, pain associated with depression, pain associated with Parkinson's disease, knee joint pain, pain associated with arthritis, neuropathic pain such as menstrual pain, intermenstrual pain, labor pain, etc., inflammatory pain, nociceptive pain, psychogenic pain, pains associated with endometriosis, and the like;
Overactive bladder, urge incontinence, stress urinary incontinence, reflex incontinence, urinary urgency, neurogenic bladder, unstable bladder, urethritis, urinary tract infections, interstitial cystitis, cystitis, bladder cancer, chemotherapy-induced urinary tract disorder, urinary tract disorders associated with brain disorders such as stroke etc., voiding dysfunction, pain, etc. associated with prostatic hyperplasia, prostatitis, etc., and the like.;
And chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, chronic cough, and the like.
The compound of the Formula (I) has an antagonistic activity on P2X3 and/or P2X2/3 receptor, and therefore, is useful as a therapeutic agent for diseases associated with a P2X3 and/or P2X2/3 receptor. Since P2X3 and/or P2X2/3 receptor is believed to associate with pain, diseases in urinary system and respiratory disease (Nature 407, 26, 1011-1015 (2000), Nature, Vol.407, No.26, 1015-1017 (2000), Non-Patent Document 1, Non-Patent Document 2, Non-Patent Documents 9-11 etc.), the compound of the Date Recue/Date Received 2020-11-26 invention is useful in the treatment, alleviation of symptoms or prevention of diseases, such as for example, pain associated with rheumatoid arthritis, pain associated with osteoarthritis, headache, migraine, orofacial pain, toothache, glossagra, pain associated with temporomandibular arthrosis, trigeminal neuralgia, shoulder pain, pain associated with hernia of intervertebral disk, pain associated with cervical spondylosis deformans, pain associated with spinal canal stenosis, pain associated with thoracic outlet syndrome, pain associated with traumatic brachial plexus injury syndrome, pain associated with shoulder-hand syndrome, pain associated with whiplash injury, chest pain, abdominal pain, colic pain, pain associated with cholelithiasis, pain associated with pancreatitis, pain associated with urinary calculosis, pain associated with irritable bowel syndrome, lumbar backache, sciatica, pain associated with bone fracture, pain associated with osteoporosis, joint pain, pain associated with gout, pain associated with cauda equina syndrome, pain associated with ankylosing spondylitis, sore muscle, pain associated with painful spasm, pain associated with myofascial pain syndrome, pain associated with fibromyalgia syndrome, complex regional pain syndrome, pain associated with arteriosclerosis obliterans, pain associated with Buerger's disease, pain associated with Raynaud's phenomenon, pain associated with zoster, causalgic pain, pain associated with entrapment neuropathy, pain associated with carpal canal syndrome, pain associated with diabetes, pain associated with Guillain-Barre syndrome, pain associated with Hansen's disease, pain associated with drug therapy, pain associated with radiation therapy, pain associated with cord injury, pain associated with syringomyelia, pain associated with stroke, thalamic pain, pain associated with deafferentation, sympathetically-maintained pain, ABC syndrome, multiple sclerosis, pain associated with skin disease, cancer pain, postoperative pain, pain associated with injury, pain associated with gangrene, pain associated with somatoform disorder, pain associated with somatization disorder, pain associated with depression, pain associated with Parkinson's disease, knee joint pain, pain associated with arthritis, neuropathic pain such as menstrual pain, intermenstrual pain, labor pain, etc., inflammatory pain, nociceptive pain, psychogenic pain, pains associated with endometriosis, and the like;
Overactive bladder, urge incontinence, stress urinary incontinence, reflex incontinence, urinary urgency, neurogenic bladder, unstable bladder, urethritis, urinary tract infections, interstitial cystitis, cystitis, bladder cancer, chemotherapy-induced urinary tract disorder, urinary tract disorders associated with brain disorders such as stroke etc., voiding dysfunction, pain, etc. associated with prostatic hyperplasia, prostatitis, etc., and the like.;
And chronic obstructive pulmonary disease (COPD), asthma, bronchospasm, chronic cough, and the like.
[0118]
"A pharmaceutical composition having an improving effect of urination disorder"
includes a pharmaceutical composition for use to improve the treatment and/or prevention of urination disorder.
"A pharmaceutical composition having an improving effect of urination disorder"
includes a pharmaceutical composition for use to improve the treatment and/or prevention of urination disorder.
[0119]
The compound of the present invention or the pharmaceutical composition of the present invention can be a drug with reduced side-effect such as effect on motor function because it has a high affinity for ATP receptor, especially P2X3 receptor, and also has high subtype selectivity and high selectivity for other receptors. Also, the compound encompassed by the present invention or the pharmaceutical composition encompassed by the present invention is advantageous because of its high P2X3 receptor inhibitor activity in the presence of RSA, high metabolic stability, high oral absorption, high solubility, good bioavailability, low total body clearance, long half-life, Date Recue/Date Received 2020-11-26 prolonged duration of action, low activity of hepatic enzyme inhibition, high unbound fraction in serum and/or high safety etc.
The compound of the present invention or the pharmaceutical composition of the present invention can be a drug with high persistence after administration because of its low total body clearance.
The compound of the present invention or the pharmaceutical composition of the present invention can be a drug with reduced side-effect such as effect on motor function because it has a high affinity for ATP receptor, especially P2X3 receptor, and also has high subtype selectivity and high selectivity for other receptors. Also, the compound encompassed by the present invention or the pharmaceutical composition encompassed by the present invention is advantageous because of its high P2X3 receptor inhibitor activity in the presence of RSA, high metabolic stability, high oral absorption, high solubility, good bioavailability, low total body clearance, long half-life, Date Recue/Date Received 2020-11-26 prolonged duration of action, low activity of hepatic enzyme inhibition, high unbound fraction in serum and/or high safety etc.
The compound of the present invention or the pharmaceutical composition of the present invention can be a drug with high persistence after administration because of its low total body clearance.
[0120]
When administering the pharmaceutical composition of the present invention, it can be administered in any method of orally and parenterally methods. Methods for parenteral administration include dermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, transnasal, ophthalmic, inner ear or vaginal administration and the like.
In case of oral administration, any forms, which are usually used, such as oral solid formulations (e.g., tablets, powders, granules, capsules, pills, films or the like), oral liquid formulations (e.g., suspension, emulsion, elixir, syrup, lemonade, spirit, aromatic water, extract, decoction, tincture or the like) and the like may prepared according to the usual method and administered. The tablets can be sugar-coated tablets, film-coated tablets, enteric-coating tablets, sustained-release tablets, troche tablets, sublingual tablets, buccal tablets, chewable tablets or orally dispersing tablets.
Powders and granules can be dry syrups. Capsules can be soft capsules, micro capsules or sustained release capsules.
In case of parenteral administration, any forms, which are usually used, such as injections, drips, external preparations (e.g., ophthalmic drops, nasal drops, ear drops, aerosols, inhalations, lotion, infusion, liniment, mouthwash, enema, ointment, plaster, jelly, cream, patch, cataplasm, external powder, suppository or the like) and the like can be preferably administered. Injections can be emulsions whose type is 0/W, W/O, 0/W/0, W/O/W or the like.
When administering the pharmaceutical composition of the present invention, it can be administered in any method of orally and parenterally methods. Methods for parenteral administration include dermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, transnasal, ophthalmic, inner ear or vaginal administration and the like.
In case of oral administration, any forms, which are usually used, such as oral solid formulations (e.g., tablets, powders, granules, capsules, pills, films or the like), oral liquid formulations (e.g., suspension, emulsion, elixir, syrup, lemonade, spirit, aromatic water, extract, decoction, tincture or the like) and the like may prepared according to the usual method and administered. The tablets can be sugar-coated tablets, film-coated tablets, enteric-coating tablets, sustained-release tablets, troche tablets, sublingual tablets, buccal tablets, chewable tablets or orally dispersing tablets.
Powders and granules can be dry syrups. Capsules can be soft capsules, micro capsules or sustained release capsules.
In case of parenteral administration, any forms, which are usually used, such as injections, drips, external preparations (e.g., ophthalmic drops, nasal drops, ear drops, aerosols, inhalations, lotion, infusion, liniment, mouthwash, enema, ointment, plaster, jelly, cream, patch, cataplasm, external powder, suppository or the like) and the like can be preferably administered. Injections can be emulsions whose type is 0/W, W/O, 0/W/0, W/O/W or the like.
[0121]
Various pharmaceutical additives such as excipients, binders, disintegrating agents and lubricants suitable for the dosage form can be mixed as necessary in an effective amount of the compound of the present invention, to make the compound into a pharmaceutical composition. Furthermore, the pharmaceutical composition can be for pediatric patients, geriatric patients, serious cases or operations by appropriately changing the effective amount of the compound of the present invention, formulation and/or various pharmaceutical additives. The pediatric pharmaceutical compositions are preferably administered to patients under 12 or 15 years old. In addition, the pediatric pharmaceutical compositions can be administered to patients who are under 27 days old after the birth, 28 days to 23 months old after the birth, 2 to 11 years old, 12 to 16 years old, or 18 years old. The geriatric pharmaceutical compositions are preferably administered to patients who are 65 years old or over.
Various pharmaceutical additives such as excipients, binders, disintegrating agents and lubricants suitable for the dosage form can be mixed as necessary in an effective amount of the compound of the present invention, to make the compound into a pharmaceutical composition. Furthermore, the pharmaceutical composition can be for pediatric patients, geriatric patients, serious cases or operations by appropriately changing the effective amount of the compound of the present invention, formulation and/or various pharmaceutical additives. The pediatric pharmaceutical compositions are preferably administered to patients under 12 or 15 years old. In addition, the pediatric pharmaceutical compositions can be administered to patients who are under 27 days old after the birth, 28 days to 23 months old after the birth, 2 to 11 years old, 12 to 16 years old, or 18 years old. The geriatric pharmaceutical compositions are preferably administered to patients who are 65 years old or over.
[0122]
Although the dosage of a pharmaceutical composition of the present invention should be determined in consideration of the patient's age and body weight, the type and degree of diseases, the administration route and the like, a usual oral dosage is 0.05 to 100 and preferably 0.1 to 10 mg/kg/day. For parenteral administration, although the dosage highly varies with administration routes, a usual dosage is 0.005 to 10 and preferably 0.01 to 1 mg/kg/day. The dosage may be administered in one to several divisions per day.
Although the dosage of a pharmaceutical composition of the present invention should be determined in consideration of the patient's age and body weight, the type and degree of diseases, the administration route and the like, a usual oral dosage is 0.05 to 100 and preferably 0.1 to 10 mg/kg/day. For parenteral administration, although the dosage highly varies with administration routes, a usual dosage is 0.005 to 10 and preferably 0.01 to 1 mg/kg/day. The dosage may be administered in one to several divisions per day.
[0123]
The dosage amount of the concomitant drug can be appropriately selected based on the clinically used dose. In addition, the blending ratio of the compound of Date Recue/Date Received 2020-11-26 the present invention to the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptoms, combination and the like. For example, when the administration subject is a human, 0.01 to parts by weight of the concomitant drug may be used, based on 1 part by weight of the compound of the present invention.
The dosage amount of the concomitant drug can be appropriately selected based on the clinically used dose. In addition, the blending ratio of the compound of Date Recue/Date Received 2020-11-26 the present invention to the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptoms, combination and the like. For example, when the administration subject is a human, 0.01 to parts by weight of the concomitant drug may be used, based on 1 part by weight of the compound of the present invention.
[0124]
Following examples illustrate the present invention in more detail, but the present invention is not limited by these examples. The meaning of each abbreviation is as folllows:
Me: methyl TMS: tetramethylsilane DMSO: dimethyl sulfoxide DMA: dimethyl acetamide DMF: dimethylformamide THF: tetrahydrofuran DBU: 1,8-diazabicyclo [5.4.0]undeca-7-ene NMP: N-methyl-2-pyrrolidone HOAt:1-hydroxy-7-azabenzotriazole HATU: 2-(7-azabenzotriazole-1-y1)-1,1,3,3-tetramethyluronium hexafluorophosphate PyBOP: benzotriazole-1-yl-oxytrispyrrolidinophosphonium hexafluorophosphate rt: room temperature M: mol/L
[Example 1]
Following examples illustrate the present invention in more detail, but the present invention is not limited by these examples. The meaning of each abbreviation is as folllows:
Me: methyl TMS: tetramethylsilane DMSO: dimethyl sulfoxide DMA: dimethyl acetamide DMF: dimethylformamide THF: tetrahydrofuran DBU: 1,8-diazabicyclo [5.4.0]undeca-7-ene NMP: N-methyl-2-pyrrolidone HOAt:1-hydroxy-7-azabenzotriazole HATU: 2-(7-azabenzotriazole-1-y1)-1,1,3,3-tetramethyluronium hexafluorophosphate PyBOP: benzotriazole-1-yl-oxytrispyrrolidinophosphonium hexafluorophosphate rt: room temperature M: mol/L
[Example 1]
[0125]
(1) Preparation of trans-3-(4-ethoxycarbonylcyclobuty1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione 000OEt NH N Ns N
f\ ,LNANH2 1.1 0 HCI
To a solution of ethyl trans-3-aminocyclobutanecarboxylate hydrochloride (340 mg, 2.3 mmol) in DMA (3.4 mL) were added 1,1'-Carbonyldiimidazole (496 g, 3.1 mmol) and DBU (0.46 mL, 3.1 mmol) under ice-cooling. The reaction mixture was stirred at room temperature for 4.5 hours, then 1-amidinopyrazole hydrochloride (340 mg, 2.3 mmol) and DBU (0.37 mL, 2.4 mmol) were added. The reaction mixture was stirred at room temperature for 7.5 hours. 1,1'-Carbonyldiimidazole (564 mg, 3.5 mmol) was added to the reaction mixture under ice-cooling, then DBU (0.52 mL, 3.5 mmol) was added. The reaction mixture was stirred at 50 C for 15 hours. 4 mol/L Hydrochloric acid (7.5 mL) was added to the reaction mixture under ice-cooling. The resulting powder was collected by filtration to give trans-3-(4-ethoxycarbonylcyclobuty1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione(376 mg, yield: 53%) as white powder.
1H-NMR (6 ppm TMS / DMSO-d6): 1.21 (3H, t, J = 6.9 Hz), 2.40 (2H, t, J = 9.4 Hz), 3.03 (2H, dd, J = 19.4, 9.9 Hz), 3.09-3.17 (1H, m), 4.12 (2H, q, J = 6.8 Hz), 5.13-5.31 (1H, m), 6.72 (1H, s), 8.05 (1H, s), 8.56 (1H, s), 13.05 (1H, br s).
(1) Preparation of trans-3-(4-ethoxycarbonylcyclobuty1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione 000OEt NH N Ns N
f\ ,LNANH2 1.1 0 HCI
To a solution of ethyl trans-3-aminocyclobutanecarboxylate hydrochloride (340 mg, 2.3 mmol) in DMA (3.4 mL) were added 1,1'-Carbonyldiimidazole (496 g, 3.1 mmol) and DBU (0.46 mL, 3.1 mmol) under ice-cooling. The reaction mixture was stirred at room temperature for 4.5 hours, then 1-amidinopyrazole hydrochloride (340 mg, 2.3 mmol) and DBU (0.37 mL, 2.4 mmol) were added. The reaction mixture was stirred at room temperature for 7.5 hours. 1,1'-Carbonyldiimidazole (564 mg, 3.5 mmol) was added to the reaction mixture under ice-cooling, then DBU (0.52 mL, 3.5 mmol) was added. The reaction mixture was stirred at 50 C for 15 hours. 4 mol/L Hydrochloric acid (7.5 mL) was added to the reaction mixture under ice-cooling. The resulting powder was collected by filtration to give trans-3-(4-ethoxycarbonylcyclobuty1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione(376 mg, yield: 53%) as white powder.
1H-NMR (6 ppm TMS / DMSO-d6): 1.21 (3H, t, J = 6.9 Hz), 2.40 (2H, t, J = 9.4 Hz), 3.03 (2H, dd, J = 19.4, 9.9 Hz), 3.09-3.17 (1H, m), 4.12 (2H, q, J = 6.8 Hz), 5.13-5.31 (1H, m), 6.72 (1H, s), 8.05 (1H, s), 8.56 (1H, s), 13.05 (1H, br s).
[0126]
(2) Preparation of trans-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione Date Recue/Date Received 2020-11-26 0 r....ThACOOEt 0 r....ThACOOEt Nfes1----1 NNV N, N, N N 0 Me Diisopropylethylamine (0.19 mL, 1.1 mmol) was added to mixture of trans-3-(4-ethoxycarbonylcyclobuty1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,311)-dione (279 mg, 0.9 mmol), 4-methylbenzyl bromide (203 mg, 1.1 mmol), and DMA (2.8 mL), and the reaction mixture was stirred at 60 C for 7 hours. The reaction mixture was acidified by 5%
aqueous solution of citric acid, and extracted with ethyl acetate. The organic layer was washed by brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to give crude trans-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (371 mg, yie1d:99%) as yellow solid.
(2) Preparation of trans-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione Date Recue/Date Received 2020-11-26 0 r....ThACOOEt 0 r....ThACOOEt Nfes1----1 NNV N, N, N N 0 Me Diisopropylethylamine (0.19 mL, 1.1 mmol) was added to mixture of trans-3-(4-ethoxycarbonylcyclobuty1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,311)-dione (279 mg, 0.9 mmol), 4-methylbenzyl bromide (203 mg, 1.1 mmol), and DMA (2.8 mL), and the reaction mixture was stirred at 60 C for 7 hours. The reaction mixture was acidified by 5%
aqueous solution of citric acid, and extracted with ethyl acetate. The organic layer was washed by brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to give crude trans-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (371 mg, yie1d:99%) as yellow solid.
[0127]
(3) Preparation of 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (1-172) CI
1....,ThAcooEt N N = 0 1.,,ACOOEt N, 0 c.,111 N 0 40 HN NV
N NO
Me 1$1 Me Mixture of trans-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (123 mg, 0.3 mmol), 4-(5-chloro-2-pyridyloxy)aniline (73 mg, 0.33 mmol), and t-butanol (1.2 mL) was heated under reflux with stirring for 2 hours. The reaction mixture was concentrated in vacuo, and the residue was purified by silica-gel chromatography(ethyl acetate/hexane) to give 644-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione(I-172, 140 mg, yie1d:83%) as pale yellow amorphous.
1H-NMR (CDC13) 6: 1.28 (3H, t, J= 6.8 Hz), 2.35 (3H, s), 2.50-2.70 (2H, m), 3.03-3.15 (2H, m), 3.16-3.30 (1H, m), 4.17 (2H, q, J= 7.0 Hz), 5.20 (2H, s), 5.34-5.58 (1H, m), 6.59-7.08 (4H, m), 7.14 (3H, dd, J= 14.4, 7.8 Hz), 7.49 (2H, d, J= 7.4 Hz), 7.56-7.71 (2H, m), 8.10 (1H, s).
[Example 2]
(3) Preparation of 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (1-172) CI
1....,ThAcooEt N N = 0 1.,,ACOOEt N, 0 c.,111 N 0 40 HN NV
N NO
Me 1$1 Me Mixture of trans-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (123 mg, 0.3 mmol), 4-(5-chloro-2-pyridyloxy)aniline (73 mg, 0.33 mmol), and t-butanol (1.2 mL) was heated under reflux with stirring for 2 hours. The reaction mixture was concentrated in vacuo, and the residue was purified by silica-gel chromatography(ethyl acetate/hexane) to give 644-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione(I-172, 140 mg, yie1d:83%) as pale yellow amorphous.
1H-NMR (CDC13) 6: 1.28 (3H, t, J= 6.8 Hz), 2.35 (3H, s), 2.50-2.70 (2H, m), 3.03-3.15 (2H, m), 3.16-3.30 (1H, m), 4.17 (2H, q, J= 7.0 Hz), 5.20 (2H, s), 5.34-5.58 (1H, m), 6.59-7.08 (4H, m), 7.14 (3H, dd, J= 14.4, 7.8 Hz), 7.49 (2H, d, J= 7.4 Hz), 7.56-7.71 (2H, m), 8.10 (1H, s).
[Example 2]
[0128]
Preparation of 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-hydroxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (1-178) Date Recue/Date Received 2020-11-26 CI CI
0 0 /..ACOOH
HN Ns * HN Ns NNO NNO
Me (el Me 4mo1/L Lithium hydroxide (0.24 mL, 0.96 mmol) was added to mixture of 64445-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (135 mg, 0.24 mmol), methanol (0.7 mL), and THF
(0.7 mL), and stirred at 50 C for 3 hours. 2mo1/L Hydrochloric acid (0.43 mL) was added to the reaction mixture, and the resulting mixture was concentrated in vacuo. The residue was purified by silica-gel chromatography (chloroform/methanol) and powderized by ethyl acetate and hexane to give 644-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-hydroxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (1-178, 103 mg, yie1d:80%) as white powder.
1H-NMR (CDC13) 6: 2.35 (3H, s), 2.52-2.72 (2H, m), 3.08-3.42 (3H, m), 5.20 (2H, s), 5.37-5.61 (1H, m), 6.82-6.95 (3H, m), 7.01-7.20 (4H, m), 7.48 (2H, d, J = 7.3 Hz), 7.61-7.81 (2H, m), 8.11 (111, s).
[Reference Example 1]
Preparation of 6-[4-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-hydroxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (1-178) Date Recue/Date Received 2020-11-26 CI CI
0 0 /..ACOOH
HN Ns * HN Ns NNO NNO
Me (el Me 4mo1/L Lithium hydroxide (0.24 mL, 0.96 mmol) was added to mixture of 64445-chloro-2-pyridyloxy)phenylimino]-3-(4-ethoxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (135 mg, 0.24 mmol), methanol (0.7 mL), and THF
(0.7 mL), and stirred at 50 C for 3 hours. 2mo1/L Hydrochloric acid (0.43 mL) was added to the reaction mixture, and the resulting mixture was concentrated in vacuo. The residue was purified by silica-gel chromatography (chloroform/methanol) and powderized by ethyl acetate and hexane to give 644-(5-chloro-2-pyridyloxy)phenylimino]-3-(4-hydroxycarbonylcyclobuty1)-1-(4-methylbenzy1)-1,3,5-triazinane-2,4-dione (1-178, 103 mg, yie1d:80%) as white powder.
1H-NMR (CDC13) 6: 2.35 (3H, s), 2.52-2.72 (2H, m), 3.08-3.42 (3H, m), 5.20 (2H, s), 5.37-5.61 (1H, m), 6.82-6.95 (3H, m), 7.01-7.20 (4H, m), 7.48 (2H, d, J = 7.3 Hz), 7.61-7.81 (2H, m), 8.11 (111, s).
[Reference Example 1]
[0129]
(1) Preparation of 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione NH
NANk A A
EtS N 0 EtS N 0 EtS NH2 A
EtSNO
HBr t-Butyl isocyanate (1.2 mL, 10.5 mmol) and DBU (1.9 mL, 12.8 mmol) were added to mixture of S-ethylthiourea hydrobromate (1.85 g, 10 mmol) and DMF(9.3 mL) under ice-cooling, and the resulting mixture was stirred for 6 hours. 1,1'-Carbonyldiimidazole (1.95 g, 12 mmol) and DBU (1.9 mL, 12.8 mmol) were added to the reaction mixture under ice-cooling and the mixture was stirred for 2 hours. 2 mol/L
Hydrochloric acid (80 mL) was added to the reaction mixture under ice-cooling over 50 minutes, and the generated powder was collected by filtration. The powder was dissolved in ethyl acetate, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 6-(ethylthio)-3-t-butyl-1,3,5-triazine-2,4(1H,3H)-dione (1.15g, yie1d:50%) as pale brown powder.
1H-NMR (6 ppm TMS / DMSO-d6): 1.27 (3H, t, J=7.3 Hz), 1.55 (9H, s), 3.03 (2H, q, J=7.3), 12.30 (1H, brs) Potassium carbonate (17.97 g, 130 mmol) was added to mixture of 6-(ethylthio)-3-t-buty1-1,3,5-triazine-2,4(1H,3H)-dione (22.93 g, 100 mmol), 4-chlorobenzyl bromide (22.60 g, 110 mmol), and acetonitrile (200 mL), and the resulting mixture was heated at reflux and stirred for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated in vacuo to give the crude product (39.9g) of 3-t-buty1-1-(4-chlorobenzy1)-6-Date Recue/Date Received 2020-11-26 (ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione as pale brown oil.
Trifluoroacetic acid (100 mL) was added to the resulting crude product, the resulting mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated in vacuo to give 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (29.03 g, yield: 97%) as pale brown powder.
1H-NMR (6 ppm TMS / d6-DMS0): 1.25 (3H, t, J=7.3 Hz), 3.08 (2H, q, J=7.3 Hz), 5.02 (2H, s), 7.30-7.33 (2H, m), 7.39-7.42 (2H, m), 11.61 (1H, s).
(1) Preparation of 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione NH
NANk A A
EtS N 0 EtS N 0 EtS NH2 A
EtSNO
HBr t-Butyl isocyanate (1.2 mL, 10.5 mmol) and DBU (1.9 mL, 12.8 mmol) were added to mixture of S-ethylthiourea hydrobromate (1.85 g, 10 mmol) and DMF(9.3 mL) under ice-cooling, and the resulting mixture was stirred for 6 hours. 1,1'-Carbonyldiimidazole (1.95 g, 12 mmol) and DBU (1.9 mL, 12.8 mmol) were added to the reaction mixture under ice-cooling and the mixture was stirred for 2 hours. 2 mol/L
Hydrochloric acid (80 mL) was added to the reaction mixture under ice-cooling over 50 minutes, and the generated powder was collected by filtration. The powder was dissolved in ethyl acetate, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 6-(ethylthio)-3-t-butyl-1,3,5-triazine-2,4(1H,3H)-dione (1.15g, yie1d:50%) as pale brown powder.
1H-NMR (6 ppm TMS / DMSO-d6): 1.27 (3H, t, J=7.3 Hz), 1.55 (9H, s), 3.03 (2H, q, J=7.3), 12.30 (1H, brs) Potassium carbonate (17.97 g, 130 mmol) was added to mixture of 6-(ethylthio)-3-t-buty1-1,3,5-triazine-2,4(1H,3H)-dione (22.93 g, 100 mmol), 4-chlorobenzyl bromide (22.60 g, 110 mmol), and acetonitrile (200 mL), and the resulting mixture was heated at reflux and stirred for 3 hours. The reaction mixture was filtered, and the filtrate was concentrated in vacuo to give the crude product (39.9g) of 3-t-buty1-1-(4-chlorobenzy1)-6-Date Recue/Date Received 2020-11-26 (ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione as pale brown oil.
Trifluoroacetic acid (100 mL) was added to the resulting crude product, the resulting mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated in vacuo to give 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (29.03 g, yield: 97%) as pale brown powder.
1H-NMR (6 ppm TMS / d6-DMS0): 1.25 (3H, t, J=7.3 Hz), 3.08 (2H, q, J=7.3 Hz), 5.02 (2H, s), 7.30-7.33 (2H, m), 7.39-7.42 (2H, m), 11.61 (1H, s).
[0130]
(2) Preparation of 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-644-(2-pyridyloxy)phenylimino[-1,3,5-triazinane-2,4-dione (R-238) N)(NH
NNThrOMe Ny 0 0 rOMe EtS N 0 Eto INLi I.- 101 HN 0 CI
Potassium carbonate(1.80 g, 13 mmol) was added to mixture of 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (2.98 g, 10 mmol), methyl bromoacetate (1.04 mL, 11 mmol), and DMF (30 mL), and the resulting mixture was stired at room temperature for 4 hours. Water (250 mL) was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate (200 mL).
The organic layer was washed by brine (250 mL), and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue were added ethyl acetate and hexane. The generated powder was collected by filtration to give 1-(4-chlorobenzy1)-3-(methoxycarbonylmethy0-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (3.26 g, yield:
88%) as colorless powder.
1H-NMR (6 ppm TMS / CDC13): 1.37 (3H, t, J=7.2 Hz), 3.23 (2H, q, J=7.2 Hz), 3.78 (3H, s), 4.68 (2H, s), 5.11 (211, s), 7.27-7.35 (4H, m).
Mixture of 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (1.0 g, 2.70 mmol), 4-(2-pyridyloxy)aniline (1.0 g, 5.4 mmol), t-butanol (10.0 mL), and acetic acid (2.3 mL) was heated under reflux with stirring for 8 hours. Saturated aqueous solution of sodium hydrogen carbonate (30 mL) was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate (20 mL
X 3). The organic layer was washed by water (20 mL) and brine (20 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-3-(methoxycarbonylmethy0-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione(R-238, 1.24 g, yie1d:93%) as pale yellow amorphous.
1H-NMR (CDC13) 6: 3.78 (3H, s), 4.59 (2H, s), 5.23 (2H, s), 6.86 (2H, d, J=7.8 Hz), 6.96 (1H, d, J=8.1 Hz), 7.00 (1H, t, J=6.0 Hz), 7.15 (2H, d, J=8.1 Hz), 7.31 (2H, d, J=7.8 Hz), 7.49 (2H, d, J=7.8 Hz), 7.71 (1H, t, J=7.8 Hz), 7.86 (1H, s), 8.15 (1H, s).
(3) Preparation of 1-(4-chlorobenzy1)-3-(hydroxylcarbonylmethyl)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-239) Date Recue/Date Received 2020-11-26 Ny Ny 0 ANOH
HNJLNThrOMe (101 HN
1.1 CI CI
4mo1/L Lithium hydroxide(2.43 mL, 9.7 mmol) was added to mixture of 144-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-[442-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (1.2 g, 2.43 mmol), methanol (12 mL), THF (12 mL), and water (12 mL), and the resulting mixture was stirred under ice-cooling for 1 hour. The reaction mixture was poured into ice water, acidified by lmol/L hydrochloric acid, and extracted with ethyl acetate (100 mL). The organic layer was washed by water (50 mL) and brine (50 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue were added ethyl acetate and diethylether, and the generated powder was collected by filtration to give 1-(4-chlorobenzy1)-3-(hydroxylcarbonylmethyl)-644-(2-pyridyloxy)phenylimino[-1,3,5-triazinane-2,4-dione (11-239, 2.23 mg, yie1d:92%) as pale brown powder.
1H-NMR (6 ppm TMS / d6-DMS0): 4.40 (2H, s), 5.30 (2H, s), 7.03 (2H, d, J=7.8 Hz), 7.12(2H, s), 7.13(1H, s), 7.37 (4H, d, J=7.5 Hz), 7.45 (4H, d, J=7.5 Hz), 7.84 (1H, t, J=7.8 Hz), 8.16 (1H, s), 9.48 (1H, brs).
(2) Preparation of 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-644-(2-pyridyloxy)phenylimino[-1,3,5-triazinane-2,4-dione (R-238) N)(NH
NNThrOMe Ny 0 0 rOMe EtS N 0 Eto INLi I.- 101 HN 0 CI
Potassium carbonate(1.80 g, 13 mmol) was added to mixture of 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (2.98 g, 10 mmol), methyl bromoacetate (1.04 mL, 11 mmol), and DMF (30 mL), and the resulting mixture was stired at room temperature for 4 hours. Water (250 mL) was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate (200 mL).
The organic layer was washed by brine (250 mL), and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue were added ethyl acetate and hexane. The generated powder was collected by filtration to give 1-(4-chlorobenzy1)-3-(methoxycarbonylmethy0-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (3.26 g, yield:
88%) as colorless powder.
1H-NMR (6 ppm TMS / CDC13): 1.37 (3H, t, J=7.2 Hz), 3.23 (2H, q, J=7.2 Hz), 3.78 (3H, s), 4.68 (2H, s), 5.11 (211, s), 7.27-7.35 (4H, m).
Mixture of 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (1.0 g, 2.70 mmol), 4-(2-pyridyloxy)aniline (1.0 g, 5.4 mmol), t-butanol (10.0 mL), and acetic acid (2.3 mL) was heated under reflux with stirring for 8 hours. Saturated aqueous solution of sodium hydrogen carbonate (30 mL) was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate (20 mL
X 3). The organic layer was washed by water (20 mL) and brine (20 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-3-(methoxycarbonylmethy0-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione(R-238, 1.24 g, yie1d:93%) as pale yellow amorphous.
1H-NMR (CDC13) 6: 3.78 (3H, s), 4.59 (2H, s), 5.23 (2H, s), 6.86 (2H, d, J=7.8 Hz), 6.96 (1H, d, J=8.1 Hz), 7.00 (1H, t, J=6.0 Hz), 7.15 (2H, d, J=8.1 Hz), 7.31 (2H, d, J=7.8 Hz), 7.49 (2H, d, J=7.8 Hz), 7.71 (1H, t, J=7.8 Hz), 7.86 (1H, s), 8.15 (1H, s).
(3) Preparation of 1-(4-chlorobenzy1)-3-(hydroxylcarbonylmethyl)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-239) Date Recue/Date Received 2020-11-26 Ny Ny 0 ANOH
HNJLNThrOMe (101 HN
1.1 CI CI
4mo1/L Lithium hydroxide(2.43 mL, 9.7 mmol) was added to mixture of 144-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-[442-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (1.2 g, 2.43 mmol), methanol (12 mL), THF (12 mL), and water (12 mL), and the resulting mixture was stirred under ice-cooling for 1 hour. The reaction mixture was poured into ice water, acidified by lmol/L hydrochloric acid, and extracted with ethyl acetate (100 mL). The organic layer was washed by water (50 mL) and brine (50 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue were added ethyl acetate and diethylether, and the generated powder was collected by filtration to give 1-(4-chlorobenzy1)-3-(hydroxylcarbonylmethyl)-644-(2-pyridyloxy)phenylimino[-1,3,5-triazinane-2,4-dione (11-239, 2.23 mg, yie1d:92%) as pale brown powder.
1H-NMR (6 ppm TMS / d6-DMS0): 4.40 (2H, s), 5.30 (2H, s), 7.03 (2H, d, J=7.8 Hz), 7.12(2H, s), 7.13(1H, s), 7.37 (4H, d, J=7.5 Hz), 7.45 (4H, d, J=7.5 Hz), 7.84 (1H, t, J=7.8 Hz), 8.16 (1H, s), 9.48 (1H, brs).
[0131]
(4) Preparation of 1-(4-chlorobenzy1)-3-(carbamoylmethyl)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-240) ii Ny J-(1\ii0H NI-1 101 NN0 0 HN)*(NI2 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (150 mg, 0.31 mmol) was dissolved in DMF (2 mL).
Ammonium chloride (16.7 mg, 0.31 mmol), 1-hydroxybenzotriazole hydrate (57.4 mg, 0.38 mmol), 4-dimethylaminopyridine (3.8 mg, 0.03 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (71.9 mg, 0.38 mmol), and triethylamine (0.05 mL, 0.38 mmol) were added to the reaction mixture, and the resulting mixture was stirred at room temperature for 16 hours. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate (20 mL) and extracted with ethyl acetate (30 mL). The organic phase was washed by water (10 mL) and brine (10 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue was added ethyl acetate, and the generated powder was collected by filtration to give 1-(4-chlorobenzy1)-3-(carbamoylmethyl)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-240, 79 mg, yie1d:53%) as pale yellow powder.
Date Recue/Date Received 2020-11-26 1H-NMR (6 ppm TMS / DMSO-d6): 4.28 (2H, s), 5.29 (2H, s), 7.03 (2H, d, J=7.2 Hz), 7.12(4H, s), 7.35 (1H, s), 7.38 (1H, d, J=7.2 Hz), 7.42 (4H, d, J=9.3 Hz), 7.54 (1H, s), 7.85 (1H, t, J=7.2 Hz), 8.16 (1H, s), 9.37 (1H,$).
[Reference Example 2]
(4) Preparation of 1-(4-chlorobenzy1)-3-(carbamoylmethyl)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-240) ii Ny J-(1\ii0H NI-1 101 NN0 0 HN)*(NI2 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (150 mg, 0.31 mmol) was dissolved in DMF (2 mL).
Ammonium chloride (16.7 mg, 0.31 mmol), 1-hydroxybenzotriazole hydrate (57.4 mg, 0.38 mmol), 4-dimethylaminopyridine (3.8 mg, 0.03 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (71.9 mg, 0.38 mmol), and triethylamine (0.05 mL, 0.38 mmol) were added to the reaction mixture, and the resulting mixture was stirred at room temperature for 16 hours. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate (20 mL) and extracted with ethyl acetate (30 mL). The organic phase was washed by water (10 mL) and brine (10 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, to the residue was added ethyl acetate, and the generated powder was collected by filtration to give 1-(4-chlorobenzy1)-3-(carbamoylmethyl)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-240, 79 mg, yie1d:53%) as pale yellow powder.
Date Recue/Date Received 2020-11-26 1H-NMR (6 ppm TMS / DMSO-d6): 4.28 (2H, s), 5.29 (2H, s), 7.03 (2H, d, J=7.2 Hz), 7.12(4H, s), 7.35 (1H, s), 7.38 (1H, d, J=7.2 Hz), 7.42 (4H, d, J=9.3 Hz), 7.54 (1H, s), 7.85 (1H, t, J=7.2 Hz), 8.16 (1H, s), 9.37 (1H,$).
[Reference Example 2]
[0132]
(1) Preparation of 3-ethy1-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione NH II
õ
N, IN ' 0N NH2 N ,k DBU (63.3 mL, 420 mmol) was added dropwise to mixture of 1-amidinopyrazole hydrochloride (58.6 g, 400 mmol), ethyl isocyanate (33.2 mL, 420 mmol), and DMA (240 mL) at -10 C over 15 minutes, and the resulting mixture was stirred under ice-cooling for 30 minutes. 1,1'-Carbonyldiimidazole (97.2 g, 600 mmol) was added to the reaction mixture under ice-cooling, and then DBU(93 mL, 620 mmol) was added at -5 C
over 30 minutes. The reaction mixture was stirred under ice-cooling for 1 hour and then stirred at room temperature for 1 hour. 2 mol/L Hydrochloric acid (1.16 L) was added to the reaction mixture at 20 C over 1 hour. The resulting powder was collected by filtration to give 3-ethyl-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (73.0 g, yie1d:88%) as pale brown powder.
1H-NMR (6 ppm TMS / CDC13): 1.30 (6H, t, J=7.0 Hz), 4.02 (2H, q, J=7.0 Hz), 6.59 (1H, m), 7.34 (111, m), 8.48 (1H, m), 9.79 (1H, brs).
(1) Preparation of 3-ethy1-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione NH II
õ
N, IN ' 0N NH2 N ,k DBU (63.3 mL, 420 mmol) was added dropwise to mixture of 1-amidinopyrazole hydrochloride (58.6 g, 400 mmol), ethyl isocyanate (33.2 mL, 420 mmol), and DMA (240 mL) at -10 C over 15 minutes, and the resulting mixture was stirred under ice-cooling for 30 minutes. 1,1'-Carbonyldiimidazole (97.2 g, 600 mmol) was added to the reaction mixture under ice-cooling, and then DBU(93 mL, 620 mmol) was added at -5 C
over 30 minutes. The reaction mixture was stirred under ice-cooling for 1 hour and then stirred at room temperature for 1 hour. 2 mol/L Hydrochloric acid (1.16 L) was added to the reaction mixture at 20 C over 1 hour. The resulting powder was collected by filtration to give 3-ethyl-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (73.0 g, yie1d:88%) as pale brown powder.
1H-NMR (6 ppm TMS / CDC13): 1.30 (6H, t, J=7.0 Hz), 4.02 (2H, q, J=7.0 Hz), 6.59 (1H, m), 7.34 (111, m), 8.48 (1H, m), 9.79 (1H, brs).
[0133]
(2) Preparation of 1-(4-chlorobenzy1)-3-ethyl-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione N, NO
Diisopropylethylamine (92 mL, 528 mmol) was added dropwise to mixture of 3-ethy1-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (89 g, 480 mmol), 4-chlorobenzyl bromide (108 g, 528 mmol), and DMA (400 mL) at room temperature over 10 minutes, and the resulting mixture was stirred at 60 C for 2 hours. Water (800 mL) was added dropwise to the reaction mixture under ice-cooling over 40 minutes, and then hexane (200 mL) was added. The resulting powder was collected by filtration to give 1-(4-chlorobenzy1)-3-ethy1-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (156 g, yie1d:97.6%) as pale brown powder.
1H-NMR (6 ppm TMS / CDC13): 1.30 (3H, t, J=7.1 Hz), 4.04 (2H, q, J=7.1 Hz), 5.86 (2H, s), 6.48 (1H, m), 7.02 (2H, d, J=8.6 Hz), 7.20-7.25 (2H, m), 7.84 (1H, m), 8.33 (1H, m).
(2) Preparation of 1-(4-chlorobenzy1)-3-ethyl-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione N, NO
Diisopropylethylamine (92 mL, 528 mmol) was added dropwise to mixture of 3-ethy1-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (89 g, 480 mmol), 4-chlorobenzyl bromide (108 g, 528 mmol), and DMA (400 mL) at room temperature over 10 minutes, and the resulting mixture was stirred at 60 C for 2 hours. Water (800 mL) was added dropwise to the reaction mixture under ice-cooling over 40 minutes, and then hexane (200 mL) was added. The resulting powder was collected by filtration to give 1-(4-chlorobenzy1)-3-ethy1-6-(1-pyrazoly1)-1,3,5-triazine-2,4(1H,3H)-dione (156 g, yie1d:97.6%) as pale brown powder.
1H-NMR (6 ppm TMS / CDC13): 1.30 (3H, t, J=7.1 Hz), 4.04 (2H, q, J=7.1 Hz), 5.86 (2H, s), 6.48 (1H, m), 7.02 (2H, d, J=8.6 Hz), 7.20-7.25 (2H, m), 7.84 (1H, m), 8.33 (1H, m).
[0134]
(3) Preparation of 1-(4-chlorobenzy1)-644-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-015) Date Recue/Date Received 2020-11-26 COOEt 0 ?1 N)"LNCI 0 N 0 (10 HN N
NNO
CI
CI
Mixture of 1-(4-chlorobenzy1)-2-ethy1-6-(1-pyrazolyD-1,3,5-triazine-2,4(1H,3H)-dione (200 mg, 0.6 mmol), 4-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)aniline (176 mg, 0.6 mmol), and t-butanol (4 mL) was stirred at 80 C for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-644-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione(R-015, 321 mg, yie1d:96%) as white powder.
1H-NMR (CDC13) 6: 1.24 (3H, t, J= 7.2 Hz), 1.39 (3H, t, J= 7.2 Hz), 3.90 (2H, q, J= 7.1 Hz), 4.39 (211, q, J= 7.1 Hz), 5.21 (211, s), 6.88 (211, dd, J= 6.5, 2.0 Hz), 7.16 (211, dd, J=
6.7, 2.1 Hz), 7.30-7.33 (2H, m), 7.52 (2H, t, J= 4.1 Hz), 7.89 (1H, s), 8.35 (1H, d, J= 2.0 Hz), 8.63 (1H, d, J= 2.0 Hz).
(3) Preparation of 1-(4-chlorobenzy1)-644-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-015) Date Recue/Date Received 2020-11-26 COOEt 0 ?1 N)"LNCI 0 N 0 (10 HN N
NNO
CI
CI
Mixture of 1-(4-chlorobenzy1)-2-ethy1-6-(1-pyrazolyD-1,3,5-triazine-2,4(1H,3H)-dione (200 mg, 0.6 mmol), 4-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)aniline (176 mg, 0.6 mmol), and t-butanol (4 mL) was stirred at 80 C for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-644-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione(R-015, 321 mg, yie1d:96%) as white powder.
1H-NMR (CDC13) 6: 1.24 (3H, t, J= 7.2 Hz), 1.39 (3H, t, J= 7.2 Hz), 3.90 (2H, q, J= 7.1 Hz), 4.39 (211, q, J= 7.1 Hz), 5.21 (211, s), 6.88 (211, dd, J= 6.5, 2.0 Hz), 7.16 (211, dd, J=
6.7, 2.1 Hz), 7.30-7.33 (2H, m), 7.52 (2H, t, J= 4.1 Hz), 7.89 (1H, s), 8.35 (1H, d, J= 2.0 Hz), 8.63 (1H, d, J= 2.0 Hz).
[0135]
(4) Preparation of 1-(4-chlorobenzy1)-644-(3-chloro-5-hydroxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-016) COOEt COOH
CI CI
lmol/L Sodium hydroxide (0.75 mL) was added to mixture of 1-(4-chlorobenzy1)-6-[4-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (209 mg, 0.38 mmol), THF (0.75 mL), and methanol(0.75 mL), and the resulting mixture was stirred at room temperature for overnight. The reaction mixture was poured into water, acidified by 5% aqueous solution of citric acid, and then extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate.
After concentrated in vacuo, to the residue was added diethylether, and the generated powder was collected by filtration to give 1-(4-chlorobenzy1)-644-(3-chloro-5-hydroxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-016, 125 mg, yie1d:63%) as white powder.
1-1-1-NMR (CDC13) 6: 1.24 (3H, q, J= 8.3 Hz), 3.93 (2H, q, J= 7.0 Hz), 5.23 (2H, s), 6.91 (2H, d, J= 8.5 Hz), 7.14 (2H, dd, J= 6.8, 2.0 Hz), 7.32 (2H, d, J= 8.3 Hz), 7.53 (2H, d, J=
8.3 Hz), 8.36 (1H, d, J= 2.0 Hz), 8.74 (1H, d, J= 1.8 Hz), 9.78 (1H, s).
[Reference Example 3]
(4) Preparation of 1-(4-chlorobenzy1)-644-(3-chloro-5-hydroxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-016) COOEt COOH
CI CI
lmol/L Sodium hydroxide (0.75 mL) was added to mixture of 1-(4-chlorobenzy1)-6-[4-(3-chloro-5-ethoxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (209 mg, 0.38 mmol), THF (0.75 mL), and methanol(0.75 mL), and the resulting mixture was stirred at room temperature for overnight. The reaction mixture was poured into water, acidified by 5% aqueous solution of citric acid, and then extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate.
After concentrated in vacuo, to the residue was added diethylether, and the generated powder was collected by filtration to give 1-(4-chlorobenzy1)-644-(3-chloro-5-hydroxycarbony1-2-pyridyloxy)phenylimino]-3-ethyl-1,3,5-triazinane-2,4-dione (R-016, 125 mg, yie1d:63%) as white powder.
1-1-1-NMR (CDC13) 6: 1.24 (3H, q, J= 8.3 Hz), 3.93 (2H, q, J= 7.0 Hz), 5.23 (2H, s), 6.91 (2H, d, J= 8.5 Hz), 7.14 (2H, dd, J= 6.8, 2.0 Hz), 7.32 (2H, d, J= 8.3 Hz), 7.53 (2H, d, J=
8.3 Hz), 8.36 (1H, d, J= 2.0 Hz), 8.74 (1H, d, J= 1.8 Hz), 9.78 (1H, s).
[Reference Example 3]
[0136]
Date Recue/Date Received 2020-11-26 (1) Preparation of (5)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1,3,5-triazinane-2,4-dione N)(NH NJ-LNI)L10,Me HO ra H1\1).LN(A)Ls crMe HO r&
HNJLNOH
A A [ Me Me EtS N-'0 -N-- EtS NO , l' N N 0 , l' N N 0 Me 1101 101 101 1:101 C I C I C I C I
Di-2-methoxyethylazo dicarboxylate (56.2g, 240 mmol) was gradually added to mixture of 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (59.6 g, 200 mmol), methyl (S)-(+)-3-hydroxyisolactate (28.4 g, 240 mmol), triphenylphosphine (62.9 g, 240 mmol) and dioxane (400 mL), and the resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was added to ice water (1000 mL) and extracted with toluene (500 mL). The organic phase was washed by brine (700 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel column chromatography (ethyl acetate/hexane) to give (5)-1-(4-chloro benzy1)-6-(ethylthio)-3-(2-methoxycarbonylpropy1)-1,3,5-triazine-2,4(1H,311)-dione (64.44 g, yie1d:81%) as white solid.
1H-NMR (6 ppm TMS / CDC13): 1.19 (3H, d, J=5.7 Hz), 1.37 (3H, t, J=7.1 Hz), 2.96 (1H, m), 3.12 (211, q, J=7.1 Hz), 3.60 (3H, s), 3,98 (1H, m), 4.21 (1H, m), 5.08 (2H, s), 7.29-7.34 (4H, m).
Mixture of (S)-1-(4-chlorobenzy1)-6-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,31)-dione (5.0 g, 12.6 mmol), 4-aminophenol (2.06 g, 18.9 mmol), acetic acid (11.32g, 189 mmol), and t-butanol (100 mL) was stirred under heating at reflux for 3 hours. After the reaction, the reaction mixture was added to saturated aqueous solution of sodium hydrogen carbonate (500 mL) and extracted with ethyl acetate (500 mL). The organic layer was washed by lmol/L hydrochloric acid (500 mL), dried over anhydrous sodium sulfate. After concentrated in vacuo, to the residue were added toluene and ethyl acetate, and heated, and the generated powder was collected by filtration to give (S)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-methoxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (5.17 g, yie1d:92%) as white powder.
2mol/L Sodium hydroxide (25 mL) was added to mixture of (5)-1-(4-chlorobenzy1)-644-hydroxyphenylimino)-3-(2-methoxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (5.13 g, 11.5 mmol) and DMSO (50 mL), the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was added 2mol/L
hydrochloric acid (25 mL), then the mixture was poured into water and extracted with ethyl acetate.
The organic phase was washed by brine (700 mL) and dried over anhydrous sodium sulfate. After concentrated in vacuo, to the residue was added ethyl acetate, and the generated powder was collected by filtration to give (S)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (3.92 g, yie1d:79%) as white powder.
1H-NMR (6 ppm TMS / d6 DMS0): 0.99 (3H, d, J= 7.0 Hz), 2.50 (1H, t, J= 1.8 Hz), 2.74 (1H, td, J= 14.5, 7.2 Hz), 3.89-3.95 (1H, m), 5.21 (2H, s), 6.70-6.75 (2H, m), 7.01 (2H, d, J
= 7.8 Hz), 7.29 (2H, d, J= 8.5 Hz), 7.41 (2H, d, J= 8.5 Hz), 9.16 (1H, br s), 9.66 (1H, hr s).
Date Recue/Date Received 2020-11-26 (1) Preparation of (5)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1,3,5-triazinane-2,4-dione N)(NH NJ-LNI)L10,Me HO ra H1\1).LN(A)Ls crMe HO r&
HNJLNOH
A A [ Me Me EtS N-'0 -N-- EtS NO , l' N N 0 , l' N N 0 Me 1101 101 101 1:101 C I C I C I C I
Di-2-methoxyethylazo dicarboxylate (56.2g, 240 mmol) was gradually added to mixture of 1-(4-chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (59.6 g, 200 mmol), methyl (S)-(+)-3-hydroxyisolactate (28.4 g, 240 mmol), triphenylphosphine (62.9 g, 240 mmol) and dioxane (400 mL), and the resulting mixture was stirred at room temperature for 3 hours. The reaction mixture was added to ice water (1000 mL) and extracted with toluene (500 mL). The organic phase was washed by brine (700 mL) and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel column chromatography (ethyl acetate/hexane) to give (5)-1-(4-chloro benzy1)-6-(ethylthio)-3-(2-methoxycarbonylpropy1)-1,3,5-triazine-2,4(1H,311)-dione (64.44 g, yie1d:81%) as white solid.
1H-NMR (6 ppm TMS / CDC13): 1.19 (3H, d, J=5.7 Hz), 1.37 (3H, t, J=7.1 Hz), 2.96 (1H, m), 3.12 (211, q, J=7.1 Hz), 3.60 (3H, s), 3,98 (1H, m), 4.21 (1H, m), 5.08 (2H, s), 7.29-7.34 (4H, m).
Mixture of (S)-1-(4-chlorobenzy1)-6-(ethylthio)-3-(2-methoxycarbonylpropyl)-1,3,5-triazine-2,4(1H,31)-dione (5.0 g, 12.6 mmol), 4-aminophenol (2.06 g, 18.9 mmol), acetic acid (11.32g, 189 mmol), and t-butanol (100 mL) was stirred under heating at reflux for 3 hours. After the reaction, the reaction mixture was added to saturated aqueous solution of sodium hydrogen carbonate (500 mL) and extracted with ethyl acetate (500 mL). The organic layer was washed by lmol/L hydrochloric acid (500 mL), dried over anhydrous sodium sulfate. After concentrated in vacuo, to the residue were added toluene and ethyl acetate, and heated, and the generated powder was collected by filtration to give (S)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-methoxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (5.17 g, yie1d:92%) as white powder.
2mol/L Sodium hydroxide (25 mL) was added to mixture of (5)-1-(4-chlorobenzy1)-644-hydroxyphenylimino)-3-(2-methoxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (5.13 g, 11.5 mmol) and DMSO (50 mL), the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was added 2mol/L
hydrochloric acid (25 mL), then the mixture was poured into water and extracted with ethyl acetate.
The organic phase was washed by brine (700 mL) and dried over anhydrous sodium sulfate. After concentrated in vacuo, to the residue was added ethyl acetate, and the generated powder was collected by filtration to give (S)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropyl)-1,3,5-triazinane-2,4-dione (3.92 g, yie1d:79%) as white powder.
1H-NMR (6 ppm TMS / d6 DMS0): 0.99 (3H, d, J= 7.0 Hz), 2.50 (1H, t, J= 1.8 Hz), 2.74 (1H, td, J= 14.5, 7.2 Hz), 3.89-3.95 (1H, m), 5.21 (2H, s), 6.70-6.75 (2H, m), 7.01 (2H, d, J
= 7.8 Hz), 7.29 (2H, d, J= 8.5 Hz), 7.41 (2H, d, J= 8.5 Hz), 9.16 (1H, br s), 9.66 (1H, hr s).
[0137]
Date Recue/Date Received 2020-11-26 (2) Preparation of (5)-1-(4-chlorobenzy1)-644-(2-benzoxazolyloxy)phenylimino]-3-(2-methoxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (R-144) HO
HNANe0H N
NNO Me H11)..LILOH
CI
CI
Cesium carbonate (454 mg, 1.39 mmol) was added to mixture of (5)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (200 mg, 0.46 mmol), 2-chlorobenzoxazol (78 mg, 0.51 mmol), and DMSO
(1 mL), and the resulting mixture was stirred overnight at room temperature. The reaction mixture was poured into water, acidified by 5% aqueous solution of citric acid, and then extracted with ethyl acetate. The organic phase was washed by brine and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by high-performance liquid chromatography (acetnitrile/water containing 0.3%
formic acid) to give (S)-1-(4-chlorobenzy1)-644-(2-benzoxazolyloxy)phenylimino]-3-(2-methoxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (R-144, 55.3 mg, yie1d:22%) as white powder.
1-H-NMR (CDC13) 6: 1.13 (3H, d, J= 6.8 Hz), 2.74-2.79 (1H, m), 3.82 (1H, dd, J= 13.3, 5.4 Hz), 4.04 (1H, dd, J= 12.8, 9.2 Hz), 5.13 (1H, d, J= 14.4 Hz), 5.22 (1H, d, J=
14.3 Hz), 6.88 (2H, d, J= 7.5 Hz), 7.23-7.49 (10H, m), 8.96 (1H, s).
[Reference Example 4]
Date Recue/Date Received 2020-11-26 (2) Preparation of (5)-1-(4-chlorobenzy1)-644-(2-benzoxazolyloxy)phenylimino]-3-(2-methoxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (R-144) HO
HNANe0H N
NNO Me H11)..LILOH
CI
CI
Cesium carbonate (454 mg, 1.39 mmol) was added to mixture of (5)-1-(4-chlorobenzy1)-6-(4-hydroxyphenylimino)-3-(2-hydroxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (200 mg, 0.46 mmol), 2-chlorobenzoxazol (78 mg, 0.51 mmol), and DMSO
(1 mL), and the resulting mixture was stirred overnight at room temperature. The reaction mixture was poured into water, acidified by 5% aqueous solution of citric acid, and then extracted with ethyl acetate. The organic phase was washed by brine and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by high-performance liquid chromatography (acetnitrile/water containing 0.3%
formic acid) to give (S)-1-(4-chlorobenzy1)-644-(2-benzoxazolyloxy)phenylimino]-3-(2-methoxycarbonylpropy1)-1,3,5-triazinane-2,4-dione (R-144, 55.3 mg, yie1d:22%) as white powder.
1-H-NMR (CDC13) 6: 1.13 (3H, d, J= 6.8 Hz), 2.74-2.79 (1H, m), 3.82 (1H, dd, J= 13.3, 5.4 Hz), 4.04 (1H, dd, J= 12.8, 9.2 Hz), 5.13 (1H, d, J= 14.4 Hz), 5.22 (1H, d, J=
14.3 Hz), 6.88 (2H, d, J= 7.5 Hz), 7.23-7.49 (10H, m), 8.96 (1H, s).
[Reference Example 4]
[0138]
(1) Preparation of 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2-propeny1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-254) ). 0 NA N NH N l'OTHP 0 jk. HNANCOH
EtS N 0 EtS N 0 =
CI CI
CI
1-(4-Chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (1090 mg, 3.65 mmol), 2-(tetrahydropyran-2-yloxy)methy1-2-propenol (628 mg, 3.65 mmol), and triphenylphosphine (956 mg, 3.65 mmol) were dissolved in 1,4-dioxane(5.0 mL).
Dimethoxyethylazadicarboxylate (854 mg, 3.65 mmol) was added to the reaction mixture, the resulting mixture was stirred at room temperature for 3 hours. Then, triphenylphosphine (478 mg, 1.82 mmol) and dimethoxyethylazadicarboxylate (478 mg, 1.82 mmol) were added to the reaction mixture, and the resulting mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated in vacuo, and to the resulting residue was added diethylether. The generated powder was removed by Date Recue/Date Received 2020-11-26 filtration. The filtrate was washed by water and brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-6-(ethylthio)-3-(2-tetrahydropyran-2-yloxymethy1-2-propeny1)-1,3,5-triazine-2,4(1H,3H)-dione (1589 mg, yie1d:96%) as colorless oil.
t-Butanol (2.4 mL), 4-(2-pyridy1oxy)aniline (148 mg, 0.8 mmol) and acetic acid (0.58 mL, 10 mmol) were added to 1-(4-chlorobenzy1)-6-(ethylthio)-3-(2-tetrahydropyran-2-yloxymethy1-2-propeny1)-1,3,5-triazine-2,4(1H,3H)-dione (300 mg, 0.66 mmol), and the reaction mixture was heated at reflux for 15 hours. To the reaction mixture was added 2mo1/L hydrochloric acid (0.33 mL) and stirred at room temperature for 8 hours. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate and extracted with ethyl acetate. The organic phase was washed by brine (30 mL) and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2-propeny1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione(R-254, 206 mg, yie1d:63%) as white amorphous.
1H-NMR (CDC13) 6: .52-2.66 (1H, m), 4.08 (2H, d, J = 5.0 Hz), 4.50 (2H, s), 5.16 (2H, d, J
= 21.1 Hz), 5.21 (2H, s), 6.86 (2H, d, J = 8.5 Hz), 6.96-7.01 (2H, m), 7.13 (2H, d, J = 8.8 Hz), 7.31 (211, d, J = 8.3 Hz), 7.51 (211, d, J = 8.5 Hz), 7.69-7.73 (ilI, m), 8.10 (ilI, d, J =
3.5 Hz), 8.14-8.40 (1H, m).
(1) Preparation of 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2-propeny1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-254) ). 0 NA N NH N l'OTHP 0 jk. HNANCOH
EtS N 0 EtS N 0 =
CI CI
CI
1-(4-Chlorobenzy1)-6-(ethylthio)-1,3,5-triazine-2,4(1H,3H)-dione (1090 mg, 3.65 mmol), 2-(tetrahydropyran-2-yloxy)methy1-2-propenol (628 mg, 3.65 mmol), and triphenylphosphine (956 mg, 3.65 mmol) were dissolved in 1,4-dioxane(5.0 mL).
Dimethoxyethylazadicarboxylate (854 mg, 3.65 mmol) was added to the reaction mixture, the resulting mixture was stirred at room temperature for 3 hours. Then, triphenylphosphine (478 mg, 1.82 mmol) and dimethoxyethylazadicarboxylate (478 mg, 1.82 mmol) were added to the reaction mixture, and the resulting mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated in vacuo, and to the resulting residue was added diethylether. The generated powder was removed by Date Recue/Date Received 2020-11-26 filtration. The filtrate was washed by water and brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The resulting residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-6-(ethylthio)-3-(2-tetrahydropyran-2-yloxymethy1-2-propeny1)-1,3,5-triazine-2,4(1H,3H)-dione (1589 mg, yie1d:96%) as colorless oil.
t-Butanol (2.4 mL), 4-(2-pyridy1oxy)aniline (148 mg, 0.8 mmol) and acetic acid (0.58 mL, 10 mmol) were added to 1-(4-chlorobenzy1)-6-(ethylthio)-3-(2-tetrahydropyran-2-yloxymethy1-2-propeny1)-1,3,5-triazine-2,4(1H,3H)-dione (300 mg, 0.66 mmol), and the reaction mixture was heated at reflux for 15 hours. To the reaction mixture was added 2mo1/L hydrochloric acid (0.33 mL) and stirred at room temperature for 8 hours. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate and extracted with ethyl acetate. The organic phase was washed by brine (30 mL) and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2-propeny1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione(R-254, 206 mg, yie1d:63%) as white amorphous.
1H-NMR (CDC13) 6: .52-2.66 (1H, m), 4.08 (2H, d, J = 5.0 Hz), 4.50 (2H, s), 5.16 (2H, d, J
= 21.1 Hz), 5.21 (2H, s), 6.86 (2H, d, J = 8.5 Hz), 6.96-7.01 (2H, m), 7.13 (2H, d, J = 8.8 Hz), 7.31 (211, d, J = 8.3 Hz), 7.51 (211, d, J = 8.5 Hz), 7.69-7.73 (ilI, m), 8.10 (ilI, d, J =
3.5 Hz), 8.14-8.40 (1H, m).
[0139]
(2) Preparation of 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2,3-dihydroxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-255) OH
HWILN-'-r0H
NNO NNO OH
CI CI
1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2-propeny1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (192 mg, 0.39 mmol) was dissolved in 95% aqueous solution of THF (2.2 mL). Potassium osmate (VI) dehydrate (14.4 mg, 0.04 mmol) and N-methylmorpholine (92 mg, 0.78 mmol) were added to the reaction mixture, the resulting mixture was stirred at room temperature for 2 hours. To the reaction mixture was added 5% aqueous solution of sodium sulfite (1.0 mL) and water (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed by brine (50 mL) and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography(chloroform/methanol) and powdered with ethyl acetate and hexane to give 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2,3-dihydroxypropy1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-255, 155 mg, yie1d:75%) as white powder.
H-NMR (DMSO-d6) 6: 3.26-3.31 (4H, m), 3.94 (2H, s), 4.31 (1H, s), 4.42 (2H, t, J = 6.0 Hz), 5.29 (2H, s), 6.97-7.18 (4H, m), 7.30-7.52 (6H, m), 7.85 (1H, t, J = 7.3 Hz), 8.16 (1H, d, J = 3.3 Hz), 9.39 (1H, s).
[Reference Example 5]
Preparation of 1-(4-chlorobenzy1)-3-(2-hydroxyethyl)-644-(2-pyridyloxy)phenylimino]-Date Recue/Date Received 2020-11-26 1,3,5-triazinane-2,4-dione (R-257) Ny Ny 0 HNJLNOH
0 r&i I.
HNNrOMe CI
CI
Lithium aluminum hydride (38 mg, 1 mmol) was added to 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (248 mg, 0.5 mmol) in THF (6 mL) under ice-cooling, and the resulting mixture was stirred at room temperature for 1.5 hours. To the reaction mixture were added water (0.04 ml) and 10% aqueous solution of sodium hydroxide (0.04 ml) and stirred at room temperature for 1 hour. The reaction mixture was filtrated through CeliteTM, washed by ethyl acetate, and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-3-(2-hydroxyethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione(R-257, 65.4 mg, yie1d:28%) as white solid.
1H-NMR (CDC13) 6: 2.25 (1H, t, J=5.7 Hz), 3.80 (2H, q, J=5.4 Hz), 4.05 (2H, t, J=5.1 Hz), 5.20 (2H, s), 6.85 (2H, d, J=8.5 Hz), 6.97 (1H, d, J=8.3 Hz), 7.00 (1H, dd, J=6.8, 5.3 Hz), 7.13 (2H, d, J=8.5 Hz), 7.30 (2H, d, J=8.3 Hz), 7.51 (2H, d, J=8.3 Hz), 7.71 (1H, t, J=8.0 Hz), 8.07 (1H, brs), 8.16 (1H, dd, J=4.8, 1.2 Hz).
[Reference Example 6]
(2) Preparation of 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2,3-dihydroxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-255) OH
HWILN-'-r0H
NNO NNO OH
CI CI
1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2-propeny1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (192 mg, 0.39 mmol) was dissolved in 95% aqueous solution of THF (2.2 mL). Potassium osmate (VI) dehydrate (14.4 mg, 0.04 mmol) and N-methylmorpholine (92 mg, 0.78 mmol) were added to the reaction mixture, the resulting mixture was stirred at room temperature for 2 hours. To the reaction mixture was added 5% aqueous solution of sodium sulfite (1.0 mL) and water (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed by brine (50 mL) and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography(chloroform/methanol) and powdered with ethyl acetate and hexane to give 1-(4-chlorobenzy1)-3-(2-hydroxymethy1-2,3-dihydroxypropy1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-255, 155 mg, yie1d:75%) as white powder.
H-NMR (DMSO-d6) 6: 3.26-3.31 (4H, m), 3.94 (2H, s), 4.31 (1H, s), 4.42 (2H, t, J = 6.0 Hz), 5.29 (2H, s), 6.97-7.18 (4H, m), 7.30-7.52 (6H, m), 7.85 (1H, t, J = 7.3 Hz), 8.16 (1H, d, J = 3.3 Hz), 9.39 (1H, s).
[Reference Example 5]
Preparation of 1-(4-chlorobenzy1)-3-(2-hydroxyethyl)-644-(2-pyridyloxy)phenylimino]-Date Recue/Date Received 2020-11-26 1,3,5-triazinane-2,4-dione (R-257) Ny Ny 0 HNJLNOH
0 r&i I.
HNNrOMe CI
CI
Lithium aluminum hydride (38 mg, 1 mmol) was added to 1-(4-chlorobenzy1)-3-(methoxycarbonylmethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (248 mg, 0.5 mmol) in THF (6 mL) under ice-cooling, and the resulting mixture was stirred at room temperature for 1.5 hours. To the reaction mixture were added water (0.04 ml) and 10% aqueous solution of sodium hydroxide (0.04 ml) and stirred at room temperature for 1 hour. The reaction mixture was filtrated through CeliteTM, washed by ethyl acetate, and dried over anhydrous magnesium sulfate. After concentrated in vacuo, the residue was purified by silica-gel chromatography (ethyl acetate/hexane) to give 1-(4-chlorobenzy1)-3-(2-hydroxyethyl)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione(R-257, 65.4 mg, yie1d:28%) as white solid.
1H-NMR (CDC13) 6: 2.25 (1H, t, J=5.7 Hz), 3.80 (2H, q, J=5.4 Hz), 4.05 (2H, t, J=5.1 Hz), 5.20 (2H, s), 6.85 (2H, d, J=8.5 Hz), 6.97 (1H, d, J=8.3 Hz), 7.00 (1H, dd, J=6.8, 5.3 Hz), 7.13 (2H, d, J=8.5 Hz), 7.30 (2H, d, J=8.3 Hz), 7.51 (2H, d, J=8.3 Hz), 7.71 (1H, t, J=8.0 Hz), 8.07 (1H, brs), 8.16 (1H, dd, J=4.8, 1.2 Hz).
[Reference Example 6]
[0140]
(1) Preparation of 1-(4-chlorobenzy1)-3-(3-tetrahydropyran-2-yloxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione HNANOTHP
NNO
CI I.
CI
Mixture of 1-(4-chlorobenzy1)-6-(ethylthio)-3-(3-tetrahydropyran-2-yloxypropy1)-1,3,5-triazine-2,4(1H,311)-dione (230 mg, 0.52 mol), 4-(2-pyridyloxy)aniline (146 mg, 0.78 mmol), acetic acid (0.45 mL), and t-butanol (4 ml) was stirred overnight under heating at reflux. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed by brine and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel column chromatography (hexane/ethyl acetate) to give 1-(4-chlorobenzy1)-3-(3-tetrahydropyran-2-yloxypropy1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (188 mg, yie1d:64%) as colorless amorphous.
1H-NMR (CDC13) 6: 1.47-1.66 (6H, m), 1.95 (2H, td, J= 12.3, 6.6 Hz), 3.42-3.49 (2H, m), 3.80-3.84 (2H, m), 3.96-4.00 (2H, m), 4.52 (1H, br s), 5.20 (211, s), 6.84 (2H, d, J= 8.6 Hz), Date Recue/Date Received 2020-11-26 6.95-7.01 (2H, m), 7.13 (2H, d, J= 8.6 Hz), 7.30 (2H, d, J= 8.3 Hz), 7.52 (2H, d, J= 8.3 Hz), 7.68-7.73 (1H, m), 7.95 (1H, s), 8.13 (1H, t, J= 2.5 Hz).
(1) Preparation of 1-(4-chlorobenzy1)-3-(3-tetrahydropyran-2-yloxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione HNANOTHP
NNO
CI I.
CI
Mixture of 1-(4-chlorobenzy1)-6-(ethylthio)-3-(3-tetrahydropyran-2-yloxypropy1)-1,3,5-triazine-2,4(1H,311)-dione (230 mg, 0.52 mol), 4-(2-pyridyloxy)aniline (146 mg, 0.78 mmol), acetic acid (0.45 mL), and t-butanol (4 ml) was stirred overnight under heating at reflux. To the reaction mixture was added saturated aqueous solution of sodium hydrogen carbonate (50 mL) and extracted with ethyl acetate (50 mL). The organic phase was washed by brine and dried over anhydrous sodium sulfate. After concentrated in vacuo, the residue was purified by silica-gel column chromatography (hexane/ethyl acetate) to give 1-(4-chlorobenzy1)-3-(3-tetrahydropyran-2-yloxypropy1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (188 mg, yie1d:64%) as colorless amorphous.
1H-NMR (CDC13) 6: 1.47-1.66 (6H, m), 1.95 (2H, td, J= 12.3, 6.6 Hz), 3.42-3.49 (2H, m), 3.80-3.84 (2H, m), 3.96-4.00 (2H, m), 4.52 (1H, br s), 5.20 (211, s), 6.84 (2H, d, J= 8.6 Hz), Date Recue/Date Received 2020-11-26 6.95-7.01 (2H, m), 7.13 (2H, d, J= 8.6 Hz), 7.30 (2H, d, J= 8.3 Hz), 7.52 (2H, d, J= 8.3 Hz), 7.68-7.73 (1H, m), 7.95 (1H, s), 8.13 (1H, t, J= 2.5 Hz).
[0141]
(2) Preparation of 1-(4-chlorobenzy1)-3-(3-hydroxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-251) HNANOTHP
io HNANOH
NNO
CI CI
p-Toluenesulfonic acid hydrate (12 mg, 0.064 mmol) was added to 1-(4-chlorobenzy1)-3-(3-tetrahydropyran-2-yloxypropy1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (180 mg, 0.32 mol) in methanol (2 ml), and the resulting mixture was stirred at 50 C for 2 hours. To the reaction mixture was added triethylamine and concentrated in vacuo. The residue was purified by silica-gel column chromatography (hexane/ethyl acetate) to give 1-(4-chlorobenzy1)-3-(3-hydroxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-251, 150 mg, yie1d:99%) as colorless amorphous.
1H-NMR (CDC13) 6: 1.83-1.89 (2H, m), 2.63 (1H, t, J= 6.5 Hz), 3.59 (2H, q, J=
5.9 Hz), 4.00 (2H, t, J= 6.1 Hz), 5.22 (2H, s), 6.86 (2H, d, J= 8.8 Hz), 6.97-7.01 (2H, m), 7.13 (2H, d, J= 8.5 Hz), 7.31 (2H, d, J= 8.5 Hz), 7.52 (2H, d, J= 8.3 Hz), 7.69-7.74 (1H, m), 8.10 (1H, dd, J= 4.9, 1.4 Hz).
(2) Preparation of 1-(4-chlorobenzy1)-3-(3-hydroxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-251) HNANOTHP
io HNANOH
NNO
CI CI
p-Toluenesulfonic acid hydrate (12 mg, 0.064 mmol) was added to 1-(4-chlorobenzy1)-3-(3-tetrahydropyran-2-yloxypropy1)-6-[4-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (180 mg, 0.32 mol) in methanol (2 ml), and the resulting mixture was stirred at 50 C for 2 hours. To the reaction mixture was added triethylamine and concentrated in vacuo. The residue was purified by silica-gel column chromatography (hexane/ethyl acetate) to give 1-(4-chlorobenzy1)-3-(3-hydroxypropy1)-644-(2-pyridyloxy)phenylimino]-1,3,5-triazinane-2,4-dione (R-251, 150 mg, yie1d:99%) as colorless amorphous.
1H-NMR (CDC13) 6: 1.83-1.89 (2H, m), 2.63 (1H, t, J= 6.5 Hz), 3.59 (2H, q, J=
5.9 Hz), 4.00 (2H, t, J= 6.1 Hz), 5.22 (2H, s), 6.86 (2H, d, J= 8.8 Hz), 6.97-7.01 (2H, m), 7.13 (2H, d, J= 8.5 Hz), 7.31 (2H, d, J= 8.5 Hz), 7.52 (2H, d, J= 8.3 Hz), 7.69-7.74 (1H, m), 8.10 (1H, dd, J= 4.9, 1.4 Hz).
[0142]
The following compounds of the invention were synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Examples, with reference to the contents described in and W02012/020749 as needed. The chemical structure of the compounds and the physical properties of them are described below.
(Method of identification for the compound) LC/MS data of compound of the present invention were measured under any one of the following 2 conditions (Methods 1 and 2), and a retention time (RT) (unit: min) and [M+H]+ are shown.
(Method 1) Column: Shim-pack XR-ODS (2.2pm, i.d.50x3.0mm) (Shimadzu) Flow rate: 1.6 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 0.1% formic acid-containing aqueous solution, and [B] is 0.1% formic acid-containing acetnitrile solution.
Gradient: Linear gradient of 10% to 100% solvent [B] for 3 minutes was performed, and 100% solvent [B] was maintained for 1 minute.
(Method 2) Column: ACQUITY UPLC (registered trademark) BEH C18 (1.7pm, i.d.2. 1x50mm) (Waters) Flow rate: 0.8 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 10 mM ammonium carbonate-containing aqueous solution, and [B] is Date Recue/Date Received 2020-11-26 acetonitrile Gradient: Linear gradient of 5% to 100% solvent [B] for 3.5 minutes was performed, and 100% solvent [B] was maintained for 0.5 minute.
The following compounds of the invention were synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Examples, with reference to the contents described in and W02012/020749 as needed. The chemical structure of the compounds and the physical properties of them are described below.
(Method of identification for the compound) LC/MS data of compound of the present invention were measured under any one of the following 2 conditions (Methods 1 and 2), and a retention time (RT) (unit: min) and [M+H]+ are shown.
(Method 1) Column: Shim-pack XR-ODS (2.2pm, i.d.50x3.0mm) (Shimadzu) Flow rate: 1.6 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 0.1% formic acid-containing aqueous solution, and [B] is 0.1% formic acid-containing acetnitrile solution.
Gradient: Linear gradient of 10% to 100% solvent [B] for 3 minutes was performed, and 100% solvent [B] was maintained for 1 minute.
(Method 2) Column: ACQUITY UPLC (registered trademark) BEH C18 (1.7pm, i.d.2. 1x50mm) (Waters) Flow rate: 0.8 mL/min UV detection wavelength: 254nm Mobile phase: [A] is 10 mM ammonium carbonate-containing aqueous solution, and [B] is Date Recue/Date Received 2020-11-26 acetonitrile Gradient: Linear gradient of 5% to 100% solvent [B] for 3.5 minutes was performed, and 100% solvent [B] was maintained for 0.5 minute.
[0143]
[Table 1]
Date Recue/Date Received 2020-11-26 Compound No Structure [M+1-1]+ RI Method F
-----Li .-----r " F o u 1-001 5 Ii ,..LN 0 572 2.61 1 Sc' F
----1---1, I N
-----f--- F 0 1......_,..i..0 0 ,--11-, 1-002 a HN N _ OH 558 2.33 1 .--41111111P N----1-N -.-L---0 Sc' F
-----L-1, I N
'-----r 0 0 1-003 0 a HVILN'7L-0 554 2A3 1 --411111111' N')--.N""--LO
Sc ri .-----L-1, I N
'----r 0 -0 1-004 a H N N"----KLO 570 2.57 Sc F
f-L-1 -....1...., N
An 1-005 HN')---N''-'-ick0F1 540 2.15 411111 N-)---'N 0 Date Recue/Date Received 2020-11-26 [Table 2]
Comround No Structure [M+I-1]+ RI Method lIal e-,----, 8 aim 1111110 HE rilIV-X1L'OH
1141---Wk--.0 556 2.28 1 Sri r-'-'-1 F .--f-N 0 0 NI-?-1---trk-0 554 2A3 1 I
......-z-õ.õ ....F
-I III
el HN-11-N
554 2.45 1 rN '-k-12I
Sri r.--1 .-_.....r, N
I HN)--- N..---)([1--0H
1-0109 NN-LO 540 2.2 1 Sri ...---............ .... F
1 [TA
--,.õ,...-.:. 0 0 8 Aii.
if HE, N'')\--)L0 H
1'1 N
...-,1õ. ,..k.0 540 2.21 1 el a Date Recue/Date Received 2020-11-26 [Table 3]
Compound No Structure [M+1-1]+ RI Method I r[j o aim Ht-AN-------rLo 1111P1 NAN --La Sc' c1 I - N -.,r 0 .---70 0 i 1-012 NN '0 570 2.58 1 Sc' _.,...-C1 41 HN'I'NOM
1-013 570 2.56 1 NC-j---N'--LO
5c, I N
--.,f 0 0 0 JI, 1-014 PreL-542 2.18 1 t 5c1 rrel 0 ahh HNAN----XII-OH
1-015 556 2.25 1 '111111 rfl-Nrk--0 . a Date Recue/Date Received 2020-11-26 [Table 4]
Compound No Structure [M+I-1]+ RI Method ....--..õ.õ,....ri I J.
0 Ail HN le-----24--OH
I-016 556 2.28 1 "111 N-i-L-N .--k---0 Sc' F
Y------N...........,-,--40) HN -1.-V-X-11.--0 H
I-017 VI---N .---L---0 538 2.13 1 Sc' F
frL-' 1-018 8, 0 HNANz-X11-"OH 538 2.11 1 114111F N.f-j---N---k--D
Sc' F
0 , 40 H
--y- N
1-019 ell HN N'' 538 2.13 1 N.--;.--1---N---k-o Sc' F
0 ..k. ,E3 ' 0 H
1-020 /40 HN re 538 2.08 1 N.---:.--1---N---k--0 III IGI
Date Recue/Date Received 2020-11-26 [Table 5]
Comround No Structure [M+H]+ RI Method F
F
-----H-.
.-..,,..-, 0 C
1-021 6 di.
HNANO --- 602 2.48 1 =0 F
a-1'F
, N 0 0 1-022 . 1 I40HN A Nr--y70 H 574 215 ,---) , Si CI
F
0'1- F
fLz--1 111P1HN -111 ---.--"-----<k0 H
NN ---L-0 588 2.22 1 so' f----1 ,,,r,,N , 1 40 1-1õ:.I.e- N -----.--(0 HND 542 2.23 1 F F
F
.1-t1 ---......r.-.N 0 8 =
--.--0 A.
1-025 . HI N ---.I.L0 542 2.22 1 r-J N 0 FSF
Date Recue/Date Received 2020-11-26 [Table 6]
Comround No Structure [M+I-1]+ RI Method ....,-...-- ....F
-I T
1-026 542 2.24 1 he-1'N -.-L---0 FSF
-1-'-'-'1 -,T,..... N
C
41 HNN --ill' OH
1-027 N 0 528 1.99 1 hi' FSF
F
e----, õIL
1-028 3 411 H....N 11--ilLOH 528 1.98 1 ........- F
I N
8 Ai.
1-029 Ilil HE i --It---NryIL-0 H
l'N0 528 2 1 FSF
----..
I F
N ,--- 0 0 . HN N -----I--0 1-030 N N_k..o 590 2.52 1 Sc' Date Recue/Date Received 2020-11-26 [Table 7]
Compound No Structure [M+1-1]+ RI Method --, I F
N .,---0 F F it, 0 HI 1,---------A----0 1-031 604 2.61 1 '.111111111P N [ 1 0 SO' ir-o Fr.-F A
401 1 111 --'0 -ill'OH
1-032 N N 576 2.28 1 11.1 Cl ----..
NI __,... F
0 F 4 A,I1, 01 HN N GH
1-033 590 2.35 1 N--->1%- N ----13 Sc' F
F F
----, j...1 I
,....y,..., N
1-034 0 is FIN1NTh 570 2A6 1 l NND
*
----, 0 --1-1--, 1-035 Ø Hil 1-417 N N 0 570 2.4 1 .-4111111111P
IP
Date Recue/Date Received 2020-11-26 [Table 8]
, Compound No Structure [M+1-1]+ RI Method F
f-LI
1-036 6ah Hwit-N----TIII 520 2.24 1 '-1111111' N N 0 1.1 F
1-037 60 HNAN--------A-1- 534 2.34 1 'lir Nr-1-N"k-13 F
F F
---, õ.1.1 t,...0 HN A N -'1[1-'0 H 556 2.21 1 F
,z,.. ...VF
---____;,, N 0 0 1-039 8ah Pl!rji-Thriji-%0H 556 2.17 1 'gill"' N N 0 F
--'-L-1 6 J-L.
1-040 0 HE, ry-11-0H 506 1.98 1 rr N 0 Date Recue/Date Received 2020-11-26 [Table 9]
Compound No Structure [M+I-1]+ RI
Method F
'ILI
40 H,...N1 li-----KiLoH 520 2.06 1 F
,-----/---.--.1 I N---..r.--IP
CI
F ----:
....1_, i F 0 -------f N 0 0 0 =401 11 ..1,4 --jt- N ----.1)---0 '-I-043 N N 0 588 2.36 1 I
'Sc' F 1 %------1--._ N
_..c-i F 0 --. 1 0 ---0 HN N '--1.11--CH
1-044 574 2.13 1 'IllitilliP rel-IT-4.0 Sc N
a 40 H N N -.-----1-0 1-045 547 2.24 1 rf-1--N".-----.0 Sc' Date Recue/Date Received 2020-11-26 [Table 10]
Compound No Structure [M+1-1]+ RI Method N*
HNAN O
1-046 --' N N 0 561 2.34 1 .1 a ii----0 N 410 HI A 1-1--11.-OH
1-047 N N 0 533 1.99 1 . GI
rj 11Nla 547 2.07 1 1101 a ,.._-... F
--)-- o o o aih 554 1.97 1 Lill N-;--1W-L.--.0 a a -,Tõ,N
a HN "'IL N XAOH
1-050 554 -1.95 1 qi-Lir N N 0 Si a Date Recue/Date Received 2020-11-26
[Table 1]
Date Recue/Date Received 2020-11-26 Compound No Structure [M+1-1]+ RI Method F
-----Li .-----r " F o u 1-001 5 Ii ,..LN 0 572 2.61 1 Sc' F
----1---1, I N
-----f--- F 0 1......_,..i..0 0 ,--11-, 1-002 a HN N _ OH 558 2.33 1 .--41111111P N----1-N -.-L---0 Sc' F
-----L-1, I N
'-----r 0 0 1-003 0 a HVILN'7L-0 554 2A3 1 --411111111' N')--.N""--LO
Sc ri .-----L-1, I N
'----r 0 -0 1-004 a H N N"----KLO 570 2.57 Sc F
f-L-1 -....1...., N
An 1-005 HN')---N''-'-ick0F1 540 2.15 411111 N-)---'N 0 Date Recue/Date Received 2020-11-26 [Table 2]
Comround No Structure [M+I-1]+ RI Method lIal e-,----, 8 aim 1111110 HE rilIV-X1L'OH
1141---Wk--.0 556 2.28 1 Sri r-'-'-1 F .--f-N 0 0 NI-?-1---trk-0 554 2A3 1 I
......-z-õ.õ ....F
-I III
el HN-11-N
554 2.45 1 rN '-k-12I
Sri r.--1 .-_.....r, N
I HN)--- N..---)([1--0H
1-0109 NN-LO 540 2.2 1 Sri ...---............ .... F
1 [TA
--,.õ,...-.:. 0 0 8 Aii.
if HE, N'')\--)L0 H
1'1 N
...-,1õ. ,..k.0 540 2.21 1 el a Date Recue/Date Received 2020-11-26 [Table 3]
Compound No Structure [M+1-1]+ RI Method I r[j o aim Ht-AN-------rLo 1111P1 NAN --La Sc' c1 I - N -.,r 0 .---70 0 i 1-012 NN '0 570 2.58 1 Sc' _.,...-C1 41 HN'I'NOM
1-013 570 2.56 1 NC-j---N'--LO
5c, I N
--.,f 0 0 0 JI, 1-014 PreL-542 2.18 1 t 5c1 rrel 0 ahh HNAN----XII-OH
1-015 556 2.25 1 '111111 rfl-Nrk--0 . a Date Recue/Date Received 2020-11-26 [Table 4]
Compound No Structure [M+I-1]+ RI Method ....--..õ.õ,....ri I J.
0 Ail HN le-----24--OH
I-016 556 2.28 1 "111 N-i-L-N .--k---0 Sc' F
Y------N...........,-,--40) HN -1.-V-X-11.--0 H
I-017 VI---N .---L---0 538 2.13 1 Sc' F
frL-' 1-018 8, 0 HNANz-X11-"OH 538 2.11 1 114111F N.f-j---N---k--D
Sc' F
0 , 40 H
--y- N
1-019 ell HN N'' 538 2.13 1 N.--;.--1---N---k-o Sc' F
0 ..k. ,E3 ' 0 H
1-020 /40 HN re 538 2.08 1 N.---:.--1---N---k--0 III IGI
Date Recue/Date Received 2020-11-26 [Table 5]
Comround No Structure [M+H]+ RI Method F
F
-----H-.
.-..,,..-, 0 C
1-021 6 di.
HNANO --- 602 2.48 1 =0 F
a-1'F
, N 0 0 1-022 . 1 I40HN A Nr--y70 H 574 215 ,---) , Si CI
F
0'1- F
fLz--1 111P1HN -111 ---.--"-----<k0 H
NN ---L-0 588 2.22 1 so' f----1 ,,,r,,N , 1 40 1-1õ:.I.e- N -----.--(0 HND 542 2.23 1 F F
F
.1-t1 ---......r.-.N 0 8 =
--.--0 A.
1-025 . HI N ---.I.L0 542 2.22 1 r-J N 0 FSF
Date Recue/Date Received 2020-11-26 [Table 6]
Comround No Structure [M+I-1]+ RI Method ....,-...-- ....F
-I T
1-026 542 2.24 1 he-1'N -.-L---0 FSF
-1-'-'-'1 -,T,..... N
C
41 HNN --ill' OH
1-027 N 0 528 1.99 1 hi' FSF
F
e----, õIL
1-028 3 411 H....N 11--ilLOH 528 1.98 1 ........- F
I N
8 Ai.
1-029 Ilil HE i --It---NryIL-0 H
l'N0 528 2 1 FSF
----..
I F
N ,--- 0 0 . HN N -----I--0 1-030 N N_k..o 590 2.52 1 Sc' Date Recue/Date Received 2020-11-26 [Table 7]
Compound No Structure [M+1-1]+ RI Method --, I F
N .,---0 F F it, 0 HI 1,---------A----0 1-031 604 2.61 1 '.111111111P N [ 1 0 SO' ir-o Fr.-F A
401 1 111 --'0 -ill'OH
1-032 N N 576 2.28 1 11.1 Cl ----..
NI __,... F
0 F 4 A,I1, 01 HN N GH
1-033 590 2.35 1 N--->1%- N ----13 Sc' F
F F
----, j...1 I
,....y,..., N
1-034 0 is FIN1NTh 570 2A6 1 l NND
*
----, 0 --1-1--, 1-035 Ø Hil 1-417 N N 0 570 2.4 1 .-4111111111P
IP
Date Recue/Date Received 2020-11-26 [Table 8]
, Compound No Structure [M+1-1]+ RI Method F
f-LI
1-036 6ah Hwit-N----TIII 520 2.24 1 '-1111111' N N 0 1.1 F
1-037 60 HNAN--------A-1- 534 2.34 1 'lir Nr-1-N"k-13 F
F F
---, õ.1.1 t,...0 HN A N -'1[1-'0 H 556 2.21 1 F
,z,.. ...VF
---____;,, N 0 0 1-039 8ah Pl!rji-Thriji-%0H 556 2.17 1 'gill"' N N 0 F
--'-L-1 6 J-L.
1-040 0 HE, ry-11-0H 506 1.98 1 rr N 0 Date Recue/Date Received 2020-11-26 [Table 9]
Compound No Structure [M+I-1]+ RI
Method F
'ILI
40 H,...N1 li-----KiLoH 520 2.06 1 F
,-----/---.--.1 I N---..r.--IP
CI
F ----:
....1_, i F 0 -------f N 0 0 0 =401 11 ..1,4 --jt- N ----.1)---0 '-I-043 N N 0 588 2.36 1 I
'Sc' F 1 %------1--._ N
_..c-i F 0 --. 1 0 ---0 HN N '--1.11--CH
1-044 574 2.13 1 'IllitilliP rel-IT-4.0 Sc N
a 40 H N N -.-----1-0 1-045 547 2.24 1 rf-1--N".-----.0 Sc' Date Recue/Date Received 2020-11-26 [Table 10]
Compound No Structure [M+1-1]+ RI Method N*
HNAN O
1-046 --' N N 0 561 2.34 1 .1 a ii----0 N 410 HI A 1-1--11.-OH
1-047 N N 0 533 1.99 1 . GI
rj 11Nla 547 2.07 1 1101 a ,.._-... F
--)-- o o o aih 554 1.97 1 Lill N-;--1W-L.--.0 a a -,Tõ,N
a HN "'IL N XAOH
1-050 554 -1.95 1 qi-Lir N N 0 Si a Date Recue/Date Received 2020-11-26
[0144]
[Table 11]
_ Comround No Structure [M+I-1]+ RI Method ----Li ----I'D
1-051 0 HN-11.-N.-----(11--a---536 2.37 1 N----:1--rek.-0 1110 ci r-----Ny------ F 0 0 0 40 HNA-N,-------1)---0----1-052 re-1--Nio 520 2.25 1 -L
F1-''-'-r-IN
0 Hii 1-053 \,-------4)---0--520 2.27 1 l',1- N=-.--0 S
---ki.
I N
---...T.,-... 0 0 1¨ 0 5 4 0 40 H [ 1 \r-y11---GH
522 2.12 1 ri4t--N--Lo 40 r, ..--LI.
I N
1¨ 0 5 5 0 op HN \I--)\-)1--0.---- 550 248 1 I'll-Nr.0 40 r, Date Recue/Date Received 2020-11-26 [Table 12]
Compound No Structure [M+I-1]+ RI Method Ers'' N ye F
,--11--41111 HI 11"-----1)LOH
.I
I ' 4111/N"---11L-0 H
506 2.02 1 S
--1-1.
1-058 osi HN --11---N ------AjoH 536 2.2 1 N-51-"N --ek0 I
F
fL1 0 c I-0 0 59 0 HN j-LN 0 I-1 554 1.94 .. 1 N----=-1---N----D o So (Cl--ill He..N A N
1-060 NNO 556 2.5 1 Sc' Date Recue/Date Received 2020-11-26 [Table 13]
Compound No Structure [M+1-1]+ RI Method fr- 0 N_,--- F
0 HN N''' el---N--k-o 566 2.52 1 . .1 NI ----- F 1? D
NND 566 2.47 1 Sc (----..---- 0 N,r__ r 1 , 0)1-0 H
1-063 st N7N,,,,,,, 538 2.14 1 [1.----- 0 N r_ F
0 aihh ... ji, , \ illil HN N
N N 0 538 2.09 1 IP e1 (--GI
N r 0 0 0 ), 0 H11 . y ---1)---OH
1-065 542 2.25 1 Date Recue/Date Received 2020-11-26 [Table 14]
Comcound No Structure [M+1-1]+ RI Method N y-_---- F 0 --"-----.0 0 giam HN -'1LN -'----K0 1-066 1111-P N------1-N----L---o 566 2A9 1 SC' ir-..
Nr. F
0 si HN AN '--X11-`01711 1-067 rel---N---L-0 538 2.12 1 I I
-iN
a T AN
1-068 540 2.35 1 '-'1111111P N IN 0 So 0 ..,..., a ,HN'jj-'N''-yILOH
I-069 IN IN 0 538 2.02 1 5c1 F
-----n-1 0 _A, I-07 110 1 N -'-y[t-OH 526 211 0 . 1 N iN ---L----0 Sc' Date Recue/Date Received 2020-11-26 [Table 15]
-Compound No Structure [M+1-1]+ RI Method F
C--LF
--, I , N
HN_1,y a 0 j....._. iit ..._, 1-071 602 2.51 1 , Sal F
0 '1-.-F
1 li'hi 1-072 0 -11, .1-J-Li, 588 2.25 1 F-1111 riq H
1.kr N'"---0 'Cl -(Aki ....,r, N 0 I ?, el HN'll'N---µ-'------.-4-'_ 0,--- 550 2.52 1-073 1 N--;-1.--N-.-L10 Sal '11.1 IA 0 I ''V, 40 . AN '¨'y---01-1 536 2.23 N-51.-N ---L-.0 IP lc, rd...--1- 0 I .. (i) 1-0 7 5 o '---.11 , ah.
HN-IL-N ---'.---/'-'0----.
..), ,..k z N N 0 561 43 2. 1 'Cl Date Recue/Date Received 2020-11-26 [Table 16]
Comcound No Structure [M+I-1]+ RI Method a H N N yD
536 2.38 1 '1111111 N 'eL
Sc' hle.eN H
N reLD 522 2.2 1 zyN
536 2.28 CI
N
0 a 0,H
538 2.04 N
0 gim H Nrelt, N OH
1-080 N0 522 2.12 1 = CI
Date Recue/Date Received 2020-11-26 [Table 17]
Compound No Structure [M+1-1]+ RI Method (-cl -N r 0 HII Nr---K11---0,-.-1-081 570 2.6 1 N N ---.0 F F
----..
1-082 0 IIN--11-1----(11---o---- 590 2.56 1 NNO
Sc' H
1-083 o i iik HIll N---1-'11-0---- 552 2 1 -"RP l'i N --LD
So a OH
a HII y ---Til'OH 538 1 37 1 -4111-11IP N 1`,10 Sc F F
----..
0 ,JI, 1-085 0 HI, II, ---x11---o--- 604 2.66 1 ti [ 1 -.-ID
Sc' Date Recue/Date Received 2020-11-26 [Table 18]
Compound No Structure [M+H]+ RI
Method N y'-, 0 0 C aitil N D
'------Kit--13H
1-086 [1L -.L 556 2.33 1 Mi Sc' (Cl.
N,...õ,...-5-.----0 H N --jj--- N `---1--Y--u.--0---' 1 -0 87 N N 0 ...),... ,...L = 570 2.64 1 '-µ11111111P
= el '--,.
I F
1-088 8si H N -1- rei0 H 576 2.33 1 N---5-1-. N .---k-D
F
....,r. N
....._,---1-089 0 gib HN1 N
."--------:'----y 570 2.17 1 Sc' F
ILI
0 -----,y0 H
1-090 a H Nji- N 542 1.88 1 '.4111411111 VI' N"--k--0 OH
= CI
Date Recue/Date Received 2020-11-26 [Table 19]
Compound No Structure [M+H]F RI Method a (-----Nr 0 1 3......}...0 . HN N , OH
1-091 NNO 2.37 1 I
r....._.)s..,F F
----.
I F
Ny>
1-0 9 2 40 HN NI"-X11-'01-1 590 2.4 1 N------1--N-L-7o o--'11 -.._--zr N I 0 1-093 0is HN N------XILO,H 552 2.23 1 N')--"N '4.0 = 0, -71), --,-,,..r...N
1-094 040 552 2.26 1 N.----k-N '----)0 Sc' '---..
5 11 -IL Nil --1.---------E_ 1-095 534 2.39 1 ri ri -------o Date Recue/Date Received 2020-11-26 [Table 20]
Compound No Structure [M+I-1]+ RI
Method fr--:-N ....f.- F
1-096 _, N N 0 520 2.11 1 *
CI
,-;----I-----1 -----s.r ki C 0 1-097 o A
0 HN N N ----'--11-0"--. 536 2.38 1 .)..... N- '1.õ
*
CI
'''-----C11 ----1,N 0 0 I.
N N 0 550 2.49 1 F -r---1.---N
----r- 0 0 0 ..---so HN A N ---.1-A0 1-099 reL.N.---k-o a--- 556 2.23 1 Sc' a k o ,,IL, a I-100 40 HN N -------1)LOH 522 2.15 1 ....j.... ,,..
*
Date Recue/Date Received 2020-11-26
[Table 11]
_ Comround No Structure [M+I-1]+ RI Method ----Li ----I'D
1-051 0 HN-11.-N.-----(11--a---536 2.37 1 N----:1--rek.-0 1110 ci r-----Ny------ F 0 0 0 40 HNA-N,-------1)---0----1-052 re-1--Nio 520 2.25 1 -L
F1-''-'-r-IN
0 Hii 1-053 \,-------4)---0--520 2.27 1 l',1- N=-.--0 S
---ki.
I N
---...T.,-... 0 0 1¨ 0 5 4 0 40 H [ 1 \r-y11---GH
522 2.12 1 ri4t--N--Lo 40 r, ..--LI.
I N
1¨ 0 5 5 0 op HN \I--)\-)1--0.---- 550 248 1 I'll-Nr.0 40 r, Date Recue/Date Received 2020-11-26 [Table 12]
Compound No Structure [M+I-1]+ RI Method Ers'' N ye F
,--11--41111 HI 11"-----1)LOH
.I
I ' 4111/N"---11L-0 H
506 2.02 1 S
--1-1.
1-058 osi HN --11---N ------AjoH 536 2.2 1 N-51-"N --ek0 I
F
fL1 0 c I-0 0 59 0 HN j-LN 0 I-1 554 1.94 .. 1 N----=-1---N----D o So (Cl--ill He..N A N
1-060 NNO 556 2.5 1 Sc' Date Recue/Date Received 2020-11-26 [Table 13]
Compound No Structure [M+1-1]+ RI Method fr- 0 N_,--- F
0 HN N''' el---N--k-o 566 2.52 1 . .1 NI ----- F 1? D
NND 566 2.47 1 Sc (----..---- 0 N,r__ r 1 , 0)1-0 H
1-063 st N7N,,,,,,, 538 2.14 1 [1.----- 0 N r_ F
0 aihh ... ji, , \ illil HN N
N N 0 538 2.09 1 IP e1 (--GI
N r 0 0 0 ), 0 H11 . y ---1)---OH
1-065 542 2.25 1 Date Recue/Date Received 2020-11-26 [Table 14]
Comcound No Structure [M+1-1]+ RI Method N y-_---- F 0 --"-----.0 0 giam HN -'1LN -'----K0 1-066 1111-P N------1-N----L---o 566 2A9 1 SC' ir-..
Nr. F
0 si HN AN '--X11-`01711 1-067 rel---N---L-0 538 2.12 1 I I
-iN
a T AN
1-068 540 2.35 1 '-'1111111P N IN 0 So 0 ..,..., a ,HN'jj-'N''-yILOH
I-069 IN IN 0 538 2.02 1 5c1 F
-----n-1 0 _A, I-07 110 1 N -'-y[t-OH 526 211 0 . 1 N iN ---L----0 Sc' Date Recue/Date Received 2020-11-26 [Table 15]
-Compound No Structure [M+1-1]+ RI Method F
C--LF
--, I , N
HN_1,y a 0 j....._. iit ..._, 1-071 602 2.51 1 , Sal F
0 '1-.-F
1 li'hi 1-072 0 -11, .1-J-Li, 588 2.25 1 F-1111 riq H
1.kr N'"---0 'Cl -(Aki ....,r, N 0 I ?, el HN'll'N---µ-'------.-4-'_ 0,--- 550 2.52 1-073 1 N--;-1.--N-.-L10 Sal '11.1 IA 0 I ''V, 40 . AN '¨'y---01-1 536 2.23 N-51.-N ---L-.0 IP lc, rd...--1- 0 I .. (i) 1-0 7 5 o '---.11 , ah.
HN-IL-N ---'.---/'-'0----.
..), ,..k z N N 0 561 43 2. 1 'Cl Date Recue/Date Received 2020-11-26 [Table 16]
Comcound No Structure [M+I-1]+ RI Method a H N N yD
536 2.38 1 '1111111 N 'eL
Sc' hle.eN H
N reLD 522 2.2 1 zyN
536 2.28 CI
N
0 a 0,H
538 2.04 N
0 gim H Nrelt, N OH
1-080 N0 522 2.12 1 = CI
Date Recue/Date Received 2020-11-26 [Table 17]
Compound No Structure [M+1-1]+ RI Method (-cl -N r 0 HII Nr---K11---0,-.-1-081 570 2.6 1 N N ---.0 F F
----..
1-082 0 IIN--11-1----(11---o---- 590 2.56 1 NNO
Sc' H
1-083 o i iik HIll N---1-'11-0---- 552 2 1 -"RP l'i N --LD
So a OH
a HII y ---Til'OH 538 1 37 1 -4111-11IP N 1`,10 Sc F F
----..
0 ,JI, 1-085 0 HI, II, ---x11---o--- 604 2.66 1 ti [ 1 -.-ID
Sc' Date Recue/Date Received 2020-11-26 [Table 18]
Compound No Structure [M+H]+ RI
Method N y'-, 0 0 C aitil N D
'------Kit--13H
1-086 [1L -.L 556 2.33 1 Mi Sc' (Cl.
N,...õ,...-5-.----0 H N --jj--- N `---1--Y--u.--0---' 1 -0 87 N N 0 ...),... ,...L = 570 2.64 1 '-µ11111111P
= el '--,.
I F
1-088 8si H N -1- rei0 H 576 2.33 1 N---5-1-. N .---k-D
F
....,r. N
....._,---1-089 0 gib HN1 N
."--------:'----y 570 2.17 1 Sc' F
ILI
0 -----,y0 H
1-090 a H Nji- N 542 1.88 1 '.4111411111 VI' N"--k--0 OH
= CI
Date Recue/Date Received 2020-11-26 [Table 19]
Compound No Structure [M+H]F RI Method a (-----Nr 0 1 3......}...0 . HN N , OH
1-091 NNO 2.37 1 I
r....._.)s..,F F
----.
I F
Ny>
1-0 9 2 40 HN NI"-X11-'01-1 590 2.4 1 N------1--N-L-7o o--'11 -.._--zr N I 0 1-093 0is HN N------XILO,H 552 2.23 1 N')--"N '4.0 = 0, -71), --,-,,..r...N
1-094 040 552 2.26 1 N.----k-N '----)0 Sc' '---..
5 11 -IL Nil --1.---------E_ 1-095 534 2.39 1 ri ri -------o Date Recue/Date Received 2020-11-26 [Table 20]
Compound No Structure [M+I-1]+ RI
Method fr--:-N ....f.- F
1-096 _, N N 0 520 2.11 1 *
CI
,-;----I-----1 -----s.r ki C 0 1-097 o A
0 HN N N ----'--11-0"--. 536 2.38 1 .)..... N- '1.õ
*
CI
'''-----C11 ----1,N 0 0 I.
N N 0 550 2.49 1 F -r---1.---N
----r- 0 0 0 ..---so HN A N ---.1-A0 1-099 reL.N.---k-o a--- 556 2.23 1 Sc' a k o ,,IL, a I-100 40 HN N -------1)LOH 522 2.15 1 ....j.... ,,..
*
Date Recue/Date Received 2020-11-26
[0145]
[Table 21]
Compound No Structure [M+1-1]+ RI Method N
H 411 HOH 536 2.22 1 1.1 HWIL N H
H 02 411"NND - 542 2.01 1 0 =
H 03 HN N 534 2.38 1 =
1.1 N 0 ir 534 2.41 1 irCs N
0 y 9 H 05 HN 520 2.1 1 =
1.1 Date Recue/Date Received 2020-11-26 [Table 22]
Comcound No Structure [M+1-1]+ RI Method F
Y-.----' I-106 0 H N N .. OH
,-1.., ,..4. 520 2.13 1 IS
1 ---.i N y-----0 i A n H N N .".-&------'''-',0 ---' 1-107 ,-..1.... E 550 2.52 1 Si 'CI
i 1-108 = 7 N------i-u- - 0 516 2.29 1 IN r 1-1 09 0 H N N i 1 ¶0-.-- 530 243 1 , N';'-i'IN -.--ID' ilL
1-110 0 00õ,..-...Ko irµI'j''N --k--70 Date Recue/Date Received 2020-11-26 [Table 23]
Cornround No Structure [M+1-1]+ RI Method ii---Ny...- -.-.
9 i oi o in F-IN -AN -A---,----H---OH
I-1 l l N ,iN 0 , ...... 536 2.23 1 Sc' irL
1-1 1 2 so Hri I-W--11LT H 502 2.04 1 fiL
0 y 1¨ 1 1 3 = I-1[ F -------IN ---A-u-'i OH 516 2.14 1 =
IC-k-N---LD
ilL
Nys---- 0 0 1-114 HWAN --------/c11-'0F1 516 2.12 NAN---Lo ....,....-õõci I ...,,,!J
----T- o o o SI HW-ILN".--y.----1-115 NNO lt--0 ...),. ...... 536 2.36 1 S
Date Recue/Date Received 2020-11-26 [Table 24]
Compound No Structure [M+I-1]+ RI Method ..---I-116 is I y ------A-1Lo N N'----0 *
--;----'-----) -----y N
CI jt_0 0 522 2.13 1 ---.
*
--.;----11 0 1-118 ,i, ..,. 40 HNAN------A-11---.H
536 2.21 1 *
.......-- Cl -y D 0 0 A, 40 1-11 7....NI0------4)--0 H
9 522 2.11 1 -----yk o y yi, I-120 0 doh N-51-- N"----0 550 2.52 1 1.1 Date Recue/Date Received 2020-11-26 [Table 25]
Comcound No Structure [M+I-1]+ RI Method F
(LI
--.....rN 0 0 ash, 11111.-- HNAkry0"---l'3 CI' 556 2.22 1 I%1 = ri I N
HNAN-----1-A0'-' I\l' N --u CI 556 2.24 1 Sc' ------11'a 1-123 0 Hrj, \I OH 536 2.24 1 1.1 F
1-124 is 1 ,i'-'--yll'OF1 542 1.99 1 I N
-,õ(--io Hy1 , ryltmoH
IH25 l' N&--0 al.--542 2.01 1 i -le a Date Recue/Date Received 2020-11-26 [Table 26]
Compound No Structure [M+1-1]+ RI Method N ye"
0 on HNe-11-1N
N--;1-1-N-e---0 522 2.28 1 Cl 1-1 2 7 = J N 508 2.02 1 Sc' I cI
1-1 28 536 2.2 1 L-N
410 We-111-D
1-129 =523 2.24NN
D
N
0 1-130 Am HNe-11-"N eey11--0H
1 509 1.99NI NO
D
Date Recue/Date Received 2020-11-26 [Table 27]
Compound No Structure [M+1-1]+ RI Method a --0 r-----T-13 0 ...1, -......._,,, N HN-11-'N----------0 H 31 N.--- -N -k.--13 522 2.27 1 SC' F
---..----)--i -y4 0 0 1-132 Hil a 1N i0 568 2.32 1 a-------ii-'-----.1111IP
1.1 F
OF
---;31-.) 0 0 Hrell--N--7\--Ae .1 -'-'-cl C , i .._1 1-134 0 HN'jt' r I _ OH
547 2.16 1 1.1 a F
0 'LF
_-.:-----C1 -yi 0 0 1-135 IAy H a 554 2.08 1 a ----ilt-C
--glir IS
Date Recue/Date Received 2020-11-26 [Table 28]
Compound No Structure [M+1-1]+ RI Method 0)--`F
N
1-136 0 568 2.15 1 HN jt-N H
NNO
(10 F
1-137 0 Am 582 2A3 1 ' 41-1 N 0 1.1 F
0 ir 1-138 c 110ash 568 2.16 1 MI"
1-139 0, Nr-i'NAD 552 2.29 1 Sc o Hfl N 0 1-140 =
11-11IP N N 0 502 2.19 1 Date Recue/Date Received 2020-11-26 [Table 29]
_ Compound No Structure [M+1-1]+ RI Method --,,,, ....L
1-141 N N 0 508 2.02 1 Sc' --....1,-...N 0 0 0 ,--I-I--0 H.11 . N -----111-0".--1-142 508 2.42 1 N N'-k--70 11161/40,e I/
r) ---.....rN 0 0 0 HNJ-LNõ---y--. ...--N-----1.-N '--..0 CL.---- 538 2.16 1 IP ci ?i, SiHN-11-- N--'"------")t'z 0 ----1-144 .) .....L.0 = 536 2.43 1 N N
Sc -------.---:-1 I 1k i 0 HAI., A GH
494 2.14 1 N "------11' N rµV-0 j144[1::1., .-..,,, Date Recue/Date Received 2020-11-26 [Table 30]
Compound No Structure [M+I-1]+ RI
Method -----I .., 'y IN
o dab 1-1 4 6 -IMII HNAN'-'yll--0 H
N';-1--V-L-.0 ---- 524 1.94 1 1101 el ----'----) 1 ..
--y-IN
O Ali HNA N OH
WI NN 'D 522 2.12 1 ill a o o 0 õIL
-i----'-------i---- ---0 HN N i OH
1-148 N N 0 ----.N ....L =
--1111111111P 488 1.94 1 IP
N.,..c.õ--1-149 N--;1--N"-L-0 536 2.39 1 Sc' Ny--O asin HN A N-----X '----W N--.----1--ND 516 2.3 1 Date Recue/Date Received 2020-11-26
[Table 21]
Compound No Structure [M+1-1]+ RI Method N
H 411 HOH 536 2.22 1 1.1 HWIL N H
H 02 411"NND - 542 2.01 1 0 =
H 03 HN N 534 2.38 1 =
1.1 N 0 ir 534 2.41 1 irCs N
0 y 9 H 05 HN 520 2.1 1 =
1.1 Date Recue/Date Received 2020-11-26 [Table 22]
Comcound No Structure [M+1-1]+ RI Method F
Y-.----' I-106 0 H N N .. OH
,-1.., ,..4. 520 2.13 1 IS
1 ---.i N y-----0 i A n H N N .".-&------'''-',0 ---' 1-107 ,-..1.... E 550 2.52 1 Si 'CI
i 1-108 = 7 N------i-u- - 0 516 2.29 1 IN r 1-1 09 0 H N N i 1 ¶0-.-- 530 243 1 , N';'-i'IN -.--ID' ilL
1-110 0 00õ,..-...Ko irµI'j''N --k--70 Date Recue/Date Received 2020-11-26 [Table 23]
Cornround No Structure [M+1-1]+ RI Method ii---Ny...- -.-.
9 i oi o in F-IN -AN -A---,----H---OH
I-1 l l N ,iN 0 , ...... 536 2.23 1 Sc' irL
1-1 1 2 so Hri I-W--11LT H 502 2.04 1 fiL
0 y 1¨ 1 1 3 = I-1[ F -------IN ---A-u-'i OH 516 2.14 1 =
IC-k-N---LD
ilL
Nys---- 0 0 1-114 HWAN --------/c11-'0F1 516 2.12 NAN---Lo ....,....-õõci I ...,,,!J
----T- o o o SI HW-ILN".--y.----1-115 NNO lt--0 ...),. ...... 536 2.36 1 S
Date Recue/Date Received 2020-11-26 [Table 24]
Compound No Structure [M+I-1]+ RI Method ..---I-116 is I y ------A-1Lo N N'----0 *
--;----'-----) -----y N
CI jt_0 0 522 2.13 1 ---.
*
--.;----11 0 1-118 ,i, ..,. 40 HNAN------A-11---.H
536 2.21 1 *
.......-- Cl -y D 0 0 A, 40 1-11 7....NI0------4)--0 H
9 522 2.11 1 -----yk o y yi, I-120 0 doh N-51-- N"----0 550 2.52 1 1.1 Date Recue/Date Received 2020-11-26 [Table 25]
Comcound No Structure [M+I-1]+ RI Method F
(LI
--.....rN 0 0 ash, 11111.-- HNAkry0"---l'3 CI' 556 2.22 1 I%1 = ri I N
HNAN-----1-A0'-' I\l' N --u CI 556 2.24 1 Sc' ------11'a 1-123 0 Hrj, \I OH 536 2.24 1 1.1 F
1-124 is 1 ,i'-'--yll'OF1 542 1.99 1 I N
-,õ(--io Hy1 , ryltmoH
IH25 l' N&--0 al.--542 2.01 1 i -le a Date Recue/Date Received 2020-11-26 [Table 26]
Compound No Structure [M+1-1]+ RI Method N ye"
0 on HNe-11-1N
N--;1-1-N-e---0 522 2.28 1 Cl 1-1 2 7 = J N 508 2.02 1 Sc' I cI
1-1 28 536 2.2 1 L-N
410 We-111-D
1-129 =523 2.24NN
D
N
0 1-130 Am HNe-11-"N eey11--0H
1 509 1.99NI NO
D
Date Recue/Date Received 2020-11-26 [Table 27]
Compound No Structure [M+1-1]+ RI Method a --0 r-----T-13 0 ...1, -......._,,, N HN-11-'N----------0 H 31 N.--- -N -k.--13 522 2.27 1 SC' F
---..----)--i -y4 0 0 1-132 Hil a 1N i0 568 2.32 1 a-------ii-'-----.1111IP
1.1 F
OF
---;31-.) 0 0 Hrell--N--7\--Ae .1 -'-'-cl C , i .._1 1-134 0 HN'jt' r I _ OH
547 2.16 1 1.1 a F
0 'LF
_-.:-----C1 -yi 0 0 1-135 IAy H a 554 2.08 1 a ----ilt-C
--glir IS
Date Recue/Date Received 2020-11-26 [Table 28]
Compound No Structure [M+1-1]+ RI Method 0)--`F
N
1-136 0 568 2.15 1 HN jt-N H
NNO
(10 F
1-137 0 Am 582 2A3 1 ' 41-1 N 0 1.1 F
0 ir 1-138 c 110ash 568 2.16 1 MI"
1-139 0, Nr-i'NAD 552 2.29 1 Sc o Hfl N 0 1-140 =
11-11IP N N 0 502 2.19 1 Date Recue/Date Received 2020-11-26 [Table 29]
_ Compound No Structure [M+1-1]+ RI Method --,,,, ....L
1-141 N N 0 508 2.02 1 Sc' --....1,-...N 0 0 0 ,--I-I--0 H.11 . N -----111-0".--1-142 508 2.42 1 N N'-k--70 11161/40,e I/
r) ---.....rN 0 0 0 HNJ-LNõ---y--. ...--N-----1.-N '--..0 CL.---- 538 2.16 1 IP ci ?i, SiHN-11-- N--'"------")t'z 0 ----1-144 .) .....L.0 = 536 2.43 1 N N
Sc -------.---:-1 I 1k i 0 HAI., A GH
494 2.14 1 N "------11' N rµV-0 j144[1::1., .-..,,, Date Recue/Date Received 2020-11-26 [Table 30]
Compound No Structure [M+I-1]+ RI
Method -----I .., 'y IN
o dab 1-1 4 6 -IMII HNAN'-'yll--0 H
N';-1--V-L-.0 ---- 524 1.94 1 1101 el ----'----) 1 ..
--y-IN
O Ali HNA N OH
WI NN 'D 522 2.12 1 ill a o o 0 õIL
-i----'-------i---- ---0 HN N i OH
1-148 N N 0 ----.N ....L =
--1111111111P 488 1.94 1 IP
N.,..c.õ--1-149 N--;1--N"-L-0 536 2.39 1 Sc' Ny--O asin HN A N-----X '----W N--.----1--ND 516 2.3 1 Date Recue/Date Received 2020-11-26
[0146]
[Table 31]
Compound No Structure [M+1-1]+ RI Method r.--1 a , o O JI, =
an HNN"----4-113--.-1-151 536 2.42 1 .--1111111111 VI- re-L-0 SO
----------).
I ----1,---P4 0 = 0 -H N N- --OH ---111.-1-152 tip 522 2.14 1 14).-- N ''-0 NrI -:--- ,,- --io o o o a 71-N-----4--* ---1-153 N N 0 552 2.22 1 WI' Sc' ii-N y,- -------an 1 :1,N)-LN '-----KH
1-154 522 2.11 1 WitilliF N N 0 1111 a ir-N., ......,..,-.., III, 1-155 so HN AN N N-----K10 ILOH
502 2.02 1 Date Recue/Date Received 2020-11-26 [Table 32]
_ Compound No Structure [M+H+ RI
Method frz o o a A
01 I N '----ill---GH
I-156 538 1.98 1 0 c, ir---N y.----0 = 0 O 40 HNAW-------)---0'-' I-157 j, ,L 522 2.32 1 fl El 0 Sc' F
---(-------, So ir--N yf, cr, O 0 H N A ..--N '-'-----AK-0 I-159 566 2.35 1 N-;-.1-.N --k---D
= GI
F
irL
Ny,----- 0 = 0 O ,--4-.. .)---___,-11-.. ..---1-160 40 HN N 0 540 2.38 1 reL-N--L'o Sc' Date Recue/Date Received 2020-11-26
[Table 31]
Compound No Structure [M+1-1]+ RI Method r.--1 a , o O JI, =
an HNN"----4-113--.-1-151 536 2.42 1 .--1111111111 VI- re-L-0 SO
----------).
I ----1,---P4 0 = 0 -H N N- --OH ---111.-1-152 tip 522 2.14 1 14).-- N ''-0 NrI -:--- ,,- --io o o o a 71-N-----4--* ---1-153 N N 0 552 2.22 1 WI' Sc' ii-N y,- -------an 1 :1,N)-LN '-----KH
1-154 522 2.11 1 WitilliF N N 0 1111 a ir-N., ......,..,-.., III, 1-155 so HN AN N N-----K10 ILOH
502 2.02 1 Date Recue/Date Received 2020-11-26 [Table 32]
_ Compound No Structure [M+H+ RI
Method frz o o a A
01 I N '----ill---GH
I-156 538 1.98 1 0 c, ir---N y.----0 = 0 O 40 HNAW-------)---0'-' I-157 j, ,L 522 2.32 1 fl El 0 Sc' F
---(-------, So ir--N yf, cr, O 0 H N A ..--N '-'-----AK-0 I-159 566 2.35 1 N-;-.1-.N --k---D
= GI
F
irL
Ny,----- 0 = 0 O ,--4-.. .)---___,-11-.. ..---1-160 40 HN N 0 540 2.38 1 reL-N--L'o Sc' Date Recue/Date Received 2020-11-26
[0147]
[Table 33]
_ ________________________________________________________________________ Compound No Structure [M+H+ RI
Method fr---1--' N y--- F
0 = 0 C ,--11-..
0 I y H 61 540 2.39 1 N N -'0 IP a fr------N
0 0 H NA' N
I- 1 62 N N 0 506 2.06 1 "CI
--ii -0 = 0 0 HNAN;'-------AOH
H 63 õI, õk. 526 214 1 SC]
ir----Ny.---- 0 .._.-.
0 I-IN N -.-----KkOH
H 64 2.07 1 SC' F
H 65 0 is, I-IN )1-- N '----------)1-'0 HI 526 2.12 1 cc, Date Recue/Date Received 2020-11-26 [Table 34]
Compound No Structure [M+H]F RI
Method fr-N y--,- F
0 = 0 a -----0 HI AN''---------)1---OH
1-166 .,-. .13 1 '44111" ri---5-1- [I 0 526 2 Sc' F
'---j---11 iiih N N.--L.0 HN -11%. N --.-- 0 H
1-167 542 1.97 1 WI
F
F
F
:::, 1 1,,j it H N )1' N-70 H
1-168 ---'w NND 542 1.99 1 F
n F ---'y N 0 0 1-169 'gar' N--' N'-k--0 542 1.98 1 F
F
J
i'l 0 1 0 cr440 0 , N N 0 548 2.49 1 Sc' Date Recue/Date Received 2020-11-26 [Table 35]
Compound No Structure [M+I-1]+ RI
Method 7.=-----)--. ,-------0 I ..._1, o ,0 si VI-N--k-CI
ad a 0 10 ..-11-, 0 HN N'''' N N 0 562 2.6 1 SI
a rk-I ---'-----0 .
1-173 0 001 NW-IL-N.'''.
N 0 562 2.54 SI
rl 0 ..--,...rN
0 frOU---0,A
v-. HN N
N';'1---rek-13 520 2.1 1 ad .r.-1 0 di ki 0 N N 0 520 2.04 1 Sc Date Recue/Date Received 2020-11-26 [Table 36]
Compound No Structure [M+1-1]+ RI
Method F
rj-1 0 j -, f N 0 jr'640 C A \, 1-176 41 HN N 546 2.47 1 ,J
N,,L N 0 F
jj, 0 0 1-177 0 in HE 1 E 1 546 2.41 1 ..), ___,I,..
N N -- a ISI
a fj---1 0 µ,...,rN
..11-, 1-178 0 410 HN N " 534 2.22 1 Nfj-N -.----0 GI
0 eithh H r J N "
VI' N -'k.---0 534 2.17 1 õrm , N ' ,), ,..
N I 1 0 528 2.42 1 Date Recue/Date Received 2020-11-26 [Table 37]
Compound No Structure [M+1-1]+ RI Method r---1 ,--------0 N
'-----r 0 1-181 528 2.35 1 F
0'111-0 H
1-182 .
NNO 518 2.07 1 ..,k.
*
F
8 .....a.i. ...
1-183 H NI 518 2.02 1 till ---L
1.1 -...,...,7- N
crit- -% 1_, 11) 1111 H N N% .' 1-184 500 2.01 1 N-----4---N---ko -1-) D
N
-----r 0 A
0 ..1... ,0% 0 H
OD
1-185 reN 13 500 1.96 1 *
Date Recue/Date Received 2020-11-26 [Table 38]
Compound No Structure [M+I-1]+ RI
Method rl 0 = '----0 Is HN -AN 0 N-5-1-N-0 502 2.23 1 rh--0 = 0 410 HN AN -5-----)1-01-1 1-187 488 1.97 1 N--'1--N---k-70 1-----'1 F -N ----r 0 = '---0 Ill HN N 0 1-188 N-j---N---LO 520 2.3 1 -' '11, F -----r 0 , 0 si HN N OH
1-189 N-2-1-1,1----0 506 2.05 1 F
---ki.
I N
0 - '---01 0 N N 0 520 2.29 1 Date Recue/Date Received 2020-11-26 [Table 39]
Compound No Structure [M+I-1]+ RI
Method F
-- ----j----z-, --.1-, 1-191 0 0 HVILN------AOH 506 2.05 1 ..)..... .,..
rr-------Ny- 0 --------0 0 0 ,..-II, HI N=-----'0 548 2.46 1 --' 40 c, (---N ,f,--; 0 0 0 4 )10 HI , ,,,, ----KILO H
1-193 520 2.08 1 N'--- N--,0 Sal --.--C-)1 0 40 HN---kN ------(11---0 1-194 N----i.-N --01 538 2.14 1 F
F
-------, 1 0 T ,T11 i si Nii---------------- OH
1-195 502 2.06 1 N.---. N --.---0 *
Date Recue/Date Received 2020-11-26 [Table 40]
Compound No Structure [M+H]F RI
Method N
o HN N
I-196 NND 520 2.33 1 F
N
0 = 0 os I-197 506 2.07 N
H 98 505 2.18 N 11 0 491 t93 Date Recue/Date Received 2020-11-26
[Table 33]
_ ________________________________________________________________________ Compound No Structure [M+H+ RI
Method fr---1--' N y--- F
0 = 0 C ,--11-..
0 I y H 61 540 2.39 1 N N -'0 IP a fr------N
0 0 H NA' N
I- 1 62 N N 0 506 2.06 1 "CI
--ii -0 = 0 0 HNAN;'-------AOH
H 63 õI, õk. 526 214 1 SC]
ir----Ny.---- 0 .._.-.
0 I-IN N -.-----KkOH
H 64 2.07 1 SC' F
H 65 0 is, I-IN )1-- N '----------)1-'0 HI 526 2.12 1 cc, Date Recue/Date Received 2020-11-26 [Table 34]
Compound No Structure [M+H]F RI
Method fr-N y--,- F
0 = 0 a -----0 HI AN''---------)1---OH
1-166 .,-. .13 1 '44111" ri---5-1- [I 0 526 2 Sc' F
'---j---11 iiih N N.--L.0 HN -11%. N --.-- 0 H
1-167 542 1.97 1 WI
F
F
F
:::, 1 1,,j it H N )1' N-70 H
1-168 ---'w NND 542 1.99 1 F
n F ---'y N 0 0 1-169 'gar' N--' N'-k--0 542 1.98 1 F
F
J
i'l 0 1 0 cr440 0 , N N 0 548 2.49 1 Sc' Date Recue/Date Received 2020-11-26 [Table 35]
Compound No Structure [M+I-1]+ RI
Method 7.=-----)--. ,-------0 I ..._1, o ,0 si VI-N--k-CI
ad a 0 10 ..-11-, 0 HN N'''' N N 0 562 2.6 1 SI
a rk-I ---'-----0 .
1-173 0 001 NW-IL-N.'''.
N 0 562 2.54 SI
rl 0 ..--,...rN
0 frOU---0,A
v-. HN N
N';'1---rek-13 520 2.1 1 ad .r.-1 0 di ki 0 N N 0 520 2.04 1 Sc Date Recue/Date Received 2020-11-26 [Table 36]
Compound No Structure [M+1-1]+ RI
Method F
rj-1 0 j -, f N 0 jr'640 C A \, 1-176 41 HN N 546 2.47 1 ,J
N,,L N 0 F
jj, 0 0 1-177 0 in HE 1 E 1 546 2.41 1 ..), ___,I,..
N N -- a ISI
a fj---1 0 µ,...,rN
..11-, 1-178 0 410 HN N " 534 2.22 1 Nfj-N -.----0 GI
0 eithh H r J N "
VI' N -'k.---0 534 2.17 1 õrm , N ' ,), ,..
N I 1 0 528 2.42 1 Date Recue/Date Received 2020-11-26 [Table 37]
Compound No Structure [M+1-1]+ RI Method r---1 ,--------0 N
'-----r 0 1-181 528 2.35 1 F
0'111-0 H
1-182 .
NNO 518 2.07 1 ..,k.
*
F
8 .....a.i. ...
1-183 H NI 518 2.02 1 till ---L
1.1 -...,...,7- N
crit- -% 1_, 11) 1111 H N N% .' 1-184 500 2.01 1 N-----4---N---ko -1-) D
N
-----r 0 A
0 ..1... ,0% 0 H
OD
1-185 reN 13 500 1.96 1 *
Date Recue/Date Received 2020-11-26 [Table 38]
Compound No Structure [M+I-1]+ RI
Method rl 0 = '----0 Is HN -AN 0 N-5-1-N-0 502 2.23 1 rh--0 = 0 410 HN AN -5-----)1-01-1 1-187 488 1.97 1 N--'1--N---k-70 1-----'1 F -N ----r 0 = '---0 Ill HN N 0 1-188 N-j---N---LO 520 2.3 1 -' '11, F -----r 0 , 0 si HN N OH
1-189 N-2-1-1,1----0 506 2.05 1 F
---ki.
I N
0 - '---01 0 N N 0 520 2.29 1 Date Recue/Date Received 2020-11-26 [Table 39]
Compound No Structure [M+I-1]+ RI
Method F
-- ----j----z-, --.1-, 1-191 0 0 HVILN------AOH 506 2.05 1 ..)..... .,..
rr-------Ny- 0 --------0 0 0 ,..-II, HI N=-----'0 548 2.46 1 --' 40 c, (---N ,f,--; 0 0 0 4 )10 HI , ,,,, ----KILO H
1-193 520 2.08 1 N'--- N--,0 Sal --.--C-)1 0 40 HN---kN ------(11---0 1-194 N----i.-N --01 538 2.14 1 F
F
-------, 1 0 T ,T11 i si Nii---------------- OH
1-195 502 2.06 1 N.---. N --.---0 *
Date Recue/Date Received 2020-11-26 [Table 40]
Compound No Structure [M+H]F RI
Method N
o HN N
I-196 NND 520 2.33 1 F
N
0 = 0 os I-197 506 2.07 N
H 98 505 2.18 N 11 0 491 t93 Date Recue/Date Received 2020-11-26
[0148]
[Table 41]
...
Compound No Structure [M+1-1]+ RI Method c 0 0 1-20 ilk HNAN'''''f)L0H
0 ,,,,-,,J,, __,L., N N -0 a\ 524 1.94 1 C2-21''.01 ? 0 de' , FINV.:00 F. 111 1-201 '-. N'LN -"ko 524 1.9 1 o o 0 ,..-0. HN AN OHI
.--14.--- N 0 506 2.15 1 1;1 0 0 A., ,"....õõit, .,,,--0------;.--'1. HN N .. 0 1-203 -,, , -1 k (5 ....'--' 538 2.16 1 L1C,I
14" lc) 0 410 FIN N NI'AN fO'F' 1-204 IA, 520 2.36 1 ) 0 Date Recue/Date Received 2020-11-26 [Table 42]
Compound No Structure [M+I-1]+ RI
Method N re F
0 "e HIN AN
1-205 -, 1 N N ,,i0 I 540 2A7 1 I
ci 0 0 Oar HN AN IA0 1-206 1 520 2.05 1 I
II "." F
N., F I '''' N
1c 0 0 lib FIN AN '' 0 I 538 2.14 1 ' F
IF
1-208 ---n-j. Hetrik-r--'1-1.91 538 2.11 1 N N
I
--.. F
I
)1L'N 1 0 1-209 1 538 2.16 1 Ni" N 0 I
..,,,'" F
Date Recue/Date Received 2020-11-26 [Table 43]
Compound No Structure [M+I-1]+ RI
Method 0 1 1-210 -1, ."--,11,-..
N )1''' NI 0 I , L.C., fr) 0 o o, ,..
I,- , HNN OHI
1-211 L:z.õ. 1 ,) ,,, N, N 0 526 219 1 40 i , ----) 1-212 ..,, ,L_A 522 214 1 I _ LC-.------, ' CI
"4...
NI F' ? 0 0 502 2.06 1 10, p, 0 0 1-214 40) HN AN -----(11L-oH
SF
Date Recue/Date Received 2020-11-26 [Table 44]
Compound No Structure [M+1-1]+ RI
Method IF 1 "Nj 0 0 0 ..." 11 MN
N N 1 )1'14 524 t89 - OH
1-215 , ,, , 1 LIC:-"F
F
I
I '''INJ
1C.
A
1-216 is HN N H 524 1.88 1 1415kW"LO
Ili F
F
A ,-,,,o -- Ill IN H
.1,-,... 524 1.91 1 ..N." N Isi - .--0 0 rik, 0 1-218 0 HN Nf IHI 518 2.08 1 Nrc) 0 0 C H N ilL' 0 L'Yr ':-.1 N HI
1-219 536 2.22 1 *1 Date Recue/Date Received 2020-11-26 [Table 45]
, -Compound No Structure [M+1-1]+ RI Method N 'T. -5:::, 0 .,__,..t.),,, - HN N H
536 2.26 1 1-220 1: ' i ,),õk,,õ --::-., , -.--, 0 6, A
1-221 0.,,,, HN iL N''''''IO
'-,,, I ---1 z 532 2.34 1 (1 ,,,." HN --11'N10 532 2.2 1 i - NNO
cN 0 0 0L . HNIAle-ijiLO"
1-223 1,,, 1 536 2.4 1 NI Nb ,,...
1-224 ,,,,t, Date Recue/Date Received 2020-11-26 [Table 46]
Compound No Structure [M+I-1]+ RI
Method c 0 .."' HNAXILO"
1-225 1 ,i _L, 550 2.51 1 N N '01 1 .."' 1 T
1 ,A0 1 HN N i 0 1-226 N Nõõo k.õ = 550 2.55 1 0) .,,, j[L, ik, HN N "
N N
1-227 I, 1 ),,, 554 2.54 1 cF 0 i 0 o .," 1 HN N . 0 1-228 -,õ ' 1õ, ' 554 2.57 1 V
"N
1-229 0 HiN VIILOH 518 t96 1 eLN"L'O
Date Recue/Date Received 2020-11-26 [Table 47] _ , Compound No Structure [M+1-1]+ RI Method Ni F 0 0 0 ;-.1-, 1-230 '-n HN N H
1,':-., )-6,,,, /51,..., ,4, 540 2.26 1 ---- N N o Ni F 1 7 0 1 It HN N '''rFOH
1-231 1 N ,,,,t, 1õ ,. 540 2.29 1 N ' 0 I
I ' 1-232 00,,......_ 1 :1L,N1 )1L '''''''IiLOH 540 2.05 1 I
SO .
'IN
I A
----r- o 0 1-233 -.IL, i y -----e-01-1 540 1.95 1 L----r("-'--------; ,,,, ii,..õ..i. ,F
1 ,..,r4 o o ' RN AN 1A0H1 1-234 .,., l' -,,,A. ,,I 524 2.22 1 Date Recue/Date Received 2020-11-26 [Table 48]
, Compound No Structure [M+1-1]+ RI Method F
.., N
AO
HN N HI 524 2.19 1 L
F
y0i F
1-237 -- H N NI '''.y.L0 538 2.46 1 Fic.,_...
, N
1-238 0 o I
D ii N 554 2.33 1 NN ...., 1, '' CI
F
II
I
1-239 DI , ,..
HN N ---.1-1L-0 554 2.23 1 111 INN )Lb git , .
_110 -Date Recue/Date Received 2020-11-26 [Table 49] _ Compound No Structure [M+H]F RI Method HO
I , N 0 0 0 õtaih, IHIN Ate-s.,,r)L0 H
NA,N 0 1-240 MO 537.952 1.5 1 CI
0:11 1-241 A 552 2.04 1 OS1 HN N AejkOHI
F
1-242 o ,--4,11,, opHN AN OH 520 1.98 1 I ,,L, c N "e "" HNIJIL'N ', ' -'0H
i 'I
1-243 ,, II ,), ,k 542 2.29 1 CII
Ni HN Nrr'ilL
,,õ,,, N N 0 512 2.33 1 Date Recue/Date Received 2020-11-26
[Table 41]
...
Compound No Structure [M+1-1]+ RI Method c 0 0 1-20 ilk HNAN'''''f)L0H
0 ,,,,-,,J,, __,L., N N -0 a\ 524 1.94 1 C2-21''.01 ? 0 de' , FINV.:00 F. 111 1-201 '-. N'LN -"ko 524 1.9 1 o o 0 ,..-0. HN AN OHI
.--14.--- N 0 506 2.15 1 1;1 0 0 A., ,"....õõit, .,,,--0------;.--'1. HN N .. 0 1-203 -,, , -1 k (5 ....'--' 538 2.16 1 L1C,I
14" lc) 0 410 FIN N NI'AN fO'F' 1-204 IA, 520 2.36 1 ) 0 Date Recue/Date Received 2020-11-26 [Table 42]
Compound No Structure [M+I-1]+ RI
Method N re F
0 "e HIN AN
1-205 -, 1 N N ,,i0 I 540 2A7 1 I
ci 0 0 Oar HN AN IA0 1-206 1 520 2.05 1 I
II "." F
N., F I '''' N
1c 0 0 lib FIN AN '' 0 I 538 2.14 1 ' F
IF
1-208 ---n-j. Hetrik-r--'1-1.91 538 2.11 1 N N
I
--.. F
I
)1L'N 1 0 1-209 1 538 2.16 1 Ni" N 0 I
..,,,'" F
Date Recue/Date Received 2020-11-26 [Table 43]
Compound No Structure [M+I-1]+ RI
Method 0 1 1-210 -1, ."--,11,-..
N )1''' NI 0 I , L.C., fr) 0 o o, ,..
I,- , HNN OHI
1-211 L:z.õ. 1 ,) ,,, N, N 0 526 219 1 40 i , ----) 1-212 ..,, ,L_A 522 214 1 I _ LC-.------, ' CI
"4...
NI F' ? 0 0 502 2.06 1 10, p, 0 0 1-214 40) HN AN -----(11L-oH
SF
Date Recue/Date Received 2020-11-26 [Table 44]
Compound No Structure [M+1-1]+ RI
Method IF 1 "Nj 0 0 0 ..." 11 MN
N N 1 )1'14 524 t89 - OH
1-215 , ,, , 1 LIC:-"F
F
I
I '''INJ
1C.
A
1-216 is HN N H 524 1.88 1 1415kW"LO
Ili F
F
A ,-,,,o -- Ill IN H
.1,-,... 524 1.91 1 ..N." N Isi - .--0 0 rik, 0 1-218 0 HN Nf IHI 518 2.08 1 Nrc) 0 0 C H N ilL' 0 L'Yr ':-.1 N HI
1-219 536 2.22 1 *1 Date Recue/Date Received 2020-11-26 [Table 45]
, -Compound No Structure [M+1-1]+ RI Method N 'T. -5:::, 0 .,__,..t.),,, - HN N H
536 2.26 1 1-220 1: ' i ,),õk,,õ --::-., , -.--, 0 6, A
1-221 0.,,,, HN iL N''''''IO
'-,,, I ---1 z 532 2.34 1 (1 ,,,." HN --11'N10 532 2.2 1 i - NNO
cN 0 0 0L . HNIAle-ijiLO"
1-223 1,,, 1 536 2.4 1 NI Nb ,,...
1-224 ,,,,t, Date Recue/Date Received 2020-11-26 [Table 46]
Compound No Structure [M+I-1]+ RI
Method c 0 .."' HNAXILO"
1-225 1 ,i _L, 550 2.51 1 N N '01 1 .."' 1 T
1 ,A0 1 HN N i 0 1-226 N Nõõo k.õ = 550 2.55 1 0) .,,, j[L, ik, HN N "
N N
1-227 I, 1 ),,, 554 2.54 1 cF 0 i 0 o .," 1 HN N . 0 1-228 -,õ ' 1õ, ' 554 2.57 1 V
"N
1-229 0 HiN VIILOH 518 t96 1 eLN"L'O
Date Recue/Date Received 2020-11-26 [Table 47] _ , Compound No Structure [M+1-1]+ RI Method Ni F 0 0 0 ;-.1-, 1-230 '-n HN N H
1,':-., )-6,,,, /51,..., ,4, 540 2.26 1 ---- N N o Ni F 1 7 0 1 It HN N '''rFOH
1-231 1 N ,,,,t, 1õ ,. 540 2.29 1 N ' 0 I
I ' 1-232 00,,......_ 1 :1L,N1 )1L '''''''IiLOH 540 2.05 1 I
SO .
'IN
I A
----r- o 0 1-233 -.IL, i y -----e-01-1 540 1.95 1 L----r("-'--------; ,,,, ii,..õ..i. ,F
1 ,..,r4 o o ' RN AN 1A0H1 1-234 .,., l' -,,,A. ,,I 524 2.22 1 Date Recue/Date Received 2020-11-26 [Table 48]
, Compound No Structure [M+1-1]+ RI Method F
.., N
AO
HN N HI 524 2.19 1 L
F
y0i F
1-237 -- H N NI '''.y.L0 538 2.46 1 Fic.,_...
, N
1-238 0 o I
D ii N 554 2.33 1 NN ...., 1, '' CI
F
II
I
1-239 DI , ,..
HN N ---.1-1L-0 554 2.23 1 111 INN )Lb git , .
_110 -Date Recue/Date Received 2020-11-26 [Table 49] _ Compound No Structure [M+H]F RI Method HO
I , N 0 0 0 õtaih, IHIN Ate-s.,,r)L0 H
NA,N 0 1-240 MO 537.952 1.5 1 CI
0:11 1-241 A 552 2.04 1 OS1 HN N AejkOHI
F
1-242 o ,--4,11,, opHN AN OH 520 1.98 1 I ,,L, c N "e "" HNIJIL'N ', ' -'0H
i 'I
1-243 ,, II ,), ,k 542 2.29 1 CII
Ni HN Nrr'ilL
,,õ,,, N N 0 512 2.33 1 Date Recue/Date Received 2020-11-26
[0149]
[Table 50]
Cornwund No Structure [M+1-1]+ RI Method 1 "----- OH
'ID' ..õ.3,,, 1 1-245 .06 1 N---- .-`11\1- 0 552 2 OH
,..- NI 0 'NO
1.--4.
1-246 -1-A H rtil 1 0 532 1.97 1 -.'-'----=" N N 0 iso ..,, ,,.., N 0 0 1411 1,11.,6 NI. ".----TA-1 566 2.28 1 N N-"---4""-t0 I
'----.
I NI
.-- 0 0 1-248 o -111, 548 2. 19 1 --0_, HN NO"--' '..-- NN0 i 0 A.
HN N OF-1-249 ...), N N ,...10,, 566 2.32 1 I I
Date Recue/Date Received 2020-11-26 [Table 51]
Compound No Structure [M+1-1]+ RI Method or,i HNAN---I0"' . l -t, ,IL 546 2.23 1 N'N' N 0 ,N 0 0 1-251 o )1, eallih HN Nr."'"IFILO 550 2.5 1 N N A 0 il ip c, NI --,,, 0, 0 0 0 IHNAN,"*.,cy-1-252 556 2.54 1 N N :f A
1 s i ri--)N -y F 0 0 ,,), 1, 526 2.6 1 1-254 532 1.95 1 -0. HNI N OH
I
IP
Date Recue/Date Received 2020-11-26 [Table 52]
Compound No Structure [M+H]+ RI
Method 0 A., 1-255 t-'"....0 Hit, IT --"1--jkoH
552 2.07 1 1.1 .....,...
----- CPI
I="'..,, ~'''' N N,0 k, 532 1.99 1 Ili ,-------:,r-----H -D
[!,,...f.. N 0 0 -4,,... IL, "L 538 1.83 1 IP CII
I
1-258 o A
OS I 1 H.1--'"-T'IL01-1I 536 2.24 1 N N "".0 =
I
II
N ,,,, 0 0 1-259 0 A.
4111 14, 13 til " '''' y ILO 1 = i 550 2.01 1 , N NO
SD
Date Recue/Date Received 2020-11-26 [Table 53]
Compound No Structure [M+I-1]+ RI
Method --, I
1-260' o --- HN AN '...1-AOH 530 1.93 1 - NNO
IP
1 ''''=- F
= ir, rryilLOHI
1-261 NNO 520 2.01 1 OH
'---...
I
1-262 o F-e HN AN OH 532 137 1 JNNO
I
ci 0 0 0 ' HN AN "FilLOH
1-263 ..õ..., II N N 0 492 2.11 1 ---F
[LrN
1-264 HN NIFIAOH 510 2.18 1 N.,,,LN,L0 t"-Nl 0 Date Recue/Date Received 2020-11-26 [Table 54]
Compound No Structure [M+H+ RI
Method i (L
1-265 .,--ra HN N 0 N FIN''''N 0 I N
1-266 13N'N o 534 2.26 1 =
1,1 ) 1-267 --" HNAN----(11--0-- 544 2.17 1 I, õ.,, õk (;) 0 0 1-268 CD "
.,..õ V NNO 506 2.37 1 F
1-269 HNIAN 0 ,7-1NDI, 524 2A3 1 Date Recue/Date Received 2020-11-26 [Table 55]
, Compound No Structure [M+1-1]+ RI
Method 1 ''''' , N 0 0 1-270 o - IH WAN -.-"IBLO 530 2.43 1 I
=
p 0 o 1-271 :: 1 HfrirliL? 527.98 2.43 1 N N ---t11 F
1 ,, 0 0 (D....a 1-1_,11." t111--yUL? 545 . . 1 NNO
I Si? CI
Icl 0 0 I õ,, 1-273 01 1 A .,1)1.10H 513.953 2.14 1 Si, CI
F
1 '14 it, 0 1-274 O.,õ MI NJ y01-Ir 532 2.19 1 N N "N
Si CI
Date Recue/Date Received 2020-11-26 [Table 56]
Cornround No Structure [M+1-1]+ RI
Method SO HN AN jiLOH 516 2.18 1 N N
I
' Ir _ N. F
F
r 0 0 1-276 c'-y--- HNIAN-"1-1-0H
546 2.32 1 Si CI
I
0 =6 = 0 ----- HN )LNI ''''''1)1L0 601 2.15 1 N N o a, 01 0= õ0 ..., 0 0 1_278 .-- HNNYAOH 587 t89 1 Ni''' N0 LIO,,)c
[Table 50]
Cornwund No Structure [M+1-1]+ RI Method 1 "----- OH
'ID' ..õ.3,,, 1 1-245 .06 1 N---- .-`11\1- 0 552 2 OH
,..- NI 0 'NO
1.--4.
1-246 -1-A H rtil 1 0 532 1.97 1 -.'-'----=" N N 0 iso ..,, ,,.., N 0 0 1411 1,11.,6 NI. ".----TA-1 566 2.28 1 N N-"---4""-t0 I
'----.
I NI
.-- 0 0 1-248 o -111, 548 2. 19 1 --0_, HN NO"--' '..-- NN0 i 0 A.
HN N OF-1-249 ...), N N ,...10,, 566 2.32 1 I I
Date Recue/Date Received 2020-11-26 [Table 51]
Compound No Structure [M+1-1]+ RI Method or,i HNAN---I0"' . l -t, ,IL 546 2.23 1 N'N' N 0 ,N 0 0 1-251 o )1, eallih HN Nr."'"IFILO 550 2.5 1 N N A 0 il ip c, NI --,,, 0, 0 0 0 IHNAN,"*.,cy-1-252 556 2.54 1 N N :f A
1 s i ri--)N -y F 0 0 ,,), 1, 526 2.6 1 1-254 532 1.95 1 -0. HNI N OH
I
IP
Date Recue/Date Received 2020-11-26 [Table 52]
Compound No Structure [M+H]+ RI
Method 0 A., 1-255 t-'"....0 Hit, IT --"1--jkoH
552 2.07 1 1.1 .....,...
----- CPI
I="'..,, ~'''' N N,0 k, 532 1.99 1 Ili ,-------:,r-----H -D
[!,,...f.. N 0 0 -4,,... IL, "L 538 1.83 1 IP CII
I
1-258 o A
OS I 1 H.1--'"-T'IL01-1I 536 2.24 1 N N "".0 =
I
II
N ,,,, 0 0 1-259 0 A.
4111 14, 13 til " '''' y ILO 1 = i 550 2.01 1 , N NO
SD
Date Recue/Date Received 2020-11-26 [Table 53]
Compound No Structure [M+I-1]+ RI
Method --, I
1-260' o --- HN AN '...1-AOH 530 1.93 1 - NNO
IP
1 ''''=- F
= ir, rryilLOHI
1-261 NNO 520 2.01 1 OH
'---...
I
1-262 o F-e HN AN OH 532 137 1 JNNO
I
ci 0 0 0 ' HN AN "FilLOH
1-263 ..õ..., II N N 0 492 2.11 1 ---F
[LrN
1-264 HN NIFIAOH 510 2.18 1 N.,,,LN,L0 t"-Nl 0 Date Recue/Date Received 2020-11-26 [Table 54]
Compound No Structure [M+H+ RI
Method i (L
1-265 .,--ra HN N 0 N FIN''''N 0 I N
1-266 13N'N o 534 2.26 1 =
1,1 ) 1-267 --" HNAN----(11--0-- 544 2.17 1 I, õ.,, õk (;) 0 0 1-268 CD "
.,..õ V NNO 506 2.37 1 F
1-269 HNIAN 0 ,7-1NDI, 524 2A3 1 Date Recue/Date Received 2020-11-26 [Table 55]
, Compound No Structure [M+1-1]+ RI
Method 1 ''''' , N 0 0 1-270 o - IH WAN -.-"IBLO 530 2.43 1 I
=
p 0 o 1-271 :: 1 HfrirliL? 527.98 2.43 1 N N ---t11 F
1 ,, 0 0 (D....a 1-1_,11." t111--yUL? 545 . . 1 NNO
I Si? CI
Icl 0 0 I õ,, 1-273 01 1 A .,1)1.10H 513.953 2.14 1 Si, CI
F
1 '14 it, 0 1-274 O.,õ MI NJ y01-Ir 532 2.19 1 N N "N
Si CI
Date Recue/Date Received 2020-11-26 [Table 56]
Cornround No Structure [M+1-1]+ RI
Method SO HN AN jiLOH 516 2.18 1 N N
I
' Ir _ N. F
F
r 0 0 1-276 c'-y--- HNIAN-"1-1-0H
546 2.32 1 Si CI
I
0 =6 = 0 ----- HN )LNI ''''''1)1L0 601 2.15 1 N N o a, 01 0= õ0 ..., 0 0 1_278 .-- HNNYAOH 587 t89 1 Ni''' N0 LIO,,)c
[0150]
The following compounds of the Reference Examples were synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Reference Examples, with reference to the contents described in W02010/092966 and W02012/020749 as needed.
The following compounds of the Reference Examples were synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Reference Examples, with reference to the contents described in W02010/092966 and W02012/020749 as needed.
[0151]
Reference Examples Date Recue/Date Received 2020-11-26 [Table 57]
Compound No Structure [M+1-1]+ RI
Method HO
N
a H < 598 2.55 1 N
Sc' oç
R-002 0 H N 40 ,NH 556 2.38 1 Sc' HO
N
R-003 a )1, HH 542 2.07 1 Sc' "IP 141-11 o H
0 am A 599 2.59 1 "IP ri';:i'rYr-LO
Date Recue/Date Received 2020-11-26 [Table 58]
Compound No Structure [M+1-1]+ RI Method I
-.-..
N HN-N--------R-005 n'el---N,---o 459 2.28 1 11101 c 1 .,--__(-,õ
R-006 40 o 585 2.24 1 ) HINFA-14'.
N
N --11-' N -------R-00 7 )1, 1...
N N - --''.0 440 2.3 1 f N N - ---'-0 11111 c I
........N ....._0_, yA0 41 L.õ...,0.
0 H N N , H
R-009 ,-i_ .._... E
N N 0 552 2.11 1 =0 - N
0 A .-1-._5 H N N _ OH
R-010 4 ,.-._[._ N N 0 553 2.05 1 =0 Date Recue/Date Received 2020-11-26 [Table 59]
, Compound No Structure IM-FHIF RI Method ........._Ni MN Ni R-01 1 411 ..),... .......
NI N 0 523 2.61 1 Sc' a 1c-r-A-I ,-.- NI
Si H N AN, )--,.
NI NI ---.-LID 542 2.47 1 101 ci ci r-LN
N 1....-I ..---. HN AN-'111'0"---.
R-01 3 ,1, N.' 557 2.37 1 le 1 ci ii--i---z.N
NI ___s_.,1 0 H N A N"-----11-0 H
R-0 1 4 N N .._.ki, 543 2.12 1 Si CI
'---1 0,..e.0 CI -.-------f--:-.N 0 R-01 5 ta A ,-..._ si H N NI -- 556 2.7 1 ....-...1, .......0 Ni Ni Date Recue/Date Received 2020-11-26 [Table 60]
Compound No Structure [M+I-1]+ RI Method axhl I N
CI ----f- 0 0 ------_, R-016 is N N 0 528 2.27 1 Sc' uyN
--..
a HN AN
R-017 III N.--:1-N -------1a --4.0 Ci 523 2.12 1 'CI
N---...------I
uyN
--..
a 0 13 411 hill'N ----K40 R-018 N.--- N '4.0 527 2.23 1 'C' N--.-.-uyN
a a ill- h IAN -----(11-0H
110 , N--.-.---) 11.1...,N
0 aah H N AN -.-----K11--OH
R-020 ...:-.-i, ....
qill N N 0 523 1.94 1 Date Recue/Date Received 2020-11-26 [Table 61]
, Compound No Structure [M+1-1]+ RI Method a ci OH
0 ,c))------r- is HI N,J, R-021 N' N''-----0 519 2 31 1 Sc' a CI a A c7 o I-1 ----ro 0 H NJ NJ
R-022 N-::-L-N '---L0 519 2.26 1 SC' a ¨ o H N N H
R-023 N ,-i, ......
N a 509 2.32 1 Sc' c, H N H AN '''' N N a 509 2.27 1 Sc' c, fri-Nj NJ y-. --I 0 0 0 .46.
R-025 -X11-13---.
N -:.1--N `---D 571 2.48 1 1110 , Date Recue/Date Received 2020-11-26 [Table 62]
Compound No Structure [M+1-1]+ RI Method F
I .----N, -.--1 R-026 0 H N'AN' --IAD e---. 588 239 1 Sc' CI
[(1-NI
N' yf,1 a a SI HN)1.1r---7\----ILOH
R-027 ..)- ,... e.....õ, 553 2 19 1 N N
Sc' F
F j, F
I --1'1, --y-11 --11-_ ..--J, N' ---Ci Ill CI
F
F F
`-'----- N
I ) ----1,- N' 0 0 R¨ 0 ill 029 ..... N ---------11---0 605 2.42 1 N' N' 0 . CI
F
F F
e"------- N' --y N
R-030 c 0 577 2.08 1 Ne--1-N--Lc IP ci Date Recue/Date Received 2020-11-26 [Table 63]
Compound No Structure [M+H]+ RI
Method F
F...1 F
I -1k R-0311 0 H N-.--------N-iLtiH 591 2 15 1 N NI -.---L---0 ......,NI rii.....
y0 0 411 HrijIIII---111--OH
R-032 ---..-NI NI a 538 2 1 IN ci ---.----N
I ' ...-= N
'T.-- F 0 a 41 H,N, AN
I
R-033 NI NI =-----Ct 541 2.13 1 ill 1 .--.--...--'--11 I ' ...-.N
-----r- F 0 0 H NI AN =------A--113 I
R-034 41111 NND 555 2.27 1 1:011 1 F
F F
NI ------) .1 1.1.....rN ...0 ....L..n.,1310H
R-035 si HI IA, 591 2.46 1 Sc' Date Recue/Date Received 2020-11-26 [Table 64]
Compound No Structure [M+H]+ RI Method F
F F
Ni ---.---) 1.1.....f....N
R-036 c 40 H N 'IL' Ni 505 2.55 1 Ni Ni 0 "----.-- Ni I .....14 ----y- F 0 0 I HI 11 ''-(11.-laH
R-037 NI' N =-.-----0, 527 1.93 1 Sc' =-=---'---.-Ni I .....14 ----y- F 0 0 en H N--11--Ni ''XiklaH
R-038 Ni--)---N '-k---.0 543 2.01 1 Sc' F
F F
N --.----1 L....f....
R-039 C Opp 577 2.22 1 N Ni 0 II' c, F , Niz...... F
I
y. o .--o H 1'1 ii--114-e-yL-C1 R-040 IP ..),. .....L
ti Ni 0 558 2.47 1 Sc' Date Recue/Date Received 2020-11-26 [Table 65]
Compound No Structure [M+I-1]+ RI
Method F...._,Nz.õ....F
I
y0 .---0 HNO )1'N
S
R I-041 N N 0 572 2.57 1 Sc' N
N.1-:.---.
H H CI '11--NJ
R-042 II) tr;f1--14.-----1-'40 537 2.03 1 Sc' N
.-.--11 .---N .1-,--- ---..0 H N-N
5c1 N
'ri '-----N
41:1 HIIII 0-Iji--- H
Sc' N
.----11- '-----N
411 H r1 -N -.-----7\--1-0 H
R-045 ,-,I, ...4.
Sc' Date Recue/Date Received 2020-11-26 [Table 66]
Compound No Structure [M+1-1]+ RI Method CI
I .... N
FIN ,.....------(11--0----, --1L-N, R-046 NNO 557 2.32 1 11110 c I
I -rj .--y, 0 0 . 0 40 J-1E-NJ ..., R-047 N - N ,--1, ..-471(1LC
0 571 2.42 1 Sc' N' ----.---1 ty,N, 0 40 Hi--u--tl------i---I--cr---R-048 NNO 541 2.27 1 Sc' LyNJ F 0 0 0 140 H1'1)1.11=----"-<11-'0"---.
R-049 N.-----LN -u'L---- 555 2.37 1 Sc' o .....14 N
.-,..r 0 0 R-050 410 F11-11ryil--0h1 N' N' 0 539 2.02 1 SC' Date Recue/Date Received 2020-11-26
Reference Examples Date Recue/Date Received 2020-11-26 [Table 57]
Compound No Structure [M+1-1]+ RI
Method HO
N
a H < 598 2.55 1 N
Sc' oç
R-002 0 H N 40 ,NH 556 2.38 1 Sc' HO
N
R-003 a )1, HH 542 2.07 1 Sc' "IP 141-11 o H
0 am A 599 2.59 1 "IP ri';:i'rYr-LO
Date Recue/Date Received 2020-11-26 [Table 58]
Compound No Structure [M+1-1]+ RI Method I
-.-..
N HN-N--------R-005 n'el---N,---o 459 2.28 1 11101 c 1 .,--__(-,õ
R-006 40 o 585 2.24 1 ) HINFA-14'.
N
N --11-' N -------R-00 7 )1, 1...
N N - --''.0 440 2.3 1 f N N - ---'-0 11111 c I
........N ....._0_, yA0 41 L.õ...,0.
0 H N N , H
R-009 ,-i_ .._... E
N N 0 552 2.11 1 =0 - N
0 A .-1-._5 H N N _ OH
R-010 4 ,.-._[._ N N 0 553 2.05 1 =0 Date Recue/Date Received 2020-11-26 [Table 59]
, Compound No Structure IM-FHIF RI Method ........._Ni MN Ni R-01 1 411 ..),... .......
NI N 0 523 2.61 1 Sc' a 1c-r-A-I ,-.- NI
Si H N AN, )--,.
NI NI ---.-LID 542 2.47 1 101 ci ci r-LN
N 1....-I ..---. HN AN-'111'0"---.
R-01 3 ,1, N.' 557 2.37 1 le 1 ci ii--i---z.N
NI ___s_.,1 0 H N A N"-----11-0 H
R-0 1 4 N N .._.ki, 543 2.12 1 Si CI
'---1 0,..e.0 CI -.-------f--:-.N 0 R-01 5 ta A ,-..._ si H N NI -- 556 2.7 1 ....-...1, .......0 Ni Ni Date Recue/Date Received 2020-11-26 [Table 60]
Compound No Structure [M+I-1]+ RI Method axhl I N
CI ----f- 0 0 ------_, R-016 is N N 0 528 2.27 1 Sc' uyN
--..
a HN AN
R-017 III N.--:1-N -------1a --4.0 Ci 523 2.12 1 'CI
N---...------I
uyN
--..
a 0 13 411 hill'N ----K40 R-018 N.--- N '4.0 527 2.23 1 'C' N--.-.-uyN
a a ill- h IAN -----(11-0H
110 , N--.-.---) 11.1...,N
0 aah H N AN -.-----K11--OH
R-020 ...:-.-i, ....
qill N N 0 523 1.94 1 Date Recue/Date Received 2020-11-26 [Table 61]
, Compound No Structure [M+1-1]+ RI Method a ci OH
0 ,c))------r- is HI N,J, R-021 N' N''-----0 519 2 31 1 Sc' a CI a A c7 o I-1 ----ro 0 H NJ NJ
R-022 N-::-L-N '---L0 519 2.26 1 SC' a ¨ o H N N H
R-023 N ,-i, ......
N a 509 2.32 1 Sc' c, H N H AN '''' N N a 509 2.27 1 Sc' c, fri-Nj NJ y-. --I 0 0 0 .46.
R-025 -X11-13---.
N -:.1--N `---D 571 2.48 1 1110 , Date Recue/Date Received 2020-11-26 [Table 62]
Compound No Structure [M+1-1]+ RI Method F
I .----N, -.--1 R-026 0 H N'AN' --IAD e---. 588 239 1 Sc' CI
[(1-NI
N' yf,1 a a SI HN)1.1r---7\----ILOH
R-027 ..)- ,... e.....õ, 553 2 19 1 N N
Sc' F
F j, F
I --1'1, --y-11 --11-_ ..--J, N' ---Ci Ill CI
F
F F
`-'----- N
I ) ----1,- N' 0 0 R¨ 0 ill 029 ..... N ---------11---0 605 2.42 1 N' N' 0 . CI
F
F F
e"------- N' --y N
R-030 c 0 577 2.08 1 Ne--1-N--Lc IP ci Date Recue/Date Received 2020-11-26 [Table 63]
Compound No Structure [M+H]+ RI
Method F
F...1 F
I -1k R-0311 0 H N-.--------N-iLtiH 591 2 15 1 N NI -.---L---0 ......,NI rii.....
y0 0 411 HrijIIII---111--OH
R-032 ---..-NI NI a 538 2 1 IN ci ---.----N
I ' ...-= N
'T.-- F 0 a 41 H,N, AN
I
R-033 NI NI =-----Ct 541 2.13 1 ill 1 .--.--...--'--11 I ' ...-.N
-----r- F 0 0 H NI AN =------A--113 I
R-034 41111 NND 555 2.27 1 1:011 1 F
F F
NI ------) .1 1.1.....rN ...0 ....L..n.,1310H
R-035 si HI IA, 591 2.46 1 Sc' Date Recue/Date Received 2020-11-26 [Table 64]
Compound No Structure [M+H]+ RI Method F
F F
Ni ---.---) 1.1.....f....N
R-036 c 40 H N 'IL' Ni 505 2.55 1 Ni Ni 0 "----.-- Ni I .....14 ----y- F 0 0 I HI 11 ''-(11.-laH
R-037 NI' N =-.-----0, 527 1.93 1 Sc' =-=---'---.-Ni I .....14 ----y- F 0 0 en H N--11--Ni ''XiklaH
R-038 Ni--)---N '-k---.0 543 2.01 1 Sc' F
F F
N --.----1 L....f....
R-039 C Opp 577 2.22 1 N Ni 0 II' c, F , Niz...... F
I
y. o .--o H 1'1 ii--114-e-yL-C1 R-040 IP ..),. .....L
ti Ni 0 558 2.47 1 Sc' Date Recue/Date Received 2020-11-26 [Table 65]
Compound No Structure [M+I-1]+ RI
Method F...._,Nz.õ....F
I
y0 .---0 HNO )1'N
S
R I-041 N N 0 572 2.57 1 Sc' N
N.1-:.---.
H H CI '11--NJ
R-042 II) tr;f1--14.-----1-'40 537 2.03 1 Sc' N
.-.--11 .---N .1-,--- ---..0 H N-N
5c1 N
'ri '-----N
41:1 HIIII 0-Iji--- H
Sc' N
.----11- '-----N
411 H r1 -N -.-----7\--1-0 H
R-045 ,-,I, ...4.
Sc' Date Recue/Date Received 2020-11-26 [Table 66]
Compound No Structure [M+1-1]+ RI Method CI
I .... N
FIN ,.....------(11--0----, --1L-N, R-046 NNO 557 2.32 1 11110 c I
I -rj .--y, 0 0 . 0 40 J-1E-NJ ..., R-047 N - N ,--1, ..-471(1LC
0 571 2.42 1 Sc' N' ----.---1 ty,N, 0 40 Hi--u--tl------i---I--cr---R-048 NNO 541 2.27 1 Sc' LyNJ F 0 0 0 140 H1'1)1.11=----"-<11-'0"---.
R-049 N.-----LN -u'L---- 555 2.37 1 Sc' o .....14 N
.-,..r 0 0 R-050 410 F11-11ryil--0h1 N' N' 0 539 2.02 1 SC' Date Recue/Date Received 2020-11-26
[0152]
[Table 67]
Compound No Structure [M+H+ RI Method ---.1 H VILNI -.-------i1-----.
R-051 N y:--- ..--)--... .,--..
NI N 0 556 2.49 1 CI
tel el H N -1LN '---------I
_.....-1õ. .....
R-052 ci N NI 0 528 2.08 1 Sc' C, j.."
.-y1 NI
R-053 0 11101 N NI A. ..----___ 556 2.61 1 ..õ-.1%. .....
CI .......
-yr* 0 R-054 H N )1---NI---------1101 .--.. ---. 528 2.19 1 N '1--N 0 III I
uy N
H NAN
OH
R-055 NI-:'.1-NI'-k.-0 527 2.01 1 IP GI
Date Recue/Date Received 2020-11-26 [Table 68]
Compound No Structure [M+I-1]+ RI
Method Ni .--.-------1 ty ht oF 1 c, ,.....õ1,..z.
H N "ANi 0 H
R-056 Ni'-:--1-Ni-------.0 541 2.1 1 Sc' F II F
----i --' ya a a SI H..õ,..t.N __A tr-ykOH
R-057 ri ri .--CI 544 2.21 1 'CI
F....._,Nz.õ....0 ,.., I
y0 G
40 Hilt' tli----IAOH
R-058 ri Ni .--ct 556 2.27 1 SC' n Ni _... NI
lip Fill------111--ct NI
R-059 Ni Ni ----o 523 2.03 1 SC' ril Ni ..-,r Ni R0 411 H N A Ni -06 -----7 \--AOH
Ni .-1--Ni a 523 1.86 1 re , Date Recue/Date Received 2020-11-26 [Table 69]
Compound No Structure [M+I-1]+ RI
Method __,..14 0 ......
---...r N
0 Fl...::..L.Nt -1-Ni' ----ik0 H
R-061 N' ri----0 539 1 94 1 Sc' -----d,,r MN' )1--N -.------- 499 2.28 1 ....), .......
Sc' 0 0 I-1 .;, 0 , ------.....
H N IN
R-063 471 1.87 1 110 a , .,... 0 ,... c, ...x, c A ..--,_ ...-.-1., N N''.--L-13 542 2.41 1 II a, ....._ .
a i)-----i- 40, H II AN' ---.---.------.y. PI . ...-..
R-065 ci N' N' o 542 2.4 1 0 c' Date Recue/Date Received 2020-11-26 [Table 70]
Compound No Structure [M+I-1]+ RI Method ,.... C I Xr I
R-066 N-11-mo 1101 --k-Sc' o a H
'---. x 41-6, y..
H N -11.' N =---------I N 41111) .;1.... ....4.
R-0 N N 67 .---%-i-Sc' H N
R-068 ,..-.1, N N --ko 510 225 1 Sc' _ 0 0 H N
R-069 ,_,-i, .....
Sc' F N F
.---1 --.
y-' a a a ID H N Arr-XLLCII-1 R-070 ,-....-1.... ....k ri N 0 558 2.29 1 SO CI
Date Recue/Date Received 2020-11-26 [Table 71]
Compound No Structure [M+H]F RI
Method F,.._,Ni........_õ0 ...., I
y -G Opp HI-11.-- rlilaH
R-071 Ni Ni .--.0 570 2.35 1 Sc' LI:(13 4111 H Ni A=Ni -.----111---7 2_-.1õ ....
Ni NL.i 0 R-072 517 2.45 1 1110 ci CIG 4111 H Ni -I-I-Ni ----XIII
,--.1.... ....L.
NNO
R-073 531 2.55 1 110 ci ¨ a a H N
H Ni ANi 0 H
R-074 Ni'---I---Ni ---.L0 495 2 1 110 c, _ D 0 N
H Ni ANi -------AAOH
R-075 H 510 2.09 1 0 c, Date Recue/Date Received 2020-11-26 [Table 72]
Compound No Structure [M+I-1]+ RI
Method JJ--.
Cy 40 H. j....N .1--ILLO H
R-076 503 2.19 1 111 c I
N N' 0 R-077 517 2.27 1 40 c, in]
N- , N
0 IAN, --.--yLLIDH
R-078 N N ---ci 509 1 77 1 IN , N, cl [t....r a µ---0 a 40 Ni HN,---u-, -.----10 R-079 ,, .,..
N c 556 2.37 1 SC' N...--õ.... cl itf..._ a µ---o a .
H NN -.---X0 R-080 Ni-51--- Ni Az) 570 2.48 1 SCI
Date Recue/Date Received 2020-11-26 [Table 73]
Compound No Structure [M+I-1]+ RI
Method Cl is 1.1 Cl a el R-082 NN 0 555 2.2 1 F N a a H N z0H
"Cl SI
c, HNAN"
R-085 N.---1-11---0H 539 1 93 1 SC' Date Recue/Date Received 2020-11-26 [Table 74]
Compound No Structure [M+I-1]+ RI Method .....tit, ....LI
I
y0 '0 0 am H N --11-"Ni ----0 R-086 L1110 Ni -1-"N 0 555 2.38 1 I. ci I
ya 'a a am in H N ji-Ni ----70 R-087 -.IP Nr-1'N 0 570 2.47 1 I. ci .....1.1,,,,c1 y0 D
Ni 0 tit H ..... NA ...--y-k.
OH
R-088 111-1111" Ni -1.--N ---.0 542 2.09 1 Sc' .....14,_,..c.I
I
y=-=
0 ...)00 ......._xiL
H NAN OH
R-089 N N 0 555 2.1 7 1 11 ci F.-..)::...., F! T F 0 0 401 Ni'N
H N 'IL N -..--1)1-1:1'---R-090 ......
-.--Li 0 559 2.55 1 161 ci Date Recue/Date Received 2020-11-26 [Table 75]
Compound No Structure [M+H]F RI
Method F
4110 H N 1Ni --KUM, ..---R-0 9 1 ..--)õ, N .,..
Ni o 573 2.58 1 Sc' ciN,......, I I
yN
41 H...1,4 -11-N ------1(11-0H
R-09 2 Ni Ni 0 557 2.15 1 110 ,i F
F 0, 0, II H NN H ---yli---0, R-09 3 N N --.0, 545 2.26 1 Sc' F
F F
F
is HNAN OH
R-094 ..1.. ,,..
Nr- Ni 0, 639 2.46 1 Sc' F.,..A...r.._,F
F
. H N AN
R-095 N(' .,4.
N 0 559 2.33 1 Sc' Date Recue/Date Received 2020-11-26 [Table 76]
Compound No Structure [M+H]F RI
Method FF F
F.,..) _....F
Fr 7 0 H N .-11--N --.---X1-0H
R-096 ,J-, ..._k N N 0 653 2.51 1 Sc' Fi 7 0 40 HNAN--------e--0 R-097 N-;1--N .-----0 555 2.49 1 IN c, F.-.....L
0 40 H N---11.-N----yik0H
R-098 N.-;1--N---0 541 2.25 1 iii c, ...-N
,...N,......._...---:-' y0 0 0 0 H N N ---4)---µ0---R-099 N-;--1--N --------u 547 2.25 1 Sc' N
.....14,.....---y0 0 0 is HN,--11--N, -----x-11-0---R-100 N--;-1-' N --.0 561 2.36 1 Sc' Date Recue/Date Received 2020-11-26
[Table 67]
Compound No Structure [M+H+ RI Method ---.1 H VILNI -.-------i1-----.
R-051 N y:--- ..--)--... .,--..
NI N 0 556 2.49 1 CI
tel el H N -1LN '---------I
_.....-1õ. .....
R-052 ci N NI 0 528 2.08 1 Sc' C, j.."
.-y1 NI
R-053 0 11101 N NI A. ..----___ 556 2.61 1 ..õ-.1%. .....
CI .......
-yr* 0 R-054 H N )1---NI---------1101 .--.. ---. 528 2.19 1 N '1--N 0 III I
uy N
H NAN
OH
R-055 NI-:'.1-NI'-k.-0 527 2.01 1 IP GI
Date Recue/Date Received 2020-11-26 [Table 68]
Compound No Structure [M+I-1]+ RI
Method Ni .--.-------1 ty ht oF 1 c, ,.....õ1,..z.
H N "ANi 0 H
R-056 Ni'-:--1-Ni-------.0 541 2.1 1 Sc' F II F
----i --' ya a a SI H..õ,..t.N __A tr-ykOH
R-057 ri ri .--CI 544 2.21 1 'CI
F....._,Nz.õ....0 ,.., I
y0 G
40 Hilt' tli----IAOH
R-058 ri Ni .--ct 556 2.27 1 SC' n Ni _... NI
lip Fill------111--ct NI
R-059 Ni Ni ----o 523 2.03 1 SC' ril Ni ..-,r Ni R0 411 H N A Ni -06 -----7 \--AOH
Ni .-1--Ni a 523 1.86 1 re , Date Recue/Date Received 2020-11-26 [Table 69]
Compound No Structure [M+I-1]+ RI
Method __,..14 0 ......
---...r N
0 Fl...::..L.Nt -1-Ni' ----ik0 H
R-061 N' ri----0 539 1 94 1 Sc' -----d,,r MN' )1--N -.------- 499 2.28 1 ....), .......
Sc' 0 0 I-1 .;, 0 , ------.....
H N IN
R-063 471 1.87 1 110 a , .,... 0 ,... c, ...x, c A ..--,_ ...-.-1., N N''.--L-13 542 2.41 1 II a, ....._ .
a i)-----i- 40, H II AN' ---.---.------.y. PI . ...-..
R-065 ci N' N' o 542 2.4 1 0 c' Date Recue/Date Received 2020-11-26 [Table 70]
Compound No Structure [M+I-1]+ RI Method ,.... C I Xr I
R-066 N-11-mo 1101 --k-Sc' o a H
'---. x 41-6, y..
H N -11.' N =---------I N 41111) .;1.... ....4.
R-0 N N 67 .---%-i-Sc' H N
R-068 ,..-.1, N N --ko 510 225 1 Sc' _ 0 0 H N
R-069 ,_,-i, .....
Sc' F N F
.---1 --.
y-' a a a ID H N Arr-XLLCII-1 R-070 ,-....-1.... ....k ri N 0 558 2.29 1 SO CI
Date Recue/Date Received 2020-11-26 [Table 71]
Compound No Structure [M+H]F RI
Method F,.._,Ni........_õ0 ...., I
y -G Opp HI-11.-- rlilaH
R-071 Ni Ni .--.0 570 2.35 1 Sc' LI:(13 4111 H Ni A=Ni -.----111---7 2_-.1õ ....
Ni NL.i 0 R-072 517 2.45 1 1110 ci CIG 4111 H Ni -I-I-Ni ----XIII
,--.1.... ....L.
NNO
R-073 531 2.55 1 110 ci ¨ a a H N
H Ni ANi 0 H
R-074 Ni'---I---Ni ---.L0 495 2 1 110 c, _ D 0 N
H Ni ANi -------AAOH
R-075 H 510 2.09 1 0 c, Date Recue/Date Received 2020-11-26 [Table 72]
Compound No Structure [M+I-1]+ RI
Method JJ--.
Cy 40 H. j....N .1--ILLO H
R-076 503 2.19 1 111 c I
N N' 0 R-077 517 2.27 1 40 c, in]
N- , N
0 IAN, --.--yLLIDH
R-078 N N ---ci 509 1 77 1 IN , N, cl [t....r a µ---0 a 40 Ni HN,---u-, -.----10 R-079 ,, .,..
N c 556 2.37 1 SC' N...--õ.... cl itf..._ a µ---o a .
H NN -.---X0 R-080 Ni-51--- Ni Az) 570 2.48 1 SCI
Date Recue/Date Received 2020-11-26 [Table 73]
Compound No Structure [M+I-1]+ RI
Method Cl is 1.1 Cl a el R-082 NN 0 555 2.2 1 F N a a H N z0H
"Cl SI
c, HNAN"
R-085 N.---1-11---0H 539 1 93 1 SC' Date Recue/Date Received 2020-11-26 [Table 74]
Compound No Structure [M+I-1]+ RI Method .....tit, ....LI
I
y0 '0 0 am H N --11-"Ni ----0 R-086 L1110 Ni -1-"N 0 555 2.38 1 I. ci I
ya 'a a am in H N ji-Ni ----70 R-087 -.IP Nr-1'N 0 570 2.47 1 I. ci .....1.1,,,,c1 y0 D
Ni 0 tit H ..... NA ...--y-k.
OH
R-088 111-1111" Ni -1.--N ---.0 542 2.09 1 Sc' .....14,_,..c.I
I
y=-=
0 ...)00 ......._xiL
H NAN OH
R-089 N N 0 555 2.1 7 1 11 ci F.-..)::...., F! T F 0 0 401 Ni'N
H N 'IL N -..--1)1-1:1'---R-090 ......
-.--Li 0 559 2.55 1 161 ci Date Recue/Date Received 2020-11-26 [Table 75]
Compound No Structure [M+H]F RI
Method F
4110 H N 1Ni --KUM, ..---R-0 9 1 ..--)õ, N .,..
Ni o 573 2.58 1 Sc' ciN,......, I I
yN
41 H...1,4 -11-N ------1(11-0H
R-09 2 Ni Ni 0 557 2.15 1 110 ,i F
F 0, 0, II H NN H ---yli---0, R-09 3 N N --.0, 545 2.26 1 Sc' F
F F
F
is HNAN OH
R-094 ..1.. ,,..
Nr- Ni 0, 639 2.46 1 Sc' F.,..A...r.._,F
F
. H N AN
R-095 N(' .,4.
N 0 559 2.33 1 Sc' Date Recue/Date Received 2020-11-26 [Table 76]
Compound No Structure [M+H]F RI
Method FF F
F.,..) _....F
Fr 7 0 H N .-11--N --.---X1-0H
R-096 ,J-, ..._k N N 0 653 2.51 1 Sc' Fi 7 0 40 HNAN--------e--0 R-097 N-;1--N .-----0 555 2.49 1 IN c, F.-.....L
0 40 H N---11.-N----yik0H
R-098 N.-;1--N---0 541 2.25 1 iii c, ...-N
,...N,......._...---:-' y0 0 0 0 H N N ---4)---µ0---R-099 N-;--1--N --------u 547 2.25 1 Sc' N
.....14,.....---y0 0 0 is HN,--11--N, -----x-11-0---R-100 N--;-1-' N --.0 561 2.36 1 Sc' Date Recue/Date Received 2020-11-26
[0153]
[Table 77]
Compound No Structure [M+H+ RI
Method o--Th o o 1--........Ni 0 H VI' N --.--iji---G'-' N'. Ni .11 ci o o 1-,....,..Ni 0 H ri --11--N -----K[1-0 Ni Ni 'LI
_..t.,_ R-102 542 2.32 1 IN 0, o-------i 0 0 1--....,..Ni IS Ni----1---Ni =.--k.ti R-103 514 1.91 1 1110 0, G--------i 0 0 1--........Ni H Ni '11--N
N1' N
Si 0, o .--IN,.----u---0 H
y ,ta 0 C
H N
1411 rej---N --u 580 1.94 'CI
Date Recue/Date Received 2020-11-26 [Table 78]
Compound No Structure [M+1-1]+ RI
Method 0 HNNi .-.---y11---0 '---.
Ni.-----.1-Ni ---.L--'0 R-106 532 2.14 1 411 ci o------1 F 0 0 [--.....,....Ni SI H 1,1 A NK-X11---0 =---.
R-107 546 2.26 1 le ci Ni--------:--____,--- Ni,.......
I
.---..(--40 H...i...Ni Ft --.*1.--0 H
R-108 Ni Ni--.-0 547 2.18 1 .I 1 a ------1 F 0 0 IDH re lL14.----11-1:1H
NrkNi =---LO
R-109 518 1.88 1 IIIII ci a -------1 F 0 0 [-....õNi SI H reILV-XIL-13H
NikNi =---LO
R-1 10 532 1.97 1 IIIII ci Date Recue/Date Received 2020-11-26 [Table 79]
Compound No Structure [M+H]F RI
Method ii------' N? o o 110 H... j....Nt i Ni R-111 NND 537 2.22 1 Sc' N N
0 Ni H N A. . )Li'v N '-1.-Ni ' 527 2.15 1 Sc' N N
'Y 0 0 0 .-.-11--R-113 IS NNO 541 2.27 1 Sc' PtY N
0 H N'ILN 0 H
Ili N---.-LO 513 1.9 1 Sc' NY N
R-115 40 H N'N''-*LoH
Ni --1-µNi ' 527 1.99 1 Sc' Date Recue/Date Received 2020-11-26 [Table so]
Compound No Structure [M+I-1]+ RI Method N' -----:------ F
u......i...7.
0 40 NH NAN" 0 H
R-116 ,-., _....
'.I N' a 540 2.08 1 S.,' Ni --'7:'.----- F
LI
121 ID H 14-11-N' OH
, , R-1 1 7 ,,), Ni Ni --.-0 544 2 12 1 S.' N' -----:------ F
u......i...7.
il G
D 410 H.....N,, NI" -.---X11-13 H
R-118 NI ri ---(3 554 2.15 1 S.,' Nr----,--, l'i 40 H 11j-14.'14.0 R-119 ,.....-1, ._...
N' N' 0 523 2.01 1 'CI
N' ---'-'.----ii N' ...._....--...----' 1 0 0 0 40 Hlij---....N it-F.---TOrH
R-120 N' N' a 509 1.77 1 5',' Date Recue/Date Received 2020-11-26 [Table 81]
'Compound No Structure [M+1-1]+ RI
Method N----'1%'---- F
iy.
HWILN ---X-11-`0H
N N o 558 2.2 1 , , , , ' N -.--.---1 :
' ItN
F 0 y HO
H N ---ilm-----------"---. 0.---R-122 40 IN' -N 0 555 2.42 1 re a , , , , , , y- 0 0 0 op HI-nik,Nr----(11.--cm = , , , , , CII N .1 ' ' I ft 40 HillI --111-µ0H
R-124 IN N ---0 543 2.07 1 , , , , , , N ---..
LlyN
F 0 I '?, H N '11.--= ri'-k------"--... L-13H
le IN 'IN' "U 541 2.13 1 IN c, , , , , , Date Recue/Date Received 2020-11-26 [Table 82]
Compound No Structure [M+I-1]+ RI Method H
I
H N AN .-----"AADH
R-126 411 .{), ....L N N a 555 1.99 1 I. 1 HNIIIH N A N ----'-'-:---)k-'0'--R-127 Nc::-L-N ---.0 524 2.39 1 Sc' H N
H N -11---NiJ --&----=---u--0 I-1 R-128 N ,i, ....k N 0 510 2.1 1 111. ci 11-7.---N
N yj a a H N'il'N'') \--ILO "---.
R-129 SI N -;:1--N --k--0 551 2.33 1 Sc' N yr--I
a 0 R-130 --14111P N--4-Irk-.0 523 1.97 1 Sc, Date Recue/Date Received 2020-11-26 [Table 83]
Compound No Structure [M+H]+ RI
Method N..? a a a 0 H N
R-131 N-4-------0 537 2.06 1 110 ci N S
j Y a ----0 a 00 H Nit- N -----10 R-132 N----j----N---LTh 542 2.38 1 Sc' /
....¨
14,-,.......s T a a a 0 HN-ii-N'---111-1:11-1 R-133 N-.)----NI---Lo 528 2.13 1 Si I
S
NY a a a 40 HN-11---N------(11---0-' R-134 ,i, .....
N NI a 529 2.2 1 Sc' NI
s''Y a a a 4/0 H N AN 0"---.
R-135 N I-14 =---LEI 543 2.27 1 Sc' Date Recue/Date Received 2020-11-26 [Table 84]
Compound No Structure [M+I-1]+ RI
Method N=.%.
N
sY a a a A
R-136 N N.--.70 543 2.31 1 = c, s' ..-fN a a a kir HN IN --------A-11-0-R-137 N.-;:1-N ---L-0 557 2.38 1 40 ,, a a 4110 HN AN -----rit-tr-' NN 'O
110 c, a a jt. _ H N N ---X11.--IV-N.:;1--N'''.0 40 c, --.-------1 F 0 0 ------"'Nj /40 HIJII---ylk-a".--40 c, Date Recue/Date Received 2020-11-26 [Table 85]
_ Compound No Structure [M+1-11+ RI
Method --------) F G G
, , H N, N,-----A-4-0---N4, =-.--.13 R-141 544 2.54 1 illi ci -------1 o o --------rl is H Ni ANi ----IAD H
..-...-1..
Ni Ni =.-4..0 R-142 512 2.17 2 .1 ci ------) o o , )-E, , HN, N, ----c14'0 H
Nr=--.1-Ni '40 R-143 526 1.77 1 .1 c, p 0 yNi G 41 H11-11:%-.-----111-0H
R-144 548 2.26 1 Ni Ni ill CI
F F
Ni¨ F S.......,- Ni R-1 40 N N HI ...4.11 -----IAGH
45 = 583 2.8 1 i 0 'CI
Date Recue/Date Received 2020-11-26 [Table 86]
Compound No Structure [M+1-1]+ RI Method ---Th F 0 0 --....___ II ...at , ...1, , H N, N, ----yI-13 H
11111. Ni-:--1-Ni '---L--0 R-146 516 2.14 1 Sc' --------i F 0 0 --Ni ISHNANCH
Ni-e)'-Ni =---L---0 R-147 530 2.23 1 Sc' ii a a el, IS Hli Ni ------A-40 R-148 a Nr-' Ni .---i3 537 2.12 1 /¨( Ni ...........,, S, 0 gbh H Ni AN ----.-X-0 R-149 LIPIA N--).---Nt ------0 556 2.49 1 Sc, ..e.N.........C1 i.._....
o igh HNNi N N ._..
-4111111 e:.--LJ 0 570 2.49 1 4111 ci Date Recue/Date Received 2020-11-26
[Table 77]
Compound No Structure [M+H+ RI
Method o--Th o o 1--........Ni 0 H VI' N --.--iji---G'-' N'. Ni .11 ci o o 1-,....,..Ni 0 H ri --11--N -----K[1-0 Ni Ni 'LI
_..t.,_ R-102 542 2.32 1 IN 0, o-------i 0 0 1--....,..Ni IS Ni----1---Ni =.--k.ti R-103 514 1.91 1 1110 0, G--------i 0 0 1--........Ni H Ni '11--N
N1' N
Si 0, o .--IN,.----u---0 H
y ,ta 0 C
H N
1411 rej---N --u 580 1.94 'CI
Date Recue/Date Received 2020-11-26 [Table 78]
Compound No Structure [M+1-1]+ RI
Method 0 HNNi .-.---y11---0 '---.
Ni.-----.1-Ni ---.L--'0 R-106 532 2.14 1 411 ci o------1 F 0 0 [--.....,....Ni SI H 1,1 A NK-X11---0 =---.
R-107 546 2.26 1 le ci Ni--------:--____,--- Ni,.......
I
.---..(--40 H...i...Ni Ft --.*1.--0 H
R-108 Ni Ni--.-0 547 2.18 1 .I 1 a ------1 F 0 0 IDH re lL14.----11-1:1H
NrkNi =---LO
R-109 518 1.88 1 IIIII ci a -------1 F 0 0 [-....õNi SI H reILV-XIL-13H
NikNi =---LO
R-1 10 532 1.97 1 IIIII ci Date Recue/Date Received 2020-11-26 [Table 79]
Compound No Structure [M+H]F RI
Method ii------' N? o o 110 H... j....Nt i Ni R-111 NND 537 2.22 1 Sc' N N
0 Ni H N A. . )Li'v N '-1.-Ni ' 527 2.15 1 Sc' N N
'Y 0 0 0 .-.-11--R-113 IS NNO 541 2.27 1 Sc' PtY N
0 H N'ILN 0 H
Ili N---.-LO 513 1.9 1 Sc' NY N
R-115 40 H N'N''-*LoH
Ni --1-µNi ' 527 1.99 1 Sc' Date Recue/Date Received 2020-11-26 [Table so]
Compound No Structure [M+I-1]+ RI Method N' -----:------ F
u......i...7.
0 40 NH NAN" 0 H
R-116 ,-., _....
'.I N' a 540 2.08 1 S.,' Ni --'7:'.----- F
LI
121 ID H 14-11-N' OH
, , R-1 1 7 ,,), Ni Ni --.-0 544 2 12 1 S.' N' -----:------ F
u......i...7.
il G
D 410 H.....N,, NI" -.---X11-13 H
R-118 NI ri ---(3 554 2.15 1 S.,' Nr----,--, l'i 40 H 11j-14.'14.0 R-119 ,.....-1, ._...
N' N' 0 523 2.01 1 'CI
N' ---'-'.----ii N' ...._....--...----' 1 0 0 0 40 Hlij---....N it-F.---TOrH
R-120 N' N' a 509 1.77 1 5',' Date Recue/Date Received 2020-11-26 [Table 81]
'Compound No Structure [M+1-1]+ RI
Method N----'1%'---- F
iy.
HWILN ---X-11-`0H
N N o 558 2.2 1 , , , , ' N -.--.---1 :
' ItN
F 0 y HO
H N ---ilm-----------"---. 0.---R-122 40 IN' -N 0 555 2.42 1 re a , , , , , , y- 0 0 0 op HI-nik,Nr----(11.--cm = , , , , , CII N .1 ' ' I ft 40 HillI --111-µ0H
R-124 IN N ---0 543 2.07 1 , , , , , , N ---..
LlyN
F 0 I '?, H N '11.--= ri'-k------"--... L-13H
le IN 'IN' "U 541 2.13 1 IN c, , , , , , Date Recue/Date Received 2020-11-26 [Table 82]
Compound No Structure [M+I-1]+ RI Method H
I
H N AN .-----"AADH
R-126 411 .{), ....L N N a 555 1.99 1 I. 1 HNIIIH N A N ----'-'-:---)k-'0'--R-127 Nc::-L-N ---.0 524 2.39 1 Sc' H N
H N -11---NiJ --&----=---u--0 I-1 R-128 N ,i, ....k N 0 510 2.1 1 111. ci 11-7.---N
N yj a a H N'il'N'') \--ILO "---.
R-129 SI N -;:1--N --k--0 551 2.33 1 Sc' N yr--I
a 0 R-130 --14111P N--4-Irk-.0 523 1.97 1 Sc, Date Recue/Date Received 2020-11-26 [Table 83]
Compound No Structure [M+H]+ RI
Method N..? a a a 0 H N
R-131 N-4-------0 537 2.06 1 110 ci N S
j Y a ----0 a 00 H Nit- N -----10 R-132 N----j----N---LTh 542 2.38 1 Sc' /
....¨
14,-,.......s T a a a 0 HN-ii-N'---111-1:11-1 R-133 N-.)----NI---Lo 528 2.13 1 Si I
S
NY a a a 40 HN-11---N------(11---0-' R-134 ,i, .....
N NI a 529 2.2 1 Sc' NI
s''Y a a a 4/0 H N AN 0"---.
R-135 N I-14 =---LEI 543 2.27 1 Sc' Date Recue/Date Received 2020-11-26 [Table 84]
Compound No Structure [M+I-1]+ RI
Method N=.%.
N
sY a a a A
R-136 N N.--.70 543 2.31 1 = c, s' ..-fN a a a kir HN IN --------A-11-0-R-137 N.-;:1-N ---L-0 557 2.38 1 40 ,, a a 4110 HN AN -----rit-tr-' NN 'O
110 c, a a jt. _ H N N ---X11.--IV-N.:;1--N'''.0 40 c, --.-------1 F 0 0 ------"'Nj /40 HIJII---ylk-a".--40 c, Date Recue/Date Received 2020-11-26 [Table 85]
_ Compound No Structure [M+1-11+ RI
Method --------) F G G
, , H N, N,-----A-4-0---N4, =-.--.13 R-141 544 2.54 1 illi ci -------1 o o --------rl is H Ni ANi ----IAD H
..-...-1..
Ni Ni =.-4..0 R-142 512 2.17 2 .1 ci ------) o o , )-E, , HN, N, ----c14'0 H
Nr=--.1-Ni '40 R-143 526 1.77 1 .1 c, p 0 yNi G 41 H11-11:%-.-----111-0H
R-144 548 2.26 1 Ni Ni ill CI
F F
Ni¨ F S.......,- Ni R-1 40 N N HI ...4.11 -----IAGH
45 = 583 2.8 1 i 0 'CI
Date Recue/Date Received 2020-11-26 [Table 86]
Compound No Structure [M+1-1]+ RI Method ---Th F 0 0 --....___ II ...at , ...1, , H N, N, ----yI-13 H
11111. Ni-:--1-Ni '---L--0 R-146 516 2.14 1 Sc' --------i F 0 0 --Ni ISHNANCH
Ni-e)'-Ni =---L---0 R-147 530 2.23 1 Sc' ii a a el, IS Hli Ni ------A-40 R-148 a Nr-' Ni .---i3 537 2.12 1 /¨( Ni ...........,, S, 0 gbh H Ni AN ----.-X-0 R-149 LIPIA N--).---Nt ------0 556 2.49 1 Sc, ..e.N.........C1 i.._....
o igh HNNi N N ._..
-4111111 e:.--LJ 0 570 2.49 1 4111 ci Date Recue/Date Received 2020-11-26
[0154]
[Table 87]
'Compound No Structure [M+H+ RI
Method l'IY---e-- 0 0 0 H N -11' Ni-e-X11--0H
R-151 Nj--`N-eL0 523 1.87 1 , , ' H0,1 , --)>---- N
y0 ----0 R-152 is H N AN 0 NNO 552 1.8 1 110 c, /
N S
' Y 0 0 R-153 41) H VII' N ---X11.--0 H
N -1-"N ' ' 542 2.22 1 . , 1 , , , , ..e.NC1 ' :
i y0 y HO
H NAN "--------"--u-'. OH
E
R-154 1411 ,I, Ni Ni--L--0 _ 556 2.21 1 ,dl .5 H0,1 y---I'N
538 1.55 1 N N 0' 40 c, , Date Recue/Date Received 2020-11-26 [Table 88]
, Compound No Structure [M+H]F RI
Method F...,_,N,..F
I
y-.---.10 HN N
0, j...}....00 NNO 572 2.6 1 Si c, F,...._,N,....õ....F
I
y ....ko 3....._Aci H N N . 0 H
a R-157 1410 ,-J, ....k.
NNO 558 2.33 1 =1 ir-----Nj N ? 0 ir IF;
HN-'11--N --.-10-R-158 N N õko 4111 551 2.38 1 Sc' ci iii----' N..--.--I) õIT, i jai, R-159 N N _ a 571 2.5 1 -u N={
SiN
Si H VILN OH
N N=---LO 529 2.02 1 Sc, Date Recue/Date Received 2020-11-26 [Table 89]
Compound No Structure [M+H]+ RI
Method ir-----Nj N , ..-T--J _it a SI H N N
N N=---k.---0 ¨ 537 2.08 1 al ci ci 1-H---N' 1 a H N N ---'-----:----"--`0 H
CI MO I I .
R-162 .õ--.1, 1._ = 557 2.23 1 N Ny------t -N=...
5:'....._,;:õN
a 411 H N .-11--11 ----)KILIZI H
R-163 .--I--.
W.- N .--.0 529 2.03 1 Sc' 1-------'11 N, .... ht ---[--- F 0 0 a 40 HN --11.--N OH
R-164 14).-- NI ---.0 527 1.93 1 r------11 N --, 11 ---r- F 1 0 a Is 71 N -----7S1-0H
R-165 N N ---..0 541 2.01 1 Date Recue/Date Received 2020-11-26 [Table 90]
Compound No Structure [M+H]F RI
Method GI
N.--1-----,.. N ...,::_.
-.--:--; T
H N IN -------N':-.--1'N =--.-L-0 509 2.42 1 Sc' uy N
0 IT ill 0 a h H N --11-N ---1-------L--0 ---.
R-167 --4110 N .:::1-"N A-13 537 2.27 1 11111 ci N .-----I
uy N
0 II Ci), 0 Ail H NA N =---A-%-:9L-13 H
R-168 -4111111 N<---1---N----ka 523 1 97 1 ci c I
N -----H 0 I ..---H ---N.----1-N --k--13 528 2.05 1 Oil ci F
õrN
HN ANN
R-170 . ...L 440 2.02 1 Date Recue/Date Received 2020-11-26 [Table 91]
Compound No Structure [M+1-11+ RI Method ei 0 ----rc 00 HNAN------,--------õ(0-___----.,..J., ....k. 8H 0 IP c, _ 0 ,,,,,,,,AN-------y-------(0,--N N 0 541 2.35 1 Sc' _ a H N AN H
R-173 ..), .....
N N o 411 2.23 1 5c1 I A
..----r F 0 0 0 ..--II--. .----4.-1,0 ----H N N
R-174 41 ,i,.... ...t..._ N N --U1 555 2.24 1 lb c, õIN
1 .....,, ---,-- F 0 R-175 -----X11-% ---N N ' 569 2.34 1 ill c, Date Recue/Date Received 2020-11-26 [Table 92]
'Compound No Structure [M +H]+ RI
Method F F
R-176 FIN--11--NKX11--ohi 591 2.3 1 Ni 0 Sc' H N N H
R-177 Ni 0 570 2.4 H
OH
N
513 2.06 0, OH
is H14 A Ni IftH 0 N
R-179 523 2.05 1 (101 H N OH
R-180 NNO 541 1.99 0, Date Recue/Date Received 2020-11-26 [Table 93]
_ ________________________________________________________________________ Compound No Structure [M+I-1]+ RI
Method 1 Aj ---y- ' F 0 0 R-181 .,-.1..., 11 N _..t.,_ 555 2.08 1 = I
i- cel N S
'''''r R-182 SI H N N -. 0 .,-.1... E
N N ---k-0 ¨ 556 2.53 1 'CI
, /
/-11,s T o R-183 00 H N IN Lit'. 0 H
N
_ N 0 - - 542 2.25 1 N.--...
Lr.
0 4 ..-1, 0 H N ri; .---yo R-1 84 N ,-I._ .....
'Ni 0 536 1.92 1 Ni.---y.
40 H r 1 r 1 ,..2L-A-....0-1-11---0H
R-185 N -14 0 522 1.66 1
[Table 87]
'Compound No Structure [M+H+ RI
Method l'IY---e-- 0 0 0 H N -11' Ni-e-X11--0H
R-151 Nj--`N-eL0 523 1.87 1 , , ' H0,1 , --)>---- N
y0 ----0 R-152 is H N AN 0 NNO 552 1.8 1 110 c, /
N S
' Y 0 0 R-153 41) H VII' N ---X11.--0 H
N -1-"N ' ' 542 2.22 1 . , 1 , , , , ..e.NC1 ' :
i y0 y HO
H NAN "--------"--u-'. OH
E
R-154 1411 ,I, Ni Ni--L--0 _ 556 2.21 1 ,dl .5 H0,1 y---I'N
538 1.55 1 N N 0' 40 c, , Date Recue/Date Received 2020-11-26 [Table 88]
, Compound No Structure [M+H]F RI
Method F...,_,N,..F
I
y-.---.10 HN N
0, j...}....00 NNO 572 2.6 1 Si c, F,...._,N,....õ....F
I
y ....ko 3....._Aci H N N . 0 H
a R-157 1410 ,-J, ....k.
NNO 558 2.33 1 =1 ir-----Nj N ? 0 ir IF;
HN-'11--N --.-10-R-158 N N õko 4111 551 2.38 1 Sc' ci iii----' N..--.--I) õIT, i jai, R-159 N N _ a 571 2.5 1 -u N={
SiN
Si H VILN OH
N N=---LO 529 2.02 1 Sc, Date Recue/Date Received 2020-11-26 [Table 89]
Compound No Structure [M+H]+ RI
Method ir-----Nj N , ..-T--J _it a SI H N N
N N=---k.---0 ¨ 537 2.08 1 al ci ci 1-H---N' 1 a H N N ---'-----:----"--`0 H
CI MO I I .
R-162 .õ--.1, 1._ = 557 2.23 1 N Ny------t -N=...
5:'....._,;:õN
a 411 H N .-11--11 ----)KILIZI H
R-163 .--I--.
W.- N .--.0 529 2.03 1 Sc' 1-------'11 N, .... ht ---[--- F 0 0 a 40 HN --11.--N OH
R-164 14).-- NI ---.0 527 1.93 1 r------11 N --, 11 ---r- F 1 0 a Is 71 N -----7S1-0H
R-165 N N ---..0 541 2.01 1 Date Recue/Date Received 2020-11-26 [Table 90]
Compound No Structure [M+H]F RI
Method GI
N.--1-----,.. N ...,::_.
-.--:--; T
H N IN -------N':-.--1'N =--.-L-0 509 2.42 1 Sc' uy N
0 IT ill 0 a h H N --11-N ---1-------L--0 ---.
R-167 --4110 N .:::1-"N A-13 537 2.27 1 11111 ci N .-----I
uy N
0 II Ci), 0 Ail H NA N =---A-%-:9L-13 H
R-168 -4111111 N<---1---N----ka 523 1 97 1 ci c I
N -----H 0 I ..---H ---N.----1-N --k--13 528 2.05 1 Oil ci F
õrN
HN ANN
R-170 . ...L 440 2.02 1 Date Recue/Date Received 2020-11-26 [Table 91]
Compound No Structure [M+1-11+ RI Method ei 0 ----rc 00 HNAN------,--------õ(0-___----.,..J., ....k. 8H 0 IP c, _ 0 ,,,,,,,,AN-------y-------(0,--N N 0 541 2.35 1 Sc' _ a H N AN H
R-173 ..), .....
N N o 411 2.23 1 5c1 I A
..----r F 0 0 0 ..--II--. .----4.-1,0 ----H N N
R-174 41 ,i,.... ...t..._ N N --U1 555 2.24 1 lb c, õIN
1 .....,, ---,-- F 0 R-175 -----X11-% ---N N ' 569 2.34 1 ill c, Date Recue/Date Received 2020-11-26 [Table 92]
'Compound No Structure [M +H]+ RI
Method F F
R-176 FIN--11--NKX11--ohi 591 2.3 1 Ni 0 Sc' H N N H
R-177 Ni 0 570 2.4 H
OH
N
513 2.06 0, OH
is H14 A Ni IftH 0 N
R-179 523 2.05 1 (101 H N OH
R-180 NNO 541 1.99 0, Date Recue/Date Received 2020-11-26 [Table 93]
_ ________________________________________________________________________ Compound No Structure [M+I-1]+ RI
Method 1 Aj ---y- ' F 0 0 R-181 .,-.1..., 11 N _..t.,_ 555 2.08 1 = I
i- cel N S
'''''r R-182 SI H N N -. 0 .,-.1... E
N N ---k-0 ¨ 556 2.53 1 'CI
, /
/-11,s T o R-183 00 H N IN Lit'. 0 H
N
_ N 0 - - 542 2.25 1 N.--...
Lr.
0 4 ..-1, 0 H N ri; .---yo R-1 84 N ,-I._ .....
'Ni 0 536 1.92 1 Ni.---y.
40 H r 1 r 1 ,..2L-A-....0-1-11---0H
R-185 N -14 0 522 1.66 1
- 155 -Date Recue/Date Received 2020-11-26 [Table 94]
_ Compound No Structure [M+H+ RI
Method Ni ----'"------ F
y.
_11%..0 ..1....õ*.0 .._ N
01H N N , 0 R-186 ,i, ....... a i Ni 0 568 2.51 1 Sc' Ni --.---::.----- F
I , y F 0 0 H N N . 0---.-R-187 SI ,I., .......
Ni Ni 0 572 2.54 1 5c1 ...---, F
y.
o II Ho o R-1 88 all H N 'IL N "-k.-----"%'. OH
,J...._ _...k.
Ni Ni 0 554 2.21 1 I. el Ni ------------- F
y. F
...L j...._)L0 H N
R-189 SI N,J., i Ni 0 558 2.25 1 1110 ei ..--.
o =----..-õr,14 0 0 R-19 41 H,..j....._Ni OH 553 2020 .
N Ni 0
_ Compound No Structure [M+H+ RI
Method Ni ----'"------ F
y.
_11%..0 ..1....õ*.0 .._ N
01H N N , 0 R-186 ,i, ....... a i Ni 0 568 2.51 1 Sc' Ni --.---::.----- F
I , y F 0 0 H N N . 0---.-R-187 SI ,I., .......
Ni Ni 0 572 2.54 1 5c1 ...---, F
y.
o II Ho o R-1 88 all H N 'IL N "-k.-----"%'. OH
,J...._ _...k.
Ni Ni 0 554 2.21 1 I. el Ni ------------- F
y. F
...L j...._)L0 H N
R-189 SI N,J., i Ni 0 558 2.25 1 1110 ei ..--.
o =----..-õr,14 0 0 R-19 41 H,..j....._Ni OH 553 2020 .
N Ni 0
- 156 -Date Recue/Date Received 2020-11-26 [Table 95]
Compound No Structure [M+1-11+ RI
Method ..--.
----j-'N
y 0 0 A ..-L,11%.
H N 14, . OH
R-191 SI ,J, __...L._ 553 2.04 1 ri, ri, 0 Sc' p syN, I A I
0 H N, N,-----. -1 -11-0H
R-192 .)., 564 2.37 1 =.--k.0 0 c, iy.... 0 ---0 H
R-193 el 14, .-1- 14.-----K0 Nr-1--Nr--0 550 2.04 1 Sc' o o o R-194 41110 , A rr-X11-70H
14, )--- N 0 536 1.75 1 1111 , I
14,=...
S.,..,_::,N
i 0 0 0 A.
H N ti C H
R-195 14111 __-), .--k7-'4A
N N 0 515 1.95 1 110 ci
Compound No Structure [M+1-11+ RI
Method ..--.
----j-'N
y 0 0 A ..-L,11%.
H N 14, . OH
R-191 SI ,J, __...L._ 553 2.04 1 ri, ri, 0 Sc' p syN, I A I
0 H N, N,-----. -1 -11-0H
R-192 .)., 564 2.37 1 =.--k.0 0 c, iy.... 0 ---0 H
R-193 el 14, .-1- 14.-----K0 Nr-1--Nr--0 550 2.04 1 Sc' o o o R-194 41110 , A rr-X11-70H
14, )--- N 0 536 1.75 1 1111 , I
14,=...
S.,..,_::,N
i 0 0 0 A.
H N ti C H
R-195 14111 __-), .--k7-'4A
N N 0 515 1.95 1 110 ci
- 157 -Date Recue/Date Received 2020-11-26 [Table 96]
Compound No Structure [M+H]F RI Method F
.----L-. N
I l' -yNi 0 0 4011 H N N eeill--13 H
527 1.88 NNJ
Sc' C' I I
H Ni Ni-e-1-'11-13H
R-197 543 1.96 a 1 ell NND
le I
F....... NH.
I ----y-Ni lip Fl..._Ni '11.-Ni ---yLLIZI H
5' rre---------- a.---y.
0 %---0 i -.------,,,d, _....L
N N 0 552 2.11 1 IP a, _,_, a ,,,,õ --__,., --, y.
R-200 a, H Ni A Ni ------A-0 N --e-L-N, 0 566 2.22 1 IS GI
Compound No Structure [M+H]F RI Method F
.----L-. N
I l' -yNi 0 0 4011 H N N eeill--13 H
527 1.88 NNJ
Sc' C' I I
H Ni Ni-e-1-'11-13H
R-197 543 1.96 a 1 ell NND
le I
F....... NH.
I ----y-Ni lip Fl..._Ni '11.-Ni ---yLLIZI H
5' rre---------- a.---y.
0 %---0 i -.------,,,d, _....L
N N 0 552 2.11 1 IP a, _,_, a ,,,,õ --__,., --, y.
R-200 a, H Ni A Ni ------A-0 N --e-L-N, 0 566 2.22 1 IS GI
- 158 -Date Recue/Date Received 2020-11-26 [0155]
[Table 97]
Compound No Structure [M+H+ RI
Method N---- G----y.. 0 0 0 H.....N 11 -----111-0H
R-201 NI NI .---CI 538 1.85 1 NI --.----->---- G---1,,,r o 0 o Hr,---u-,1, ...4. 0HR-202 N NI 0 552 1.94 1 el 1 0 N,FI
I --- N
rx NI y-J-e 0 y --?
R-203 0 H N A NI ---.---0e--....4. 581 2.12 1 Sc' ¨',.
CI yNI
G 41 H.......1,14-11:%------110H
R-204 549 1.97 1 NI NI
Sc' 1,..õ....... 0 ---0 40 H NI j-- NI ---yCl ..-.....-L, .....
NI NI 0 522 1.94 1 Ill ci
[Table 97]
Compound No Structure [M+H+ RI
Method N---- G----y.. 0 0 0 H.....N 11 -----111-0H
R-201 NI NI .---CI 538 1.85 1 NI --.----->---- G---1,,,r o 0 o Hr,---u-,1, ...4. 0HR-202 N NI 0 552 1.94 1 el 1 0 N,FI
I --- N
rx NI y-J-e 0 y --?
R-203 0 H N A NI ---.---0e--....4. 581 2.12 1 Sc' ¨',.
CI yNI
G 41 H.......1,14-11:%------110H
R-204 549 1.97 1 NI NI
Sc' 1,..õ....... 0 ---0 40 H NI j-- NI ---yCl ..-.....-L, .....
NI NI 0 522 1.94 1 Ill ci
- 159 -Date Recue/Date Received 2020-11-26 [Table 98]
Compound No Structure [M+H]F RI
Method .....N.....
G --.0 G -IL
go HI N-----1-0 IS ci ri ------,_ y G G
G
R-207 N 1\1 o 508 1.69 1 _...14 ..., y--1 41 H NAN -.-----(11---GH
14 14 G 508 1.39 1 1.1 ci (N
.----`
G CI
H ri, A ri=------(11-13,---R-209 40 111-;-1-14 --.-LO 519 1.7 1 y 0 a H NAN, '----TILOH
R-210 1111 Nr----1-14 '---L-0 505 1.51 1 ID
I
Compound No Structure [M+H]F RI
Method .....N.....
G --.0 G -IL
go HI N-----1-0 IS ci ri ------,_ y G G
G
R-207 N 1\1 o 508 1.69 1 _...14 ..., y--1 41 H NAN -.-----(11---GH
14 14 G 508 1.39 1 1.1 ci (N
.----`
G CI
H ri, A ri=------(11-13,---R-209 40 111-;-1-14 --.-LO 519 1.7 1 y 0 a H NAN, '----TILOH
R-210 1111 Nr----1-14 '---L-0 505 1.51 1 ID
I
- 160 -Date Recue/Date Received 2020-11-26 [Table 99]
Compound No Structure [M+I-1]+ RI
Method r------ -N, 14 yILCI 0 0 4111 H N 1 Ni OH
R-211 ,J, Ni Ni--LO 543 2.1 1 Sc' N -, I
y- 0 if 110 R-212 1410 H N 'jt--Ni------. OH
.-;.-1, ,..k N Ni 0 547 2.11 1 Si \
_\
S ...õ, II
1 0 if HO
HNiN-}--------.11--- i . 0 R-213 41 ,..-i, ....k...0 = 1 Ni Ni ' 536 2.44 1 SO
\
_\
s;z,ri 40 ,a_V-11-liO'-' R-214 Ni Ni o 522 2.3 1 .s,;,.,,,N
R-215 40 herXILO'-' Ni Ni o 536 2.4 1
Compound No Structure [M+I-1]+ RI
Method r------ -N, 14 yILCI 0 0 4111 H N 1 Ni OH
R-211 ,J, Ni Ni--LO 543 2.1 1 Sc' N -, I
y- 0 if 110 R-212 1410 H N 'jt--Ni------. OH
.-;.-1, ,..k N Ni 0 547 2.11 1 Si \
_\
S ...õ, II
1 0 if HO
HNiN-}--------.11--- i . 0 R-213 41 ,..-i, ....k...0 = 1 Ni Ni ' 536 2.44 1 SO
\
_\
s;z,ri 40 ,a_V-11-liO'-' R-214 Ni Ni o 522 2.3 1 .s,;,.,,,N
R-215 40 herXILO'-' Ni Ni o 536 2.4 1
- 161 -Date Recue/Date Received 2020-11-26 [Table 100]
Compound No Structure [M+I-1]+ RI
Method N
R-216 --1100 MN' Ni 0 H 568 2.16 1 1.1 \\/=\
H Irklek.-~=~}1'13 H
\?=., H N N OH
R-218 508 2.05 1 ¨\
0 aih R-219 ' rej--N
o 'a H N
R-220 491 2.44 1 1.1
Compound No Structure [M+I-1]+ RI
Method N
R-216 --1100 MN' Ni 0 H 568 2.16 1 1.1 \\/=\
H Irklek.-~=~}1'13 H
\?=., H N N OH
R-218 508 2.05 1 ¨\
0 aih R-219 ' rej--N
o 'a H N
R-220 491 2.44 1 1.1
- 162 -Date Recue/Date Received 2020-11-26 [Table 101]
'Compound No Structure [M+I-1]+ RI
Method F
0, HN
R-221 N 520 2.21 0 a H N OH
N N o 477 2.19 1 NF
R-223 N 506 1.95 1 I I
N
548 2.1 1 H N
R-225 N 508 2.19 1
'Compound No Structure [M+I-1]+ RI
Method F
0, HN
R-221 N 520 2.21 0 a H N OH
N N o 477 2.19 1 NF
R-223 N 506 1.95 1 I I
N
548 2.1 1 H N
R-225 N 508 2.19 1
- 163 -Date Recue/Date Received 2020-11-26 [Table 102]
'Compound No Structure [M+H+ RI
Method R-226 488 2.1 1 --TN
R-227 508 1.88 = 5 , N414, R-228 494 1.66 1 o õr R-229 N1ND, 493 1.82 , o 410 H N Ni R-230 H 507 1.88 1
'Compound No Structure [M+H+ RI
Method R-226 488 2.1 1 --TN
R-227 508 1.88 = 5 , N414, R-228 494 1.66 1 o õr R-229 N1ND, 493 1.82 , o 410 H N Ni R-230 H 507 1.88 1
- 164 -Date Recue/Date Received 2020-11-26 [Table 103]
Compound No Structure [M+H]F RI
Method N' 3 I N
N' OpOH
NN' -40 . I
r---r-0 H N ...-1--..
õJ., .....
NNO 461 1.9 1 Sc' ryb'N H
-ly NI 0 0 .--.4-, -----.
410 H N N -----.-R-233 ,...-..L. __L. 521 2.07 1 N' N' Sill CI
HN'll'14----y\o R-234 So N'f-j--- NAZI / 536 2.32 1 01 ci r-1 H ri-j1-1r----4-------OH
R-235 111-A, ....k-...a 0 H 1 NiNN' 496 1 8 1 'Sc'
Compound No Structure [M+H]F RI
Method N' 3 I N
N' OpOH
NN' -40 . I
r---r-0 H N ...-1--..
õJ., .....
NNO 461 1.9 1 Sc' ryb'N H
-ly NI 0 0 .--.4-, -----.
410 H N N -----.-R-233 ,...-..L. __L. 521 2.07 1 N' N' Sill CI
HN'll'14----y\o R-234 So N'f-j--- NAZI / 536 2.32 1 01 ci r-1 H ri-j1-1r----4-------OH
R-235 111-A, ....k-...a 0 H 1 NiNN' 496 1 8 1 'Sc'
- 165 -Date Recue/Date Received 2020-11-26 [Table 104]
'Compound No Structure [M+H+ RI
Method r.--1 0 )1.-.
110 H N N-.-----"-------' R-236 0, N N-4,0, .---0,--1\ 564 2.43 1 SO c, , rThl ' , 40 H N A re-ylk-OH
N N0, 523 1.98 1 'CI
, , , , :
0, = H N
R-238 KNi -----y-13 ---el-- Ni '40, 494 2.13 1 'CI
, , õ
, õ
--yri H N AOH
R-239 0 N -------,,"
11, N N . 00 , 480 1.93 1 0 , , , , 5 r----) R-240' = H Ni Ni----11 0, Nj.---N, -4,0, 479 1.8 1 õ
, , ,
'Compound No Structure [M+H+ RI
Method r.--1 0 )1.-.
110 H N N-.-----"-------' R-236 0, N N-4,0, .---0,--1\ 564 2.43 1 SO c, , rThl ' , 40 H N A re-ylk-OH
N N0, 523 1.98 1 'CI
, , , , :
0, = H N
R-238 KNi -----y-13 ---el-- Ni '40, 494 2.13 1 'CI
, , õ
, õ
--yri H N AOH
R-239 0 N -------,,"
11, N N . 00 , 480 1.93 1 0 , , , , 5 r----) R-240' = H Ni Ni----11 0, Nj.---N, -4,0, 479 1.8 1 õ
, , ,
- 166 -Date Recue/Date Received 2020-11-26 [Table 105]
Compound No Structure [M+1-11+ RI
Method rl H
H N' 'It' N' .--.--y rl ---.-,----/-.. 0 N N a 493 1.87 1 Sc, ,....r.11' H
0 N' R-242 01 H N -11-. N ------r --------0 H
__...
N'.---1-"N 0 523 1.75 1 Sc' rl --...f... N
0 u F
0 n \ ..... F
R-243 40 H II' A N' -------ii N --------,F
....k.
N.-;:1-- N 0 561 2.12 1 Sc' r.--1 R-244 SO H N N --------'.----0 H
.-A, ..... .-_, N N' 0 OH 524 1.94 1 101 ci H N A N' 0 R-245 40 N''::-I-- N' --La----.--C:i-t 550 2.3 1 11111 ci
Compound No Structure [M+1-11+ RI
Method rl H
H N' 'It' N' .--.--y rl ---.-,----/-.. 0 N N a 493 1.87 1 Sc, ,....r.11' H
0 N' R-242 01 H N -11-. N ------r --------0 H
__...
N'.---1-"N 0 523 1.75 1 Sc' rl --...f... N
0 u F
0 n \ ..... F
R-243 40 H II' A N' -------ii N --------,F
....k.
N.-;:1-- N 0 561 2.12 1 Sc' r.--1 R-244 SO H N N --------'.----0 H
.-A, ..... .-_, N N' 0 OH 524 1.94 1 101 ci H N A N' 0 R-245 40 N''::-I-- N' --La----.--C:i-t 550 2.3 1 11111 ci
- 167 -Date Recue/Date Received 2020-11-26 [Table 106]
Compound No Structure [M+I-1]+ RI
Method N' ...lt N ' N
y a a R-246 0 tim 534 2.02 1 '1111111P N''---k-N'''LO
'Sc' r'S'l a so HNAV-----f----)3 R-247 NN0 / 536 2.33 1 Sc' r--1 -....t...- N' 0 a . H NAN ''''"----.----0 R-248 Nr)---N=---L--.0 0 ".-1--- 564 2.5 1 I.
c I
N' ...lt N' ' N
y ),....0 .1.....)1 R-249 a 0 H N' N' , 0 H 548 2.13 1 N'--4.13 r---1 IN N N
H N'jtir-------'----i GH
R-250 I =---k-.13 H 496 1 8 1 Sc,
Compound No Structure [M+I-1]+ RI
Method N' ...lt N ' N
y a a R-246 0 tim 534 2.02 1 '1111111P N''---k-N'''LO
'Sc' r'S'l a so HNAV-----f----)3 R-247 NN0 / 536 2.33 1 Sc' r--1 -....t...- N' 0 a . H NAN ''''"----.----0 R-248 Nr)---N=---L--.0 0 ".-1--- 564 2.5 1 I.
c I
N' ...lt N' ' N
y ),....0 .1.....)1 R-249 a 0 H N' N' , 0 H 548 2.13 1 N'--4.13 r---1 IN N N
H N'jtir-------'----i GH
R-250 I =---k-.13 H 496 1 8 1 Sc,
- 168 -Date Recue/Date Received 2020-11-26 [0156]
[Table 107]
Comround No Structure [M+1-11+ RI
Method r---'1 G 40 H N'ji--14---------------01-1 R-251 NNi=---.L---0 480 1.97 1 Sc' Ni õr-----.
0 is H 14, AN, =-.---."-------------Att ----.
R-252 Ni.::1-=Ni =-.---0 536 2.35 1 Sc' r' Ni T-----.
0 ,,,, ,-1, 40-------------------k-o----R-253 ..,L
Ni--)1--Ni 1:1 516 2.25 1 1.1 1--\-0 0 H Willi -------------GH
R-254 Ni-;-1.-Ni---.-LO 492 2.02 1 -1------z.
0 , OH
A
R-255 II P H Pt Ni--.----------.----OH
.---I---. .---L---.-..-.
Ni-- Ni =u .--01-1 526 1.77 1
[Table 107]
Comround No Structure [M+1-11+ RI
Method r---'1 G 40 H N'ji--14---------------01-1 R-251 NNi=---.L---0 480 1.97 1 Sc' Ni õr-----.
0 is H 14, AN, =-.---."-------------Att ----.
R-252 Ni.::1-=Ni =-.---0 536 2.35 1 Sc' r' Ni T-----.
0 ,,,, ,-1, 40-------------------k-o----R-253 ..,L
Ni--)1--Ni 1:1 516 2.25 1 1.1 1--\-0 0 H Willi -------------GH
R-254 Ni-;-1.-Ni---.-LO 492 2.02 1 -1------z.
0 , OH
A
R-255 II P H Pt Ni--.----------.----OH
.---I---. .---L---.-..-.
Ni-- Ni =u .--01-1 526 1.77 1
- 169 -Date Recue/Date Received 2020-11-26 [Table 108]
Compound No Structure [M+1-11+ RI
Method r-.)---...f. N 0 H
0 4 H.
R-256 .1 HN--.11-14--------r N y' ....k. 0 0 reLN, 0 522 1.86 1 Sc' .,....r.N!
H NAN '-'-------'cill R-257 1:01 N14 -k-D 466 1.93 1 Sc' irk's N y--- 0 0 H N 'It' NI ----------------)L-OH
R-258 4110 re---1--V-.L0 522 2.05 1 Sc' c----H N -11-11K--.--)--0-' R-259 N N 0 506 1.96 1 F
r----N .....(..-- 0 0 41111 H Wili -----%-----LL-CIH
R-260 Nr--:---1-N---.0 492 1.75 1
Compound No Structure [M+1-11+ RI
Method r-.)---...f. N 0 H
0 4 H.
R-256 .1 HN--.11-14--------r N y' ....k. 0 0 reLN, 0 522 1.86 1 Sc' .,....r.N!
H NAN '-'-------'cill R-257 1:01 N14 -k-D 466 1.93 1 Sc' irk's N y--- 0 0 H N 'It' NI ----------------)L-OH
R-258 4110 re---1--V-.L0 522 2.05 1 Sc' c----H N -11-11K--.--)--0-' R-259 N N 0 506 1.96 1 F
r----N .....(..-- 0 0 41111 H Wili -----%-----LL-CIH
R-260 Nr--:---1-N---.0 492 1.75 1
- 170 -Date Recue/Date Received 2020-11-26 [Table 109]
Compound No Structure [M+1-1]+ RI
Method rr 0 40 Hri--11-14--------A0 R-261 Ni 0 524 2.03 1 41110 HN Att R-262 N 0 502 1.96 1 R-263 510 1.81 o 0 R-264 w NK0 516 2.26 1 r), ID H
R-265 Ni ND 536 2.36 SI
Compound No Structure [M+1-1]+ RI
Method rr 0 40 Hri--11-14--------A0 R-261 Ni 0 524 2.03 1 41110 HN Att R-262 N 0 502 1.96 1 R-263 510 1.81 o 0 R-264 w NK0 516 2.26 1 r), ID H
R-265 Ni ND 536 2.36 SI
- 171 -Date Recue/Date Received 2020-11-26 [Table 110]
Compound No Structure [M+1-11+ RI
Method (1---------14 I õ
0 si A ..-------H N N -R-266 ....k N N 0 473 2.04 1 rl 0 si 0 H N A N '--------'--y R-267 ,...-1, N N --.----n OH 488 1.9 1 SI
o -----, o H
I
c-1A
' H N AN -------R-268 õJ., k...0 492 1.85 1 N N
SF
41111 H N A N="------%-----.------el R-269 ,_-.I._...
N N=-k-D OH
508 1.99 1 SO , o 0 H ,---%,JI, ..---N 41111 H N A N ,, 0 ,-.1-.... ....k..
R-270 472 1.73 1 SI I
Compound No Structure [M+1-11+ RI
Method (1---------14 I õ
0 si A ..-------H N N -R-266 ....k N N 0 473 2.04 1 rl 0 si 0 H N A N '--------'--y R-267 ,...-1, N N --.----n OH 488 1.9 1 SI
o -----, o H
I
c-1A
' H N AN -------R-268 õJ., k...0 492 1.85 1 N N
SF
41111 H N A N="------%-----.------el R-269 ,_-.I._...
N N=-k-D OH
508 1.99 1 SO , o 0 H ,---%,JI, ..---N 41111 H N A N ,, 0 ,-.1-.... ....k..
R-270 472 1.73 1 SI I
- 172 -Date Recue/Date Received 2020-11-26 [Table 111]
Compound No Structure [M+I-1]+ RI Method H
Ni HN)LN'.-------0=
0 Ni N 0 R-271 414 1.77 1 0 c, Eh 1 0 HNArey1LOH
R-272 N .,...-1., i Ni--k-70 548 2.25 1 Sc' o 0 H
N H N AN -.---------)---01-1 0 _ ,..k..
o N. N 0 R-273 458 1 .5 1 0 c, c, rris--N
Nõ,,...J, R-2 7 4 40 H Ni'll'N'-y11"0 H
Ni Ni-.4.0 523 2.04 1
Compound No Structure [M+I-1]+ RI Method H
Ni HN)LN'.-------0=
0 Ni N 0 R-271 414 1.77 1 0 c, Eh 1 0 HNArey1LOH
R-272 N .,...-1., i Ni--k-70 548 2.25 1 Sc' o 0 H
N H N AN -.---------)---01-1 0 _ ,..k..
o N. N 0 R-273 458 1 .5 1 0 c, c, rris--N
Nõ,,...J, R-2 7 4 40 H Ni'll'N'-y11"0 H
Ni Ni-.4.0 523 2.04 1
- 173 -Date Recue/Date Received 2020-11-26 [0157]
[Table 112]
Compound No Structure [M+I-1]+ RI
Method F
0 0 ..-.--,,..A HN A N OH
NNO 510 t 84 1 F
1?F 0 0 ---H HN AN "--..'")1L011 R-276 --õ, ' -5...L.
N NO 510 t 83 1 FX ...1 N
i 0 .A, II HN N ---------ro R-277 506 t 98 1 OH
F
I
.e- N 0 R-278 ...-- I FIN! AIN o 506 1.99 1 '''.. -Ø.., A,N N..-1/4)14---N.---...1:-1 F
-,..
1 ," N 0 HN N'''''''''''N) R-279 OH 506 2.02 1 O
[Table 112]
Compound No Structure [M+I-1]+ RI
Method F
0 0 ..-.--,,..A HN A N OH
NNO 510 t 84 1 F
1?F 0 0 ---H HN AN "--..'")1L011 R-276 --õ, ' -5...L.
N NO 510 t 83 1 FX ...1 N
i 0 .A, II HN N ---------ro R-277 506 t 98 1 OH
F
I
.e- N 0 R-278 ...-- I FIN! AIN o 506 1.99 1 '''.. -Ø.., A,N N..-1/4)14---N.---...1:-1 F
-,..
1 ," N 0 HN N'''''''''''N) R-279 OH 506 2.02 1 O
- 174 -Date Recue/Date Received 2020-11-26 [Table 113]
Compound No Structure [M+H+ RI
Method Cl 0 H N A N '')H
R-280 I , I N N L0 492 2.06 1 ? 0 0 H N'ilLNOH
R-281 I, N N",õ0 L, 512 2.12 1 ? 0 0 0 Fl N "LN 01-1 R-282 I, I N N 0 õL. 488 1.98 1 I
c) I1:1, I-i N il's"N ''-)L0f-11 R-283 1,,, I ij.,, I, 508 2.07 1 N N '''''''''0 LI:I.,c ---- I
CI
R-284 0 s FINI'' 'N'N'''-"AOIHI 528 219 WI:kW/Lb
Compound No Structure [M+H+ RI
Method Cl 0 H N A N '')H
R-280 I , I N N L0 492 2.06 1 ? 0 0 H N'ilLNOH
R-281 I, N N",õ0 L, 512 2.12 1 ? 0 0 0 Fl N "LN 01-1 R-282 I, I N N 0 õL. 488 1.98 1 I
c) I1:1, I-i N il's"N ''-)L0f-11 R-283 1,,, I ij.,, I, 508 2.07 1 N N '''''''''0 LI:I.,c ---- I
CI
R-284 0 s FINI'' 'N'N'''-"AOIHI 528 219 WI:kW/Lb
- 175 -Date Recue/Date Received 2020-11-26 [Table 114]
Compound No Structure [M+1-1]+ RI
Method N
o R-285 HNANOH 508 2.11 1 No -F
HI, 0 R-286 N 0 524 2.05 I
R-287 NNO 542 2.38 1 tit H
R-288 N-AN)Lt, 524 2.03 1 r R-289 op NNO 522 2.3 1
Compound No Structure [M+1-1]+ RI
Method N
o R-285 HNANOH 508 2.11 1 No -F
HI, 0 R-286 N 0 524 2.05 I
R-287 NNO 542 2.38 1 tit H
R-288 N-AN)Lt, 524 2.03 1 r R-289 op NNO 522 2.3 1
- 176 -Date Recue/Date Received 2020-11-26 [Table 115]
Compound No Structure [M+I-1]+ RI
Method N. 0 ...õ i hi rsriN 10"' R-290 1 i 1 r 502 2.23 1 IN '-''''N '0 IP
. 0 0 ...aõ,õ N*( 'N- MIN AN ""N*--)1L0/-R-291 mil i . 522 2.33 1 '0 L-C--, ,:.---- 1 R-292 1, *1-, ,eµ. 1 A 'N-Ae 1 MIN N
506 2.29 1 I
,;-::-.------,,, icl Cr '''' 1 H N ."11 L,N A0 ,,, R-293 1,, 1 NN' tõ 526 2.37 1 '0 Ilin 1 ,,,,'''''NI
R-294 4011 HIN N ''''''''''''''y ,,,L. ,k, 0,,,, 534 2.35 1 N N C
Compound No Structure [M+I-1]+ RI
Method N. 0 ...õ i hi rsriN 10"' R-290 1 i 1 r 502 2.23 1 IN '-''''N '0 IP
. 0 0 ...aõ,õ N*( 'N- MIN AN ""N*--)1L0/-R-291 mil i . 522 2.33 1 '0 L-C--, ,:.---- 1 R-292 1, *1-, ,eµ. 1 A 'N-Ae 1 MIN N
506 2.29 1 I
,;-::-.------,,, icl Cr '''' 1 H N ."11 L,N A0 ,,, R-293 1,, 1 NN' tõ 526 2.37 1 '0 Ilin 1 ,,,,'''''NI
R-294 4011 HIN N ''''''''''''''y ,,,L. ,k, 0,,,, 534 2.35 1 N N C
- 177 -Date Recue/Date Received 2020-11-26 [Table 116]
Compound No Structure [M+I-1]+ RI
Method F
õFIN' '''.---"/ HN N `''''''''-'""..I 534 2.34 1 (110 frl/
0õ A
R-296 a ,--- HN N'''-y "k 1 o, 534 2.36 1 co -y-- il NI IN o H rslAl i rsi OH
---,,L), 528 2.22 1 LICIõr ip. 0 0 0 0 HN)LN OHI
0 R-298 I N N 0 õL. 508 2.14 1 I
IP
R-299 = 536 1.98 1 iN N '''''t
Compound No Structure [M+I-1]+ RI
Method F
õFIN' '''.---"/ HN N `''''''''-'""..I 534 2.34 1 (110 frl/
0õ A
R-296 a ,--- HN N'''-y "k 1 o, 534 2.36 1 co -y-- il NI IN o H rslAl i rsi OH
---,,L), 528 2.22 1 LICIõr ip. 0 0 0 0 HN)LN OHI
0 R-298 I N N 0 õL. 508 2.14 1 I
IP
R-299 = 536 1.98 1 iN N '''''t
- 178 -Date Recue/Date Received 2020-11-26 [Table 117]
Compound No Structure [M+H]+ RI
Method N F` CII 0 0 CI' ,ailih H NIA N )IL0'."
R-300 Op N N---0 542 2.46 1 ' '.-IL, --7-'-ci cll 1:2 0 0 0 1 ,k, R-301 y- - - -, - HN N õ, L1--N -1, L 522 2.38 1 Ar-------!? , i Y.
R-302 IFIN )1'N '''''''"-)L0-""
550 2.22 1 so , , I
R-303 .-- IHNIAN'"--"*"-)Le 550 2.17 1 ,,,,.
11-il R-304 1 , }0..,,, ik tiJ 552 2 1 ''''' L''Ir'l
Compound No Structure [M+H]+ RI
Method N F` CII 0 0 CI' ,ailih H NIA N )IL0'."
R-300 Op N N---0 542 2.46 1 ' '.-IL, --7-'-ci cll 1:2 0 0 0 1 ,k, R-301 y- - - -, - HN N õ, L1--N -1, L 522 2.38 1 Ar-------!? , i Y.
R-302 IFIN )1'N '''''''"-)L0-""
550 2.22 1 so , , I
R-303 .-- IHNIAN'"--"*"-)Le 550 2.17 1 ,,,,.
11-il R-304 1 , }0..,,, ik tiJ 552 2 1 ''''' L''Ir'l
- 179 -Date Recue/Date Received 2020-11-26 [Table 118] .
Compound No Structure [M+1-1]+ RI Method ------. HN N OHI 536 1 .93 1 ,,, CI
OH
'--, N ....-- 0 0 R-306 ---- HNAV---')ILOH 538 1 .79 1 I ,, CI
Icl''N 0 Cit HN AN Thrip'") R-307 ,,,, It, A ,,,,L 0 1 'F
I I 'N cl R-308 1 HN N-Thr I ), NNO 464 138 1 =
F
F
R-309 is HN NThr-C`"
I, .õ1L, 0 526 2.29 1 Le) -=.- .--CII
Compound No Structure [M+1-1]+ RI Method ------. HN N OHI 536 1 .93 1 ,,, CI
OH
'--, N ....-- 0 0 R-306 ---- HNAV---')ILOH 538 1 .79 1 I ,, CI
Icl''N 0 Cit HN AN Thrip'") R-307 ,,,, It, A ,,,,L 0 1 'F
I I 'N cl R-308 1 HN N-Thr I ), NNO 464 138 1 =
F
F
R-309 is HN NThr-C`"
I, .õ1L, 0 526 2.29 1 Le) -=.- .--CII
- 180 -Date Recue/Date Received 2020-11-26 [Table 119]
Compound No Structure [M+H+ RI
Method (r1 ' rib HINI 'N ''"TrA).' R-310 542 2.44 1 `'.141w 14.------LN)----,0 ISO
, I
IF
l[r'l )1..., R-311 0 ,-------),,,,õ HN N OH ----nr 498 L96 1 ' 0 0, R-312 010 HN AN i01-11 514 2.1 1 III
e.',-,-- NJ
I '`---µ
i õ,- N
R-313 HN N,, tr0- 533 2.23 1 A, õ,,k,, 0 CI
1 ,N 0 Illt IX ,,,,,,r 505 1.91 1 .....l. =NI NI '''' -0
Compound No Structure [M+H+ RI
Method (r1 ' rib HINI 'N ''"TrA).' R-310 542 2.44 1 `'.141w 14.------LN)----,0 ISO
, I
IF
l[r'l )1..., R-311 0 ,-------),,,,õ HN N OH ----nr 498 L96 1 ' 0 0, R-312 010 HN AN i01-11 514 2.1 1 III
e.',-,-- NJ
I '`---µ
i õ,- N
R-313 HN N,, tr0- 533 2.23 1 A, õ,,k,, 0 CI
1 ,N 0 Illt IX ,,,,,,r 505 1.91 1 .....l. =NI NI '''' -0
- 181 -Date Recue/Date Received 2020-11-26 [0158]
The following compounds of the invention can be synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Examples, with reference to the contents described in W02010/092966 and W02012/020749 as needed.
A IRc N N
H
le (R2.)rn
The following compounds of the invention can be synthesized in a similar manner to those described in the above general procedures for the synthesis of the compound of the invention and Examples, with reference to the contents described in W02010/092966 and W02012/020749 as needed.
A IRc N N
H
le (R2.)rn
- 182 -Date Recue/Date Received 2020-11-26 [Table 120]
R3 Rc (R2')m 4-(2-Pyridy00-Ph CH2CHMeCOOH 4-CH F2 4-(2-Pyridy00-Ph CH(Me)CH(Me)COOHR 4-Me 4-(3-F-2-Pyridy00-Ph (CH2)3COOH 4-Me 4-(5-F-2-Pyridy00-Ph (CH2)3COOH 4-Me 4-(6-F-2-Pyridy00-Ph (CH2)3COOH 4-Me 4-(5-F-3-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(2-F-4-Pyridy00-Ph CH2C(Me)2COOH 4-Me 4-(2-F-4-Pyridy00-Ph CH(Me)CH(Me)COOH 4-Me 4-(5-C1-2-Pyridy00-Ph (CH2)2COOH 4-CI
4-(5-C1-2-Pyridy00-Ph (CH2)2COOH 4-Me 4-(5-C1-3-Pyricly00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-C1-4-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(3-Me0-2-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(5-Me0-2-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(6-Me0-2-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(5-Me0-3-Pyridy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Me0-4-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(2-Me0-4-Pyridy00-Ph CH2C(Me)2COOH 4-CI
4-(5-H0C0-2-thiazoly00-Ph Et 4-CH2F
4-(5-H0C0-2-Pyridy00-Ph Et 4-CH2F
4-(5-H0C0-2-Pyridy00-3-Me-Ph Et 4-CH2F
4-(5-H0C0-3-Pyridy00-Ph Et 4-CH2F
4-(2-H0C0-4-Pyridy00-Ph Et 4-CH2F
4-(6-H0C0-3-Pyridaziny1)0-Ph Et 4-CH2F
4-(6-H2NC0-3-Pyridaziny00-Ph Et 4-CH2F
4-(2-Pyrimidy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyrimidy00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-C1-4-Pyrimid0O-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-F-4-Pyrimidy1)0-Ph CH2C(Me)2COOH 4-CI
4-(6-F-4-Pyrimidy1)0-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Me-4-Pyrimidy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-CN-5-Pyrimidy00-Ph CH2C(Me)2COOH 4-CI
4-(5-C1-2-Pyraziny00-Ph CH2C(Me)2COOH 4-Me 4-(5-C1-2-Pyraziny00-Ph CH(Me)CH(Me)COOH 4-Me 4-(5-CF3-2-Pyraziny00-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-Pyridaziny00-Ph CH2CHMeCOOH 4-Me 4-(3-Pyridazinyl)O-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-Pyridaziny00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-Me-3-Pyridaziny00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-Me0-3-Pyridaziny00-Ph CH2CHMeCOOH 4-Me 4-(6-CF3-3-Pyridaziny00-Ph CH(Me)CH(Me)COOH 4-CI
4-(4-Pyridaziny00-3-F-Ph CH2CHMeCOOH 4-CI
4-(4-Pyridaziny00-3-F-Ph CH2C(Me)2COOH 4-CI
4-(4-Pyridaziny00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
R3 Rc (R2')m 4-(2-Pyridy00-Ph CH2CHMeCOOH 4-CH F2 4-(2-Pyridy00-Ph CH(Me)CH(Me)COOHR 4-Me 4-(3-F-2-Pyridy00-Ph (CH2)3COOH 4-Me 4-(5-F-2-Pyridy00-Ph (CH2)3COOH 4-Me 4-(6-F-2-Pyridy00-Ph (CH2)3COOH 4-Me 4-(5-F-3-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(2-F-4-Pyridy00-Ph CH2C(Me)2COOH 4-Me 4-(2-F-4-Pyridy00-Ph CH(Me)CH(Me)COOH 4-Me 4-(5-C1-2-Pyridy00-Ph (CH2)2COOH 4-CI
4-(5-C1-2-Pyridy00-Ph (CH2)2COOH 4-Me 4-(5-C1-3-Pyricly00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-C1-4-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(3-Me0-2-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(5-Me0-2-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(6-Me0-2-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(5-Me0-3-Pyridy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Me0-4-Pyridy00-Ph CH2CHMeCOOH 4-Me 4-(2-Me0-4-Pyridy00-Ph CH2C(Me)2COOH 4-CI
4-(5-H0C0-2-thiazoly00-Ph Et 4-CH2F
4-(5-H0C0-2-Pyridy00-Ph Et 4-CH2F
4-(5-H0C0-2-Pyridy00-3-Me-Ph Et 4-CH2F
4-(5-H0C0-3-Pyridy00-Ph Et 4-CH2F
4-(2-H0C0-4-Pyridy00-Ph Et 4-CH2F
4-(6-H0C0-3-Pyridaziny1)0-Ph Et 4-CH2F
4-(6-H2NC0-3-Pyridaziny00-Ph Et 4-CH2F
4-(2-Pyrimidy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyrimidy00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-C1-4-Pyrimid0O-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-F-4-Pyrimidy1)0-Ph CH2C(Me)2COOH 4-CI
4-(6-F-4-Pyrimidy1)0-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Me-4-Pyrimidy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-CN-5-Pyrimidy00-Ph CH2C(Me)2COOH 4-CI
4-(5-C1-2-Pyraziny00-Ph CH2C(Me)2COOH 4-Me 4-(5-C1-2-Pyraziny00-Ph CH(Me)CH(Me)COOH 4-Me 4-(5-CF3-2-Pyraziny00-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-Pyridaziny00-Ph CH2CHMeCOOH 4-Me 4-(3-Pyridazinyl)O-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-Pyridaziny00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-Me-3-Pyridaziny00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-Me0-3-Pyridaziny00-Ph CH2CHMeCOOH 4-Me 4-(6-CF3-3-Pyridaziny00-Ph CH(Me)CH(Me)COOH 4-CI
4-(4-Pyridaziny00-3-F-Ph CH2CHMeCOOH 4-CI
4-(4-Pyridaziny00-3-F-Ph CH2C(Me)2COOH 4-CI
4-(4-Pyridaziny00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
- 183 -Date Recue/Date Received 2020-11-26 [Table 121]
R3 Rc (R2')m 4-(2-oxazoly00-Ph CH2CH MeCOOH 4-CI
4-(2-oxazoly00-Ph CH2CH MeCOOH 4-Me 4-(2-oxazoly00-Ph CH2C(Me)2COOH 4-CI
4-(2-oxazoly00-Ph CH(Me)CH(Me)COOH 4-CI
4-(1 ,2,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-CI
4-(1 ,2,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,4-oxadiazol-2-00-Ph CH2C(Me)2COOH 4-CI
4-(1 ,2,4-oxadiazol-2-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(1 ,3,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-CI
4-(1 ,3,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(1 ,3,4-oxadiazol-2-00-Ph CH2C(Me)2COOH 4-CI
4-(1 ,3,4-oxadiazol-2-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-isothiazoly00-Ph CH2CH MeCOOH 4-CI
4-(3-isothiazoly00-Ph CH2CH MeCOOH 4-Me 4-(3-isothiazoly00-Ph CH2C(Me)2COOH 4-CI
4-(3-isothiazoly00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-thiazoly00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,4-thiadiazol-5-00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,4-thiadiazol-5-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-Me-1,2,4-thiadiazol-5-00-Ph CH2CH MeCOOH 4-Me 4-(3-Me-1,2,4-thiadiazol-5-00-Ph CH2CH MeCOOH 4-CI
4-(3-Me-1,2,4-thiadiazol-5-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(1 ,2,5-thiadiazol-3-00-Ph CH2CH MeCOOH 4-CI
4-(1 ,2,5-thiadiazol-3-y00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,5-thiadiazol-3-00-Ph CH2C(Me)2COOH 4-CI
4-(1 ,2,5-thiadiazol-3-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4-CI
4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-F-Ph CH2CH MeCOOH 4-CI
4-(2-Pyridy00-3-F-Ph CH2CH MeCOOH 4-Me 4-(2-Pyridy00-3-F-Ph CH2C(Me)2COOH 4-CI
4-(2-Pyridy00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4-CI
4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-Me-Ph CH2CH MeCOOH 4-CI
4-(2-Pyridy00-3-Me-Ph CH2CH MeCOOH 4-Me 4-(2-Pyridy1)0-3-Me-Ph CH2C(Me)2COOH 4-CI
4-(2-Pyridy00-3-Me-Ph CH(Me)CH(Me)COOH 4-CI
4-(5-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-CI
4-(5-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-Me 4-(5-Et-2-Pyridy00-Ph CH2C(Me)2COOH 4-CI
4-(5-Et-2-Pyridy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-CI
4-(6-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-Me
R3 Rc (R2')m 4-(2-oxazoly00-Ph CH2CH MeCOOH 4-CI
4-(2-oxazoly00-Ph CH2CH MeCOOH 4-Me 4-(2-oxazoly00-Ph CH2C(Me)2COOH 4-CI
4-(2-oxazoly00-Ph CH(Me)CH(Me)COOH 4-CI
4-(1 ,2,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-CI
4-(1 ,2,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,4-oxadiazol-2-00-Ph CH2C(Me)2COOH 4-CI
4-(1 ,2,4-oxadiazol-2-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(1 ,3,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-CI
4-(1 ,3,4-oxadiazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(1 ,3,4-oxadiazol-2-00-Ph CH2C(Me)2COOH 4-CI
4-(1 ,3,4-oxadiazol-2-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-isothiazoly00-Ph CH2CH MeCOOH 4-CI
4-(3-isothiazoly00-Ph CH2CH MeCOOH 4-Me 4-(3-isothiazoly00-Ph CH2C(Me)2COOH 4-CI
4-(3-isothiazoly00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-thiazoly00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,4-thiadiazol-5-00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,4-thiadiazol-5-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(3-Me-1,2,4-thiadiazol-5-00-Ph CH2CH MeCOOH 4-Me 4-(3-Me-1,2,4-thiadiazol-5-00-Ph CH2CH MeCOOH 4-CI
4-(3-Me-1,2,4-thiadiazol-5-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(1 ,2,5-thiadiazol-3-00-Ph CH2CH MeCOOH 4-CI
4-(1 ,2,5-thiadiazol-3-y00-Ph CH2CH MeCOOH 4-Me 4-(1 ,2,5-thiadiazol-3-00-Ph CH2C(Me)2COOH 4-CI
4-(1 ,2,5-thiadiazol-3-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4-CI
4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-F-Ph CH2CH MeCOOH 4-CI
4-(2-Pyridy00-3-F-Ph CH2CH MeCOOH 4-Me 4-(2-Pyridy00-3-F-Ph CH2C(Me)2COOH 4-CI
4-(2-Pyridy00-3-F-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4-CI
4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-Me-Ph CH2CH MeCOOH 4-CI
4-(2-Pyridy00-3-Me-Ph CH2CH MeCOOH 4-Me 4-(2-Pyridy1)0-3-Me-Ph CH2C(Me)2COOH 4-CI
4-(2-Pyridy00-3-Me-Ph CH(Me)CH(Me)COOH 4-CI
4-(5-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-CI
4-(5-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-Me 4-(5-Et-2-Pyridy00-Ph CH2C(Me)2COOH 4-CI
4-(5-Et-2-Pyridy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(6-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-CI
4-(6-Et-2-Pyridy00-Ph CH2CH MeCOOH 4-Me
- 184 -Date Recue/Date Received 2020-11-26 [Table 122]
R3 Rc (R2')m 4-(6-Et-2-Pyridy00-Ph CH2C(Me)2COOH 4-CI
4-(6-Et-2-Pyridy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(3-F-2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(5-F-2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(6-F-2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(5-F-3-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(B enzoxazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(4-Azabenzoxazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(B enzoth iazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(3-Me-1 ,2-Benzizoxazol-6-00-Ph CH2CH MeCOOH 4-CI
4-(3-Me-1 ,2-Benzizoxazol-6-00-Ph CH2CH MeCOOH 4-Me 4-(5-Benzoimidazoly00-Ph CH2CH MeCOOH 4-CI
4-(5-Benzoimidazoly00-Ph CH2CH MeCOOH 4-Me 4-(Imidazopyridaziin-3-00-Ph CH2CH MeCOOH 4-Me 4-(Imidazopyridaziin-3-00-Ph CH2C(Me)2COOH 4-CI
4-(Imidazopyridaziin-3-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(Imidazopyridaziin-3-00-Ph (CH2)20H 4-CI
4-(Imidazopyridaziin-3-00-Ph (CH2)30H 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2CH(OH)CH2OH 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2CH(CH2OH)2 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2CMe(CH2OH)2 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2COH(CH2OH)2 4-CI
[0159]
N
A N Rc H b_ z (R )m
R3 Rc (R2')m 4-(6-Et-2-Pyridy00-Ph CH2C(Me)2COOH 4-CI
4-(6-Et-2-Pyridy00-Ph CH(Me)CH(Me)COOH 4-CI
4-(2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(3-F-2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(5-F-2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(6-F-2-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(5-F-3-Pyridy00-Ph CH2CH MeCOOH 4-CH2F
4-(B enzoxazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(4-Azabenzoxazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(B enzoth iazol-2-00-Ph CH2CH MeCOOH 4-Me 4-(3-Me-1 ,2-Benzizoxazol-6-00-Ph CH2CH MeCOOH 4-CI
4-(3-Me-1 ,2-Benzizoxazol-6-00-Ph CH2CH MeCOOH 4-Me 4-(5-Benzoimidazoly00-Ph CH2CH MeCOOH 4-CI
4-(5-Benzoimidazoly00-Ph CH2CH MeCOOH 4-Me 4-(Imidazopyridaziin-3-00-Ph CH2CH MeCOOH 4-Me 4-(Imidazopyridaziin-3-00-Ph CH2C(Me)2COOH 4-CI
4-(Imidazopyridaziin-3-00-Ph CH(Me)CH(Me)COOH 4-CI
4-(Imidazopyridaziin-3-00-Ph (CH2)20H 4-CI
4-(Imidazopyridaziin-3-00-Ph (CH2)30H 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2CH(OH)CH2OH 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2CH(CH2OH)2 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2CMe(CH2OH)2 4-CI
4-(Imidazopyridaziin-3-00-Ph CH2COH(CH2OH)2 4-CI
[0159]
N
A N Rc H b_ z (R )m
- 185 -Date Recue/Date Received 2020-11-26 [Table 123]
R3 RC ( R2) m 4-(2-Pyridy00-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-Ph (CH2)2COOH 4,4-(CH2)2 4-(2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-F-Ph CH2CHMeCOOH 4-Me 4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4,4-(CH2)2 4-(2-Pyridy00-3-F-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-Me-Ph CH2CHMeCOOH 4-Me 4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4,4-(CH2)2 4-(2-Pyridy00-3-Me-Ph CH2CHMeCOOH 4,4-(CF12)2 4-(3-F-2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(5-F-2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(6-F-2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(5-F-3-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(4-H0C0-2-Pyridy00-Ph Et 4,4-(CH2)2 4-(5-H0C0-2-Pyridy00-Ph Et 4,4-(CH2)2 4-(6-H0C0-2-Pyridy00-Ph Et 4,4-(CH2)2 4-(5-H0C0-2-Pyridy00-3-Me-Ph Et 4,4-(CH2)2 4-(6-H0C0-2-Pyridy00-3-Me-Ph Et 4,4-(CH2)2 4-(5-H0C0-2-Pyridy00-3-F-Ph Et 4,4-(CH2)2 4-(6-H0C0-2-Pyridy00-3-F-Ph Et 4,4-(CH2)2 [0160]
Biological test examples for compounds of the present invention were described below.
[0161]
Test Examples Test Example 1 Evaluation of human P2X3 receptor inhibitory activity Stably expressing cell line (C6BU-1 cell transfected with human P2X3 receptor gene (GenBank accession number Y07683) was used. The cells were seeded in a 384-well PDL-coated microtiter plate at a concentration of 3000 cells/well and cultured in the medium (8.3% fetal bovine serum, 8.3% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-3-AM solution (20 mM HEPES, 137 mM NaCl, 2.7 mM KC1, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.5% BSA, and 0.04%
PluronicTM F-127, pH 7.5) and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KC1, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5mM probenecid, pH7.5), and each well was added with 20 p_L of the washing buffer. The plate was placed in High-Throughput Screening System FLIPR 384 (Molecular Device Co.). Measurement of fluorescence intensity by FLIPR 384 was started, and 20 p_L of DMSO solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KC1, 0.9 mM MgCl2, 5.0 mM
CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 150
R3 RC ( R2) m 4-(2-Pyridy00-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-Ph (CH2)2COOH 4,4-(CH2)2 4-(2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-F-Ph CH2CHMeCOOH 4-Me 4-(2-Pyridy00-3-F-Ph (CH2)2COOH 4,4-(CH2)2 4-(2-Pyridy00-3-F-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4-Me 4-(2-Pyridy00-3-Me-Ph CH2CHMeCOOH 4-Me 4-(2-Pyridy00-3-Me-Ph (CH2)2COOH 4,4-(CH2)2 4-(2-Pyridy00-3-Me-Ph CH2CHMeCOOH 4,4-(CF12)2 4-(3-F-2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(5-F-2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(6-F-2-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(5-F-3-Pyridy00-Ph CH2CHMeCOOH 4,4-(CH2)2 4-(4-H0C0-2-Pyridy00-Ph Et 4,4-(CH2)2 4-(5-H0C0-2-Pyridy00-Ph Et 4,4-(CH2)2 4-(6-H0C0-2-Pyridy00-Ph Et 4,4-(CH2)2 4-(5-H0C0-2-Pyridy00-3-Me-Ph Et 4,4-(CH2)2 4-(6-H0C0-2-Pyridy00-3-Me-Ph Et 4,4-(CH2)2 4-(5-H0C0-2-Pyridy00-3-F-Ph Et 4,4-(CH2)2 4-(6-H0C0-2-Pyridy00-3-F-Ph Et 4,4-(CH2)2 [0160]
Biological test examples for compounds of the present invention were described below.
[0161]
Test Examples Test Example 1 Evaluation of human P2X3 receptor inhibitory activity Stably expressing cell line (C6BU-1 cell transfected with human P2X3 receptor gene (GenBank accession number Y07683) was used. The cells were seeded in a 384-well PDL-coated microtiter plate at a concentration of 3000 cells/well and cultured in the medium (8.3% fetal bovine serum, 8.3% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-3-AM solution (20 mM HEPES, 137 mM NaCl, 2.7 mM KC1, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.5% BSA, and 0.04%
PluronicTM F-127, pH 7.5) and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KC1, 0.9 mM MgCl2, 5.0 mM CaCl2, 5.6 mM D-glucose, 2.5mM probenecid, pH7.5), and each well was added with 20 p_L of the washing buffer. The plate was placed in High-Throughput Screening System FLIPR 384 (Molecular Device Co.). Measurement of fluorescence intensity by FLIPR 384 was started, and 20 p_L of DMSO solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 2.7 mM KC1, 0.9 mM MgCl2, 5.0 mM
CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 150
- 186 -Date Recue/Date Received 2020-11-26 nM ATP solution (25 11_0 prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC5o) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. The specific maximum fluorescence intensity and were calculated using Spotfire (Science & Technology Systems, Inc.) The data of the compounds of the present invention are as shown in the following Tables.
- 187 -Date Recue/Date Received 2020-11-26 [0162]
[Table 124]
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) -001 0.044 -051 0.006 -101 0.005 -002 0.005 -052 0.006 -102 0.005 -003 0.007 -053 0.006 -103 0.007 -004 0.014 -054 0.005 -104 0.005 -005 0.008 -055 0.009 -105 0.007 -006 0.005 -056 0.007 -106 0.006 -007 0.009 -057 0.005 -107 0.031 -008 0.007 -058 0.006 -108 0.004 -009 0.007 -059 0.016 -109 0.006 -010 0.005 -060 0.024 -110 0.004 -011 0.018 -061 0.062 -111 0.009 -012 0.025 -062 0.031 -112 0.004 -013 0.058 -063 0.009 -113 0.005 -014 0.007 -064 0.01 -114 0.006 -015 0.009 -065 0.008 -115 0.006 -016 0.008 -066 0.015 -116 0.007 -017 0.006 -067 0.011 -117 0.005 -018 0.012 -068 0.005 -118 0.009 -019 0.007 -069 0.007 -119 0.006 -020 0.009 -070 0.005 -120 0.009 -021 0.025 -071 0.038 -121 0.006 -022 0.004 -072 0.006 -122 0.004 -023 0.007 -073 0.015 -123 0.005 -024 0.034 -074 0.005 -124 0.005 -025 0.023 -075 0.021 -125 0.005 -026 0.017 -076 0.022 -126 0.005 -027 0.039 -077 0.01 -127 0.004 -028 0.02 -078 0.019 -128 0.008 -029 0.014 -079 0.005 -129 0.004 -030 0.176 -080 0.01 -130 0.006 -031 0.199 -081 0.038 -131 0.008 -032 0.011 -082 0.112 -132 0.008 -033 0.023 -083 0.006 -133 0.008 -034 0.009 -084 0.008 -134 0.007 -035 0.012 -085 0.225 -135 0.004 -036 0.005 -086 0.033 -136 0.007 -037 0.006 -087 0.107 -137 0.014 -038 0.005 -088 0.015 -138 0.007 -039 0.008 -089 0.008 -139 0.01 -040 0.006 -090 0.072 -140 0.003 -041 0.009 -091 0.01 -141 0.014 -042 0.004 -092 0.068 -142 0.007 -043 0.117 -093 0.016 -143 0.005 -044 0.026 -094 0.011 -144 0.009 -045 0.019 -095 0.009 -145 0.006 -046 0.019 -096 0.008 -146 0.005 -047 0.022 -097 0.005 -147 0.007 -048 0.03 -098 0.007 -148 0.009 -049 0.015 -099 0.006 -149 0.005 -050 0.028 -100 0.004 -150 0.004
[Table 124]
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) -001 0.044 -051 0.006 -101 0.005 -002 0.005 -052 0.006 -102 0.005 -003 0.007 -053 0.006 -103 0.007 -004 0.014 -054 0.005 -104 0.005 -005 0.008 -055 0.009 -105 0.007 -006 0.005 -056 0.007 -106 0.006 -007 0.009 -057 0.005 -107 0.031 -008 0.007 -058 0.006 -108 0.004 -009 0.007 -059 0.016 -109 0.006 -010 0.005 -060 0.024 -110 0.004 -011 0.018 -061 0.062 -111 0.009 -012 0.025 -062 0.031 -112 0.004 -013 0.058 -063 0.009 -113 0.005 -014 0.007 -064 0.01 -114 0.006 -015 0.009 -065 0.008 -115 0.006 -016 0.008 -066 0.015 -116 0.007 -017 0.006 -067 0.011 -117 0.005 -018 0.012 -068 0.005 -118 0.009 -019 0.007 -069 0.007 -119 0.006 -020 0.009 -070 0.005 -120 0.009 -021 0.025 -071 0.038 -121 0.006 -022 0.004 -072 0.006 -122 0.004 -023 0.007 -073 0.015 -123 0.005 -024 0.034 -074 0.005 -124 0.005 -025 0.023 -075 0.021 -125 0.005 -026 0.017 -076 0.022 -126 0.005 -027 0.039 -077 0.01 -127 0.004 -028 0.02 -078 0.019 -128 0.008 -029 0.014 -079 0.005 -129 0.004 -030 0.176 -080 0.01 -130 0.006 -031 0.199 -081 0.038 -131 0.008 -032 0.011 -082 0.112 -132 0.008 -033 0.023 -083 0.006 -133 0.008 -034 0.009 -084 0.008 -134 0.007 -035 0.012 -085 0.225 -135 0.004 -036 0.005 -086 0.033 -136 0.007 -037 0.006 -087 0.107 -137 0.014 -038 0.005 -088 0.015 -138 0.007 -039 0.008 -089 0.008 -139 0.01 -040 0.006 -090 0.072 -140 0.003 -041 0.009 -091 0.01 -141 0.014 -042 0.004 -092 0.068 -142 0.007 -043 0.117 -093 0.016 -143 0.005 -044 0.026 -094 0.011 -144 0.009 -045 0.019 -095 0.009 -145 0.006 -046 0.019 -096 0.008 -146 0.005 -047 0.022 -097 0.005 -147 0.007 -048 0.03 -098 0.007 -148 0.009 -049 0.015 -099 0.006 -149 0.005 -050 0.028 -100 0.004 -150 0.004
- 188 -Date Recue/Date Received 2020-11-26 [Table 125]
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) -151 0.01 R-001 0.007 R-054 0.026 -152 0.006 R-002 0.363 R-055 0.007 -153 0.013 R-003 0.004 R-056 0.01 -154 0.008 R-004 0.123 R-057 0.006 -155 0.008 R-005 0.608 R-058 0.004 -156 0.012 R-006 0.004 R-059 0.005 -157 0.005 R-007 0.301 R-060 0.016 -158 0.006 R-009 0.007 R-061 0.007 -159 0.009 R-010 0.01 R-062 0.318 -160 0.005 R-011 0.049 R-063 0.456 -161 0.01 R-012 0.005 R-064 0.012 -162 0.007 R-013 0.006 R-066 0.058 -163 0.008 R-014 0.005 R-068 0.04 -164 0.029 R-015 0.104 R-069 0.051 -165 0.015 R-016 0.006 R-070 0.007 -166 0.013 R-017 0.006 R-071 0.006 -167 0.019 R-018 0.005 R-072 0.016 -168 0.012 R-019 0.006 R-073 0.031 -169 0.021 R-020 0.013 R-074 0.013 -170 0.015 R-021 0.015 R-075 0.013 -171 0.009 R-022 0.012 R-076 0.013 -172 0.026 R-023 0.021 R-077 0.024 -173 0.008 R-024 0.018 R-078 0.01 -174 0.006 R-025 0.005 R-079 0.011 -175 0.009 R-026 0.008 R-080 0.013 -176 0.007 R-027 0.006 R-081 0.005 -177 0.006 R-028 0.007 R-082 0.007 -178 0.005 R-029 0.007 R-083 0.007 -179 0.006 R-030 0.008 R-084 0.006 -180 0.005 R-031 0.012 R-085 0.006 -181 0.005 R-032 0.004 R-086 0.007 -182 0.008 R-033 0.006 R-087 0.012 -183 0.012 R-034 0.005 R-088 0.006 -184 0.006 R-035 0.008 R-089 0.007 -185 0.009 R-036 0.011 R-090 0.07 -186 0.005 R-037 0.007 R-091 0.108 -187 0.008 R-038 0.007 R-092 0.01 -188 0.007 R-039 0.006 R-093 0.013
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) -151 0.01 R-001 0.007 R-054 0.026 -152 0.006 R-002 0.363 R-055 0.007 -153 0.013 R-003 0.004 R-056 0.01 -154 0.008 R-004 0.123 R-057 0.006 -155 0.008 R-005 0.608 R-058 0.004 -156 0.012 R-006 0.004 R-059 0.005 -157 0.005 R-007 0.301 R-060 0.016 -158 0.006 R-009 0.007 R-061 0.007 -159 0.009 R-010 0.01 R-062 0.318 -160 0.005 R-011 0.049 R-063 0.456 -161 0.01 R-012 0.005 R-064 0.012 -162 0.007 R-013 0.006 R-066 0.058 -163 0.008 R-014 0.005 R-068 0.04 -164 0.029 R-015 0.104 R-069 0.051 -165 0.015 R-016 0.006 R-070 0.007 -166 0.013 R-017 0.006 R-071 0.006 -167 0.019 R-018 0.005 R-072 0.016 -168 0.012 R-019 0.006 R-073 0.031 -169 0.021 R-020 0.013 R-074 0.013 -170 0.015 R-021 0.015 R-075 0.013 -171 0.009 R-022 0.012 R-076 0.013 -172 0.026 R-023 0.021 R-077 0.024 -173 0.008 R-024 0.018 R-078 0.01 -174 0.006 R-025 0.005 R-079 0.011 -175 0.009 R-026 0.008 R-080 0.013 -176 0.007 R-027 0.006 R-081 0.005 -177 0.006 R-028 0.007 R-082 0.007 -178 0.005 R-029 0.007 R-083 0.007 -179 0.006 R-030 0.008 R-084 0.006 -180 0.005 R-031 0.012 R-085 0.006 -181 0.005 R-032 0.004 R-086 0.007 -182 0.008 R-033 0.006 R-087 0.012 -183 0.012 R-034 0.005 R-088 0.006 -184 0.006 R-035 0.008 R-089 0.007 -185 0.009 R-036 0.011 R-090 0.07 -186 0.005 R-037 0.007 R-091 0.108 -187 0.008 R-038 0.007 R-092 0.01 -188 0.007 R-039 0.006 R-093 0.013
-189 0.012 R-040 0.007 R-094 0.029
-190 0.005 R-041 0.011 R-095 0.045
-191 0.011 R-042 0.005 R-096 0.156
-192 0.005 R-043 0.005 R-097 0.212
-193 0.008 R-044 0.01 R-098 0.08
-194 0.012 R-045 0.014 R-099 0.004
-195 0.007 R-046 0.006 R-100 0.006 R-047 0.009 R-101 0.201 R-048 0.006 R-102 0.1 R-049 0.008 R-105 0.007 R-050 0.014 R-106 0.379 R-053 0.052 R-107 0.217 Date Recue/Date Received 2020-11-26 [Table 126]
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) R-108 0.008 R-160 0.008 R-210 0.006 R-111 0.005 R-161 0.01 R-211 0.007 R-112 0.017 R-162 0.006 R-212 0.008 R-113 0.013 R-163 0.014 R-213 0.012 R-114 0.039 R-164 0.01 R-214 0.006 R-115 0.065 R-165 0.014 R-215 0.006 R-116 0.005 R-166 0.048 R-216 0.007 R-117 0.006 R-167 0.011 R-217 0.008 R-118 0.005 R-168 0.017 R-218 0.006 R-119 0.005 R-169 0.304 R-219 0.011 R-120 0.008 R-170 0.193 R-220 0.022 R-121 0.005 R-171 0.033 R-221 0.005 R-122 0.013 R-172 0.033 R-222 0.009 R-123 0.005 R-173 0.376 R-223 0.007 R-124 0.009 R-174 0.01 R-224 0.012 R-125 0.007 R-175 0.019 R-225 0.004 R-126 0.01 R-176 0.007 R-226 0.003 R-127 0.09 R-177 0.005 R-227 0.035 R-128 0.011 R-178 0.045 R-229 0.007 R-129 0.007 R-179 0.056 R-230 0.005 R-130 0.009 R-180 0.007 R-231 0.005 R-131 0.009 R-181 0.007 R-232 0.061 R-132 0.01 R-182 0.026 R-233 0.318 R-133 0.006 R-183 0.007 R-234 0.003 R-134 0.005 R-184 0.01 R-235 0.01 R-135 0.005 R-185 0.012 R-236 0.004 R-136 0.006 R-186 0.026 R-237 0.009 R-137 0.006 R-187 0.021 R-238 0.007 R-138 0.078 R-188 0.009 R-239 0.399 R-139 0.119 R-189 0.008 R-240 0.011 R-140 0.037 R-190 0.009 R-241 0.009 R-141 0.047 R-191 0.012 R-242 0.005 R-142 0.069 R-192 0.004 R-243 0.004 R-143 0.097 R-193 0.011 R-244 0.004 R-144 0.005 R-194 0.013 R-245 0.004 R-145 0.011 R-195 0.009 R-246 0.006 R-146 0.033 R-196 0.011 R-247 0.005 R-147 0.051 R-197 0.007 R-248 0.005 R-148 0.005 R-198 0.009 R-249 0.006 R-149 0.012 R-199 0.007 R-250 0.009 R-150 0.018 R-200 0.008 R-251 0.005 R-151 0.011 R-201 0.008 R-254 0.003 R-152 0.005 R-202 0.012 R-255 0.005 R-153 0.008 R-203 0.006 R-256 0.002 R-154 0.008 R-204 0.008 R-257 0.01 R-155 0.01 R-205 0.008 R-156 0.035 R-206 0.005 R-157 0.006 R-207 0.009 R-158 0.012 R-208 0.005 R-159 0.018 R-209 0.005 Date Recue/Date Received 2020-11-26 [Table 127]
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) 1-200 0.042 1-250 0.031 R-275 0.023 1-201 0.013 1-251 0.008 R-276 0.042 1-202 0.008 1-252 0.014 R-277 0.014 1-203 0.003 1-253 0.009 R-278 0.015 1-204 0.004 1-254 0.006 R-279 0.007 1-205 0.012 1-255 0.018 R-280 0.009 1-206 0.010 1-256 0.029 R-281 0.007 1-207 0.012 1-257 0.016 R-282 0.023 1-208 0.012 1-258 0.004 R-283 0.028 1-209 0.008 1-259 0.005 R-284 0.005 1-210 0.007 1-260 0.005 R-285 0.006 1-211 0.007 1-261 0.008 R-286 0.006 1-212 0.010 1-262 0.007 R-287 0.006 1-213 0.012 1-263 0.005 R-288 0.012 1-214 0.011 1-264 0.005 R-289 0.005 1-215 0.016 1-265 0.010 R-290 0.006 1-216 0.017 1-266 0.008 R-291 0.006 1-217 0.011 1-267 0.003 R-292 0.004 1-218 0.010 1-268 0.003 R-293 0.004 1-219 0.012 1-269 0.004 R-294 0.006 1-220 0.010 1-270 0.004 R-295 0.006 1-221 0.011 1-271 0.010 R-296 0.005 1-222 0.004 1-272 0.008 R-297 0.008 1-223 0.011 1-273 0.005 R-298 0.009 1-224 0.006 1-274 0.005 R-299 0.020 1-225 0.014 1-275 0.004 R-300 0.008 1-226 0.038 1-276 0.019 R-301 0.005 1-227 0.031 1-277 0.004 R-302 0.006 1-228 0.021 1-278 0.006 R-303 0.003 1-229 0.006 R-304 0.004 1-230 0.011 R-305 0.007 1-231 0.007 R-306 0.014 1-232 0.005 R-307 0.013 1-233 0.006 R-309 0.004 1-234 0.007 R-310 0.004 1-235 0.009 R-311 0.428 1-236 0.016 R-312 0.350 1-237 0.014 R-313 0.003 1-238 0.005 R-314 0.048 1-239 0.006 1-240 0.022 1-241 0.008 1-242 0.008 1-243 0.007 1-244 0.008 1-245 0.014 1-246 0.014 1-247 0.006 1-248 0.005 1-249 0.036 [0163]
Test Example 2 Evaluation of human P2X3 receptor inhibitory activity in the presense Date Recue/Date Received 2020-11-26 of human serum albumin (HSA) Stably expressing cell line (C6BU-1 cell transfected with human P2X3 receptor gene (GenBank accession number Y07683) was used. The cells were seeded in a 96-well microtiter plate at a concentration of 8000 cells/well and cultured in the medium (7.0%
fetal bovine serum, 7.0% horse serum, 1% antibiotic and antifungal, and 2.0%
glutamine in DMEM) for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-3-AM solution (20 mM HEPES, 137 mM NaCl, 5.37 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.5% BSA, and 0.04%
PluronicTM F-127, pH 7.5) and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5mM probenecid, pH7.5), and each well was added with 40 iL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 iL of DMSO solutions containing 1% HSA (final concentrations) different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM
KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1%
PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 p_L) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC5o) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC5o was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.) The data of the compounds of the present invention are as shown in the following Tables.
Date Recue/Date Received 2020-11-26 [0164]
[Table 128]
Compound P2X3+HSA
No. IC50 ( M) 1-019 0.068 1-040 0.018 1-056 0.023 1-070 0.037 1-079 0.037 R-123 0.018 [0165]
Test Example 3 Evaluation of rat P2X3 receptor inhibitory activity Rat P2X3 receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The C6BU-1 cells were seeded in a 96-well microtiter plate at a concentration of 2500 cells/well and cultured in the medium (7.0% fetal bovine serum, 7.0% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37 C under % carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Promega). The transfected cells were cultured in the medium for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-3-AM solution (pH7.5) containing 20 mM HEPES, 137 mM
NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 1%
BSA, and 0.08% PluronicTM F-127, and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM
HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5mM
probenecid, pH7.5), and each well was added with 40 p_L of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.).
Measurement of fluorescence intensity by FDSS 3000 was started, and 40 p_L of DMSO
solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM
MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser.
Five minutes after, 50 nM ATP solution (50 - L) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC5o) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC5o was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.).
The data of the compounds of the present invention are as shown in the following Table.
Date Recue/Date Received 2020-11-26 [Table 129]
Compound ratP2X3 No. IC50 ( Li M) 1-002 0.006 R-009 0.004 [0166]
Test Example 4 Evaluation of rat P2X3 receptor inhibitory activity in the presence of rat serum albumin (RSA) Rat P2X3 receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The C6BU-1 cells were seeded in a 96-well microtiter plate at a concentration of 2500 cells/well and cultured in the medium (7.0% fetal bovine serum, 7.0% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37 C under % carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Promega). The transfected cells were cultured in the medium for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-4-AM solution (p117. 5) containing 20 mM IIEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 10%
BSA, and 0.08% PluronicTM F-127, and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM
HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5mM
probenecid, p117.5), and each well was added with 40 p_I_, of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.).
Measurement of fluorescence intensity by FDSS 3000 was started, and 40 p_I_, of DMSO
solutions containing 1% RSA (final concentrations) and different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM
NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM
probenecid, 0.1% PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 p_L) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC 50) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC50 was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.).
The data of the compounds of the present invention are as shown in the following Table.
Date Recue/Date Received 2020-11-26 [Table 130]
Compound ratP2X3+RSA
No. IC50 (Li M) 1-019 0.011 1-022 0.011 1-040 0.009 1-100 0.009 1-113 0.010 R-014 0.006 R-019 0.008 R-037 0.008 As shown, the compounds described in the present specification showed inhibiting activity on P2X3 receptor. Furthermore, as the compounds of the invention are effective on P2X3 subtype, the compounds are also considered to have inhibiting activity on P2X2/3 receptor, which comprises P2X2 subtype.
[0167]
Test Example 5 Evaluation of the urinary function in a rat model of cystitis Surgery for cystometry A rat is fixed in the supine position after being given anesthesia through the inhalation of 2% isoflurane (Anesthetic background; Nitrous oxide: Oxygen =
73). A
midline incision is made in its abdomen to expose the bladder. A cannula (made by processing a polyethylene tube (PE-50: Becton Dickinson)) is inserted through a small incision on top of the bladder and fixed to create a bladder fistula. The other end of the cannula is led through the hypodermal tissue to the back, and the muscular coat and skin are sutured. The cannula, which is led to the back, is protected with a stainless spring in the middle and connected to the cannula swivel.
Acetic acid infusion Two days after the surgery, 0.3% acetic acid is infused into the bladder through the indwelled cannula at a rate of 4 mL/hr for 30 minutes to induce cystitis.
The animals, where acetic acid is not infused, are used as normal animals.
Cystometry measurement Two or three days after the acetic acid infusion, the other end of the cannula inserted into the bladder is connected to a T shape stopcock and then the intravesical pressure is recorded continuously using a pressure amplifier while infusing warmed normal saline solution at a rate of 3.0 mL/hr from one side and through a pressure transducer on the other side. The baseline of the intravesical pressure is measured (for approximately 40 minutes) after a measurement for stable duration (for approximately 20 minutes). After that, a vehicle, positive control compound or test compound are administered, and the value after administration is measured for approximately minutes. A compound of the present invention is crushed with a mortar and pestle so as to be 0.1-2 mg/mL/kg solution or suspension using 0.5% methylcellulose solution, and administered to an animal orally with an oral sonde. At the same time, the voided urine is received on scales under the cage to measure the variation in weight simultaneously.
Date Recue/Date Received 2020-11-26 Data adoption criteria Based on the voiding interval, normal animals whose voiding interval is 10 minutes or longer were adopted and those whose voiding interval is shorter than that were excluded. In the case of the animals into which acetic acid is infused, those whose voiding interval is less than half the average value of the normal animals are adopted as animals with cystitis and those whose voiding interval is longer than that were excluded.
Collection of residual urine After the completion of the measurement, the infusion of normal saline solution is stopped immediately after urination to collect the residual urine under pentobarbital sodium anesthesia. The collected residual urine is transferred to the voided urine receiver and recorded on the chart.
Analysis items Intravesical pressure one to two hours after the start of the measurement (pressure during rest and pressure during urination), voiding interval, voided volume per urination, and residual urine volume The following value is used as an indicator of the effect on the voiding interval:
Improvement rate of the urinary function = (Voiding interval of an animal with cystitis after drug treatment ¨ Voiding interval of an animal with cystitis before drug treatment) / (Mean voiding interval of normal animals before drug treatment ¨ Voiding interval of an animal with cystitis before drug treatmenDx100 The following value is used as an indicator of the effect on the voided volume per urination:
Improvement rate of the voided volume per urination = (Voided volume per urination of a rat with cystitis after drug treatment ¨
Voided volume per urination of an animal with cystitis before drug treatment) / (Mean voided volume per urination of normal animals before drug treatment ¨ Voided volume per urination of an animal with cystitis before drug treatment)x100 [0168]
Test Example 6 Analgesic Effect in a Seltzer model Preparation of Partial Sciatic Nerve Ligation model in Rats Rats were anaesthetized using isoflurane/02 inhalation anaesthesia. After induction of anesthesia, the left thigh was shaved. An incision was made in the skin just below the hip bone. The muscle was bluntly dissected to expose the sciatic nerve. One third (1/3) to one half (1/2) of the sciatic nerve thickness was tightly ligated and the wound was closed. The right thigh is used as a sham-operated control. The right thigh undergoes an identical procedure with the left hind limb, however, the sciatic nerve is not manipulated or ligated.
Evaluation (1) Two weeks after nerve ligation, the effect on mechanical allodynia was assessed using a series of von Frey filaments. For habituation, the rats were placed into a plastic cage on a wire mesh bottom. The mechanical sensitivity (mechanical threshold) of the hind paws was estimated with a series of von Frey filaments (0.4 - 26 g). The measurement of mechanical sensitivity of the right and left hind paws was performed to obtain predose mechanical sensitivity. The rats showing the threshold change from 0.6 to 2 g (in nerve ligated side) and 8 to 15 g (in sham operated side) were used in the experiments. On the day before the experiment, the rats were evaluated with a series of von Frey filaments to familiarize them with the test procedure. The adopted animal was administrated with the test compounds. The test compounds were
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) R-108 0.008 R-160 0.008 R-210 0.006 R-111 0.005 R-161 0.01 R-211 0.007 R-112 0.017 R-162 0.006 R-212 0.008 R-113 0.013 R-163 0.014 R-213 0.012 R-114 0.039 R-164 0.01 R-214 0.006 R-115 0.065 R-165 0.014 R-215 0.006 R-116 0.005 R-166 0.048 R-216 0.007 R-117 0.006 R-167 0.011 R-217 0.008 R-118 0.005 R-168 0.017 R-218 0.006 R-119 0.005 R-169 0.304 R-219 0.011 R-120 0.008 R-170 0.193 R-220 0.022 R-121 0.005 R-171 0.033 R-221 0.005 R-122 0.013 R-172 0.033 R-222 0.009 R-123 0.005 R-173 0.376 R-223 0.007 R-124 0.009 R-174 0.01 R-224 0.012 R-125 0.007 R-175 0.019 R-225 0.004 R-126 0.01 R-176 0.007 R-226 0.003 R-127 0.09 R-177 0.005 R-227 0.035 R-128 0.011 R-178 0.045 R-229 0.007 R-129 0.007 R-179 0.056 R-230 0.005 R-130 0.009 R-180 0.007 R-231 0.005 R-131 0.009 R-181 0.007 R-232 0.061 R-132 0.01 R-182 0.026 R-233 0.318 R-133 0.006 R-183 0.007 R-234 0.003 R-134 0.005 R-184 0.01 R-235 0.01 R-135 0.005 R-185 0.012 R-236 0.004 R-136 0.006 R-186 0.026 R-237 0.009 R-137 0.006 R-187 0.021 R-238 0.007 R-138 0.078 R-188 0.009 R-239 0.399 R-139 0.119 R-189 0.008 R-240 0.011 R-140 0.037 R-190 0.009 R-241 0.009 R-141 0.047 R-191 0.012 R-242 0.005 R-142 0.069 R-192 0.004 R-243 0.004 R-143 0.097 R-193 0.011 R-244 0.004 R-144 0.005 R-194 0.013 R-245 0.004 R-145 0.011 R-195 0.009 R-246 0.006 R-146 0.033 R-196 0.011 R-247 0.005 R-147 0.051 R-197 0.007 R-248 0.005 R-148 0.005 R-198 0.009 R-249 0.006 R-149 0.012 R-199 0.007 R-250 0.009 R-150 0.018 R-200 0.008 R-251 0.005 R-151 0.011 R-201 0.008 R-254 0.003 R-152 0.005 R-202 0.012 R-255 0.005 R-153 0.008 R-203 0.006 R-256 0.002 R-154 0.008 R-204 0.008 R-257 0.01 R-155 0.01 R-205 0.008 R-156 0.035 R-206 0.005 R-157 0.006 R-207 0.009 R-158 0.012 R-208 0.005 R-159 0.018 R-209 0.005 Date Recue/Date Received 2020-11-26 [Table 127]
Compound P2X3 Compound P2X3 Compound P2X3 No. 1050 (,u M) No. 1050 (,u M) No. 1050 (,u M) 1-200 0.042 1-250 0.031 R-275 0.023 1-201 0.013 1-251 0.008 R-276 0.042 1-202 0.008 1-252 0.014 R-277 0.014 1-203 0.003 1-253 0.009 R-278 0.015 1-204 0.004 1-254 0.006 R-279 0.007 1-205 0.012 1-255 0.018 R-280 0.009 1-206 0.010 1-256 0.029 R-281 0.007 1-207 0.012 1-257 0.016 R-282 0.023 1-208 0.012 1-258 0.004 R-283 0.028 1-209 0.008 1-259 0.005 R-284 0.005 1-210 0.007 1-260 0.005 R-285 0.006 1-211 0.007 1-261 0.008 R-286 0.006 1-212 0.010 1-262 0.007 R-287 0.006 1-213 0.012 1-263 0.005 R-288 0.012 1-214 0.011 1-264 0.005 R-289 0.005 1-215 0.016 1-265 0.010 R-290 0.006 1-216 0.017 1-266 0.008 R-291 0.006 1-217 0.011 1-267 0.003 R-292 0.004 1-218 0.010 1-268 0.003 R-293 0.004 1-219 0.012 1-269 0.004 R-294 0.006 1-220 0.010 1-270 0.004 R-295 0.006 1-221 0.011 1-271 0.010 R-296 0.005 1-222 0.004 1-272 0.008 R-297 0.008 1-223 0.011 1-273 0.005 R-298 0.009 1-224 0.006 1-274 0.005 R-299 0.020 1-225 0.014 1-275 0.004 R-300 0.008 1-226 0.038 1-276 0.019 R-301 0.005 1-227 0.031 1-277 0.004 R-302 0.006 1-228 0.021 1-278 0.006 R-303 0.003 1-229 0.006 R-304 0.004 1-230 0.011 R-305 0.007 1-231 0.007 R-306 0.014 1-232 0.005 R-307 0.013 1-233 0.006 R-309 0.004 1-234 0.007 R-310 0.004 1-235 0.009 R-311 0.428 1-236 0.016 R-312 0.350 1-237 0.014 R-313 0.003 1-238 0.005 R-314 0.048 1-239 0.006 1-240 0.022 1-241 0.008 1-242 0.008 1-243 0.007 1-244 0.008 1-245 0.014 1-246 0.014 1-247 0.006 1-248 0.005 1-249 0.036 [0163]
Test Example 2 Evaluation of human P2X3 receptor inhibitory activity in the presense Date Recue/Date Received 2020-11-26 of human serum albumin (HSA) Stably expressing cell line (C6BU-1 cell transfected with human P2X3 receptor gene (GenBank accession number Y07683) was used. The cells were seeded in a 96-well microtiter plate at a concentration of 8000 cells/well and cultured in the medium (7.0%
fetal bovine serum, 7.0% horse serum, 1% antibiotic and antifungal, and 2.0%
glutamine in DMEM) for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-3-AM solution (20 mM HEPES, 137 mM NaCl, 5.37 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.5% BSA, and 0.04%
PluronicTM F-127, pH 7.5) and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5mM probenecid, pH7.5), and each well was added with 40 iL of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.). Measurement of fluorescence intensity by FDSS 3000 was started, and 40 iL of DMSO solutions containing 1% HSA (final concentrations) different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM
KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1%
PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 p_L) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC5o) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC5o was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.) The data of the compounds of the present invention are as shown in the following Tables.
Date Recue/Date Received 2020-11-26 [0164]
[Table 128]
Compound P2X3+HSA
No. IC50 ( M) 1-019 0.068 1-040 0.018 1-056 0.023 1-070 0.037 1-079 0.037 R-123 0.018 [0165]
Test Example 3 Evaluation of rat P2X3 receptor inhibitory activity Rat P2X3 receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The C6BU-1 cells were seeded in a 96-well microtiter plate at a concentration of 2500 cells/well and cultured in the medium (7.0% fetal bovine serum, 7.0% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37 C under % carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Promega). The transfected cells were cultured in the medium for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-3-AM solution (pH7.5) containing 20 mM HEPES, 137 mM
NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 1%
BSA, and 0.08% PluronicTM F-127, and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM
HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5mM
probenecid, pH7.5), and each well was added with 40 p_L of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.).
Measurement of fluorescence intensity by FDSS 3000 was started, and 40 p_L of DMSO
solutions containing different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM
MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 0.1% PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser.
Five minutes after, 50 nM ATP solution (50 - L) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC5o) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC5o was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.).
The data of the compounds of the present invention are as shown in the following Table.
Date Recue/Date Received 2020-11-26 [Table 129]
Compound ratP2X3 No. IC50 ( Li M) 1-002 0.006 R-009 0.004 [0166]
Test Example 4 Evaluation of rat P2X3 receptor inhibitory activity in the presence of rat serum albumin (RSA) Rat P2X3 receptor gene (GenBank accession number NM_031075) was expressed in C6BU-1 cell. The C6BU-1 cells were seeded in a 96-well microtiter plate at a concentration of 2500 cells/well and cultured in the medium (7.0% fetal bovine serum, 7.0% horse serum, and 1% antibiotic and antifungal in DMEM) for one day at 37 C under % carbon dioxide atmosphere. The plasmid was transfected into the cells using transfection reagent FuGENE6 (Promega). The transfected cells were cultured in the medium for one day at 37 C under 5 % carbon dioxide atmosphere. The medium was replaced with 4 p_M Fluo-4-AM solution (p117. 5) containing 20 mM IIEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM probenecid, 10%
BSA, and 0.08% PluronicTM F-127, and incubated at 37 C under 5% dioxide carbon atmosphere for one hour. The plate was washed with washing buffer (20 mM
HEPES, 137 mM NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5mM
probenecid, p117.5), and each well was added with 40 p_I_, of this buffer. The plate was placed in High-Throughput Screening System FDSS 3000 (Hamamatsu Photonics K.K.).
Measurement of fluorescence intensity by FDSS 3000 was started, and 40 p_I_, of DMSO
solutions containing 1% RSA (final concentrations) and different concentrations of the test compound as prepared by dilution with dilution buffer (20 mM HEPES, 137 mM
NaCl, 5.27 mM KC1, 0.9 mM MgCl2, 1.26 mM CaCl2, 5.6 mM D-glucose, 2.5 mM
probenecid, 0.1% PluronicTM F-127, pH7.5) were dispensed to each well through the built-in automatic dispenser. Five minutes after, 50 nM ATP solution (50 p_L) prepared by dilution with the dilution buffer was dispensed through the built-in automatic dispenser, and the measurement of fluorescence intensity was continued for 4 min. For each well, the specific maximum fluorescence intensity was calculated as the ratio of the maximum fluorescence intensity after addition of the ATP solution to the fluorescence intensity at the starting of the measurement. The 50% inhibitory concentration (IC 50) was calculated under the assumption that the specific maximum fluorescence intensity without test compound is 0% inhibition and that the specific maximum fluorescence intensity when the dilution buffer was added in place of ATP solution is 100% inhibition, to evaluate the inhibitory activity of the test compound. FDSS software (Hamamatsu Photonics K.K.) was used for calculation of the specific maximum fluorescence intensity. IC50 was calculated using Microsoft Excel (Microsoft Corporation) and XLfit (idbs Ltd.).
The data of the compounds of the present invention are as shown in the following Table.
Date Recue/Date Received 2020-11-26 [Table 130]
Compound ratP2X3+RSA
No. IC50 (Li M) 1-019 0.011 1-022 0.011 1-040 0.009 1-100 0.009 1-113 0.010 R-014 0.006 R-019 0.008 R-037 0.008 As shown, the compounds described in the present specification showed inhibiting activity on P2X3 receptor. Furthermore, as the compounds of the invention are effective on P2X3 subtype, the compounds are also considered to have inhibiting activity on P2X2/3 receptor, which comprises P2X2 subtype.
[0167]
Test Example 5 Evaluation of the urinary function in a rat model of cystitis Surgery for cystometry A rat is fixed in the supine position after being given anesthesia through the inhalation of 2% isoflurane (Anesthetic background; Nitrous oxide: Oxygen =
73). A
midline incision is made in its abdomen to expose the bladder. A cannula (made by processing a polyethylene tube (PE-50: Becton Dickinson)) is inserted through a small incision on top of the bladder and fixed to create a bladder fistula. The other end of the cannula is led through the hypodermal tissue to the back, and the muscular coat and skin are sutured. The cannula, which is led to the back, is protected with a stainless spring in the middle and connected to the cannula swivel.
Acetic acid infusion Two days after the surgery, 0.3% acetic acid is infused into the bladder through the indwelled cannula at a rate of 4 mL/hr for 30 minutes to induce cystitis.
The animals, where acetic acid is not infused, are used as normal animals.
Cystometry measurement Two or three days after the acetic acid infusion, the other end of the cannula inserted into the bladder is connected to a T shape stopcock and then the intravesical pressure is recorded continuously using a pressure amplifier while infusing warmed normal saline solution at a rate of 3.0 mL/hr from one side and through a pressure transducer on the other side. The baseline of the intravesical pressure is measured (for approximately 40 minutes) after a measurement for stable duration (for approximately 20 minutes). After that, a vehicle, positive control compound or test compound are administered, and the value after administration is measured for approximately minutes. A compound of the present invention is crushed with a mortar and pestle so as to be 0.1-2 mg/mL/kg solution or suspension using 0.5% methylcellulose solution, and administered to an animal orally with an oral sonde. At the same time, the voided urine is received on scales under the cage to measure the variation in weight simultaneously.
Date Recue/Date Received 2020-11-26 Data adoption criteria Based on the voiding interval, normal animals whose voiding interval is 10 minutes or longer were adopted and those whose voiding interval is shorter than that were excluded. In the case of the animals into which acetic acid is infused, those whose voiding interval is less than half the average value of the normal animals are adopted as animals with cystitis and those whose voiding interval is longer than that were excluded.
Collection of residual urine After the completion of the measurement, the infusion of normal saline solution is stopped immediately after urination to collect the residual urine under pentobarbital sodium anesthesia. The collected residual urine is transferred to the voided urine receiver and recorded on the chart.
Analysis items Intravesical pressure one to two hours after the start of the measurement (pressure during rest and pressure during urination), voiding interval, voided volume per urination, and residual urine volume The following value is used as an indicator of the effect on the voiding interval:
Improvement rate of the urinary function = (Voiding interval of an animal with cystitis after drug treatment ¨ Voiding interval of an animal with cystitis before drug treatment) / (Mean voiding interval of normal animals before drug treatment ¨ Voiding interval of an animal with cystitis before drug treatmenDx100 The following value is used as an indicator of the effect on the voided volume per urination:
Improvement rate of the voided volume per urination = (Voided volume per urination of a rat with cystitis after drug treatment ¨
Voided volume per urination of an animal with cystitis before drug treatment) / (Mean voided volume per urination of normal animals before drug treatment ¨ Voided volume per urination of an animal with cystitis before drug treatment)x100 [0168]
Test Example 6 Analgesic Effect in a Seltzer model Preparation of Partial Sciatic Nerve Ligation model in Rats Rats were anaesthetized using isoflurane/02 inhalation anaesthesia. After induction of anesthesia, the left thigh was shaved. An incision was made in the skin just below the hip bone. The muscle was bluntly dissected to expose the sciatic nerve. One third (1/3) to one half (1/2) of the sciatic nerve thickness was tightly ligated and the wound was closed. The right thigh is used as a sham-operated control. The right thigh undergoes an identical procedure with the left hind limb, however, the sciatic nerve is not manipulated or ligated.
Evaluation (1) Two weeks after nerve ligation, the effect on mechanical allodynia was assessed using a series of von Frey filaments. For habituation, the rats were placed into a plastic cage on a wire mesh bottom. The mechanical sensitivity (mechanical threshold) of the hind paws was estimated with a series of von Frey filaments (0.4 - 26 g). The measurement of mechanical sensitivity of the right and left hind paws was performed to obtain predose mechanical sensitivity. The rats showing the threshold change from 0.6 to 2 g (in nerve ligated side) and 8 to 15 g (in sham operated side) were used in the experiments. On the day before the experiment, the rats were evaluated with a series of von Frey filaments to familiarize them with the test procedure. The adopted animal was administrated with the test compounds. The test compounds were
- 196 -Date Recue/Date Received 2020-11-26 homogenized with mortar and pestle and suspended or diluted in 0.5% Methyl Cellulose to prepare 0.1 - 2.0 mg/mL/kg suspension and orally administered to rat using a syringe attached with a sonde. Post-dose mechanical sensitivities of the right and left hind paws were measured at approximately 1 to 5 hours after drug administration.
Percent reversal of mechanical allodynia for each rat was calculated using the following formula.
The analgesic effects of the compounds were compared.
Logio (Postdose mechanical sensitivity in nerve ligated side) - Logio (Predose mechanical sensitivity in nerve ligated side) % Reversal =
Logio (Predose mechanical sensitivity in sham operated side) - Logio (Predose mechanical sensitivity in nerve ligated side) The analgesic effects of the compounds of the present invention after single administration of 1 mg/kg at 3 hours are as shown in the following Table.
[Table 131]
Compound %reversal No.
1-019 27.9 1-057 21.4 Evaluation (2) Mechanical hyperalgesia is evaluated using an analgesy meter. Two weeks after nerve ligation, the paw pressure test is performed using an analgesy meter (stimulus pressure increased 16g per second) to obtain paw withdrawal thresholds (PWT). Measurements are made on both sides of the hind paw and to obtain pre-dose PWT. The rats showing the threshold change from 60 to 90 g (in nerve ligated side) and 100 to 175 g (in sham operated side) are used in the experiments. On the day before the experiment, the rats have their hind paws set on the apparatus to familiarize them with the test procedure. The adopted animal is administrated with the test compounds. The test compounds are homogenized with mortar and pestle and suspended or diluted in 0.5% Methyl Cellulose to prepare 0.03 - 100 mg/2mL/kg suspension and orally administered to rat using a syringe attached with a sonde. Post-dose PWT of the right and left hind paws are measured at approximately 1 to 5 hours after drug administration. Percent reversal of mechanical hyperalgesia for each rat is calculated using the following formula. The analgesic effects of the compounds are compared.
Postdose PWT in nerve ligated side - Predose PWT in nerve ligated side % Reversal =
Predose PWT in sham operated side - Predose PWT in nerve ligated side [0169]
Test Example 7 CYP3A4 fluorescent MBI test The CYP3A4 fluorescent MBI test is a test of investigating enhancement of CYP3A4 inhibition of a compound by a metabolism reaction, and the test was performed using, as CYP3A4 enzyme expressed in Escherichia coil and employing, as an index, a reaction in which 7-benzyloxytrifluoromethylchmarin (BFC) is debenzylated by the CYP3A4 enzyme to produce a metabolite, 7-hydroxytrifluoromethylchmarin (HFC)
Percent reversal of mechanical allodynia for each rat was calculated using the following formula.
The analgesic effects of the compounds were compared.
Logio (Postdose mechanical sensitivity in nerve ligated side) - Logio (Predose mechanical sensitivity in nerve ligated side) % Reversal =
Logio (Predose mechanical sensitivity in sham operated side) - Logio (Predose mechanical sensitivity in nerve ligated side) The analgesic effects of the compounds of the present invention after single administration of 1 mg/kg at 3 hours are as shown in the following Table.
[Table 131]
Compound %reversal No.
1-019 27.9 1-057 21.4 Evaluation (2) Mechanical hyperalgesia is evaluated using an analgesy meter. Two weeks after nerve ligation, the paw pressure test is performed using an analgesy meter (stimulus pressure increased 16g per second) to obtain paw withdrawal thresholds (PWT). Measurements are made on both sides of the hind paw and to obtain pre-dose PWT. The rats showing the threshold change from 60 to 90 g (in nerve ligated side) and 100 to 175 g (in sham operated side) are used in the experiments. On the day before the experiment, the rats have their hind paws set on the apparatus to familiarize them with the test procedure. The adopted animal is administrated with the test compounds. The test compounds are homogenized with mortar and pestle and suspended or diluted in 0.5% Methyl Cellulose to prepare 0.03 - 100 mg/2mL/kg suspension and orally administered to rat using a syringe attached with a sonde. Post-dose PWT of the right and left hind paws are measured at approximately 1 to 5 hours after drug administration. Percent reversal of mechanical hyperalgesia for each rat is calculated using the following formula. The analgesic effects of the compounds are compared.
Postdose PWT in nerve ligated side - Predose PWT in nerve ligated side % Reversal =
Predose PWT in sham operated side - Predose PWT in nerve ligated side [0169]
Test Example 7 CYP3A4 fluorescent MBI test The CYP3A4 fluorescent MBI test is a test of investigating enhancement of CYP3A4 inhibition of a compound by a metabolism reaction, and the test was performed using, as CYP3A4 enzyme expressed in Escherichia coil and employing, as an index, a reaction in which 7-benzyloxytrifluoromethylchmarin (BFC) is debenzylated by the CYP3A4 enzyme to produce a metabolite, 7-hydroxytrifluoromethylchmarin (HFC)
- 197 -Date Recue/Date Received 2020-11-26 emitting fluorescent light.
[0170]
The reaction conditions were as follows: substrate, 5.6 vimol/L 7-BFC; pre-reaction time, 0 or 30 minutes; reaction time, 15 minutes; reaction temperature, 25 C
(room temperature); CYP3A4 content (expressed in Escherichia call), at pre-reaction 62.5 pmol/mL, at reaction 6.25 pmol/mL (at 10-fold dilution); test drug concentration, 1.56, 3.125, 6.25, 12.5, 25, 50 vimol/L (six points).
[0171]
An enzyme in a K-Pi buffer (pH 7.4) and a test drug solution as a pre-reaction solution were added to a 96-well plate at the composition of the pre-reaction, a part of it was transferred to another 96-well plate so that it was 1/10 diluted by a substrate in a K-Pi buffer, NADPH as a co-factor was added to initiate a reaction as an index (without preincubation) and, after a predetermined time of a reaction, acetonitri1e:0.5 mol/L Tris (trishydroxyaminomethane) = 4:1 was added to stop the reaction. In addition, NADPH
was added to a remaining preincubation solution to initiate a preincubation (with preincubation) and, after a predetermined time of a preincubation, a part was transferred to another plate so that it was 1/10 diluted with a substrate and a K-Pi buffer to initiate a reaction as an index. After a predetermined time of a reaction, acetonitri1e:0.5 mol/L Tris (trishydroxyaminomethane) = 4:1 was added to stop the reaction. For the plate on which each index reaction had been performed, a fluorescent value of 7-HFC which is a metabolite was measured with a fluorescent plate reader. (Ex = 420 nm, Em = 535 nm).
[0172]
Addition of only DMSO which is a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution, and IC5o was calculated by reverse-presumption by a logistic model using a concentration and an inhibition rate.
When a difference between IC5o values is 5 viM or more, this was defined as (+) and, when the difference is 3 viM or less, this was defined as (-).
The results of the compounds of the present invention are as shown in the following Table.
[Table 132]
Compound MB!
No.
1-041 (-) 1-057 (-) 1-063 (-) 1-069 (-) 1-106 (-) R-010 (-) R-014 (-) R-027 (-) R-058 (-) [0173]
Test Example 8 CYP inhibition test
[0170]
The reaction conditions were as follows: substrate, 5.6 vimol/L 7-BFC; pre-reaction time, 0 or 30 minutes; reaction time, 15 minutes; reaction temperature, 25 C
(room temperature); CYP3A4 content (expressed in Escherichia call), at pre-reaction 62.5 pmol/mL, at reaction 6.25 pmol/mL (at 10-fold dilution); test drug concentration, 1.56, 3.125, 6.25, 12.5, 25, 50 vimol/L (six points).
[0171]
An enzyme in a K-Pi buffer (pH 7.4) and a test drug solution as a pre-reaction solution were added to a 96-well plate at the composition of the pre-reaction, a part of it was transferred to another 96-well plate so that it was 1/10 diluted by a substrate in a K-Pi buffer, NADPH as a co-factor was added to initiate a reaction as an index (without preincubation) and, after a predetermined time of a reaction, acetonitri1e:0.5 mol/L Tris (trishydroxyaminomethane) = 4:1 was added to stop the reaction. In addition, NADPH
was added to a remaining preincubation solution to initiate a preincubation (with preincubation) and, after a predetermined time of a preincubation, a part was transferred to another plate so that it was 1/10 diluted with a substrate and a K-Pi buffer to initiate a reaction as an index. After a predetermined time of a reaction, acetonitri1e:0.5 mol/L Tris (trishydroxyaminomethane) = 4:1 was added to stop the reaction. For the plate on which each index reaction had been performed, a fluorescent value of 7-HFC which is a metabolite was measured with a fluorescent plate reader. (Ex = 420 nm, Em = 535 nm).
[0172]
Addition of only DMSO which is a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution, and IC5o was calculated by reverse-presumption by a logistic model using a concentration and an inhibition rate.
When a difference between IC5o values is 5 viM or more, this was defined as (+) and, when the difference is 3 viM or less, this was defined as (-).
The results of the compounds of the present invention are as shown in the following Table.
[Table 132]
Compound MB!
No.
1-041 (-) 1-057 (-) 1-063 (-) 1-069 (-) 1-106 (-) R-010 (-) R-014 (-) R-027 (-) R-058 (-) [0173]
Test Example 8 CYP inhibition test
- 198 -Date Recue/Date Received 2020-11-26 Using commercially available pooled human hepatic microsome, and employing, as markers, 7-ethoxyresorufin 0-deethylation (CYP1A2), tolbutamide methyl-hydroxylation (CYP2C9), mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan 0-demethylation (CYP2D6), and terfenedine hydroxylation as typical substrate metabolism reactions of human main five CYP enzyme forms (CYP1A2, 2C9, 2C19, 2D6, 3A4), an inhibitory degree of each metabolite production amount by a test compound was assessed .
[0174]
The reaction conditions were as follows: substrate, 0.5 vimol/L
ethoxyresorufin (CYP1A2), 100 vimol/L tolbutamide (CYP2C9), 50 vimol/L S-mephenitoin (CYP2C19), 5 vimol/L dextromethorphan (CYP2D6), 1 vimol/L terfenedine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37 C; enzyme, pooled human hepatic microsome 0.2 mg protein/mL; test drug concentration, 1.0, 5.0, 10, 20 vimol/L (four points).
[0175]
Each five kinds of substrates, human hepatic microsome, or a test drug in 50 mmol/L Hepes buffer as a reaction solution was added to a 96-well plate at the composition as described above, NADPH, as a cofactor was added to initiate metabolism reactions as markers and, after the incubation at 37 C for 15 minutes, a methanol/acetonitrile = 1/1 (v/v) solution was added to stop the reaction.
After the centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the supernatant was quantified by a fluorescent multilabel counter and tributamide hydroxide (CYP2CP metabolite), mephenytoin 4' hydroxide (CYP2C19 metabolite), dextromethorphan (CYP2D6 metabolite), and terfenadine alcohol (CYP3A4 metabolite) were quantified by LC/MS/MS.
[0176]
Addition of only DMSO being a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution and IC5o was calculated by reverse presumption by a logistic model using a concentration and an inhibition rate.
The data of the compounds of the present invention are as shown in the following Table.
[Table 133]
Compound CYP1A2 0YP209 0YP201 9 CYP2D6 CYP3A4 No. ( M01/0 (II M01/0 (II MOI/L) (II M01/0 (II MOI/L) 1-041 >20 >20 >20 >20 >20 1-057 >20 >20 >20 >20 >20 1-063 >20 >20 >20 >20 >20 1-069 >20 >20 >20 >20 >20 1-106 >20 >20 >20 >20 >20 R-010 >20 >20 >20 >20 >20 R-014 >20 >20 >20 >20 >20 R-027 >20 >20 >20 >20 >20 R-058 >20 >20 >20 >20 >20 [0177]
Test Example 9 Fluctuation Ames Test
[0174]
The reaction conditions were as follows: substrate, 0.5 vimol/L
ethoxyresorufin (CYP1A2), 100 vimol/L tolbutamide (CYP2C9), 50 vimol/L S-mephenitoin (CYP2C19), 5 vimol/L dextromethorphan (CYP2D6), 1 vimol/L terfenedine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37 C; enzyme, pooled human hepatic microsome 0.2 mg protein/mL; test drug concentration, 1.0, 5.0, 10, 20 vimol/L (four points).
[0175]
Each five kinds of substrates, human hepatic microsome, or a test drug in 50 mmol/L Hepes buffer as a reaction solution was added to a 96-well plate at the composition as described above, NADPH, as a cofactor was added to initiate metabolism reactions as markers and, after the incubation at 37 C for 15 minutes, a methanol/acetonitrile = 1/1 (v/v) solution was added to stop the reaction.
After the centrifugation at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the supernatant was quantified by a fluorescent multilabel counter and tributamide hydroxide (CYP2CP metabolite), mephenytoin 4' hydroxide (CYP2C19 metabolite), dextromethorphan (CYP2D6 metabolite), and terfenadine alcohol (CYP3A4 metabolite) were quantified by LC/MS/MS.
[0176]
Addition of only DMSO being a solvent dissolving a drug to a reaction system was adopted as a control (100%), remaining activity (%) was calculated at each concentration of a test drug added as the solution and IC5o was calculated by reverse presumption by a logistic model using a concentration and an inhibition rate.
The data of the compounds of the present invention are as shown in the following Table.
[Table 133]
Compound CYP1A2 0YP209 0YP201 9 CYP2D6 CYP3A4 No. ( M01/0 (II M01/0 (II MOI/L) (II M01/0 (II MOI/L) 1-041 >20 >20 >20 >20 >20 1-057 >20 >20 >20 >20 >20 1-063 >20 >20 >20 >20 >20 1-069 >20 >20 >20 >20 >20 1-106 >20 >20 >20 >20 >20 R-010 >20 >20 >20 >20 >20 R-014 >20 >20 >20 >20 >20 R-027 >20 >20 >20 >20 >20 R-058 >20 >20 >20 >20 >20 [0177]
Test Example 9 Fluctuation Ames Test
- 199 -Date Recue/Date Received 2020-11-26 Mutagenicity of compounds of the present invention was evaluated.
20 !IL of freezing-stored rat typhoid bacillus (Salmonella typhimurium TA98 strain, TA100 strain) was inoculated on 10 mL of a liquid nutrient medium (2.5% Oxoid nutrient broth No.2), and this was cultured before shaking at 37 C for 10 hours. 7.70 mL of a bacterial solution of the TA98 strain was centrifuged (2000 x g, 10 minutes) to remove a culturing solution. The bacteria was suspended in 7.70 mL of a Micro F buffer (K2HPO4: 3.5 g/L, KH2PO4: 1 g/L, (NH4)2504: 1 g/L, trisodium citrate dehydrate: 0.25 g/L, MgSO4 = 7H20: 0.1 g/L), the suspension was added to 110 mL of an Exposure medium (Micro F buffer containing Biotin: 8 vig/mL, histidine: 0.2 vig/mL, glucose: 8 mg/mL). The TA100 strain was added to 120 mL of the Exposure medium relative to 3.42 mL of the bacterial solution to prepare a test bacterial solution. Each 12 viL of DMS0 solution of a compound of the present invention (several stage dilution from maximum dose 50 mg/mL
at 2 to 3 fold ratio), DMS0 as a negative control, and 50 g/mL of 4-nitroquinoline-1-oxide DMS0 solution for the TA98 strain, 0.25 vig/mL of 2-(2-fury1)-3-(5-nitro-furyDacrylamide DMS0 solution for the TA100 strain under the non-metabolism activating condition, 40 vig/mL of 2-aminoanthracene DMS0 solution for the TA98 strain, 20 vig/mL of 2-aminoanthracene DMS0 solution for the TA100 strain under the metabolism activating condition as a positive control, and 588 viL of the test bacterial solution (a mixed solution of 498 IA of the test bacterial solution and 90 I_LL of S9 mix under the metabolism activating condition) were mixed, and this was shaking-cultured at 37 C for 90 minutes. 460 viL of the bacterial solution exposed to a compound of the present invention was mixed with 2300 viL of an Indicator medium (Micro F
buffer containing biotin: 8 vig/mL, histidine: 0.2 ug/mL, glucose: 8 mg/mL, Bromo Cresol Purple:
37.5 vig/mL), each 50 viL was dispensed into microplate 48 wells/dose, and this was subjected to stationary culturing at 37 C for 3 days. Since a well containing a bacterium which has obtained the proliferation ability by mutation of an amino acid (histidine) synthesizing enzyme gene turns from purple to yellow due to a pH change, the bacterium proliferation well which has turned to yellow in 48 wells per dose is counted, and was assessed by comparing with a negative control group. (-) means that mutagenicity is negative and (+) is positive.
The data of the compounds of the present invention are as shown in the following Table.
[Table 134]
Compound FAT
No.
1-002 (-) 1-019 (-) 1-040 (-) 1-057 (-) 1-070 (-) [0178]
Test Example 10 Solubility test The solubility of a compound was determined under a condition in which 1%
DMS0 was added. 10 mmol/L compound solution was prepared using DMSO, and then uL of the compound solution was added to 198 uL of artificial intestinal juice in pH 6.8 (to 250 mL of 0.2 mol/L potassium dihydrogen phosphate reagent solution was
20 !IL of freezing-stored rat typhoid bacillus (Salmonella typhimurium TA98 strain, TA100 strain) was inoculated on 10 mL of a liquid nutrient medium (2.5% Oxoid nutrient broth No.2), and this was cultured before shaking at 37 C for 10 hours. 7.70 mL of a bacterial solution of the TA98 strain was centrifuged (2000 x g, 10 minutes) to remove a culturing solution. The bacteria was suspended in 7.70 mL of a Micro F buffer (K2HPO4: 3.5 g/L, KH2PO4: 1 g/L, (NH4)2504: 1 g/L, trisodium citrate dehydrate: 0.25 g/L, MgSO4 = 7H20: 0.1 g/L), the suspension was added to 110 mL of an Exposure medium (Micro F buffer containing Biotin: 8 vig/mL, histidine: 0.2 vig/mL, glucose: 8 mg/mL). The TA100 strain was added to 120 mL of the Exposure medium relative to 3.42 mL of the bacterial solution to prepare a test bacterial solution. Each 12 viL of DMS0 solution of a compound of the present invention (several stage dilution from maximum dose 50 mg/mL
at 2 to 3 fold ratio), DMS0 as a negative control, and 50 g/mL of 4-nitroquinoline-1-oxide DMS0 solution for the TA98 strain, 0.25 vig/mL of 2-(2-fury1)-3-(5-nitro-furyDacrylamide DMS0 solution for the TA100 strain under the non-metabolism activating condition, 40 vig/mL of 2-aminoanthracene DMS0 solution for the TA98 strain, 20 vig/mL of 2-aminoanthracene DMS0 solution for the TA100 strain under the metabolism activating condition as a positive control, and 588 viL of the test bacterial solution (a mixed solution of 498 IA of the test bacterial solution and 90 I_LL of S9 mix under the metabolism activating condition) were mixed, and this was shaking-cultured at 37 C for 90 minutes. 460 viL of the bacterial solution exposed to a compound of the present invention was mixed with 2300 viL of an Indicator medium (Micro F
buffer containing biotin: 8 vig/mL, histidine: 0.2 ug/mL, glucose: 8 mg/mL, Bromo Cresol Purple:
37.5 vig/mL), each 50 viL was dispensed into microplate 48 wells/dose, and this was subjected to stationary culturing at 37 C for 3 days. Since a well containing a bacterium which has obtained the proliferation ability by mutation of an amino acid (histidine) synthesizing enzyme gene turns from purple to yellow due to a pH change, the bacterium proliferation well which has turned to yellow in 48 wells per dose is counted, and was assessed by comparing with a negative control group. (-) means that mutagenicity is negative and (+) is positive.
The data of the compounds of the present invention are as shown in the following Table.
[Table 134]
Compound FAT
No.
1-002 (-) 1-019 (-) 1-040 (-) 1-057 (-) 1-070 (-) [0178]
Test Example 10 Solubility test The solubility of a compound was determined under a condition in which 1%
DMS0 was added. 10 mmol/L compound solution was prepared using DMSO, and then uL of the compound solution was added to 198 uL of artificial intestinal juice in pH 6.8 (to 250 mL of 0.2 mol/L potassium dihydrogen phosphate reagent solution was
- 200 -Date Recue/Date Received 2020-11-26 added 118 mL of 0.2 mol/L NaOH reagent solution and water to provide a final volume of 1000 mL). After standing at 25 degrees Celsius for 16 hours, the mixed solution was filtrated with suction. The filtrate was diluted twice with methanol/water (1/1), and then a concentration in the filtration was measured with HPLC or LC/MS/MS by the absolute calibration method.
The reslults of the compounds of the present invention are as shown in the following Table.
[Table 135]
Compound Solubulity No. (II m01/0 1-002 > 50 1-019 >50 1-038 > 50 1-039 > 50 1-040 > 50 1-041 > 50 1-057 > 50 1-063 > 50 [0179]
Test Example 11 Metabolism Stability Test Using commercially available pooled human hepatic microsomes, a test compound is reacted for a constant time, a remaining rate is calculated by comparing a reacted sample and an unreacted sample, thereby, a degree of metabolism in liver is assessed.
[0180]
A reaction was performed (oxidative reaction) at 37 C for 0 minute or 30 minutes in the presence of 1 mmol/L NADPH in 0.2 mL of a buffer (50 mmol/L
tris-HC1 pH 7.4, 150 mmol/L potassium chloride, 10 mmol/L magnesium chloride) containing 0.5 mg protein/mL of human liver microsomes. After the reaction, 50 viL of the reaction solution was added to 100 viL of a methanol/acetonitrile = 1/1 (v/v), mixed and centrifuged at 3000 rpm for 15 minutes. The test compound in the supernatant was quantified by LC/MS/MS, and a remaining amount of the test compound after the reaction was calculated, letting a compound amount at 0 minute reaction time to be 100%.
The data of the compounds of the present invention are as shown in the following Table. The remaining rate at the compound concentration 0.5 vimol/L
are shown below.
The reslults of the compounds of the present invention are as shown in the following Table.
[Table 135]
Compound Solubulity No. (II m01/0 1-002 > 50 1-019 >50 1-038 > 50 1-039 > 50 1-040 > 50 1-041 > 50 1-057 > 50 1-063 > 50 [0179]
Test Example 11 Metabolism Stability Test Using commercially available pooled human hepatic microsomes, a test compound is reacted for a constant time, a remaining rate is calculated by comparing a reacted sample and an unreacted sample, thereby, a degree of metabolism in liver is assessed.
[0180]
A reaction was performed (oxidative reaction) at 37 C for 0 minute or 30 minutes in the presence of 1 mmol/L NADPH in 0.2 mL of a buffer (50 mmol/L
tris-HC1 pH 7.4, 150 mmol/L potassium chloride, 10 mmol/L magnesium chloride) containing 0.5 mg protein/mL of human liver microsomes. After the reaction, 50 viL of the reaction solution was added to 100 viL of a methanol/acetonitrile = 1/1 (v/v), mixed and centrifuged at 3000 rpm for 15 minutes. The test compound in the supernatant was quantified by LC/MS/MS, and a remaining amount of the test compound after the reaction was calculated, letting a compound amount at 0 minute reaction time to be 100%.
The data of the compounds of the present invention are as shown in the following Table. The remaining rate at the compound concentration 0.5 vimol/L
are shown below.
- 201 -Date Recue/Date Received 2020-11-26 [Table 136]
Compound Metabolism No. Stability (%) [0181]
Test Example 12 Metabolism Stability Test The test compound is reacted for a given period of time using cryopreserved rat hepatocytes that are prepared and the residual ratio is calculated based on the comparison between reacted and unreacted samples to evaluate the degree of hepatic metabolism.
[0182]
The compound is reacted in the Williams E medium containing 1.0 x 106 cells/mL of cryopreserved rat hepatocytes at a temperature of 37 C for 0, 1 or 2 hours.
After reaction, 50 of reaction solution is added to and mixed with 100 !IL
of a solution containing methanol and acetonitrile in the proportion of one to one (v/v) and the mixture is centrifuged at 3000 rpm for 15 minutes. The test compound contained in the centrifugal supernatant is quantitated using a LC/MS/MS system and the residual ratio of the test compound after reaction is calculated regarding the amount of compound after the reaction for 0 minute as 100%.
[0183]
Test Example 13 hERG Test For the purpose of assessing risk of an electrocardiogram QT interval prolongation of the compound of the present invention, effects of the compound of the present invention on delayed rectifier K+ current (Nr), which plays an important role in the ventricular repolarization process, was studied using CHO cells expressing human ether-a-go-go related gene (hERG) channel.
After a cell was retained at a membrane potential of -80 mV by whole cell patch clamp method using an automated patch clamp system (QPatch; Sophion Bioscience A/S) and gave a leak potential of -50 mV, Ixr induced by depolarization pulse stimulation at +20 mV for 2 seconds and, further, repolarization pulse stimulation at -50 mV
for 2 seconds, was recorded. After the generated current was stabilized, extracellular solution (NaCl: 145 mmol/L, KC1: 4 mmol/L, CaCl2: 2 mmol/L, MgCl2: 1 mmol/L, glucose:
mmol/L, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid): 10 mmol/L, pH=7.4), in which the compound of the present invention had been dissolved at an objective concentration, was applied to the cell at room temperature for 10 minutes.
From the recording ficr, an absolute value of the tail peak current was measured based on the current value at the resting membrane potential using analysis software (Falster Patch;Sophion Bioscience A/S). Further, the % inhibition relative to the tail peak current before application of the compound of the present invention was
Compound Metabolism No. Stability (%) [0181]
Test Example 12 Metabolism Stability Test The test compound is reacted for a given period of time using cryopreserved rat hepatocytes that are prepared and the residual ratio is calculated based on the comparison between reacted and unreacted samples to evaluate the degree of hepatic metabolism.
[0182]
The compound is reacted in the Williams E medium containing 1.0 x 106 cells/mL of cryopreserved rat hepatocytes at a temperature of 37 C for 0, 1 or 2 hours.
After reaction, 50 of reaction solution is added to and mixed with 100 !IL
of a solution containing methanol and acetonitrile in the proportion of one to one (v/v) and the mixture is centrifuged at 3000 rpm for 15 minutes. The test compound contained in the centrifugal supernatant is quantitated using a LC/MS/MS system and the residual ratio of the test compound after reaction is calculated regarding the amount of compound after the reaction for 0 minute as 100%.
[0183]
Test Example 13 hERG Test For the purpose of assessing risk of an electrocardiogram QT interval prolongation of the compound of the present invention, effects of the compound of the present invention on delayed rectifier K+ current (Nr), which plays an important role in the ventricular repolarization process, was studied using CHO cells expressing human ether-a-go-go related gene (hERG) channel.
After a cell was retained at a membrane potential of -80 mV by whole cell patch clamp method using an automated patch clamp system (QPatch; Sophion Bioscience A/S) and gave a leak potential of -50 mV, Ixr induced by depolarization pulse stimulation at +20 mV for 2 seconds and, further, repolarization pulse stimulation at -50 mV
for 2 seconds, was recorded. After the generated current was stabilized, extracellular solution (NaCl: 145 mmol/L, KC1: 4 mmol/L, CaCl2: 2 mmol/L, MgCl2: 1 mmol/L, glucose:
mmol/L, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid): 10 mmol/L, pH=7.4), in which the compound of the present invention had been dissolved at an objective concentration, was applied to the cell at room temperature for 10 minutes.
From the recording ficr, an absolute value of the tail peak current was measured based on the current value at the resting membrane potential using analysis software (Falster Patch;Sophion Bioscience A/S). Further, the % inhibition relative to the tail peak current before application of the compound of the present invention was
- 202 -Date Recue/Date Received 2020-11-26 calculated, and compared with the vehicle-applied group (0.1% dimethyl sulfoxide solution) to assess influence of the compound of the present invention on Ixr.
The data of the compounds of the present invention are as shown in the following Table.
[Table 137]
Compound hERG
No. Inhibition (%) 1-002 7.3 1-006 5.3 [0184]
Test Example 14 Protein binding test The unbound fraction of the present compound in serum was measured using serum of various species.
[0185]
The reactive conditions are as follows: Evaluation method, Equilibrium dialysis;
Reaction time, 24 hours; Reaction temperature, 370C; Concentration of the present compound, 2 g/mL
[0186]
The test solution was added to each serum and the mixture was agitated to prepare the serum samples at the concentration mentioned above. Each serum sample was added into one side of the cell and phosphate buffered saline (PBS) was added into the other side to perform equilibrium dialysis at 37 C for 24 hours. Then, the concentration of the compounds in the samples that were obtained from both sides was measured by LC/MS/MS.
The data of the compounds of the present invention are as shown in the following Table. The ratio of PBS concentration to serum concentration is expressed as unbound fraction (fu).
[Table 138]
Compound fu No. %) 1-029 1.7 1-040 3.5 1-056 1.8 1-057 1.7 R-019 1.8 [0187]
Test Example 15 Pharmacokinetic test Materials and Methods (1) Animals: SD rats were used (2) Breeding conditions: SD rats were allowed to freely take solid food and sterilized tap water.
(3) Dose and grouping: orally or intravenously administered at a predetermined dose;
The data of the compounds of the present invention are as shown in the following Table.
[Table 137]
Compound hERG
No. Inhibition (%) 1-002 7.3 1-006 5.3 [0184]
Test Example 14 Protein binding test The unbound fraction of the present compound in serum was measured using serum of various species.
[0185]
The reactive conditions are as follows: Evaluation method, Equilibrium dialysis;
Reaction time, 24 hours; Reaction temperature, 370C; Concentration of the present compound, 2 g/mL
[0186]
The test solution was added to each serum and the mixture was agitated to prepare the serum samples at the concentration mentioned above. Each serum sample was added into one side of the cell and phosphate buffered saline (PBS) was added into the other side to perform equilibrium dialysis at 37 C for 24 hours. Then, the concentration of the compounds in the samples that were obtained from both sides was measured by LC/MS/MS.
The data of the compounds of the present invention are as shown in the following Table. The ratio of PBS concentration to serum concentration is expressed as unbound fraction (fu).
[Table 138]
Compound fu No. %) 1-029 1.7 1-040 3.5 1-056 1.8 1-057 1.7 R-019 1.8 [0187]
Test Example 15 Pharmacokinetic test Materials and Methods (1) Animals: SD rats were used (2) Breeding conditions: SD rats were allowed to freely take solid food and sterilized tap water.
(3) Dose and grouping: orally or intravenously administered at a predetermined dose;
- 203 -Date Recue/Date Received 2020-11-26 grouping was as follows (Dose depends on the compound) Oral administration: 1 mg/kg (n=2) Intravenous administration: 0.5 mg/kg (n=2) (4) Preparation of dosing solution: for oral administration, in a solution or a suspension state; for intravenous administration, in a solubilized state (5) Administration method: in oral administration, forcedly administer into yentriculus with oral probe; in intravenous administration, administer from caudal vein with a needle-equipped syringe (6) Evaluation items: blood was collected over time, and the plasma concentration of drug was measured by LC/MS/MS
(7) Statistical analysis: regarding the transition of the plasma concentration of the present compound, the area under the plasma concentration-time curve (AUC) was calculated by non-linear least squares program WinNonlin (Registered trade name), and the bioavailability (BA) was calculated from the AUCs of the oral administration group and intravenous administration group. The total body clearance (CLtot) was calculated by dividing the dose by the AUC of the intravenous administration group.
The data of the compounds of the present invention are as shown in the following Table.
[Table 139]
Compound AUC (po) AUC (iv) BA CLtot No. (ng=hr/mL) (ng=hr/mL) (%) (mL/min/kg) 1-014 4890 2300 106.2 4 1-017 6110 3790 80.7 2.3 1-040 410 291 70.3 28.6 1-057 487 367 66.4 22.9 1-058 2030 1510 67.2 5.8 1-127 2460 2330 52.8 3.8 [0188]
Test Example 16 Powder solubility test Appropriate quantity of the compound of the present invention is put in a suitable container and 200 p_L of JP-1 solution (water was added to 2.0 g of sodium chloride and 7.0 mL of hydrochloric acid to reach 1000 mL), JP-2 solution (500 mL of water is added to 500 mL of phosphate buffer with a pH of 6.8) or 20 mmol/L sodium taurocholate (TCA)/JP-2 solution (JP-2 solution was added to 1.08 g of TCA to reach 100 mL) is independently added to each container. When total amount is dissolved after adding the test reagent, the compound of the present invention is added appropriately.
After sealing and shaking at 37 C for 1 hour, solution is filtrated and 10011L of methanol was added to 100 id., of each filtrate to dilute two-fold. The dilution rate is changed as necessary. After checking that there is no bubble and deposit, the container is sealed and shaken. The compound of the present invention is measured using HPLC by absolute calibration curve method.
[0189]
Preparation Example The following Formulation Examples are only exemplified and not intended to limit the scope of the invention.
Formulation Example 1: Tablet
(7) Statistical analysis: regarding the transition of the plasma concentration of the present compound, the area under the plasma concentration-time curve (AUC) was calculated by non-linear least squares program WinNonlin (Registered trade name), and the bioavailability (BA) was calculated from the AUCs of the oral administration group and intravenous administration group. The total body clearance (CLtot) was calculated by dividing the dose by the AUC of the intravenous administration group.
The data of the compounds of the present invention are as shown in the following Table.
[Table 139]
Compound AUC (po) AUC (iv) BA CLtot No. (ng=hr/mL) (ng=hr/mL) (%) (mL/min/kg) 1-014 4890 2300 106.2 4 1-017 6110 3790 80.7 2.3 1-040 410 291 70.3 28.6 1-057 487 367 66.4 22.9 1-058 2030 1510 67.2 5.8 1-127 2460 2330 52.8 3.8 [0188]
Test Example 16 Powder solubility test Appropriate quantity of the compound of the present invention is put in a suitable container and 200 p_L of JP-1 solution (water was added to 2.0 g of sodium chloride and 7.0 mL of hydrochloric acid to reach 1000 mL), JP-2 solution (500 mL of water is added to 500 mL of phosphate buffer with a pH of 6.8) or 20 mmol/L sodium taurocholate (TCA)/JP-2 solution (JP-2 solution was added to 1.08 g of TCA to reach 100 mL) is independently added to each container. When total amount is dissolved after adding the test reagent, the compound of the present invention is added appropriately.
After sealing and shaking at 37 C for 1 hour, solution is filtrated and 10011L of methanol was added to 100 id., of each filtrate to dilute two-fold. The dilution rate is changed as necessary. After checking that there is no bubble and deposit, the container is sealed and shaken. The compound of the present invention is measured using HPLC by absolute calibration curve method.
[0189]
Preparation Example The following Formulation Examples are only exemplified and not intended to limit the scope of the invention.
Formulation Example 1: Tablet
- 204 -Date Recue/Date Received 2020-11-26 Compound of the present invention 15 mg Lactose 15 mg Calcium Stearate 3 mg The above ingredients other than Calcium Stearate are uniformly mixed, crushed, granule, dried to prepare granules of suitable size. After addition of Calcium Stearate, the mixture is compressed to prepare tables.
[0190]
Formulation Example 2: Capsules Compound of the present invention 10 mg Magnecium Stearate 10 mg Lactose 80 mg The above ingredients are uniformly mixed to prepare powdered medicine as powder or fine particles, which are put into capsule containers to prepare capsules.
[0191]
Formulation Example 3: Granules Compound of the present invention 30 g Lactose 265 g Magnecium Stearate 5 g The above ingredients are fully mixed, compressed, crushed, selected the size to prepare granules of suitable size.
[0192]
Formulation Example 4: Orally dispersing tablets The compounds of the present invention and crystalline cellulose are mixed, granulated and tablets are made to give orally dispersing tablets.
[0193]
Formulation Example 5: Dry syrups The compounds of the present invention and lactose are mixed, crushed, granulated and sieved to give suitable sizes of dry syrups.
[0194]
Formulation Example 6: Injections The compounds of the present invention and phosphate buffer are mixed to give injection.
[0195]
Formulation Example 7: Infusions The compounds of the present invention and phosphate buffer are mixed to give injection.
[0196]
Formulation Example 8: Inhalations The compound of the present invention and lactose are mixed and crushed finely to give inhalations.
[0197]
Formulation Example 9: Ointments The compounds of the present invention and petrolatum are mixed to give ointments.
[0198]
Formulation Example 10: Patches The compounds of the present invention and base such as adhesive plaster or the like are mixed to give patches.
[0190]
Formulation Example 2: Capsules Compound of the present invention 10 mg Magnecium Stearate 10 mg Lactose 80 mg The above ingredients are uniformly mixed to prepare powdered medicine as powder or fine particles, which are put into capsule containers to prepare capsules.
[0191]
Formulation Example 3: Granules Compound of the present invention 30 g Lactose 265 g Magnecium Stearate 5 g The above ingredients are fully mixed, compressed, crushed, selected the size to prepare granules of suitable size.
[0192]
Formulation Example 4: Orally dispersing tablets The compounds of the present invention and crystalline cellulose are mixed, granulated and tablets are made to give orally dispersing tablets.
[0193]
Formulation Example 5: Dry syrups The compounds of the present invention and lactose are mixed, crushed, granulated and sieved to give suitable sizes of dry syrups.
[0194]
Formulation Example 6: Injections The compounds of the present invention and phosphate buffer are mixed to give injection.
[0195]
Formulation Example 7: Infusions The compounds of the present invention and phosphate buffer are mixed to give injection.
[0196]
Formulation Example 8: Inhalations The compound of the present invention and lactose are mixed and crushed finely to give inhalations.
[0197]
Formulation Example 9: Ointments The compounds of the present invention and petrolatum are mixed to give ointments.
[0198]
Formulation Example 10: Patches The compounds of the present invention and base such as adhesive plaster or the like are mixed to give patches.
- 205 -Date Recue/Date Received 2020-11-26 [Industrial Applicability]
[0199]
The compounds represented by Formula (I) have an antagonistic activity on P2X3 and/or P2X2/3 receptor and are useful in the treatment of diseases or conditions associated with a P2X3 and/or P2X2/3 receptor, such as chronic pain, urination disorder, respiratory disease, and the like.
[0199]
The compounds represented by Formula (I) have an antagonistic activity on P2X3 and/or P2X2/3 receptor and are useful in the treatment of diseases or conditions associated with a P2X3 and/or P2X2/3 receptor, such as chronic pain, urination disorder, respiratory disease, and the like.
- 206 -Date Recue/Date Received 2020-11-26
Claims (7)
1. A compound of formula:
F
0)F CI
el N
HN AN
A)LOH
0 H11 y )i).LOH 0 C
N NO
I.CI , 0 Nr0 0 H NAN 0 -µilLOH
or 0 cl or its pharmaceutically-acceptable salt.
F
0)F CI
el N
HN AN
A)LOH
0 H11 y )i).LOH 0 C
N NO
I.CI , 0 Nr0 0 H NAN 0 -µilLOH
or 0 cl or its pharmaceutically-acceptable salt.
2. The compound according to claim 1, which is:
F
OLF
N
HN 0AN .L'L(:)H
or its pharmaceutically-acceptable salt.
Date Recue/Date Received 2020-1 1 -26
F
OLF
N
HN 0AN .L'L(:)H
or its pharmaceutically-acceptable salt.
Date Recue/Date Received 2020-1 1 -26
3. The compound according to claim 1, which is:
HNAN ,LOH
NNO
or its pharmaceutically-acceptable salt.
HNAN ,LOH
NNO
or its pharmaceutically-acceptable salt.
4. The compound according to claim 1, which is:
Nr0 0 HNAN iOH
-)1 NNO
1$1 CI
or its pharmaceutically-acceptable salt.
Nr0 0 HNAN iOH
-)1 NNO
1$1 CI
or its pharmaceutically-acceptable salt.
5. A pharmaceutical composition comprising:
the compound according to any one of claims 1 to 4, or its pharmaceutically-acceptable salt, as active ingredient, and a pharmaceutical additive.
the compound according to any one of claims 1 to 4, or its pharmaceutically-acceptable salt, as active ingredient, and a pharmaceutical additive.
6. The pharmaceutical composition according to claim 5, wherein the composition has P2X3 and/or P2X2/3 receptor antagonistic activity.
7. A compound according to any one of claims 1 to 4, or its pharmaceutically-acceptable salt, for use in treating and/or preventing a disease related to P2X3 and/or P2X2/3 receptor.
Date Recue/Date Received 2020-11-26
Date Recue/Date Received 2020-11-26
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013-125134 | 2013-06-14 | ||
| JP2013125134 | 2013-06-14 | ||
| PCT/JP2014/065678 WO2014200078A1 (en) | 2013-06-14 | 2014-06-13 | Amino-triazine derivatives and pharmaceutical composition containing said derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2915325A1 CA2915325A1 (en) | 2014-12-18 |
| CA2915325C true CA2915325C (en) | 2021-09-14 |
Family
ID=52022364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2915325A Active CA2915325C (en) | 2013-06-14 | 2014-06-13 | Amino-triazine derivatives and pharmaceutical composition containing said derivative |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9732060B2 (en) |
| EP (1) | EP3009432B1 (en) |
| JP (1) | JP6132371B2 (en) |
| KR (2) | KR20170116177A (en) |
| CN (1) | CN105452234B (en) |
| AR (1) | AR096620A1 (en) |
| AU (1) | AU2014279116B2 (en) |
| BR (1) | BR112015031079B1 (en) |
| CA (1) | CA2915325C (en) |
| DK (1) | DK3009432T3 (en) |
| EA (1) | EA030198B1 (en) |
| ES (1) | ES2675528T3 (en) |
| IL (1) | IL243042A0 (en) |
| MX (1) | MX362995B (en) |
| PH (1) | PH12015502775A1 (en) |
| PL (1) | PL3009432T3 (en) |
| SG (1) | SG11201510179PA (en) |
| TR (1) | TR201809085T4 (en) |
| TW (1) | TWI637949B (en) |
| WO (1) | WO2014200078A1 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2399910T3 (en) | 2009-02-13 | 2014-09-30 | Shionogi & Co | Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them |
| RU2565073C2 (en) | 2010-08-10 | 2015-10-20 | Сионоги Энд Ко., Лтд. | Triazine derivative and pharmaceutical composition including it, possessing analgesic activity |
| US9212130B2 (en) * | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
| TWI637949B (en) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | Aminotriazine derivative and pharmaceutical composition comprising the same |
| US9988373B2 (en) | 2013-12-26 | 2018-06-05 | Shionogi & Co., Ltd. | Nitrogen-containing six-membered cyclic derivatives and pharmaceutical composition comprising the same |
| JPWO2016084922A1 (en) * | 2014-11-28 | 2017-09-07 | 塩野義製薬株式会社 | 1,2,4-Triazine derivative and pharmaceutical composition thereof |
| BR112017022654A2 (en) | 2015-04-24 | 2018-07-10 | Shionogi & Co., Ltd. | 6-membered heterocyclic derivative and pharmaceutical composition comprising the same |
| MA43821A (en) * | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | PYRIMIDINS AND VARIANTS THEREOF, AND THEIR USES |
| US10662162B2 (en) | 2016-03-25 | 2020-05-26 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| KR102528627B1 (en) | 2016-10-17 | 2023-05-03 | 시오노기 앤드 컴파니, 리미티드 | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical compositions containing them |
| KR20200003328A (en) | 2018-06-29 | 2020-01-09 | 삼성디스플레이 주식회사 | Display device |
| JP6725188B1 (en) | 2018-10-05 | 2020-07-15 | 塩野義製薬株式会社 | Medicine for the treatment of chronic cough |
| AU2020348089A1 (en) * | 2019-09-19 | 2022-03-31 | Shionogi & Co., Ltd. | Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same |
| TW202128675A (en) | 2019-12-06 | 2021-08-01 | 美商維泰克斯製藥公司 | Substituted tetrahydrofurans as modulators of sodium channels |
| TW202203929A (en) * | 2020-04-03 | 2022-02-01 | 日商塩野義製藥股份有限公司 | Medicament for the treatment of pain |
| TW202203930A (en) * | 2020-04-03 | 2022-02-01 | 日商塩野義製藥股份有限公司 | Medicament for the treatment of sleep apnea syndrome |
| EP4151219A4 (en) * | 2020-05-15 | 2024-05-15 | Shionogi & Co., Ltd | Impurity production-inhibited drug composition |
| KR102494188B1 (en) * | 2021-04-14 | 2023-01-31 | 시오노기 앤드 컴파니, 리미티드 | Triazine derivatives having virus growth inhibitory activity and pharmaceutical compositions containing them |
| PE20241335A1 (en) | 2021-06-04 | 2024-07-03 | Vertex Pharma | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS |
| CN113773300B (en) * | 2021-09-27 | 2022-10-11 | 成都施贝康生物医药科技有限公司 | Sulfonamide compound, preparation method and application thereof |
| CN113801097B (en) * | 2021-09-27 | 2022-11-22 | 成都施贝康生物医药科技有限公司 | Dihydropyrimidine compound, preparation method and application thereof |
| CN113620888B (en) * | 2021-09-27 | 2023-06-06 | 成都施贝康生物医药科技有限公司 | Dihydropyrimidine compound and preparation method and application thereof |
| MX2024003600A (en) | 2021-09-28 | 2024-04-09 | Shionogi & Co | Pharmaceutical composition containing triazine derivative. |
| TW202320793A (en) | 2021-09-28 | 2023-06-01 | 日商塩野義製藥股份有限公司 | Pharmaceutical composition comprising triazine derivative |
| AU2022333823A1 (en) | 2021-11-24 | 2024-05-02 | Shionogi & Co., Ltd. | Preparation for oral administration containing triazine derivative |
| WO2023095860A1 (en) * | 2021-11-26 | 2023-06-01 | 塩野義製薬株式会社 | Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug |
| TW202339757A (en) | 2022-01-19 | 2023-10-16 | 日商塩野義製藥股份有限公司 | Medicament for treating novel coronavirus infection |
| CN115650959B (en) * | 2022-05-20 | 2023-10-20 | 南京济群医药科技股份有限公司 | Process for the preparation or purification of compounds |
| WO2024169781A1 (en) * | 2023-02-15 | 2024-08-22 | 南京明德新药研发有限公司 | Pyrimidinone derivative and pharmaceutical application thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598815A (en) | 1968-10-25 | 1971-08-10 | Goodrich Co B F | Bis-(hydroxyphenylalkylene) alkyl isocyanurates |
| JPS5132324A (en) | 1974-09-12 | 1976-03-18 | Fuji Photo Film Co Ltd | Netsugenzokankozairyo |
| CH622536A5 (en) | 1976-07-08 | 1981-04-15 | Ciba Geigy Ag | |
| CH623840A5 (en) | 1976-10-18 | 1981-06-30 | Ciba Geigy Ag | |
| US4158724A (en) | 1976-10-18 | 1979-06-19 | Ciba-Geigy Corporation | Tris-tetrazoles as chemical blowing agents |
| GB1599518A (en) | 1977-02-21 | 1981-10-07 | Ici Ltd | 1,3,5-triazine-2,6-diones and pharmaceutical compositions thereof |
| DE2962124D1 (en) | 1978-05-26 | 1982-03-25 | Ici Plc | Analgesic 6-acylaminotetrahydro-1,3,5-triazine-2,4-dione derivatives, pharmaceutical compositions thereof, and process for their manufacture |
| JPS57144269A (en) | 1981-03-03 | 1982-09-06 | Taiho Yakuhin Kogyo Kk | Triazine derivative and its preparation |
| DE3375432D1 (en) | 1982-11-26 | 1988-02-25 | Ciba Geigy Ag | Colour-photographic recording material |
| JPS62156110A (en) | 1985-12-27 | 1987-07-11 | Res Inst For Prod Dev | Polymer containing isocyanurate structure in side chain and having adsorption capability |
| JPS62156110U (en) | 1986-03-26 | 1987-10-03 | ||
| EP0401707B1 (en) | 1989-06-05 | 1994-09-21 | Daiichi Pharmaceutical Co., Ltd. | Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity |
| RU2057754C1 (en) | 1989-06-05 | 1996-04-10 | Дайити Фармасьютикал Ко., Лтд. | Heterocyclic compounds or their acid-additive salts |
| DE4141721A1 (en) | 1991-12-18 | 1993-06-24 | Bayer Ag | SUBSTITUTED HETEROCYCLYLTRIAZINDIONE |
| JP3542482B2 (en) | 1997-12-25 | 2004-07-14 | 日研化学株式会社 | 3-anilino-2-cycloalkenone derivatives |
| WO1999052881A1 (en) | 1998-04-15 | 1999-10-21 | Sagami Chemical Research Center | 2-anilinopyrimidinone derivatives, intermediates in the production thereof, process for producing the same and pesticides containing the same as the active ingredient |
| JP2995293B1 (en) | 1998-08-25 | 1999-12-27 | 工業技術院長 | Method for producing 1,6-disubstituted-1,3,5-triazine-2,4 (1H, 3H) -dione compound |
| US6177437B1 (en) | 1998-09-04 | 2001-01-23 | University Of Massachusetts Medical Center | Inhibitors of Herpes Simplex virus uracil-DNA glycosylase |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| US6713486B1 (en) | 1999-03-04 | 2004-03-30 | Korea Research Institute Of Chemical Technology | Antiviral 2,4-pyrimidinedione derivatives and process for the preparation thereof |
| JP4674676B2 (en) | 1999-11-08 | 2011-04-20 | 公益財団法人相模中央化学研究所 | 2-Substituted aminopyrimidinone derivatives, methods for producing them, and insecticides and acaricides containing them as active ingredients |
| WO2001055093A1 (en) | 2000-01-25 | 2001-08-02 | Japan Tobacco Inc. | N-arylhydrazide compounds and use thereof as drugs |
| US20020049320A1 (en) | 2000-04-27 | 2002-04-25 | American Cyanamid Company | 6-amino-2,4-dioxo-3,4-dihydro-1,3,5-triazine derivatives and methods for the solid phase synthesis thereof |
| JP2005508288A (en) | 2001-05-18 | 2005-03-31 | アボット・ラボラトリーズ | Tri-substituted-N-[(1S) -1,2,3,4-tetrahydro-1-naphthalenyl] benzamides that inhibit P2X3 and P2X2 / 3-containing receptors |
| WO2004054617A1 (en) | 2002-12-13 | 2004-07-01 | Kyowa Hakko Kogyo Co., Ltd. | Preventives and/or remedies for central diseases |
| JP2006528640A (en) | 2003-07-22 | 2006-12-21 | ニューロジェン・コーポレーション | Substituted pyridin-2-ylamine analogues |
| KR100822530B1 (en) | 2004-03-05 | 2008-04-16 | 에프. 호프만-라 로슈 아게 | Diaminopyrimidines as p2x3 and p2x2/3 antagonists |
| AU2005266887B2 (en) | 2004-07-22 | 2011-08-18 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
| ATE519759T1 (en) | 2004-12-30 | 2011-08-15 | Exelixis Inc | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHODS OF APPLICATION |
| KR20070116915A (en) | 2005-03-24 | 2007-12-11 | 얀센 파마슈티카 엔.브이. | Pyrimidindione derivatives as prokineticin 2 receptor antagonists |
| JP2008537548A (en) | 2005-03-24 | 2008-09-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Prokineticin 1 receptor |
| CN101326168A (en) | 2005-03-24 | 2008-12-17 | 詹森药业有限公司 | Prokineticin 1 receptor antagonists |
| US8507415B2 (en) | 2005-05-03 | 2013-08-13 | Southwest Research Institute | Lubricant oils and greases containing nanoparticle additives |
| CA2606760C (en) | 2005-05-04 | 2014-12-23 | Renovis, Inc. | Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and disfunctions |
| JP4987871B2 (en) | 2005-08-15 | 2012-07-25 | エフ．ホフマン−ラ ロシュ アーゲー | Piperidine and piperazine derivatives as P2X3 antagonists |
| CN101253159B (en) | 2005-09-01 | 2011-12-07 | 弗·哈夫曼-拉罗切有限公司 | Diaminopyrimidines as P2X3 and P2X2/3 modulators |
| DK1924264T5 (en) | 2005-09-01 | 2014-03-24 | Hoffmann La Roche | Diaminopyrimidines as P2X3- and P2X2 / 3 modulators |
| EP1924564B1 (en) | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| JP4850913B2 (en) | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Diaminopyridines as P2X3 and P2X2 / 3 regulators |
| US7902358B2 (en) | 2005-12-29 | 2011-03-08 | Janssen Pharmaceutica Nv | Prokineticin 1 receptor antagonists |
| CA2635845A1 (en) | 2005-12-29 | 2007-07-12 | Janssen Pharmaceutica N.V. | Prokineticin 2 receptor antagonists |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| EP2044037A2 (en) | 2006-07-24 | 2009-04-08 | Gilead Sciences, Inc. | Hiv reverse transcriptase inhibitors |
| CL2008000065A1 (en) | 2007-01-12 | 2008-09-22 | Smithkline Beecham Corp | COMPOUNDS DERIVED FROM N-SUBSTITUTED GLYCINE, INHIBITORS OF HIF PROLIL HYDROXYLASES; YOUR PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEMIA. |
| CN101679445A (en) | 2007-04-13 | 2010-03-24 | 先灵公司 | Pyrimidinedione derivative and application thereof |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| JP2009007258A (en) | 2007-06-26 | 2009-01-15 | Kowa Pharmaceutical Co Ltd | 3-anilino-2-cycloalkenone derivative having inhibitory action on production of pai-1 |
| CA2704185C (en) | 2007-10-30 | 2016-02-16 | Janssen Pharmaceutica N.V. | Amino-heteroaryl-containing prokineticin 1 receptor antagonists |
| JPWO2009101917A1 (en) | 2008-02-13 | 2011-06-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Bicycloamine derivatives |
| JP5608655B2 (en) | 2008-09-18 | 2014-10-15 | エヴォテック アーゲー | Modulator of P2X3 receptor activity |
| MX2011004570A (en) | 2008-10-31 | 2011-06-17 | Merck Sharp & Dohme | P2x3, receptor antagonists for treatment of pain. |
| PL2399910T3 (en) | 2009-02-13 | 2014-09-30 | Shionogi & Co | Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them |
| SG177308A1 (en) | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel biphenyl and phenyl-pyridine amides |
| IN2012DN00838A (en) | 2009-08-05 | 2015-06-26 | Du Pont | |
| CA2806572C (en) | 2010-07-30 | 2018-10-30 | Expression Pathology, Inc. | C-src selected reaction monitoring assay |
| US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
| RU2565073C2 (en) * | 2010-08-10 | 2015-10-20 | Сионоги Энд Ко., Лтд. | Triazine derivative and pharmaceutical composition including it, possessing analgesic activity |
| EP2693881B1 (en) | 2011-04-01 | 2019-09-04 | University of Utah Research Foundation | Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase |
| TW201331188A (en) | 2011-12-15 | 2013-08-01 | Shionogi & Co | Substituted triazine derivative and pharmaceutical composition comprising the same |
| JP6124351B2 (en) | 2012-02-09 | 2017-05-10 | 塩野義製薬株式会社 | Heterocyclic and carbocyclic derivatives |
| TWI637949B (en) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | Aminotriazine derivative and pharmaceutical composition comprising the same |
-
2014
- 2014-06-04 TW TW103119435A patent/TWI637949B/en active
- 2014-06-13 JP JP2015522870A patent/JP6132371B2/en active Active
- 2014-06-13 KR KR1020177027171A patent/KR20170116177A/en not_active Application Discontinuation
- 2014-06-13 WO PCT/JP2014/065678 patent/WO2014200078A1/en active Application Filing
- 2014-06-13 TR TR2018/09085T patent/TR201809085T4/en unknown
- 2014-06-13 ES ES14810134.8T patent/ES2675528T3/en active Active
- 2014-06-13 US US14/897,836 patent/US9732060B2/en active Active
- 2014-06-13 MX MX2015016877A patent/MX362995B/en unknown
- 2014-06-13 CA CA2915325A patent/CA2915325C/en active Active
- 2014-06-13 KR KR1020167000768A patent/KR101813411B1/en active IP Right Grant
- 2014-06-13 AR ARP140102276A patent/AR096620A1/en unknown
- 2014-06-13 BR BR112015031079-6A patent/BR112015031079B1/en active IP Right Grant
- 2014-06-13 PL PL14810134T patent/PL3009432T3/en unknown
- 2014-06-13 EP EP14810134.8A patent/EP3009432B1/en active Active
- 2014-06-13 DK DK14810134.8T patent/DK3009432T3/en active
- 2014-06-13 SG SG11201510179PA patent/SG11201510179PA/en unknown
- 2014-06-13 AU AU2014279116A patent/AU2014279116B2/en active Active
- 2014-06-13 EA EA201690019A patent/EA030198B1/en not_active IP Right Cessation
- 2014-06-13 CN CN201480043967.6A patent/CN105452234B/en active Active
-
2015
- 2015-12-10 IL IL243042A patent/IL243042A0/en unknown
- 2015-12-14 PH PH12015502775A patent/PH12015502775A1/en unknown
-
2017
- 2017-06-29 US US15/637,967 patent/US10065941B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2915325C (en) | Amino-triazine derivatives and pharmaceutical composition containing said derivative | |
| JP6124351B2 (en) | Heterocyclic and carbocyclic derivatives | |
| JP5765753B2 (en) | Triazine derivative and pharmaceutical composition containing the same having analgesic action | |
| JP5692747B2 (en) | Novel triazine derivative and pharmaceutical composition containing the same | |
| JP5766198B2 (en) | Condensed aminodihydropyrimidine derivatives | |
| WO2013089212A1 (en) | Substituted triazine derivative and pharmaceutical composition containing same | |
| CA3102063A1 (en) | Polycyclic carbamoylpyridone derivative | |
| CA3101950A1 (en) | Polycyclic pyridone derivative | |
| WO2016084922A1 (en) | 1,2,4-triazine derivative and pharmaceutical composition thereof | |
| WO2016088838A1 (en) | Purine derivative and pharmaceutical composition thereof | |
| AU2023207390A1 (en) | Six-membered cyclothiazole compound and use thereof | |
| CA3166597A1 (en) | Muscarinic receptor 4 antagonists and methods of use | |
| WO2017204318A1 (en) | 1,2,4-triazine derivative | |
| WO2017209267A1 (en) | Purine derivative | |
| TWI831325B (en) | Naphthyridine derivatives as ATR inhibitors and preparation methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190524 |